NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE

Abstract
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
Description
FIELD OF INVENTION

Embodiments of the invention are directed to novel compounds useful as modulators of 5-hydroxytryptamine receptor 7 (5-HT7) activity and their method of use. Embodiments are further directed to a novel chemotype useful for the treatment diseases that are associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.


BACKGROUND OF THE INVENTION

Serotonin was discovered in the late 1940s and is present in both the peripheral and central nervous systems [Physiol. Res, 60 (2011) 15-25; Psychopharmacology 213 (2011) 167-169]. Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter of the indolalkylamine group that acts at synapses of nerve cells. Seven distinct families of serotonin receptors have been identified and at least 20 subpopulations have been cloned on the basis of sequence similarity, signal transduction coupling and pharmacological characteristics. The seven families of 5-HT receptor are named 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 and each of these receptors in turn has subfamilies or subpopulations. The signal transduction mechanism for all seven families have been studied and it is known that activation of 5-HT1 and 5-HT5 receptors causes a decrease in intracellular cAMP whereas activation of 5-HT2, 5-HT3, 5-HT4, 5-HT6, and 5-HT7 results in an increase in intracellular IP3 and DAG. The 5-HT pathways in the brain are important targets for drug development in the area of CNS disorders. The neurotransmitter binds to its a G-protein coupled receptor and is involved in a wide variety of actions including cognition, mood, anxiety, attention, appetite, cardiovascular function, vasoconstriction, sleep (ACS Medicinal Chemistry Letters, 2011, 2, 929-932; Physiological Research, 2011, 60, 15-25), inflammatory bowel disease (IBD), and intestinal inflammation (WO 2012058769, Khan, W. I., et. al. Journal of Immunology, 2013, 190, 4795-4804), epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9) among others.


BRIEF SUMMARY OF THE INVENTION

The present invention is directed toward novel 5-hydroxytryptamine receptor 7 (5-HT7) activity modulators, compounds of formula (I),




embedded image


Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:


A is selected from a group consisting of




embedded image


X is selected from the group consisting of O, S, SO, SO2, NR;


n1 is 0, 1, 2;


n2 is 0, 1, 2;


R is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,




embedded image


COR2, CO2R2a, CONR2bR2c, SO2NR2bR2c, and SO2R2d;


R1a, R1b, R1c, R1d, and R1e are at each occurrence independently selected from the group consisting of H, OH, NO2, halogen, CN, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, CJ-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, C1-6 linear haloalkyl, C3-7 branched haloalkyl, C1-6 linear haloalkoxy, —S(C1-6 linear alkyl), S(C3-7 branched alkyl), —S(C3-7 cycloalkyl), COR6, CO2R7, CONR8aR8b, SO2NR8aR8b, NR9aR9b, NR9aCOR10, NR9aSO2R11, and NR9aSO2NR12aR12b;


R2 is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2a is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2b is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2c is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2d is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, C1-6 linear haloalkyl, C3-7 branched haloalkyl, —(CH2)qCN, —(CH2)qSO2R13, —(CH2)qOR14,




embedded image


R3 is selected from a group consisting of C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, optionally substituted aryl,




embedded image


R4 is an optionally substituted aryl;


R5a and R5b are each independently optionally substituted aryl;


R6 is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R7 is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R8a is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R8b is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R9a is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R9b is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R10 is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R11 is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R12a is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R12b is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R13 is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R14 is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


n is 1, 2, or 3;


m is 1 or 2;


and q is 1, 2, or 3;


The present invention further relates to compositions comprising: an effective amount of one or more compounds according to the present invention and an excipient.


The present invention also relates to a method for treating or preventing diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, including, for example, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction said method comprising administering to a subject an effective amount of a compound or composition according to the present invention.


The present invention yet further relates to a method for treating or preventing diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, including, for example, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar, disorder inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.


The present invention also relates to a method for treating or preventing diseases or conditions associated with circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction and diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity. Said methods comprise administering to a subject an effective amount of a compound or composition according to the present invention.


The present invention yet further relates to a method for treating or preventing diseases or conditions associated with circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, and bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, alcohol addiction and diseases that involve dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.


The present invention also relates to a method for treating or preventing diseases or conditions associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. Said methods comprise administering to a subject an effective amount of a compound or composition according to the present invention.


The present invention yet further relates to a method for treating or preventing diseases or conditions associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, wherein said method comprises administering to a subject a composition comprising an effective amount of one or more compounds according to the present invention and an excipient.


The present invention further relates to a process for preparing the 5-hydroxytryptamine receptor 7 activity modulators of the present invention.


These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (° C.) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.







DETAILED DESCRIPTION OF THE INVENTION

There is evidence that suggests a role for the 5-HT7 receptor in a number of medical disorders. 5-HT7 receptor activity modulators are likely to have a beneficial effect on patients suffering from these disorders. The disorders in which 5-HT7 dysregulation plays a role and modulation of 5-HT7 receptor activity by a therapeutic agent may be a viable approach to therapeutic relief include, but are not limited to, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine (Vanhoenacker, P. et al. Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder (WO20100197700) attention deficit/hyperactivity disorder (ADHD) (WO20100069390), anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), intestinal inflammation (WO 2012058769, Khan, W. I., et. al. Journal of Immunology, 2013, 190, 4795-4804), epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9).


There is a long felt need for new 5-HT7 modulators that will provide therapeutic relief from patients suffering from diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The invention addresses the need to identify novel 5-HT7 modulators capable of treating disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The present invention addresses the need to develop new therapeutic agents for the treatment and prevention of circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation epilepsy, seizure disorders, drug addiction, and alcohol addiction.


The 5-hydroxytryptamine receptor 7 activity modulators of the present invention are capable of treating and preventing diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, for example circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction. It has been discovered that the 5-hydroxytryptamine receptor 7 play a role in a number of medical disorders, and therefore, 5-HT7 receptor activity modulators are likely to have a beneficial effect on patients suffering from these disorders. The disorders in which 5-HT7 dysregulation plays a role and modulation of 5-HT7 receptor activity by a therapeutic agent may be a viable approach to therapeutic relief include, but are not limited to, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine (Vanhoenacker, P. et. al. Trends in Pharmacological Sciences, 2000, 21, 2, 70-77), neuropathic pain, peripheral pain, allodynia (EP1875899), thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder (WO20100197700) attention deficit/hyperactivity disorder (ADHD) (WO20100069390), anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder (WO20040229874), inflammatory bowel disease (IBD), intestinal inflammation (WO 2012058769) epilepsy, seizure disorders (Epilepsy Research (2007) 75, 39), drug addiction, and alcohol addiction (Hauser, S. R. et. al. Frontiers in Neuroscience, 2015, 8, 1-9).


Without wishing to be limited by theory, it is believed that 5-hydroxytryptamine receptor 7 receptor activity modulators of the present invention can ameliorate, abate, otherwise cause to be controlled, diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity. The diseases include, but are not limited to circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, bipolar disorder, inflammatory bowel disease (IBD), intestinal inflammation, epilepsy, seizure disorders, drug addiction, and alcohol addiction.


Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes are described as having, including, or comprising specific process steps, it is contemplated that compositions of the present teachings also consist essentially of, or consist of, the recited components, and that the processes of the present teachings also consist essentially of, or consist of, the recited processing steps.


In the application, where an element or component is said to be included in and/or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components and can be selected from a group consisting of two or more of the recited elements or components.


The use of the singular herein includes the plural (and vice versa) unless specifically stated otherwise. In addition, where the use of the term “about” is before a quantitative value, the present teachings also include the specific quantitative value itself, unless specifically stated otherwise.


It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present teachings remain operable. Moreover, two or more steps or actions can be conducted simultaneously.


As used herein, the term “halogen” shall mean chlorine, bromine, fluorine and iodine.


As used herein, unless otherwise noted, “alkyl” and/or “aliphatic” whether used alone or as part of a substituent group refers to straight and branched carbon chains having 1 to 20 carbon atoms or any number within this range, for example 1 to 6 carbon atoms or 1 to 4 carbon atoms. Designated numbers of carbon atoms (e.g. C1-6) shall refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, and the like. Alkyl groups can be optionally substituted. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, 3-carboxypropyl, and the like. In substituent groups with multiple alkyl groups such as (C1-6alkyl)2amino, the alkyl groups may be the same or different.


As used herein, the terms “alkenyl” and “alkynyl” groups, whether used alone or as part of a substituent group, refer to straight and branched carbon chains having 2 or more carbon atoms, preferably 2 to 20, wherein an alkenyl chain has at least one double bond in the chain and an alkynyl chain has at least one triple bond in the chain. Alkenyl and alkynyl groups can be optionally substituted. Nonlimiting examples of alkenyl groups include ethenyl, 3-propenyl, 1-propenyl (also 2-methylethenyl), isopropenyl (also 2-methylethen-2-yl), buten-4-yl, and the like. Nonlimiting examples of substituted alkenyl groups include 2-chloroethenyl (also 2-chlorovinyl), 4-hydroxybuten-1-yl, 7-hydroxy-7-methyloct-4-en-2-yl, 7-hydroxy-7-methyloct-3,5-dien-2-yl, and the like. Nonlimiting examples of alkynyl groups include ethynyl, prop-2-ynyl (also propargyl), propyn-1-yl, and 2-methyl-hex-4-yn-1-yl. Nonlimiting examples of substituted alkynyl groups include, 5-hydroxy-5-methylhex-3-ynyl, 6-hydroxy-6-methylhept-3-yn-2-yl, 5-hydroxy-5-ethylhept-3-ynyl, and the like.


As used herein, “cycloalkyl,” whether used alone or as part of another group, refers to a non-aromatic carbon-containing ring including cyclized alkyl, alkenyl, and alkynyl groups, e.g., having from 3 to 14 ring carbon atoms, preferably from 3 to 7 or 3 to 6 ring carbon atoms, or even 3 to 4 ring carbon atoms, and optionally containing one or more (e.g., 1, 2, or 3) double or triple bond. Cycloalkyl groups can be monocyclic (e.g., cyclohexyl) or polycyclic (e.g., containing fused, bridged, and/or spiro ring systems), wherein the carbon atoms are located inside or outside of the ring system. Any suitable ring position of the cycloalkyl group can be covalently linked to the defined chemical structure. Cycloalkyl rings can be optionally substituted. Nonlimiting examples of cycloalkyl groups include: cyclopropyl, 2-methyl-cyclopropyl, cyclopropenyl, cyclobutyl, 2,3-dihydroxycyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclopentadienyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctanyl, decalinyl, 2,5-dimethylcyclopentyl, 3,5-dichlorocyclohexyl, 4-hydroxycyclohexyl, 3,3,5-trimethylcyclohex-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazulenyl; bicyclo[6.2.0]decanyl, decahydronaphthalenyl, and dodecahydro-1H-fluorenyl. The term “cycloalkyl” also includes carbocyclic rings which are bicyclic hydrocarbon rings, non-limiting examples of which include, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.


“Haloalkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen. Haloalkyl groups include perhaloalkyl groups, wherein all hydrogens of an alkyl group have been replaced with halogens (e.g., —CF3, —CF2CF3). Haloalkyl groups can optionally be substituted with one or more substituents in addition to halogen. Examples of haloalkyl groups include, but are not limited to, fluoromethyl, dichloroethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl groups.


The term “alkoxy” refers to the group —O-alkyl, wherein the alkyl group is as defined above. Alkoxy groups optionally may be substituted. The term C3-C6 cyclic alkoxy refers to a ring containing 3 to 6 carbon atoms and at least one oxygen atom (e.g., tetrahydrofuran, tetrahydro-2H-pyran). C3-C6 cyclic alkoxy groups optionally may be substituted.


The term “haloalkoxy” refers to the group —O-haloalkyl, wherein the haloalkyl group is as defined above. Examples of haloalkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, and pentafluoroethoxyl.


The term “aryl,” wherein used alone or as part of another group, is defined herein as an unsaturated, aromatic monocyclic ring of 6 carbon members or to an unsaturated, aromatic polycyclic ring of from 10 to 14 carbon members. Aryl rings can be, for example, phenyl or naphthyl ring each optionally substituted with one or more moieties capable of replacing one or more hydrogen atoms. Non-limiting examples of aryl groups include: phenyl, naphthylen-1-yl, naphthylen-2-yl, 4-fluorophenyl, 2-hydroxyphenyl, 3-methylphenyl, 2-amino-4-fluorophenyl, 2-(N,N-diethylamino)phenyl, 2-cyanophenyl, 2,6-di-tert-butylphenyl, 3-methoxyphenyl, 8-hydroxynaphthylen-2-yl 4,5-dimethoxynaphthylen-1-yl, and 6-cyano-naphthylen-1-yl. Aryl groups also include, for example, phenyl or naphthyl rings fused with one or more saturated or partially saturated carbon rings (e.g., bicyclo[4.2.0]octa-1,3,5-trienyl, indanyl), which can be substituted at one or more carbon atoms of the aromatic and/or saturated or partially saturated rings.


The term “arylalkyl” or “aralkyl” refers to the group -alkyl-aryl, where the alkyl and aryl groups are as defined herein. Aralkyl groups of the present invention are optionally substituted. Examples of arylalkyl groups include, for example, benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, fluorenylmethyl and the like.


The terms “heterocyclic” and/or “heterocycle” and/or “heterocylyl,” whether used alone or as part of another group, are defined herein as one or more ring having from 3 to 20 atoms wherein at least one atom in at least one ring is a heteroatom selected from nitrogen (N), oxygen (O), or sulfur (S), and wherein further the ring that includes the heteroatom is non-aromatic. In heterocycle groups that include 2 or more fused rings, the non-heteroatom bearing ring may be aryl (e.g., indolinyl, tetrahydroquinolinyl, chromanyl). Exemplary heterocycle groups have from 3 to 14 ring atoms of which from 1 to 5 are heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heterocycle group can be oxidized. Heterocycle groups can be optionally substituted.


Non-limiting examples of heterocyclic units having a single ring include: diazirinyl, aziridinyl, urazolyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolidinyl, isothiazolyl, isothiazolinyl oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl (valerolactam), 2,3,4,5-tetrahydro-1H-azepinyl, 2,3-dihydro-1H-indole, and 1,2,3,4-tetrahydro-quinoline. Non-limiting examples of heterocyclic units having 2 or more rings include: hexahydro-1H-pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl, chromanyl, isochromanyl, indolinyl, isoindolinyl, and decahydro-1H-cycloocta[b]pyrrolyl.


The term “heteroaryl,” whether used alone or as part of another group, is defined herein as one or more rings having from 5 to 20 atoms wherein at least one atom in at least one ring is a heteroatom chosen from nitrogen (N), oxygen (O), or sulfur (S), and wherein further at least one of the rings that includes a heteroatom is aromatic. In heteroaryl groups that include 2 or more fused rings, the non-heteroatom bearing ring may be a carbocycle (e.g., 6,7-Dihydro-5H-cyclopentapyrimidine) or aryl (e.g., benzofuranyl, benzothiophenyl, indolyl). Exemplary heteroaryl groups have from 5 to 14 ring atoms and contain from 1 to 5 ring heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). One or more N or S atoms in a heteroaryl group can be oxidized. Heteroaryl groups can be substituted. Non-limiting examples of heteroaryl rings containing a single ring include: 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, furanyl, thiopheneyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl. Non-limiting examples of heteroaryl rings containing 2 or more fused rings include: benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, cinnolinyl, naphthyridinyl, phenanthridinyl, 7H-purinyl, 9H-purinyl, 6-amino-9H-purinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 2-phenylbenzo[d]thiazolyl, 1H-indolyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, 5-methylquinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, 1H-benzo[d]imidazol-2(3H)-onyl, 1H-benzo[d]imidazolyl, and isoquinolinyl.


One non-limiting example of a heteroaryl group as described above is C1-C5 heteroaryl, which has 1 to 5 carbon ring atoms and at least one additional ring atom that is a heteroatom (preferably 1 to 4 additional ring atoms that are heteroatoms) independently selected from nitrogen (N), oxygen (O), or sulfur (S). Examples of C1-C5 heteroaryl include, but are not limited to, triazinyl, thiazol-2-yl, thiazol-4-yl, imidazol-1-yl, 1H-imidazol-2-yl, 1H-imidazol-4-yl, isoxazolin-5-yl, furan-2-yl, furan-3-yl, thiophen-2-yl, thiophen-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl.


Unless otherwise noted, when two substituents are taken together to form a ring having a specified number of ring atoms (e.g., R2 and R3 taken together with the nitrogen (N) to which they are attached to form a ring having from 3 to 7 ring members), the ring can have carbon atoms and optionally one or more (e.g., 1 to 3) additional heteroatoms independently selected from nitrogen (N), oxygen (O), or sulfur (S). The ring can be saturated or partially saturated and can be optionally substituted.


For the purposed of the present invention fused ring units, as well as spirocyclic rings, bicyclic rings and the like, which comprise a single heteroatom will be considered to belong to the cyclic family corresponding to the heteroatom containing ring. For example, 1,2,3,4-tetrahydroquinoline having the formula:




embedded image


is, for the purposes of the present invention, considered a heterocyclic unit. 6,7-Dihydro-5H-cyclopentapyrimidine having the formula:




embedded image


is, for the purposes of the present invention, considered a heteroaryl unit. When a fused ring unit contains heteroatoms in both a saturated and an aryl ring, the aryl ring will predominate and determine the type of category to which the ring is assigned. For example, 1,2,3,4-tetrahydro-[1,8]naphthyridine having the formula:




embedded image


is, for the purposes of the present invention, considered a heteroaryl unit.


Whenever a term or either of their prefix roots appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, whenever the term “alkyl” or “aryl” or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for “alkyl” and “aryl.”


The term “substituted” is used throughout the specification. The term “substituted” is defined herein as a moiety, whether acyclic or cyclic, which has one or more hydrogen atoms replaced by a substituent or several (e.g., 1 to 10) substituents as defined herein below. The substituents are capable of replacing one or two hydrogen atoms of a single moiety at a time. In addition, these substituents can replace two hydrogen atoms on two adjacent carbons to form said substituent, new moiety or unit. For example, a substituted unit that requires a single hydrogen atom replacement includes halogen, hydroxyl, and the like. A two hydrogen atom replacement includes carbonyl, oximino, and the like. A two hydrogen atom replacement from adjacent carbon atoms includes epoxy, and the like. The term “substituted” is used throughout the present specification to indicate that a moiety can have one or more of the hydrogen atoms replaced by a substituent. When a moiety is described as “substituted” any number of the hydrogen atoms may be replaced. For example, difluoromethyl is a substituted C1 alkyl; trifluoromethyl is a substituted C1 alkyl; 4-hydroxyphenyl is a substituted aromatic ring; (N,N-dimethyl-5-amino)octanyl is a substituted C8 alkyl; 3-guanidinopropyl is a substituted C3 alkyl; and 2-carboxypyridinyl is a substituted heteroaryl.


The variable groups defined herein, e.g., alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryloxy, aryl, heterocycle and heteroaryl groups defined herein, whether used alone or as part of another group, can be optionally substituted. Optionally substituted groups will be so indicated.


The following are non-limiting examples of substituents which can substitute for hydrogen atoms on a moiety: halogen (chlorine (Cl), bromine (Br), fluorine (F) and iodine(I)), —CN, —NO2, oxo (═O), —OR15, —SR15, —N(R15)2, —NR15C(O)R15, —SO2R15, —SO2OR15, —SO2N(R15)2, —C(O)R15, —C(O)OR15, —C(O)N(R15)2, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C2-8 alkenyl, C2-8 alkynyl, C3-14 cycloalkyl, aryl, heterocycle, or heteroaryl, wherein each of the alkyl, haloalkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heterocycle, and heteroaryl groups is optionally substituted with 1-10 (e.g., 1-6 or 1-4) groups selected independently from halogen, —CN, —NO2, oxo, and R15; wherein R15, at each occurrence, independently is hydrogen, —OR16, —SR16, —C(O)R16, —C(O)OR16, —C(O)N(R16)2, —SO2R16, —S(O)2OR16, —N(R16)2, —NR16C(O)R16, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, cycloalkyl (e.g., C3-6 cycloalkyl), aryl, heterocycle, or heteroaryl, or two R15 units taken together with the atom(s) to which they are bound form an optionally substituted carbocycle or heterocycle wherein said carbocycle or heterocycle has 3 to 7 ring atoms; wherein R16, at each occurrence, independently is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-8 alkenyl, C2-8 alkynyl, cycloalkyl (e.g., C3-6 cycloalkyl), aryl, heterocycle, or heteroaryl, or two R16 units taken together with the atom(s) to which they are bound form an optionally substituted carbocycle or heterocycle wherein said carbocycle or heterocycle preferably has 3 to 7 ring atoms.


In some embodiments, the substituents are selected from

    • i) —OR17; for example, —OH, —OCH3, —OCH2CH3, —OCH2CH2CH3;
    • ii) —C(O)R17; for example, —COCH3, —COCH2CH3, —COCH2CH2CH3;
    • iii) —C(O)OR17; for example, —CO2CH3, —CO2CH2CH3, —CO2CH2CH2CH3;
    • iv) —C(O)N(R17)2; for example, —CONH2, —CONHCH3, —CON(CH3)2;
    • v) —N(R17)2; for example, —NH2, —NHCH3, —N(CH3)2, —NH(CH2CH3);
    • vi) halogen: —F, —Cl, —Br, and —I;
    • vii) —CHeXg; wherein X is halogen, m is from 0 to 2, e+g=3; for example, —CH2F, —CHF2, —CF3, —CCl3, or —CBr3;
    • viii) —SO2R17; for example, —SO2H; —SO2CH3; —SO2C6H5;
    • ix) C1-C6 linear, branched, or cyclic alkyl;
    • x) Cyano
    • xi) Nitro;
    • xii) N(R17)C(O)R7;
    • xiii) Oxo (═O);
    • xiv) Heterocycle; and
    • xv) Heteroaryl.


      wherein each R17 is independently hydrogen, optionally substituted C1-C6 linear or branched alkyl (e.g., optionally substituted C1-C4 linear or branched alkyl), or optionally substituted C3-C6 cycloalkyl (e.g optionally substituted C3-C4 cycloalkyl); or two R17 units can be taken together to form a ring comprising 3-7 ring atoms. In certain aspects, each R17 is independently hydrogen, C1-C6 linear or branched alkyl optionally substituted with halogen or C3-C6 cycloalkyl or C3-C6 cycloalkyl.


At various places in the present specification, substituents of compounds are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges. For example, the term “C1-6 alkyl” is specifically intended to individually disclose C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6, alkyl.


For the purposes of the present invention the terms “compound,” “analog,” and “composition of matter” stand equally well for the 5-hydroxytryptamine receptor 7 activity modulators described herein, including all enantiomeric forms, diastereomeric forms, salts, and the like, and the terms “compound,” “analog,” and “composition of matter” are used interchangeably throughout the present specification.


Compounds described herein can contain an asymmetric atom (also referred as a chiral center), and some of the compounds can contain one or more asymmetric atoms or centers, which can thus give rise to optical isomers (enantiomers) and diastereomers. The present teachings and compounds disclosed herein include such enantiomers and diastereomers, as well as the racemic and resolved, enantiomerically pure R and S stereoisomers, as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof. Optical isomers can be obtained in pure form by standard procedures known to those skilled in the art, which include, but are not limited to, diastereomeric salt formation, kinetic resolution, and asymmetric synthesis. The present teachings also encompass cis and trans isomers of compounds containing alkenyl moieties (e.g., alkenes and imines). It is also understood that the present teachings encompass all possible regioisomers, and mixtures thereof, which can be obtained in pure form by standard separation procedures known to those skilled in the art, and include, but are not limited to, column chromatography, thin-layer chromatography, and high-performance liquid chromatography.


Pharmaceutically acceptable salts of compounds of the present teachings, which can have an acidic moiety, can be formed using organic and inorganic bases. Both mono and polyanionic salts are contemplated, depending on the number of acidic hydrogens available for deprotonation. Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, or magnesium salts; ammonia salts and organic amine salts, such as those formed with morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine (e.g., ethyl-tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropylamine), or a mono-, di-, or trihydroxy lower alkylamine (e.g., mono-, di- or triethanolamine). Specific non-limiting examples of inorganic bases include NaHCO3, Na2CO3, KHCO3, K2CO3, Cs2CO3, LiOH, NaOH, KOH, NaH2PO4, Na2HPO4, and Na3PO4. Internal salts also can be formed. Similarly, when a compound disclosed herein contains a basic moiety, salts can be formed using organic and inorganic acids. For example, salts can be formed from the following acids: acetic, propionic, lactic, benzenesulfonic, benzoic, camphorsulfonic, citric, tartaric, succinic, dichloroacetic, ethenesulfonic, formic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, malonic, mandelic, methanesulfonic, mucic, napthalenesulfonic, nitric, oxalic, pamoic, pantothenic, phosphoric, phthalic, propionic, succinic, sulfuric, tartaric, toluenesulfonic, and camphorsulfonic as well as other known pharmaceutically acceptable acids.


When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence (e.g., in N(R9)2, each R9 may be the same or different than the other). Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.


The terms “treat” and “treating” and “treatment” as used herein, refer to partially or completely alleviating, inhibiting, ameliorating and/or relieving a condition from which a patient is suspected to suffer.


As used herein, “therapeutically effective” and “effective dose” refer to a substance or an amount that elicits a desirable biological activity or effect.


Except when noted, the terms “subject” or “patient” are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats, and mice, and other animals. Accordingly, the term “subject” or “patient” as used herein means any mammalian patient or subject to which the compounds of the invention can be administered. In an exemplary embodiment of the present invention, to identify subject patients for treatment according to the methods of the invention, accepted screening methods are employed to determine risk factors associated with a targeted or suspected disease or condition or to determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine risk factors that may be associated with the targeted or suspected disease or condition. These and other routine methods allow the clinician to select patients in need of therapy using the methods and compounds of the present invention.


The 5-Hydroxytryptamine Receptor 7 Activity Modulators


The 5-hydroxytryptamine receptor 7 activity modulators of the present invention include all enantiomeric and diastereomeric forms alts thereof having the formula




embedded image


Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:


A is selected from a group consisting of




embedded image


X is selected from the group consisting of O, S, SO, SO2, NR;


n1 is 0, 1, 2;


n2 is 0, 1, 2;


R is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl,




embedded image


COR2, CO2R2a, CONR2bR2c, SO2NR2bR2c, and SO2R2d;


R1a, R1b, R1c, R1d, and R1e are at each occurrence independently selected from the group consisting of H, OH, NO2, halogen, CN, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, C1-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, C1-6 linear haloalkyl, C3-7 branched haloalkyl, C1-6 linear haloalkoxy, —S(C1-6 linear alkyl), S(C3-7 branched alkyl), —S(C3-7 cycloalkyl), COR6, CO2R7, CONR8aR8b, SO2NR8aR8b, NR9aR9b, NR9aCOR10, NR9aSO2R11, and NR9aSO2NR12aR12b;


R2 is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2a is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2b is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2c is selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R2d is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, C1-6 linear haloalkyl, C3-7 branched haloalkyl, —(CH2)qCN, —(CH2)qSO2R13, —(CH2)qOR14,




embedded image


R3 is selected from a group consisting of C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, optionally substituted aryl,




embedded image


R4 is an optionally substituted aryl;


R5a and R5b are each independently optionally substituted aryl;


R6 is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R7 is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R8a is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R8b is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R9a is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R9b is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R10 is at each occurrence independently selected from the group consisting of H, C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R11 is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R12a is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R12b is at each occurrence independently selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R13 is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


R14 is selected from the group consisting of C1-6 linear alkyl, C3-7 branched alkyl, and C3-7 cycloalkyl;


n is 1, 2, or 3;


m is 1 or 2;


and q is 1, 2, or 3;


The embodiments of the present invention include compounds having formula (II):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (III):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (IV):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (V):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (VI):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (VII):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (VIII):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (IX):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (X):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (XI):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (XII):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (XIII):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (XIV):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (XV):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


The embodiments of the present invention include compounds having formula (XVI):




embedded image


Including hydrates, solvates, enantiomers, diastereomers, pharmaceutically acceptable salts, and complexes thereof.


In some embodiments A is




embedded image


In some embodiments A is




embedded image


In some embodiments A is,




embedded image


In some embodiments A is




embedded image


In some embodiments A is




embedded image


In some embodiments X is O.


In some embodiments X is S.


In some embodiments X is SO.


In some embodiments X is SO2.


In some embodiments X is NR


In some embodiments n1 is 0.


In some embodiments n1 is 1.


In some embodiments n1 is 2.


In some embodiments n2 is 0.


In some embodiments n2 is 1.


In some embodiments n2 is 2.


In some embodiments R is H.


In some embodiments R is C1-6 linear alkyl.


In some embodiments R is C3-7 branched alkyl.


In some embodiments R is C3-7 cycloalkyl.


In some embodiments R is,




embedded image


In some embodiments R is COR2.


In some embodiments R is CO2R2a.


In some embodiments R is CONR2bR2c.


In some embodiments R is SO2NR2bR2c.


In some embodiments R is SO2R2d.


In some embodiments R1a is H.


In some embodiments R1a is OH.


In some embodiments R1a is NO2.


In some embodiments R1a is halogen.


In some embodiments R1a is CN.


In some embodiments R1a is C1-6 linear alkyl.


In some embodiments R1a is C3-7 branched alkyl.


In some embodiments R1a is C3-7 cycloalkyl.


In some embodiments R1a is C1-6 linear alkoxy.


In some embodiments R1a is C3-7 branched alkoxy.


In some embodiments R1a is C3-7 cycloalkoxy.


In some embodiments R1a is C1-6 linear haloalkyl.


In some embodiments R1a is C3-7 branched haloalkyl.


In some embodiments R1a is C1-6 linear haloalkoxy.


In some embodiments R1a is —S(C1-6 linear alkyl).


In some embodiments R1a is S(C3-7 branched alkyl).


In some embodiments R1a is —S(C3-7 cycloalkyl).


In some embodiments R1a is COR6.


In some embodiments R1a is CO2R7.


In some embodiments R1a is CONR8aR8b.


In some embodiments R1a is SO2NR8aR8b.


In some embodiments R1a is NR9aR9b.


In some embodiments R1a is NR9aCOR10.


In some embodiments R1a is NR9aSO2R11.


In some embodiments R1a is NR9aSO2NR12aR12b.


In some embodiments R1b is H.


In some embodiments R1b is OH.


In some embodiments R1b is NO2.


In some embodiments R1b is halogen.


In some embodiments R1b is CN.


In some embodiments R1b is C1-6 linear alkyl.


In some embodiments R1b is C3-7 branched alkyl.


In some embodiments R1b is C3-7 cycloalkyl.


In some embodiments R1b is C1-6 linear alkoxy.


In some embodiments R1b is C3-7 branched alkoxy.


In some embodiments R1b is C3-7 cycloalkoxy.


In some embodiments R1b is C1-6 linear haloalkyl.


In some embodiments R1b is C3-7 branched haloalkyl.


In some embodiments R1b is C1-6 linear haloalkoxy.


In some embodiments R1b is —S(C1-6 linear alkyl).


In some embodiments R1b is S(C3-7 branched alkyl).


In some embodiments R1b is —S(C3-7 cycloalkyl).


In some embodiments R1b is COR6.


In some embodiments R1b is CO2R7.


In some embodiments R1b is CONR8aR8b.


In some embodiments R1b is SO2NR8aR8b.


In some embodiments R1b is NR9aR9b.


In some embodiments R1b is NR9aCOR10.


In some embodiments R1b is NR9aSO2R11.


In some embodiments R1b is NR9aSO2NR12aR12b.


In some embodiments R1c is H.


In some embodiments R1c is OH.


In some embodiments R1c is NO2.


In some embodiments R1c is halogen.


In some embodiments R1c is CN.


In some embodiments R1c is C1-6 linear alkyl.


In some embodiments R1c is C3-7 branched alkyl.


In some embodiments R1c is C3-7 cycloalkyl.


In some embodiments R1c is C1-6 linear alkoxy.


In some embodiments R1c is C3-7 branched alkoxy.


In some embodiments R1c is C3-7 cycloalkoxy.


In some embodiments R1c is CJ-6 linear haloalkyl.


In some embodiments R1c is C3-7 branched haloalkyl.


In some embodiments R1c is C1-6 linear haloalkoxy.


In some embodiments R1c is —S(C1-6 linear alkyl).


In some embodiments R1c is S(C3-7 branched alkyl).


In some embodiments R1c is —S(C3-7 cycloalkyl).


In some embodiments R1c is COR6.


In some embodiments R1c is CO2R7.


In some embodiments R1c is CONR8aR8b.


In some embodiments R1c is SO2NR8aR8b.


In some embodiments R1c is NR9aR9b.


In some embodiments R1c is NR9aCOR10.


In some embodiments R1c is NR9aSO2R11.


In some embodiments R1c is NR9aSO2NR12aR12b.


In some embodiments R1d is H.


In some embodiments R1d is OH.


In some embodiments R1d is NO2.


In some embodiments R1d is halogen.


In some embodiments R1d is CN.


In some embodiments R1d is C1-6 linear alkyl.


In some embodiments R1d is C3-7 branched alkyl.


In some embodiments R1d is C3-7 cycloalkyl.


In some embodiments R1d is C1-6 linear alkoxy.


In some embodiments R1d is C3-7 branched alkoxy.


In some embodiments R1d is C3-7 cycloalkoxy.


In some embodiments R1d is C1-6 linear haloalkyl.


In some embodiments R1d is C3-7 branched haloalkyl.


In some embodiments R1d is C1-6 linear haloalkoxy.


In some embodiments R1d is —S(C1-6 linear alkyl).


In some embodiments R1d is S(C3-7 branched alkyl).


In some embodiments R1d is —S(C3-7 cycloalkyl).


In some embodiments R1d is COR6.


In some embodiments R1d is CO2R7.


In some embodiments R1d is CONR8aR8b.


In some embodiments R1d is SO2NR8aR8b.


In some embodiments R1d is NR9aR9b.


In some embodiments R1d is NR9aCOR10.


In some embodiments R1d is NR9aSO2R11.


In some embodiments R1d is NR9aSO2NR12aR12b.


In some embodiments R1e is H.


In some embodiments R1e is OH.


In some embodiments R1e is NO2.


In some embodiments R1e is halogen.


In some embodiments R1e is CN.


In some embodiments R1e is C1-6 linear alkyl.


In some embodiments R1e is C3-7 branched alkyl.


In some embodiments R1e is C3-7 cycloalkyl.


In some embodiments R1e is C1-6 linear alkoxy.


In some embodiments R1e is C3-7 branched alkoxy.


In some embodiments R1e is C3-7 cycloalkoxy.


In some embodiments R1e is C1-6 linear haloalkyl.


In some embodiments R1e is C3-7 branched haloalkyl.


In some embodiments R1e is C1-6 linear haloalkoxy.


In some embodiments R1e is —S(C1-6 linear alkyl).


In some embodiments R1e is S(C3-7 branched alkyl).


In some embodiments R1e is —S(C3-7 cycloalkyl).


In some embodiments R1e is COR6.


In some embodiments R1e is CO2R7.


In some embodiments R1e is CONR8aR8b.


In some embodiments R1e is SO2NR8aR8b.


In some embodiments R1e is NR9aR9b.


In some embodiments R1e is NR9aCOR10.


In some embodiments R1e is NR9aSO2R11.


In some embodiments R1e is NR9aSO2NR12aR12b.


In some embodiments R2 is H.


In some embodiments R2 is C1-6 linear alkyl.


In some embodiments R2 is, C3-7 branched alkyl.


In some embodiments R2 is C3-7 cycloalkyl.


In some embodiments R2a is C1-6 linear alkyl.


In some embodiments R2a is C3-7 branched alkyl.


In some embodiments R2a is C3-7 cycloalkyl.


In some embodiments R2b is H.


In some embodiments R2b is C1-6 linear alkyl.


In some embodiments R2b is, C3-7 branched alkyl.


In some embodiments R2b is C3-7 cycloalkyl.


In some embodiments R2c is H.


In some embodiments R2c is C1-6 linear alkyl.


In some embodiments R2c is, C3-7 branched alkyl.


In some embodiments R2c is C3-7 cycloalkyl.


In some embodiments R2d is C1-6 linear alkyl.


In some embodiments R2d is C3-7 branched alkyl.


In some embodiments R2d is C3-7 cycloalkyl.


In some embodiments R2d is C1-6 linear haloalkyl.


In some embodiments R2d is C3-7 branched haloalkyl.


In some embodiments R2d is —(CH2)qCN.


In some embodiments R2d is —(CH2)qSO2R13.


In some embodiments R2d is —(CH2)qOR14.


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R2d is




embedded image


In some embodiments R3 is C1-6 linear alkyl.


In some embodiments R3 is C3-7 branched alkyl.


In some embodiments R3 is C3-7 cycloalkyl.


In some embodiments R3 is optionally substituted aryl.


In some embodiments R3 is phenyl.


In some embodiments R3 is an optionally aryl substituted with 1 to 4 units independently selected from the group consisting of OH, NO2, halogen, CN, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, C1-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, C1-6 linear haloalkyl, C3-7 branched haloalkyl, C1-6 linear haloalkoxy, —S(C1-6 linear alkyl), S(C3-7 branched alkyl), —S(C3-7 cycloalkyl), COR6, CO2R7, CONR8aR8b, SO2NR8aR8b, NR9aR9b, NR9aCOR10, NR9aSO2R11, NR9aSO2NR12aR12b,




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R3 is




embedded image


In some embodiments R4 is optionally substituted aryl.


In some embodiments R4 is an optionally substituted aryl substituted with 1 to 4 units independently selected from the group consisting of OH, NO2, halogen, CN, C1-6 linear alkyl, C3-7 branched alkyl, C3-7 cycloalkyl, C1-6 linear alkoxy, C3-7 branched alkoxy, C3-7 cycloalkoxy, C1-6 linear haloalkyl, C3-7 branched haloalkyl, C1-6 linear haloalkoxy, —S(C1-6 linear alkyl), S(C3-7 branched alkyl), —S(C3-7 cycloalkyl), COR6, CO2R7, CONR8aR8b, SO2NR8aR8b, NR9aR9b, NR9aCOR10, NR9aSO2R11, NR9aSO2NR12aR12b,




embedded image


In some embodiments R5 is optionally substituted aryl.


In some embodiments R5 is optionally substituted aryl.


In some embodiments R6 is H.


In some embodiments R6 is C1-6 linear alkyl.


In some embodiments R6 is C3-7 branched alkyl.


In some embodiments R6 is C3-7 cycloalkyl.


In some embodiments R7 is C1-6 linear alkyl.


In some embodiments R7 is C3-7 branched alkyl.


In some embodiments R7 is C3-7 cycloalkyl.


In some embodiments R8a is H.


In some embodiments R8a is C1-6 linear alkyl.


In some embodiments R8a is C3-7 branched alkyl.


In some embodiments R8a is C3-7 cycloalkyl.


In some embodiments R8b is H.


In some embodiments R8b is C1-6 linear alkyl.


In some embodiments R8b is C3-7 branched alkyl.


In some embodiments R8b is C3-7 cycloalkyl.


In some embodiments R9a is H.


In some embodiments R9a is C1-6 linear alkyl.


In some embodiments R9a is C3-7 branched alkyl.


In some embodiments R9a is C3-7 cycloalkyl.


In some embodiments R9b is H.


In some embodiments R9b is C1-6 linear alkyl.


In some embodiments R9b is C3-7 branched alkyl.


In some embodiments R9b is C3-7 cycloalkyl.


In some embodiments R10 is H.


In some embodiments R10 is C1-6 linear alkyl.


In some embodiments R10 is C3-7 branched alkyl.


In some embodiments R10 is C3-7 cycloalkyl.


In some embodiments R11 is C1-6 linear alkyl.


In some embodiments R11 is C3-7 branched alkyl.


In some embodiments R11 is C3-7 cycloalkyl.


In some embodiments R10 is C1-6 linear alkyl.


In some embodiments R10 is C3-7 branched alkyl.


In some embodiments R10 is C3-7 cycloalkyl.


In some embodiments R12a is C1-6 linear alkyl.


In some embodiments R12a is C3-7 branched alkyl.


In some embodiments R12a is C3-7 cycloalkyl.


In some embodiments R12b is C1-6 linear alkyl.


In some embodiments R12b is C3-7 branched alkyl.


In some embodiments R12b is C3-7 cycloalkyl.


In some embodiments R13 is C1-6 linear alkyl.


In some embodiments R13 is C3-7 branched alkyl.


In some embodiments R13 is C3-7 cycloalkyl.


In some embodiments R14 is C1-6 linear alkyl.


In some embodiments R14 is C3-7 branched alkyl.


In some embodiments R14 is C3-7 cycloalkyl.


In some embodiments n is 1.


In some embodiments n is 2.


In some embodiments n is 3.


In some embodiments m is 1.


In some embodiments m is 2.


In some embodiments q is 1.


In some embodiments q is 2.


In some embodiments q is 3.


Exemplary embodiments include compounds having the formula (XVII)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 1.














TABLE 1







Entry
n
R
R3





















1
1
H
Phenyl



2
2
H
Phenyl



3
3
H
Phenyl



4
1
Me
Phenyl



5
2
Me
Phenyl



6
3
Me
Phenyl



7
1
CH2Ph
Phenyl



8
2
CH2Ph
Phenyl



9
3
CH2Ph
Phenyl



10
1
COMe
Phenyl



11
2
COMe
Phenyl



12
3
COMe
Phenyl



13
1
CO2Me
Phenyl



14
2
CO2Me
Phenyl



15
3
CO2Me
Phenyl



16
1
CO2tBu
Phenyl



17
2
CO2tBu
Phenyl



18
3
CO2tBu
Phenyl



19
1
CONHMe
Phenyl



20
2
CONHMe
Phenyl



21
3
CONHMe
Phenyl



22
1
SO2Me
Phenyl



23
2
SO2Me
Phenyl



24
3
SO2Me
Phenyl



25
1
SO2NH2
Phenyl



26
2
SO2NH2
Phenyl



27
3
SO2NH2
Phenyl



28
1
H
3-OH-Phenyl



29
2
H
3-OH-Phenyl



30
3
H
3-OH-Phenyl



31
1
Me
3-OH-Phenyl



32
2
Me
3-OH-Phenyl



33
3
Me
3-OH-Phenyl



34
1
CH2Ph
3-OH-Phenyl



35
2
CH2Ph
3-OH-Phenyl



36
3
CH2Ph
3-OH-Phenyl



37
1
COMe
3-OH-Phenyl



38
2
COMe
3-OH-Phenyl



39
3
COMe
3-OH-Phenyl



40
1
CO2Me
3-OH-Phenyl



41
2
CO2Me
3-OH-Phenyl



42
3
CO2Me
3-OH-Phenyl



43
1
CO2tBu
3-OH-Phenyl



44
2
CO2tBu
3-OH-Phenyl



45
3
CO2tBu
3-OH-Phenyl



46
1
CONHMe
3-OH-Phenyl



47
2
CONHMe
3-OH-Phenyl



48
3
CONHMe
3-OH-Phenyl



49
1
SO2Me
3-OH-Phenyl



50
2
SO2Me
3-OH-Phenyl



51
3
SO2Me
3-OH-Phenyl



52
1
SO2NH2
3-OH-Phenyl



53
2
SO2NH2
3-OH-Phenyl



54
3
SO2NH2
3-OH-Phenyl



55
1
H
4-NO2-Phenyl



56
2
H
4-NO2-Phenyl



57
3
H
4-NO2-Phenyl



58
1
Me
4-NO2-Phenyl



59
2
Me
4-NO2-Phenyl



60
3
Me
4-NO2-Phenyl



61
1
CH2Ph
4-NO2-Phenyl



62
2
CH2Ph
4-NO2-Phenyl



63
3
CH2Ph
4-NO2-Phenyl



64
1
COMe
4-NO2-Phenyl



65
2
COMe
4-NO2-Phenyl



66
3
COMe
4-NO2-Phenyl



67
1
CO2Me
4-NO2-Phenyl



68
2
CO2Me
4-NO2-Phenyl



69
3
CO2Me
4-NO2-Phenyl



70
1
CO2tBu
4-NO2-Phenyl



71
2
CO2tBu
4-NO2-Phenyl



72
3
CO2tBu
4-NO2-Phenyl



73
1
CONHMe
4-NO2-Phenyl



74
2
CONHMe
4-NO2-Phenyl



75
3
CONHMe
4-NO2-Phenyl



76
1
SO2Me
4-NO2-Phenyl



77
2
SO2Me
4-NO2-Phenyl



78
3
SO2Me
4-NO2-Phenyl



79
1
SO2NH2
4-NO2-Phenyl



80
2
SO2NH2
4-NO2-Phenyl



81
3
SO2NH2
4-NO2-Phenyl



82
1
H
3-OMe-Phenyl



83
2
H
3-OMe-Phenyl



84
3
H
3-OMe-Phenyl



85
1
Me
3-OMe-Phenyl



86
2
Me
3-OMe-Phenyl



87
3
Me
3-OMe-Phenyl



88
1
CH2Ph
3-OMe-Phenyl



89
2
CH2Ph
3-OMe-Phenyl



90
3
CH2Ph
3-OMe-Phenyl



01
1
COMe
3-OMe-Phenyl



92
2
COMe
3-OMe-Phenyl



93
3
COMe
3-OMe-Phenyl



94
1
CO2Me
3-OMe-Phenyl



95
2
CO2Me
3-OMe-Phenyl



96
3
CO2Me
3-OMe-Phenyl



97
1
CO2tBu
3-OMe-Phenyl



98
2
CO2tBu
3-OMe-Phenyl



99
3
CO2tBu
3-OMe-Phenyl



100
1
CONHMe
3-OMe-Phenyl



101
2
CONHMe
3-OMe-Phenyl



102
3
CONHMe
3-OMe-Phenyl



103
1
SO2Me
3-OMe-Phenyl



104
2
SO2Me
3-OMe-Phenyl



105
3
SO2Me
3-OMe-Phenyl



106
1
SO2NH2
3-OMe-Phenyl



107
2
SO2NH2
3-OMe-Phenyl



108
3
SO2NH2
3-OMe-Phenyl



109
1
H
4-CN-Phenyl



110
2
H
4-CN-Phenyl



111
3
H
4-CN-Phenyl



112
1
Me
4-CN-Phenyl



113
2
Me
4-CN-Phenyl



114
3
Me
4-CN-Phenyl



115
1
CH2Ph
4-CN-Phenyl



116
2
CH2Ph
4-CN-Phenyl



117
3
CH2Ph
4-CN-Phenyl



118
1
COMe
4-CN-Phenyl



119
2
COMe
4-CN-Phenyl



120
3
COMe
4-CN-Phenyl



121
1
CO2Me
4-CN-Phenyl



122
2
CO2Me
4-CN-Phenyl



123
3
CO2Me
4-CN-Phenyl



124
1
CO2tBu
4-CN-Phenyl



125
2
CO2tBu
4-CN-Phenyl



126
3
CO2tBu
4-CN-Phenyl



127
1
CONHMe
4-CN-Phenyl



128
2
CONHMe
4-CN-Phenyl



129
3
CONHMe
4-CN-Phenyl



130
1
SO2Me
4-CN-Phenyl



131
2
SO2Me
4-CN-Phenyl



132
3
SO2Me
4-CN-Phenyl



133
1
SO2NH2
4-CN-Phenyl



134
2
SO2NH2
4-CN-Phenyl



135
3
SO2NH2
4-CN-Phenyl



136
1
H
2-CN-Phenyl



137
2
H
2-CN-Phenyl



138
3
H
2-CN-Phenyl



139
1
Me
2-CN-Phenyl



140
2
Me
2-CN-Phenyl



141
3
Me
2-CN-Phenyl



142
1
CH2Ph
2-CN-Phenyl



143
2
CH2Ph
2-CN-Phenyl



144
3
CH2Ph
2-CN-Phenyl



145
1
COMe
2-CN-Phenyl



146
2
COMe
2-CN-Phenyl



147
3
COMe
2-CN-Phenyl



148
1
CO2Me
2-CN-Phenyl



149
2
CO2Me
2-CN-Phenyl



150
3
CO2Me
2-CN-Phenyl



151
1
CO2tBu
2-CN-Phenyl



152
2
CO2tBu
2-CN-Phenyl



153
3
CO2tBu
2-CN-Phenyl



154
1
CONHMe
2-CN-Phenyl



155
2
CONHMe
2-CN-Phenyl



156
3
CONHMe
2-CN-Phenyl



157
1
SO2Me
2-CN-Phenyl



158
2
SO2Me
2-CN-Phenyl



159
3
SO2Me
2-CN-Phenyl



160
1
SO2NH2
2-CN-Phenyl



161
2
SO2NH2
2-CN-Phenyl



162
3
SO2NH2
2-CN-Phenyl



163
1
H
3-Me-Phenyl



164
2
H
3-Me-Phenyl



165
3
H
3-Me-Phenyl



166
1
Me
3-Me-Phenyl



167
2
Me
3-Me-Phenyl



168
3
Me
3-Me-Phenyl



169
1
CH2Ph
3-Me-Phenyl



170
2
CH2Ph
3-Me-Phenyl



171
3
CH2Ph
3-Me-Phenyl



172
1
COMe
3-Me-Phenyl



173
2
COMe
3-Me-Phenyl



174
3
COMe
3-Me-Phenyl



175
1
CO2Me
3-Me-Phenyl



176
2
CO2Me
3-Me-Phenyl



177
3
CO2Me
3-Me-Phenyl



178
1
CO2tBu
3-Me-Phenyl



179
2
CO2tBu
3-Me-Phenyl



180
3
CO2tBu
3-Me-Phenyl



181
1
CONHMe
3-Me-Phenyl



182
2
CONHMe
3-Me-Phenyl



183
3
CONHMe
3-Me-Phenyl



184
1
SO2Me
3-Me-Phenyl



185
2
SO2Me
3-Me-Phenyl



186
3
SO2Me
3-Me-Phenyl



187
1
SO2NH2
3-Me-Phenyl



188
2
SO2NH2
3-Me-Phenyl



189
3
SO2NH2
3-Me-Phenyl



190
1
H
2-F-Phenyl



191
2
H
2-F-Phenyl



192
3
H
2-F-Phenyl



193
1
Me
2-F-Phenyl



194
2
Me
2-F-Phenyl



195
3
Me
2-F-Phenyl



196
1
CH2Ph
2-F-Phenyl



197
2
CH2Ph
2-F-Phenyl



198
3
CH2Ph
2-F-Phenyl



199
1
COMe
2-F-Phenyl



200
2
COMe
2-F-Phenyl



201
3
COMe
2-F-Phenyl



202
1
CO2Me
2-F-Phenyl



293
2
CO2Me
2-F-Phenyl



204
3
CO2Me
2-F-Phenyl



205
1
CO2tBu
2-F-Phenyl



206
2
CO2tBu
2-F-Phenyl



297
3
CO2tBu
2-F-Phenyl



208
1
CONHMe
2-F-Phenyl



209
2
CONHMe
2-F-Phenyl



210
3
CONHMe
2-F-Phenyl



211
1
SO2Me
2-F-Phenyl



212
2
SO2Me
2-F-Phenyl



213
3
SO2Me
2-F-Phenyl



214
1
SO2NH2
2-F-Phenyl



215
2
SO2NH2
2-F-Phenyl



216
3
SO2NH2
2-F-Phenyl



217
1
H
4-F-Phenyl



218
2
H
4-F-Phenyl



219
3
H
4-F-Phenyl



220
1
Me
4-F-Phenyl



221
2
Me
4-F-Phenyl



222
3
Me
4-F-Phenyl



223
1
CH2Ph
4-F-Phenyl



224
2
CH2Ph
4-F-Phenyl



225
3
CH2Ph
4-F-Phenyl



226
1
COMe
4-F-Phenyl



227
2
COMe
4-F-Phenyl



228
3
COMe
4-F-Phenyl



229
1
CO2Me
4-F-Phenyl



230
2
CO2Me
4-F-Phenyl



231
3
CO2Me
4-F-Phenyl



232
1
CO2tBu
4-F-Phenyl



233
2
CO2tBu
4-F-Phenyl



234
3
CO2tBu
4-F-Phenyl



235
1
CONHMe
4-F-Phenyl



236
2
CONHMe
4-F-Phenyl



237
3
CONHMe
4-F-Phenyl



238
1
SO2Me
4-F-Phenyl



239
2
SO2Me
4-F-Phenyl



240
3
SO2Me
4-F-Phenyl



241
1
SO2NH2
4-F-Phenyl



242
2
SO2NH2
4-F-Phenyl



243
3
SO2NH2
4-F-Phenyl



244
1
H
3-Cl-Phenyl



245
2
H
3-Cl-Phenyl



246
3
H
3-Cl-Phenyl



247
1
Me
3-Cl-Phenyl



248
2
Me
3-Cl-Phenyl



249
3
Me
3-Cl-Phenyl



250
1
CH2Ph
3-Cl-Phenyl



251
2
CH2Ph
3-Cl-Phenyl



252
3
CH2Ph
3-Cl-Phenyl



253
1
COMe
3-Cl-Phenyl



254
2
COMe
3-Cl-Phenyl



255
3
COMe
3-Cl-Phenyl



256
1
CO2Me
3-Cl-Phenyl



257
2
CO2Me
3-Cl-Phenyl



258
3
CO2Me
3-Cl-Phenyl



259
1
CO2tBu
3-Cl-Phenyl



260
2
CO2tBu
3-Cl-Phenyl



261
3
CO2tBu
3-Cl-Phenyl



262
1
CONHMe
3-Cl-Phenyl



263
2
CONHMe
3-Cl-Phenyl



264
3
CONHMe
3-Cl-Phenyl



265
1
SO2Me
3-Cl-Phenyl



266
2
SO2Me
3-Cl-Phenyl



267
3
SO2Me
3-Cl-Phenyl



268
1
SO2NH2
3-Cl-Phenyl



269
2
SO2NH2
3-Cl-Phenyl



270
3
SO2NH2
3-Cl-Phenyl



271
1
H
2-Br-Phenyl



272
2
H
2-Br-Phenyl



273
3
H
2-Br-Phenyl



274
1
Me
2-Br-Phenyl



275
2
Me
2-Br-Phenyl



276
3
Me
2-Br-Phenyl



277
1
CH2Ph
2-Br-Phenyl



278
2
CH2Ph
2-Br-Phenyl



279
3
CH2Ph
2-Br-Phenyl



280
1
COMe
2-Br-Phenyl



281
2
COMe
2-Br-Phenyl



282
3
COMe
2-Br-Phenyl



283
1
CO2Me
2-Br-Phenyl



284
2
CO2Me
2-Br-Phenyl



285
3
CO2Me
2-Br-Phenyl



286
1
CO2tBu
2-Br-Phenyl



287
2
CO2tBu
2-Br-Phenyl



288
3
CO2tBu
2-Br-Phenyl



289
1
CONHMe
2-Br-Phenyl



290
2
CONHMe
2-Br-Phenyl



291
3
CONHMe
2-Br-Phenyl



292
1
SO2Me
2-Br-Phenyl



293
2
SO2Me
2-Br-Phenyl



294
3
SO2Me
2-Br-Phenyl



295
1
SO2NH2
2-Br-Phenyl



296
2
SO2NH2
2-Br-Phenyl



297
3
SO2NH2
2-Br-Phenyl



298
1
H
4-Br-Phenyl



299
2
H
4-Br-Phenyl



300
3
H
4-Br-Phenyl



301
1
Me
4-Br-Phenyl



302
2
Me
4-Br-Phenyl



303
3
Me
4-Br-Phenyl



304
1
CH2Ph
4-Br-Phenyl



305
2
CH2Ph
4-Br-Phenyl



306
3
CH2Ph
4-Br-Phenyl



307
1
COMe
4-Br-Phenyl



308
2
COMe
4-Br-Phenyl



309
3
COMe
4-Br-Phenyl



310
1
CO2Me
4-Br-Phenyl



311
2
CO2Me
4-Br-Phenyl



312
3
CO2Me
4-Br-Phenyl



313
1
CO2tBu
4-Br-Phenyl



314
2
CO2tBu
4-Br-Phenyl



315
3
CO2tBu
4-Br-Phenyl



316
1
CONHMe
4-Br-Phenyl



317
2
CONHMe
4-Br-Phenyl



318
3
CONHMe
4-Br-Phenyl



319
1
SO2Me
4-Br-Phenyl



320
2
SO2Me
4-Br-Phenyl



321
3
SO2Me
4-Br-Phenyl



322
1
SO2NH2
4-Br-Phenyl



323
2
SO2NH2
4-Br-Phenyl



324
3
SO2NH2
4-Br-Phenyl



325
1
H
3-CF3-Phenyl



326
2
H
3-CF3-Phenyl



327
3
H
3-CF3-Phenyl



328
1
Me
3-CF3-Phenyl



329
2
Me
3-CF3-Phenyl



330
3
Me
3-CF3-Phenyl



331
1
CH2Ph
3-CF3-Phenyl



332
2
CH2Ph
3-CF3-Phenyl



333
3
CH2Ph
3-CF3-Phenyl



334
1
COMe
3-CF3-Phenyl



335
2
COMe
3-CF3-Phenyl



336
3
COMe
3-CF3-Phenyl



337
1
CO2Me
3-CF3-Phenyl



338
2
CO2Me
3-CF3-Phenyl



339
3
CO2Me
3-CF3-Phenyl



340
1
CO2tBu
3-CF3-Phenyl



341
2
CO2tBu
3-CF3-Phenyl



342
3
CO2tBu
3-CF3-Phenyl



343
1
CONHMe
3-CF3-Phenyl



344
2
CONHMe
3-CF3-Phenyl



345
3
CONHMe
3-CF3-Phenyl



346
1
SO2Me
3-CF3-Phenyl



347
2
SO2Me
3-CF3-Phenyl



348
3
SO2Me
3-CF3-Phenyl



349
1
SO2NH2
3-CF3-Phenyl



350
2
SO2NH2
3-CF3-Phenyl



351
3
SO2NH2
3-CF3-Phenyl



352
1
H
2-iPr-Phenyl



353
2
H
2-iPr-Phenyl



354
3
H
2-iPr-Phenyl



355
1
Me
2-iPr-Phenyl



356
2
Me
2-iPr-Phenyl



357
3
Me
2-iPr-Phenyl



358
1
CH2Ph
2-iPr-Phenyl



359
2
CH2Ph
2-iPr-Phenyl



360
3
CH2Ph
2-iPr-Phenyl



361
1
COMe
2-iPr-Phenyl



362
2
COMe
2-iPr-Phenyl



363
3
COMe
2-iPr-Phenyl



364
1
CO2Me
2-iPr-Phenyl



365
2
CO2Me
2-iPr-Phenyl



366
3
CO2Me
2-iPr-Phenyl



367
1
CO2tBu
2-iPr-Phenyl



368
2
CO2tBu
2-iPr-Phenyl



369
3
CO2tBu
2-iPr-Phenyl



370
1
CONHMe
2-iPr-Phenyl



371
2
CONHMe
2-iPr-Phenyl



372
3
CONHMe
2-iPr-Phenyl



373
1
SO2Me
2-iPr-Phenyl



374
2
SO2Me
2-iPr-Phenyl



375
3
SO2Me
2-iPr-Phenyl



376
1
SO2NH2
2-iPr-Phenyl



377
2
SO2NH2
2-iPr-Phenyl



378
3
SO2NH2
2-iPr-Phenyl



379
1
H
4-iPr-Phenyl



380
2
H
4-iPr-Phenyl



381
3
H
4-iPr-Phenyl



382
1
Me
4-iPr-Phenyl



383
2
Me
4-iPr-Phenyl



384
3
Me
4-iPr-Phenyl



385
1
CH2Ph
4-iPr-Phenyl



386
2
CH2Ph
4-iPr-Phenyl



387
3
CH2Ph
4-iPr-Phenyl



388
1
COMe
4-iPr-Phenyl



389
2
COMe
4-iPr-Phenyl



390
3
COMe
4-iPr-Phenyl



391
1
CO2Me
4-iPr-Phenyl



392
2
CO2Me
4-iPr-Phenyl



393
3
CO2Me
4-iPr-Phenyl



394
1
CO2tBu
4-iPr-Phenyl



395
2
CO2tBu
4-iPr-Phenyl



396
3
CO2tBu
4-iPr-Phenyl



397
1
CONHMe
4-iPr-Phenyl



398
2
CONHMe
4-iPr-Phenyl



399
3
CONHMe
4-iPr-Phenyl



400
1
SO2Me
4-iPr-Phenyl



401
2
SO2Me
4-iPr-Phenyl



402
3
SO2Me
4-iPr-Phenyl



403
1
SO2NH2
4-iPr-Phenyl



404
2
SO2NH2
4-iPr-Phenyl



405
3
SO2NH2
4-iPr-Phenyl



406
1
H
3-NH2-Phenyl



407
2
H
3-NH2-Phenyl



408
3
H
3-NH2-Phenyl



409
1
Me
3-NH2-Phenyl



410
2
Me
3-NH2-Phenyl



411
3
Me
3-NH2-Phenyl



412
1
CH2Ph
3-NH2-Phenyl



413
2
CH2Ph
3-NH2-Phenyl



414
3
CH2Ph
3-NH2-Phenyl



415
1
COMe
3-NH2-Phenyl



416
2
COMe
3-NH2-Phenyl



417
3
COMe
3-NH2-Phenyl



418
1
CO2Me
3-NH2-Phenyl



419
2
CO2Me
3-NH2-Phenyl



420
3
CO2Me
3-NH2-Phenyl



421
1
CO2tBu
3-NH2-Phenyl



422
2
CO2tBu
3-NH2-Phenyl



423
3
CO2tBu
3-NH2-Phenyl



424
1
CONHMe
3-NH2-Phenyl



425
2
CONHMe
3-NH2-Phenyl



426
3
CONHMe
3-NH2-Phenyl



427
1
SO2Me
3-NH2-Phenyl



428
2
SO2Me
3-NH2-Phenyl



429
3
SO2Me
3-NH2-Phenyl



430
1
SO2NH2
3-NH2-Phenyl



431
2
SO2NH2
3-NH2-Phenyl



432
3
SO2NH2
3-NH2-Phenyl



433
1
H
2,4-di-Me-Phenyl



434
2
H
2,4-di-Me-Phenyl



435
3
H
2,4-di-Me-Phenyl



436
1
Me
2,4-di-Me-Phenyl



437
2
Me
2,4-di-Me-Phenyl



438
3
Me
2,4-di-Me-Phenyl



439
1
CH2Ph
2,4-di-Me-Phenyl



440
2
CH2Ph
2,4-di-Me-Phenyl



441
3
CH2Ph
2,4-di-Me-Phenyl



442
1
COMe
2,4-di-Me-Phenyl



443
2
COMe
2,4-di-Me-Phenyl



444
3
COMe
2,4-di-Me-Phenyl



445
1
CO2Me
2,4-di-Me-Phenyl



446
2
CO2Me
2,4-di-Me-Phenyl



447
3
CO2Me
2,4-di-Me-Phenyl



448
1
CO2tBu
2,4-di-Me-Phenyl



449
2
CO2tBu
2,4-di-Me-Phenyl



450
3
CO2tBu
2,4-di-Me-Phenyl



451
1
CONHMe
2,4-di-Me-Phenyl



452
2
CONHMe
2,4-di-Me-Phenyl



453
3
CONHMe
2,4-di-Me-Phenyl



454
1
SO2Me
2,4-di-Me-Phenyl



455
2
SO2Me
2,4-di-Me-Phenyl



456
3
SO2Me
2,4-di-Me-Phenyl



457
1
SO2NH2
2,4-di-Me-Phenyl



458
2
SO2NH2
2,4-di-Me-Phenyl



459
3
SO2NH2
2,4-di-Me-Phenyl



460
1
H
2,6-di-iPr-Phenyl



461
2
H
2,6-di-iPr-Phenyl



462
3
H
2,6-di-iPr-Phenyl



463
1
Me
2,6-di-iPr-Phenyl



464
2
Me
2,6-di-iPr-Phenyl



465
3
Me
2,6-di-iPr-Phenyl



466
1
CH2Ph
2,6-di-iPr-Phenyl



467
2
CH2Ph
2,6-di-iPr-Phenyl



468
3
CH2Ph
2,6-di-iPr-Phenyl



469
1
COMe
2,6-di-iPr-Phenyl



470
2
COMe
2,6-di-iPr-Phenyl



471
3
COMe
2,6-di-iPr-Phenyl



472
1
CO2Me
2,6-di-iPr-Phenyl



473
2
CO2Me
2,6-di-iPr-Phenyl



474
3
CO2Me
2,6-di-iPr-Phenyl



475
1
CO2tBu
2,6-di-iPr-Phenyl



476
2
CO2tBu
2,6-di-iPr-Phenyl



477
3
CO2tBu
2,6-di-iPr-Phenyl



478
1
CONHMe
2,6-di-iPr-Phenyl



479
2
CONHMe
2,6-di-iPr-Phenyl



480
3
CONHMe
2,6-di-iPr-Phenyl



481
1
SO2Me
2,6-di-iPr-Phenyl



482
2
SO2Me
2,6-di-iPr-Phenyl



483
3
SO2Me
2,6-di-iPr-Phenyl



484
1
SO2NH2
2,6-di-iPr-Phenyl



485
2
SO2NH2
2,6-di-iPr-Phenyl



486
3
SO2NH2
2,6-di-iPr-Phenyl



487
1
H
3-Ph-Phenyl



488
2
H
3-Ph-Phenyl



489
3
H
3-Ph-Phenyl



490
1
Me
3-Ph-Phenyl



491
2
Me
3-Ph-Phenyl



492
3
Me
3-Ph-Phenyl



493
1
CH2Ph
3-Ph-Phenyl



494
2
CH2Ph
3-Ph-Phenyl



495
3
CH2Ph
3-Ph-Phenyl



496
1
COMe
3-Ph-Phenyl



497
2
COMe
3-Ph-Phenyl



498
3
COMe
3-Ph-Phenyl



499
1
CO2Me
3-Ph-Phenyl



500
2
CO2Me
3-Ph-Phenyl



501
3
CO2Me
3-Ph-Phenyl



502
1
CO2tBu
3-Ph-Phenyl



503
2
CO2tBu
3-Ph-Phenyl



504
3
CO2tBu
3-Ph-Phenyl



505
1
CONHMe
3-Ph-Phenyl



506
2
CONHMe
3-Ph-Phenyl



507
3
CONHMe
3-Ph-Phenyl



508
1
SO2Me
3-Ph-Phenyl



509
2
SO2Me
3-Ph-Phenyl



510
3
SO2Me
3-Ph-Phenyl



511
1
SO2NH2
3-Ph-Phenyl



512
2
SO2NH2
3-Ph-Phenyl



513
3
SO2NH2
3-Ph-Phenyl



514
1
H
2-morpholino-phenyl



515
2
H
2-morpholino-phenyl



516
3
H
2-morpholino-phenyl



517
1
Me
2-morpholino-phenyl



518
2
Me
2-morpholino-phenyl



519
3
Me
2-morpholino-phenyl



520
1
CH2Ph
2-morpholino-phenyl



521
2
CH2Ph
2-morpholino-phenyl



522
3
CH2Ph
2-morpholino-phenyl



523
1
COMe
2-morpholino-phenyl



524
2
COMe
2-morpholino-phenyl



525
3
COMe
2-morpholino-phenyl



526
1
CO2Me
2-morpholino-phenyl



527
2
CO2Me
2-morpholino-phenyl



528
3
CO2Me
2-morpholino-phenyl



529
1
CO2tBu
2-morpholino-phenyl



530
2
CO2tBu
2-morpholino-phenyl



531
3
CO2tBu
2-morpholino-phenyl



532
1
CONHMe
2-morpholino-phenyl



533
2
CONHMe
2-morpholino-phenyl



534
3
CONHMe
2-morpholino-phenyl



535
1
SO2Me
2-morpholino-phenyl



536
2
SO2Me
2-morpholino-phenyl



537
3
SO2Me
2-morpholino-phenyl



538
1
SO2NH2
2-morpholino-phenyl



539
2
SO2NH2
2-morpholino-phenyl



540
3
SO2NH2
2-morpholino-phenyl



541
1
H
4-morpholino-phenyl



542
2
H
4-morpholino-phenyl



543
3
H
4-morpholino-phenyl



544
1
Me
4-morpholino-phenyl



545
2
Me
4-morpholino-phenyl



546
3
Me
4-morpholino-phenyl



547
1
CH2Ph
4-morpholino-phenyl



548
2
CH2Ph
4-morpholino-phenyl



549
3
CH2Ph
4-morpholino-phenyl



550
1
COMe
4-morpholino-phenyl



551
2
COMe
4-morpholino-phenyl



552
3
COMe
4-morpholino-phenyl



553
1
CO2Me
4-morpholino-phenyl



554
2
CO2Me
4-morpholino-phenyl



555
3
COMe
4-morpholino-phenyl



556
1
CO2tBu
4-morpholino-phenyl



557
2
CO2tBu
4-morpholino-phenyl



558
3
CO2tBu
4-morpholino-phenyl



559
1
CONHMe
4-morpholino-phenyl



560
2
CONHMe
4-morpholino-phenyl



561
3
CONHMe
4-morpholino-phenyl



562
1
SO2Me
4-morpholino-phenyl



563
2
SO2Me
4-morpholino-phenyl



564
3
SO2Me
4-morpholino-phenyl



565
1
SO2NH2
4-morpholino-phenyl



566
2
SO2NH2
4-morpholino-phenyl



567
3
SO2NH2
4-morpholino-phenyl



568
1
H
2-pyrimidinyl



569
2
H
2-pyrimidinyl



570
3
H
2-pyrimidinyl



571
1
Me
2-pyrimidinyl



572
2
Me
2-pyrimidinyl



573
3
Me
2-pyrimidinyl



574
1
CH2Ph
2-pyrimidinyl



575
2
CH2Ph
2-pyrimidinyl



576
3
CH2Ph
2-pyrimidinyl



577
1
COMe
2-pyrimidinyl



578
2
COMe
2-pyrimidinyl



579
3
COMe
2-pyrimidinyl



580
1
CO2Me
2-pyrimidinyl



581
2
CO2Me
2-pyrimidinyl



582
3
CO2Me
2-pyrimidinyl



583
1
CO2tBu
2-pyrimidinyl



584
2
CO2tBu
2-pyrimidinyl



585
3
CO2tBu
2-pyrimidinyl



586
1
CONHMe
2-pyrimidinyl



587
2
CONHMe
2-pyrimidinyl



588
3
CONHMe
2-pyrimidinyl



589
1
SO2Me
2-pyrimidinyl



590
2
SO2Me
2-pyrimidinyl



591
3
SO2Me
2-pyrimidinyl



592
1
SO2NH2
2-pyrimidinyl



593
2
SO2NH2
2-pyrimidinyl



594
3
SO2NH2
2-pyrimidinyl



595
1
H
2-methyl-1H-






benzo[d]imidazol-4-yl



596
2
H
2-methyl-1H-






benzo[d]imidazol-4-yl



597
3
H
2-methyl-1H-






benzo[d]imidazol-4-yl



598
1
Me
2-methyl-1H-






benzo[d]imidazol-4-yl



599
2
Me
2-methyl-1H-






benzo[d]imidazol-4-yl



600
3
Me
2-methyl-1H-






benzo[d]imidazol-4-yl



601
1
CH2Ph
2-methyl-1H-






benzo[d]imidazol-4-yl



602
2
CH2Ph
2-methyl-1H-






benzo[d]imidazol-4-yl



603
3
CH2Ph
2-methyl-1H-






benzo[d]imidazol-4-yl



604
1
COMe
2-methyl-1H-






benzo[d]imidazol-4-yl



605
2
COMe
2-methyl-1H-






benzo[d]imidazol-4-yl



606
3
COMe
2-methyl-1H-






benzo[d]imidazol-4-yl



607
1
CO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



608
2
CO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



609
3
CO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



610
1
CO2tBu
2-methyl-1H-






benzo[d]imidazol-4-yl



611
2
CO2tBu
2-methyl-1H-






benzo[d]imidazol-4-yl



612
3
CO2tBu
2-methyl-1H-






benzo[d]imidazol-4-yl



613
1
CONHMe
2-methyl-1H-






benzo[d]imidazol-4-yl



614
2
CONHMe
2-methyl-1H-






benzo[d]imidazol-4-yl



615
3
CONHMe
2-methyl-1H-






benzo[d]imidazol-4-yl



616
1
SO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



617
2
SO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



618
3
SO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



619
1
SO2NH2
2-methyl-1H-






benzo[d]imidazol-4-yl



620
2
SO2NH2
2-methyl-1H-






benzo[d]imidazol-4-yl



621
3
SO2NH2
2-methyl-1H-






benzo[d]imidazol-4-yl



622
1
H
4-OH-Phenyl



623
2
H
4-OH-Phenyl



624
3
H
4-OH-Phenyl



625
1
Me
4-OH-Phenyl



626
2
Me
4-OH-Phenyl



627
3
Me
4-OH-Phenyl



628
1
CH2Ph
4-OH-Phenyl



629
2
CH2Ph
4-OH-Phenyl



639
3
CH2Ph
4-OH-Phenyl



631
1
COMe
4-OH-Phenyl



632
2
COMe
4-OH-Phenyl



633
3
COMe
4-OH-Phenyl



634
1
CO2Me
4-OH-Phenyl



635
2
CO2Me
4-OH-Phenyl



636
3
CO2Me
4-OH-Phenyl



637
1
CO2tBu
4-OH-Phenyl



638
2
CO2tBu
4-OH-Phenyl



639
3
CO2tBu
4-OH-Phenyl



640
1
CONHMe
4-OH-Phenyl



641
2
CONHMe
4-OH-Phenyl



642
3
CONHMe
4-OH-Phenyl



643
1
SO2Me
4-OH-Phenyl



644
2
SO2Me
4-OH-Phenyl



645
3
SO2Me
4-OH-Phenyl



646
1
SO2NH2
4-OH-Phenyl



647
2
SO2NH2
4-OH-Phenyl



648
3
SO2NH2
4-OH-Phenyl



649
1
H
2-OH-Phenyl



650
2
H
2-OH-Phenyl



651
3
H
2-OH-Phenyl



652
1
Me
2-OH-Phenyl



653
2
Me
2-OH-Phenyl



654
3
Me
2-OH-Phenyl



655
1
CH2Ph
2-OH-Phenyl



656
2
CH2Ph
2-OH-Phenyl



657
3
CH2Ph
2-OH-Phenyl



658
1
COMe
2-OH-Phenyl



659
2
COMe
2-OH-Phenyl



660
3
COMe
2-OH-Phenyl



661
1
CO2Me
2-OH-Phenyl



662
2
CO2Me
2-OH-Phenyl



663
3
CO2Me
2-OH-Phenyl



664
1
CO2tBu
2-OH-Phenyl



665
2
CO2tBu
2-OH-Phenyl



666
3
CO2tBu
2-OH-Phenyl



667
1
CONHMe
2-OH-Phenyl



668
2
CONHMe
2-OH-Phenyl



669
3
CONHMe
2-OH-Phenyl



670
1
SO2Me
2-OH-Phenyl



671
2
SO2Me
2-OH-Phenyl



672
3
SO2Me
2-OH-Phenyl



673
1
SO2NH2
2-OH-Phenyl



674
2
SO2NH2
2-OH-Phenyl



675
3
SO2NH2
2-OH-Phenyl



676
1
H
4-OMe-Phenyl



677
2
H
4-OMe-Phenyl



678
3
H
4-OMe-Phenyl



679
1
Me
4-OMe-Phenyl



680
2
Me
4-OMe-Phenyl



681
3
Me
4-OMe-Phenyl



682
1
CH2Ph
4-OMe-Phenyl



683
2
CH2Ph
4-OMe-Phenyl



684
3
CH2Ph
4-OMe-Phenyl



685
1
COMe
4-OMe-Phenyl



686
2
COMe
4-OMe-Phenyl



687
3
COMe
4-OMe-Phenyl



688
1
CO2Me
4-OMe-Phenyl



689
2
CO2Me
4-OMe-Phenyl



690
3
CO2Me
4-OMe-Phenyl



691
1
CO2tBu
4-OMe-Phenyl



692
2
CO2tBu
4-OMe-Phenyl



693
3
CO2tBu
4-OMe-Phenyl



694
1
CONHMe
4-OMe-Phenyl



695
2
CONHMe
4-OMe-Phenyl



696
3
CONHMe
4-OMe-Phenyl



697
1
SO2Me
4-OMe-Phenyl



698
2
SO2Me
4-OMe-Phenyl



699
3
SO2Me
4-OMe-Phenyl



700
1
SO2NH2
4-OMe-Phenyl



701
2
SO2NH2
4-OMe-Phenyl



702
3
SO2NH2
4-OMe-Phenyl



703
1
H
2-OMe-Phenyl



704
2
H
2-OMe-Phenyl



705
3
H
2-OMe-Phenyl



706
1
Me
2-OMe-Phenyl



707
2
Me
2-OMe-Phenyl



708
3
Me
2-OMe-Phenyl



709
1
CH2Ph
2-OMe-Phenyl



710
2
CH2Ph
2-OMe-Phenyl



711
3
CH2Ph
2-OMe-Phenyl



712
1
COMe
2-OMe-Phenyl



713
2
COMe
2-OMe-Phenyl



714
3
COMe
2-OMe-Phenyl



715
1
CO2Me
2-OMe-Phenyl



716
2
CO2Me
2-OMe-Phenyl



717
3
CO2Me
2-OMe-Phenyl



718
1
CO2tBu
2-OMe-Phenyl



719
2
CO2tBu
2-OMe-Phenyl



720
3
CO2tBu
2-OMe-Phenyl



721
1
CONHMe
2-OMe-Phenyl



722
2
CONHMe
2-OMe-Phenyl



723
3
CONHMe
2-OMe-Phenyl



724
1
SO2Me
2-OMe-Phenyl



725
2
SO2Me
2-OMe-Phenyl



726
3
SO2Me
2-OMe-Phenyl



727
1
SO2NH2
2-OMe-Phenyl



728
2
SO2NH2
2-OMe-Phenyl



729
3
SO2NH2
2-OMe-Phenyl



730
1
H
3-CN-Phenyl



731
2
H
3-CN-Phenyl



732
3
H
3-CN-Phenyl



733
1
Me
3-CN-Phenyl



734
2
Me
3-CN-Phenyl



735
3
Me
3-CN-Phenyl



736
1
CH2Ph
3-CN-Phenyl



737
2
CH2Ph
3-CN-Phenyl



738
3
CH2Ph
3-CN-Phenyl



739
1
COMe
3-CN-Phenyl



740
2
COMe
3-CN-Phenyl



741
3
COMe
3-CN-Phenyl



742
1
CO2Me
3-CN-Phenyl



743
2
CO2Me
3-CN-Phenyl



744
3
COMe
3-CN-Phenyl



745
1
CO2tBu
3-CN-Phenyl



746
2
CO2tBu
3-CN-Phenyl



747
3
CO2tBu
3-CN-Phenyl



748
1
CONHMe
3-CN-Phenyl



749
2
CONHMe
3-CN-Phenyl



750
3
CONHMe
3-CN-Phenyl



751
1
SO2Me
3-CN-Phenyl



752
2
SO2Me
3-CN-Phenyl



753
3
SO2Me
3-CN-Phenyl



754
1
SO2NH2
3-CN-Phenyl



755
2
SO2NH2
3-CN-Phenyl



756
3
SO2NH2
3-CN-Phenyl



757
1
H
2-Me-Phenyl



758
2
H
2-Me-Phenyl



759
3
H
2-Me-Phenyl



760
1
Me
2-Me-Phenyl



761
2
Me
2-Me-Phenyl



762
3
Me
2-Me-Phenyl



763
1
CH2Ph
2-Me-Phenyl



764
2
CH2Ph
2-Me-Phenyl



765
3
CH2Ph
2-Me-Phenyl



766
1
COMe
2-Me-Phenyl



767
2
COMe
2-Me-Phenyl



768
3
COMe
2-Me-Phenyl



769
1
CO2Me
2-Me-Phenyl



770
2
CO2Me
2-Me-Phenyl



771
3
CO2Me
2-Me-Phenyl



772
1
CO2tBu
2-Me-Phenyl



773
2
CO2tBu
2-Me-Phenyl



774
3
CO2tBu
2-Me-Phenyl



775
1
CONHMe
2-Me-Phenyl



776
2
CONHMe
2-Me-Phenyl



777
3
CONHMe
2-Me-Phenyl



778
1
SO2Me
2-Me-Phenyl



779
2
SO2Me
2-Me-Phenyl



780
3
SO2Me
2-Me-Phenyl



781
1
SO2NH2
2-Me-Phenyl



782
2
SO2NH2
2-Me-Phenyl



783
3
SO2NH2
2-Me-Phenyl



784
1
H
4-Me-Phenyl



785
2
H
4-Me-Phenyl



786
3
H
4-Me-Phenyl



787
1
Me
4-Me-Phenyl



788
2
Me
4-Me-Phenyl



789
3
Me
4-Me-Phenyl



790
1
CH2Ph
4-Me-Phenyl



791
2
CH2Ph
4-Me-Phenyl



792
3
CH2Ph
4-Me-Phenyl



793
1
COMe
4-Me-Phenyl



794
2
COMe
4-Me-Phenyl



795
3
COMe
4-Me-Phenyl



796
1
CO2Me
4-Me-Phenyl



797
2
CO2Me
4-Me-Phenyl



798
3
CO2Me
4-Me-Phenyl



799
1
CO2tBu
4-Me-Phenyl



800
2
CO2tBu
4-Me-Phenyl



801
3
CO2tBu
4-Me-Phenyl



802
1
CONHMe
4-Me-Phenyl



803
2
CONHMe
4-Me-Phenyl



804
3
CONHMe
4-Me-Phenyl



805
1
SO2Me
4-Me-Phenyl



806
2
SO2Me
4-Me-Phenyl



897
3
SO2Me
4-Me-Phenyl



808
1
SO2NH2
4-Me-Phenyl



809
2
SO2NH2
4-Me-Phenyl



810
3
SO2NH2
4-Me-Phenyl



811
1
H
3-F-Phenyl



812
2
H
3-F-Phenyl



813
3
H
3-F-Phenyl



814
1
Me
3-F-Phenyl



815
2
Me
3-F-Phenyl



816
3
Me
3-F-Phenyl



817
1
CH2Ph
3-F-Phenyl



818
2
CH2Ph
3-F-Phenyl



819
3
CH2Ph
3-F-Phenyl



820
1
COMe
3-F-Phenyl



821
2
COMe
3-F-Phenyl



822
3
COMe
3-F-Phenyl



823
1
CO2Me
3-F-Phenyl



824
2
CO2Me
3-F-Phenyl



825
3
CO2Me
3-F-Phenyl



826
1
CO2tBu
3-F-Phenyl



827
2
CO2tBu
3-F-Phenyl



828
3
CO2tBu
3-F-Phenyl



829
1
CONHMe
3-F-Phenyl



830
2
CONHMe
3-F-Phenyl



831
3
CONHMe
3-F-Phenyl



832
1
SO2Me
3-F-Phenyl



833
2
SO2Me
3-F-Phenyl



834
3
SO2Me
3-F-Phenyl



835
1
SO2NH2
3-F-Phenyl



836
2
SO2NH2
3-F-Phenyl



837
3
SO2NH2
3-F-Phenyl



838
1
H
2-Cl-Phenyl



839
2
H
2-Cl-Phenyl



840
3
H
2-Cl-Phenyl



841
1
Me
2-Cl-Phenyl



842
2
Me
2-Cl-Phenyl



843
3
Me
2-Cl-Phenyl



844
1
CH2Ph
2-Cl-Phenyl



845
2
CH2Ph
2-Cl-Phenyl



846
3
CH2Ph
2-Cl-Phenyl



847
1
COMe
2-Cl-Phenyl



848
2
COMe
2-Cl-Phenyl



849
3
COMe
2-Cl-Phenyl



850
1
CO2Me
2-Cl-Phenyl



851
2
CO2Me
2-Cl-Phenyl



852
3
CO2Me
2-Cl-Phenyl



853
1
CO2tBu
2-Cl-Phenyl



854
2
CO2tBu
2-Cl-Phenyl



855
3
CO2tBu
2-Cl-Phenyl



856
1
CONHMe
2-Cl-Phenyl



857
2
CONHMe
2-Cl-Phenyl



858
3
CONHMe
2-Cl-Phenyl



859
1
SO2Me
2-Cl-Phenyl



860
2
SO2Me
2-Cl-Phenyl



861
3
SO2Me
2-Cl-Phenyl



862
1
SO2NH2
2-Cl-Phenyl



863
2
SO2NH2
2-Cl-Phenyl



864
3
SO2NH2
2-Cl-Phenyl



865
1
H
4-Cl-Phenyl



866
2
H
4-Cl-Phenyl



867
3
H
4-Cl-Phenyl



868
1
Me
4-Cl-Phenyl



869
2
Me
4-Cl-Phenyl



870
3
Me
4-Cl-Phenyl



871
1
CH2Ph
4-Cl-Phenyl



872
2
CH2Ph
4-Cl-Phenyl



873
3
CH2Ph
4-Cl-Phenyl



874
1
COMe
4-Cl-Phenyl



875
2
COMe
4-Cl-Phenyl



876
3
COMe
4-Cl-Phenyl



877
1
CO2Me
4-Cl-Phenyl



878
2
CO2Me
4-Cl-Phenyl



879
3
CO2Me
4-Cl-Phenyl



880
1
CO2tBu
4-Cl-Phenyl



881
2
CO2tBu
4-Cl-Phenyl



882
3
CO2tBu
4-Cl-Phenyl



883
1
CONHMe
4-Cl-Phenyl



884
2
CONHMe
4-Cl-Phenyl



885
3
CONHMe
4-Cl-Phenyl



886
1
SO2Me
4-Cl-Phenyl



887
2
SO2Me
4-Cl-Phenyl



888
3
SO2Me
4-Cl-Phenyl



889
1
SO2NH2
4-Cl-Phenyl



890
2
SO2NH2
4-Cl-Phenyl



891
3
SO2NH2
4-Cl-Phenyl



892
1
H
3-Br-Phenyl



893
2
H
3-Br-Phenyl



894
3
H
3-Br-Phenyl



895
1
Me
3-Br-Phenyl



896
2
Me
3-Br-Phenyl



897
3
Me
3-Br-Phenyl



898
1
CH2Ph
3-Br-Phenyl



899
2
CH2Ph
3-Br-Phenyl



900
3
CH2Ph
3-Br-Phenyl



901
1
COMe
3-Br-Phenyl



902
2
COMe
3-Br-Phenyl



903
3
COMe
3-Br-Phenyl



904
1
CO2Me
3-Br-Phenyl



905
2
CO2Me
3-Br-Phenyl



906
3
CO2Me
3-Br-Phenyl



907
1
CO2tBu
3-Br-Phenyl



908
2
CO2tBu
3-Br-Phenyl



909
3
CO2tBu
3-Br-Phenyl



910
1
CONHMe
3-Br-Phenyl



911
2
CONHMe
3-Br-Phenyl



912
3
CONHMe
3-Br-Phenyl



913
1
SO2Me
3-Br-Phenyl



914
2
SO2Me
3-Br-Phenyl



915
3
SO2Me
3-Br-Phenyl



916
1
SO2NH2
3-Br-Phenyl



917
2
SO2NH2
3-Br-Phenyl



918
3
SO2NH2
3-Br-Phenyl



919
1
H
2-CF3-Phenyl



920
2
H
2-CF3-Phenyl



921
3
H
2-CF3-Phenyl



922
1
Me
2-CF3-Phenyl



923
2
Me
2-CF3-Phenyl



924
3
Me
2-CF3-Phenyl



925
1
CH2Ph
2-CF3-Phenyl



926
2
CH2Ph
2-CF3-Phenyl



927
3
CH2Ph
2-CF3-Phenyl



928
1
COMe
2-CF3-Phenyl



929
2
COMe
2-CF3-Phenyl



930
3
COMe
2-CF3-Phenyl



931
1
CO2Me
2-CF3-Phenyl



932
2
CO2Me
2-CF3-Phenyl



933
3
CO2Me
2-CF3-Phenyl



934
1
CO2tBu
2-CF3-Phenyl



935
2
CO2tBu
2-CF3-Phenyl



936
3
CO2tBu
2-CF3-Phenyl



937
1
CONHMe
2-CF3-Phenyl



938
2
CONHMe
2-CF3-Phenyl



939
3
CONHMe
2-CF3-Phenyl



940
1
SO2Me
2-CF3-Phenyl



941
2
SO2Me
2-CF3-Phenyl



942
3
SO2Me
2-CF3-Phenyl



943
1
SO2NH2
2-CF3-Phenyl



944
2
SO2NH2
2-CF3-Phenyl



945
3
SO2NH2
2-CF3-Phenyl



946
1
H
4-CF3-Phenyl



947
2
H
4-CF3-Phenyl



948
3
H
4-CF3-Phenyl



949
1
Me
4-CF3-Phenyl



950
2
Me
4-CF3-Phenyl



951
3
Me
4-CF3-Phenyl



952
1
CH2Ph
4-CF3-Phenyl



953
2
CH2Ph
4-CF3-Phenyl



954
3
CH2Ph
4-CF3-Phenyl



955
1
COMe
4-CF3-Phenyl



956
2
COMe
4-CF3-Phenyl



957
3
COMe
4-CF3-Phenyl



958
1
CO2Me
4-CF3-Phenyl



959
2
CO2Me
4-CF3-Phenyl



960
3
CO2Me
4-CF3-Phenyl



961
1
CO2tBu
4-CF3-Phenyl



962
2
CO2tBu
4-CF3-Phenyl



963
3
CO2tBu
4-CF3-Phenyl



964
1
CONHMe
4-CF3-Phenyl



965
2
CONHMe
4-CF3-Phenyl



966
3
CONHMe
4-CF3-Phenyl



967
1
SO2Me
4-CF3-Phenyl



968
2
SO2Me
4-CF3-Phenyl



969
3
SO2Me
4-CF3-Phenyl



970
1
SO2NH2
4-CF3-Phenyl



971
2
SO2NH2
4-CF3-Phenyl



972
3
SO2NH2
4-CF3-Phenyl



973
1
H
3-iPr-Phenyl



974
2
H
3-iPr-Phenyl



975
3
H
3-iPr-Phenyl



976
1
Me
3-iPr-Phenyl



977
2
Me
3-iPr-Phenyl



978
3
Me
3-iPr-Phenyl



979
1
CH2Ph
3-iPr-Phenyl



980
2
CH2Ph
3-iPr-Phenyl



981
3
CH2Ph
3-iPr-Phenyl



982
1
COMe
3-iPr-Phenyl



983
2
COMe
3-iPr-Phenyl



984
3
COMe
3-iPr-Phenyl



985
1
CO2Me
3-iPr-Phenyl



986
2
CO2Me
3-iPr-Phenyl



987
3
CO2Me
3-iPr-Phenyl



988
1
CO2tBu
3-iPr-Phenyl



989
2
CO2tBu
3-iPr-Phenyl



990
3
CO2tBu
3-iPr-Phenyl



991
1
CONHMe
3-iPr-Phenyl



992
2
CONHMe
3-iPr-Phenyl



993
3
CONHMe
3-iPr-Phenyl



994
1
SO2Me
3-iPr-Phenyl



995
2
SO2Me
3-iPr-Phenyl



996
3
SO2Me
3-iPr-Phenyl



997
1
SO2NH2
3-iPr-Phenyl



998
2
SO2NH2
3-iPr-Phenyl



999
3
SO2NH2
3-iPr-Phenyl



1000
1
H
4-NH2-Phenyl



1001
2
H
4-NH2-Phenyl



1002
3
H
4-NH2-Phenyl



1003
1
Me
4-NH2-Phenyl



1004
2
Me
4-NH2-Phenyl



1005
3
Me
4-NH2-Phenyl



1006
1
CH2Ph
4-NH2-Phenyl



1007
2
CH2Ph
4-NH2-Phenyl



1008
3
CH2Ph
4-NH2-Phenyl



1009
1
COMe
4-NH2-Phenyl



1010
2
COMe
4-NH2-Phenyl



1011
3
COMe
4-NH2-Phenyl



1012
1
CO2Me
4-NH2-Phenyl



1013
2
CO2Me
4-NH2-Phenyl



1014
3
CO2Me
4-NH2-Phenyl



1015
1
CO2tBu
4-NH2-Phenyl



1016
2
CO2tBu
4-NH2-Phenyl



1017
3
CO2tBu
4-NH2-Phenyl



1018
1
CONHMe
4-NH2-Phenyl



1019
2
CONHMe
4-NH2-Phenyl



1020
3
CONHMe
4-NH2-Phenyl



1021
1
SO2Me
4-NH2-Phenyl



1022
2
SO2Me
4-NH2-Phenyl



1023
3
SO2Me
4-NH2-Phenyl



1024
1
SO2NH2
4-NH2-Phenyl



1025
2
SO2NH2
4-NH2-Phenyl



1026
3
SO2NH2
4-NH2-Phenyl



1027
1
H
2-NH2-Phenyl



1028
2
H
2-NH2-Phenyl



1029
3
H
2-NH2-Phenyl



1030
1
Me
2-NH2-Phenyl



1031
2
Me
2-NH2-Phenyl



1032
3
Me
2-NH2-Phenyl



1033
1
CH2Ph
2-NH2-Phenyl



1034
2
CH2Ph
2-NH2-Phenyl



1035
3
CH2Ph
2-NH2-Phenyl



1036
1
COMe
2-NH2-Phenyl



1037
2
COMe
2-NH2-Phenyl



1038
3
COMe
2-NH2-Phenyl



1039
1
CO2Me
2-NH2-Phenyl



1040
2
CO2Me
2-NH2-Phenyl



1041
3
CO2Me
2-NH2-Phenyl



1042
1
CO2tBu
2-NH2-Phenyl



1043
2
CO2tBu
2-NH2-Phenyl



1044
3
CO2tBu
2-NH2-Phenyl



1045
1
CONHMe
2-NH2-Phenyl



1046
2
CONHMe
2-NH2-Phenyl



1047
3
CONHMe
2-NH2-Phenyl



1048
1
SO2Me
2-NH2-Phenyl



1049
2
SO2Me
2-NH2-Phenyl



1050
3
SO2Me
2-NH2-Phenyl



1051
1
SO2NH2
2-NH2-Phenyl



1052
2
SO2NH2
2-NH2-Phenyl



1053
3
SO2NH2
2-NH2-Phenyl



1054
1
H
2,6-di-Me-Phenyl



1055
2
H
2,6-di-Me-Phenyl



1056
3
H
2,6-di-Me-Phenyl



1057
1
Me
2,6-di-Me-Phenyl



1058
2
Me
2,6-di-Me-Phenyl



1059
3
Me
2,6-di-Me-Phenyl



1060
1
CH2Ph
2,6-di-Me-Phenyl



1061
2
CH2Ph
2,6-di-Me-Phenyl



1062
3
CH2Ph
2,6-di-Me-Phenyl



1063
1
COMe
2,6-di-Me-Phenyl



1064
2
COMe
2,6-di-Me-Phenyl



1065
3
COMe
2,6-di-Me-Phenyl



1066
1
CO2Me
2,6-di-Me-Phenyl



1067
2
CO2Me
2,6-di-Me-Phenyl



1068
3
CO2Me
2,6-di-Me-Phenyl



1069
1
CO2tBu
2,6-di-Me-Phenyl



1070
2
CO2tBu
2,6-di-Me-Phenyl



1071
3
CO2tBu
2,6-di-Me-Phenyl



1072
1
CONHMe
2,6-di-Me-Phenyl



1073
2
CONHMe
2,6-di-Me-Phenyl



1074
3
CONHMe
2,6-di-Me-Phenyl



1075
1
SO2Me
2,6-di-Me-Phenyl



1076
2
SO2Me
2,6-di-Me-Phenyl



1077
3
SO2Me
2,6-di-Me-Phenyl



1078
1
SO2NH2
2,6-di-Me-Phenyl



1079
2
SO2NH2
2,6-di-Me-Phenyl



1080
3
SO2NH2
2,6-di-Me-Phenyl



1081
1
H
2-Ph-Phenyl



1082
2
H
2-Ph-Phenyl



1083
3
H
2-Ph-Phenyl



1084
1
Me
2-Ph-Phenyl



1085
2
Me
2-Ph-Phenyl



1086
3
Me
2-Ph-Phenyl



1087
1
CH2Ph
2-Ph-Phenyl



1088
2
CH2Ph
2-Ph-Phenyl



1089
3
CH2Ph
2-Ph-Phenyl



1090
1
COMe
2-Ph-Phenyl



1091
2
COMe
2-Ph-Phenyl



1092
3
COMe
2-Ph-Phenyl



1093
1
CO2Me
2-Ph-Phenyl



1094
2
CO2Me
2-Ph-Phenyl



1095
3
CO2Me
2-Ph-Phenyl



1096
1
CO2tBu
2-Ph-Phenyl



1097
2
CO2tBu
2-Ph-Phenyl



1098
3
CO2tBu
2-Ph-Phenyl



1099
1
CONHMe
2-Ph-Phenyl



1100
2
CONHMe
2-Ph-Phenyl



1101
3
CONHMe
2-Ph-Phenyl



1102
1
SO2Me
2-Ph-Phenyl



1103
2
SO2Me
2-Ph-Phenyl



1104
3
SO2Me
2-Ph-Phenyl



1105
1
SO2NH2
2-Ph-Phenyl



1106
2
SO2NH2
2-Ph-Phenyl



1107
3
SO2NH2
2-Ph-Phenyl



1108
1
H
4-Ph-Phenyl



1109
2
H
4-Ph-Phenyl



1110
3
H
4-Ph-Phenyl



1111
1
Me
4-Ph-Phenyl



1112
2
Me
4-Ph-Phenyl



1113
3
Me
4-Ph-Phenyl



1114
1
CH2Ph
4-Ph-Phenyl



1115
2
CH2Ph
4-Ph-Phenyl



1116
3
CH2Ph
4-Ph-Phenyl



1117
1
COMe
4-Ph-Phenyl



1118
2
COMe
4-Ph-Phenyl



1119
3
COMe
4-Ph-Phenyl



1120
1
CO2Me
4-Ph-Phenyl



1121
2
CO2Me
4-Ph-Phenyl



1122
3
CO2Me
4-Ph-Phenyl



1123
1
CO2tBu
4-Ph-Phenyl



1124
2
CO2tBu
4-Ph-Phenyl



1125
3
CO2tBu
4-Ph-Phenyl



1126
1
CONHMe
4-Ph-Phenyl



1127
2
CONHMe
4-Ph-Phenyl



1128
3
CONHMe
4-Ph-Phenyl



1129
1
SO2Me
4-Ph-Phenyl



1130
2
SO2Me
4-Ph-Phenyl



1131
3
SO2Me
4-Ph-Phenyl



1132
1
SO2NH2
4-Ph-Phenyl



1133
2
SO2NH2
4-Ph-Phenyl



1134
3
SO2NH2
4-Ph-Phenyl



1135
1
H
3-morpholino-phenyl



1136
2
H
3-morpholino-phenyl



1137
3
H
3-morpholino-phenyl



1138
1
Me
3-morpholino-phenyl



1139
2
Me
3-morpholino-phenyl



1140
3
Me
3-morpholino-phenyl



1141
1
CH2Ph
3-morpholino-phenyl



1142
2
CH2Ph
3-morpholino-phenyl



1143
3
CH2Ph
3-morpholino-phenyl



1144
1
COMe
3-morpholino-phenyl



1145
2
COMe
3-morpholino-phenyl



1146
3
COMe
3-morpholino-phenyl



1147
1
CO2Me
3-morpholino-phenyl



1148
2
CO2Me
3-morpholino-phenyl



1149
3
CO2Me
3-morpholino-phenyl



1150
1
CO2tBu
3-morpholino-phenyl



1151
2
CO2tBu
3-morpholino-phenyl



1152
3
CO2tBu
3-morpholino-phenyl



1153
1
CONHMe
3-morpholino-phenyl



1154
2
CONHMe
3-morpholino-phenyl



1155
3
CONHMe
3-morpholino-phenyl



1156
1
SO2Me
3-morpholino-phenyl



1157
2
SO2Me
3-morpholino-phenyl



1158
3
SO2Me
3-morpholino-phenyl



1159
1
SO2NH2
3-morpholino-phenyl



1160
2
SO2NH2
3-morpholino-phenyl



1161
3
SO2NH2
3-morpholino-phenyl



1162
1
H
2-pyrazinyl



1163
2
H
2-pyrazinyl



1164
3
H
2-pyrazinyl



1165
1
Me
2-pyrazinyl



1166
2
Me
2-pyrazinyl



1167
3
Me
2-pyrazinyl



1168
1
CH2Ph
2-pyrazinyl



1169
2
CH2Ph
2-pyrazinyl



1170
3
CH2Ph
2-pyrazinyl



1171
1
COMe
2-pyrazinyl



1172
2
COMe
2-pyrazinyl



1173
3
COMe
2-pyrazinyl



1174
1
CO2Me
2-pyrazinyl



1175
2
CO2Me
2-pyrazinyl



1176
3
CO2Me
2-pyrazinyl



1177
1
CO2tBu
2-pyrazinyl



1178
2
CO2tBu
2-pyrazinyl



1179
3
CO2tBu
2-pyrazinyl



1180
1
CONHMe
2-pyrazinyl



1181
2
CONHMe
2-pyrazinyl



1182
3
CONHMe
2-pyrazinyl



1183
1
SO2Me
2-pyrazinyl



1184
2
SO2Me
2-pyrazinyl



1185
3
SO2Me
2-pyrazinyl



1186
1
SO2NH2
2-pyrazinyl



1187
2
SO2NH2
2-pyrazinyl



1188
3
SO2NH2
2-pyrazinyl



1189
1
H
5-indolyl



1190
2
H
5-indolyl



1191
3
H
5-indolyl



1192
1
Me
5-indolyl



1193
2
Me
5-indolyl



1194
3
Me
5-indolyl



1195
1
CH2Ph
5-indolyl



1196
2
CH2Ph
5-indolyl



1197
3
CH2Ph
5-indolyl



1198
1
COMe
5-indolyl



1199
2
COMe
5-indolyl



1200
3
COMe
5-indolyl



1201
1
CO2Me
5-indolyl



1202
2
CO2Me
5-indolyl



1203
3
CO2Me
5-indolyl



1204
1
CO2tBu
5-indolyl



1205
2
CO2tBu
5-indolyl



1206
3
CO2tBu
5-indolyl



1207
1
CONHMe
5-indolyl



1208
2
CONHMe
5-indolyl



1209
3
CONHMe
5-indolyl



1210
1
SO2Me
5-indolyl



1211
2
SO2Me
5-indolyl



1212
3
SO2Me
5-indolyl



1213
1
SO2NH2
5-indolyl



1214
2
SO2NH2
5-indolyl



1215
3
SO2NH2
5-indolyl



1216
1
H
1H-benzo[d]imidazol-






4-yl



1217
2
H
1H-benzo[d]imidazol-






4-yl



1218
3
H
1H-benzo[d]imidazol-






4-yl



1219
1
Me
1H-benzo[d]imidazol-






4-yl



1220
2
Me
1H-benzo[d]imidazol-






4-yl



1221
3
Me
1H-benzo[d]imidazol-






4-yl



1222
1
CH2Ph
1H-benzo[d]imidazol-






4-yl



1223
2
CH2Ph
1H-benzo[d]imidazol-






4-yl



1224
3
CH2Ph
1H-benzo[d]imidazol-






4-yl



1225
1
COMe
1H-benzo[d]imidazol-






4-yl



1226
2
COMe
1H-benzo[d]imidazol-






4-yl



1227
3
COMe
1H-benzo[d]imidazol-






4-yl



1228
1
COMe
1H-benzo[d]imidazol-






4-yl



1229
2
CO2Me
1H-benzo[d]imidazol-






4-yl



1230
3
CO2Me
1H-benzo[d]imidazol-






4-yl



1231
1
CO2tBu
1H-benzo[d]imidazol-






4-yl



1232
2
CO2tBu
1H-benzo[d]imidazol-






4-yl



1233
3
CO2tBu
1H-benzo[d]imidazol-






4-yl



1234
1
CONHMe
1H-benzo[d]imidazol-






4-yl



1235
2
CONHMe
1H-benzo[d]imidazol-






4-yl



1236
3
CONHMe
1H-benzo[d]imidazol-






4-yl



1237
1
SO2Me
1H-benzo[d]imidazol-






4-yl



1238
2
SO2Me
1H-benzo[d]imidazol-






4-yl



1239
3
SO2Me
1H-benzo[d]imidazol-






4-yl



1240
1
SO2NH2
1H-benzo[d]imidazol-






4-yl



1241
2
SO2NH2
1H-benzo[d]imidazol-






4-yl



1242
3
SO2NH2
1H-benzo[d]imidazol-






4-yl










Exemplary embodiments include compounds having the formula (XVIII)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 2.














TABLE 2







Entry
n
R
R3





















1
1
H
Phenyl



2
2
H
Phenyl



3
3
H
Phenyl



4
1
Me
Phenyl



5
2
Me
Phenyl



6
3
Me
Phenyl



7
1
CH2Ph
Phenyl



8
2
CH2Ph
Phenyl



9
3
CH2Ph
Phenyl



10
1
COMe
Phenyl



11
2
COMe
Phenyl



12
3
COMe
Phenyl



13
1
CO2Me
Phenyl



14
2
CO2Me
Phenyl



15
3
CO2Me
Phenyl



16
1
CO2tBu
Phenyl



17
2
CO2tBu
Phenyl



18
3
CO2tBu
Phenyl



19
1
CONHMe
Phenyl



20
2
CONHMe
Phenyl



21
3
CONHMe
Phenyl



22
1
SO2Me
Phenyl



23
2
SO2Me
Phenyl



24
3
SO2Me
Phenyl



25
1
SO2NH2
Phenyl



26
2
SO2NH2
Phenyl



27
3
SO2NH2
Phenyl



28
1
H
3-OH-Phenyl



29
2
H
3-OH-Phenyl



30
3
H
3-OH-Phenyl



31
1
Me
3-OH-Phenyl



32
2
Me
3-OH-Phenyl



33
3
Me
3-OH-Phenyl



34
1
CH2Ph
3-OH-Phenyl



35
2
CH2Ph
3-OH-Phenyl



36
3
CH2Ph
3-OH-Phenyl



37
1
COMe
3-OH-Phenyl



38
2
COMe
3-OH-Phenyl



39
3
COMe
3-OH-Phenyl



40
1
CO2Me
3-OH-Phenyl



41
2
CO2Me
3-OH-Phenyl



42
3
CO2Me
3-OH-Phenyl



43
1
CO2tBu
3-OH-Phenyl



44
2
CO2tBu
3-OH-Phenyl



45
3
CO2tBu
3-OH-Phenyl



46
1
CONHMe
3-OH-Phenyl



47
2
CONHMe
3-OH-Phenyl



48
3
CONHMe
3-OH-Phenyl



49
1
SO2Me
3-OH-Phenyl



50
2
SO2Me
3-OH-Phenyl



51
3
SO2Me
3-OH-Phenyl



52
1
SO2NH2
3-OH-Phenyl



53
2
SO2NH2
3-OH-Phenyl



54
3
SO2NH2
3-OH-Phenyl



55
1
H
4-NO2-Phenyl



56
2
H
4-NO2-Phenyl



57
3
H
4-NO2-Phenyl



58
1
Me
4-NO2-Phenyl



59
2
Me
4-NO2-Phenyl



60
3
Me
4-NO2-Phenyl



61
1
CH2Ph
4-NO2-Phenyl



62
2
CH2Ph
4-NO2-Phenyl



63
3
CH2Ph
4-NO2-Phenyl



64
1
COMe
4-NO2-Phenyl



65
2
COMe
4-NO2-Phenyl



66
3
COMe
4-NO2-Phenyl



67
1
CO2Me
4-NO2-Phenyl



68
2
CO2Me
4-NO2-Phenyl



69
3
CO2Me
4-NO2-Phenyl



70
1
CO2tBu
4-NO2-Phenyl



71
2
CO2tBu
4-NO2-Phenyl



72
3
CO2tBu
4-NO2-Phenyl



73
1
CONHMe
4-NO2-Phenyl



74
2
CONHMe
4-NO2-Phenyl



75
3
CONHMe
4-NO2-Phenyl



76
1
SO2Me
4-NO2-Phenyl



77
2
SO2Me
4-NO2-Phenyl



78
3
SO2Me
4-NO2-Phenyl



79
1
SO2NH2
4-NO2-Phenyl



80
2
SO2NH2
4-NO2-Phenyl



81
3
SO2NH2
4-NO2-Phenyl



82
1
H
3-OMe-Phenyl



83
2
H
3-OMe-Phenyl



84
3
H
3-OMe-Phenyl



85
1
Me
3-OMe-Phenyl



86
2
Me
3-OMe-Phenyl



87
3
Me
3-OMe-Phenyl



88
1
CH2Ph
3-OMe-Phenyl



89
2
CH2Ph
3-OMe-Phenyl



90
3
CH2Ph
3-OMe-Phenyl



91
1
COMe
3-OMe-Phenyl



92
2
COMe
3-OMe-Phenyl



93
3
COMe
3-OMe-Phenyl



94
1
CO2Me
3-OMe-Phenyl



95
2
CO2Me
3-OMe-Phenyl



96
3
CO2Me
3-OMe-Phenyl



97
1
CO2tBu
3-OMe-Phenyl



98
2
CO2tBu
3-OMe-Phenyl



99
3
CO2tBu
3-OMe-Phenyl



100
1
CONHMe
3-OMe-Phenyl



101
2
CONHMe
3-OMe-Phenyl



102
3
CONHMe
3-OMe-Phenyl



103
1
SO2Me
3-OMe-Phenyl



104
2
SO2Me
3-OMe-Phenyl



105
3
SO2Me
3-OMe-Phenyl



106
1
SO2NH2
3-OMe-Phenyl



107
2
SO2NH2
3-OMe-Phenyl



108
3
SO2NH2
3-OMe-Phenyl



109
1
H
4-CN-Phenyl



110
2
H
4-CN-Phenyl



111
3
H
4-CN-Phenyl



112
1
Me
4-CN-Phenyl



113
2
Me
4-CN-Phenyl



114
3
Me
4-CN-Phenyl



115
1
CH2Ph
4-CN-Phenyl



116
2
CH2Ph
4-CN-Phenyl



117
3
CH2Ph
4-CN-Phenyl



118
1
COMe
4-CN-Phenyl



119
2
COMe
4-CN-Phenyl



120
3
COMe
4-CN-Phenyl



121
1
CO2Me
4-CN-Phenyl



122
2
CO2Me
4-CN-Phenyl



123
3
CO2Me
4-CN-Phenyl



124
1
CO2tBu
4-CN-Phenyl



125
2
CO2tBu
4-CN-Phenyl



126
3
CO2tBu
4-CN-Phenyl



127
1
CONHMe
4-CN-Phenyl



128
2
CONHMe
4-CN-Phenyl



129
3
CONHMe
4-CN-Phenyl



130
1
SO2Me
4-CN-Phenyl



131
2
SO2Me
4-CN-Phenyl



132
3
SO2Me
4-CN-Phenyl



133
1
SO2NH2
4-CN-Phenyl



134
2
SO2NH2
4-CN-Phenyl



135
3
SO2NH2
4-CN-Phenyl



136
1
H
2-CN-Phenyl



137
2
H
2-CN-Phenyl



138
3
H
2-CN-Phenyl



139
1
Me
2-CN-Phenyl



140
2
Me
2-CN-Phenyl



141
3
Me
2-CN-Phenyl



142
1
CH2Ph
2-CN-Phenyl



143
2
CH2Ph
2-CN-Phenyl



144
3
CH2Ph
2-CN-Phenyl



145
1
COMe
2-CN-Phenyl



146
2
COMe
2-CN-Phenyl



147
3
COMe
2-CN-Phenyl



148
1
CO2Me
2-CN-Phenyl



149
2
CO2Me
2-CN-Phenyl



150
3
CO2Me
2-CN-Phenyl



151
1
CO2tBu
2-CN-Phenyl



152
2
CO2tBu
2-CN-Phenyl



153
3
CO2tBu
2-CN-Phenyl



154
1
CONHMe
2-CN-Phenyl



155
2
CONHMe
2-CN-Phenyl



156
3
CONHMe
2-CN-Phenyl



157
1
SO2Me
2-CN-Phenyl



158
2
SO2Me
2-CN-Phenyl



159
3
SO2Me
2-CN-Phenyl



160
1
SO2NH2
2-CN-Phenyl



161
2
SO2NH2
2-CN-Phenyl



162
3
SO2NH2
2-CN-Phenyl



163
1
H
3-Me-Phenyl



164
2
H
3-Me-Phenyl



165
3
H
3-Me-Phenyl



166
1
Me
3-Me-Phenyl



167
2
Me
3-Me-Phenyl



168
3
Me
3-Me-Phenyl



169
1
CH2Ph
3-Me-Phenyl



170
2
CH2Ph
3-Me-Phenyl



171
3
CH2Ph
3-Me-Phenyl



172
1
COMe
3-Me-Phenyl



173
2
COMe
3-Me-Phenyl



174
3
COMe
3-Me-Phenyl



175
1
CO2Me
3-Me-Phenyl



176
2
CO2Me
3-Me-Phenyl



177
3
CO2Me
3-Me-Phenyl



178
1
CO2tBu
3-Me-Phenyl



179
2
CO2tBu
3-Me-Phenyl



180
3
CO2tBu
3-Me-Phenyl



181
1
CONHMe
3-Me-Phenyl



182
2
CONHMe
3-Me-Phenyl



183
3
CONHMe
3-Me-Phenyl



184
1
SO2Me
3-Me-Phenyl



185
2
SO2Me
3-Me-Phenyl



186
3
SO2Me
3-Me-Phenyl



187
1
SO2NH2
3-Me-Phenyl



188
2
SO2NH2
3-Me-Phenyl



189
3
SO2NH2
3-Me-Phenyl



190
1
H
2-F-Phenyl



191
2
H
2-F-Phenyl



192
3
H
2-F-Phenyl



193
1
Me
2-F-Phenyl



194
2
Me
2-F-Phenyl



195
3
Me
2-F-Phenyl



196
1
CH2Ph
2-F-Phenyl



197
2
CH2Ph
2-F-Phenyl



198
3
CH2Ph
2-F-Phenyl



199
1
COMe
2-F-Phenyl



200
2
COMe
2-F-Phenyl



201
3
COMe
2-F-Phenyl



202
1
CO2Me
2-F-Phenyl



203
2
CO2Me
2-F-Phenyl



204
3
CO2Me
2-F-Phenyl



205
1
CO2tBu
2-F-Phenyl



206
2
CO2tBu
2-F-Phenyl



207
3
CO2tBu
2-F-Phenyl



208
1
CONHMe
2-F-Phenyl



209
2
CONHMe
2-F-Phenyl



210
3
CONHMe
2-F-Phenyl



211
1
SO2Me
2-F-Phenyl



212
2
SO2Me
2-F-Phenyl



213
3
SO2Me
2-F-Phenyl



214
1
SO2NH2
2-F-Phenyl



215
2
SO2NH2
2-F-Phenyl



216
3
SO2NH2
2-F-Phenyl



217
1
H
4-F-Phenyl



218
2
H
4-F-Phenyl



219
3
H
4-F-Phenyl



220
1
Me
4-F-Phenyl



221
2
Me
4-F-Phenyl



222
3
Me
4-F-Phenyl



223
1
CH2Ph
4-F-Phenyl



224
2
CH2Ph
4-F-Phenyl



225
3
CH2Ph
4-F-Phenyl



226
1
COMe
4-F-Phenyl



227
2
COMe
4-F-Phenyl



228
3
COMe
4-F-Phenyl



229
1
CO2Me
4-F-Phenyl



230
2
CO2Me
4-F-Phenyl



231
3
CO2Me
4-F-Phenyl



232
1
CO2tBu
4-F-Phenyl



233
2
CO2tBu
4-F-Phenyl



234
3
CO2tBu
4-F-Phenyl



235
1
CONHMe
4-F-Phenyl



236
2
CONHMe
4-F-Phenyl



237
3
CONHMe
4-F-Phenyl



238
1
SO2Me
4-F-Phenyl



239
2
SO2Me
4-F-Phenyl



240
3
SO2Me
4-F-Phenyl



241
1
SO2NH2
4-F-Phenyl



242
2
SO2NH2
4-F-Phenyl



243
3
SO2NH2
4-F-Phenyl



244
1
H
3-Cl-Phenyl



245
2
H
3-Cl-Phenyl



246
3
H
3-Cl-Phenyl



247
1
Me
3-Cl-Phenyl



248
2
Me
3-Cl-Phenyl



249
3
Me
3-Cl-Phenyl



250
1
CH2Ph
3-Cl-Phenyl



251
2
CH2Ph
3-Cl-Phenyl



252
3
CH2Ph
3-Cl-Phenyl



253
1
COMe
3-Cl-Phenyl



254
2
COMe
3-Cl-Phenyl



255
3
COMe
3-Cl-Phenyl



256
1
CO2Me
3-Cl-Phenyl



257
2
CO2Me
3-Cl-Phenyl



258
3
CO2Me
3-Cl-Phenyl



259
1
CO2tBu
3-Cl-Phenyl



260
2
CO2tBu
3-Cl-Phenyl



261
3
CO2tBu
3-Cl-Phenyl



262
1
CONHMe
3-Cl-Phenyl



263
2
CONHMe
3-Cl-Phenyl



264
3
CONHMe
3-Cl-Phenyl



265
1
SO2Me
3-Cl-Phenyl



266
2
SO2Me
3-Cl-Phenyl



267
3
SO2Me
3-Cl-Phenyl



268
1
SO2NH2
3-Cl-Phenyl



269
2
SO2NH2
3-Cl-Phenyl



270
3
SO2NH2
3-Cl-Phenyl



271
1
H
2-Br-Phenyl



272
2
H
2-Br-Phenyl



273
3
H
2-Br-Phenyl



274
1
Me
2-Br-Phenyl



275
2
Me
2-Br-Phenyl



276
3
Me
2-Br-Phenyl



277
1
CH2Ph
2-Br-Phenyl



278
2
CH2Ph
2-Br-Phenyl



279
3
CH2Ph
2-Br-Phenyl



280
1
COMe
2-Br-Phenyl



281
2
COMe
2-Br-Phenyl



282
3
COMe
2-Br-Phenyl



283
1
CO2Me
2-Br-Phenyl



284
2
CO2Me
2-Br-Phenyl



285
3
CO2Me
2-Br-Phenyl



286
1
CO2tBu
2-Br-Phenyl



287
2
CO2tBu
2-Br-Phenyl



288
3
CO2tBu
2-Br-Phenyl



289
1
CONHMe
2-Br-Phenyl



290
2
CONHMe
2-Br-Phenyl



291
3
CONHMe
2-Br-Phenyl



292
1
SO2Me
2-Br-Phenyl



293
2
SO2Me
2-Br-Phenyl



294
3
SO2Me
2-Br-Phenyl



295
1
SO2NH2
2-Br-Phenyl



296
2
SO2NH2
2-Br-Phenyl



297
3
SO2NH2
2-Br-Phenyl



298
1
H
4-Br-Phenyl



299
2
H
4-Br-Phenyl



300
3
H
4-Br-Phenyl



301
1
Me
4-Br-Phenyl



302
2
Me
4-Br-Phenyl



303
3
Me
4-Br-Phenyl



304
1
CH2Ph
4-Br-Phenyl



305
2
CH2Ph
4-Br-Phenyl



306
3
CH2Ph
4-Br-Phenyl



307
1
COMe
4-Br-Phenyl



308
2
COMe
4-Br-Phenyl



309
3
COMe
4-Br-Phenyl



310
1
CO2Me
4-Br-Phenyl



311
2
CO2Me
4-Br-Phenyl



312
3
CO2Me
4-Br-Phenyl



313
1
CO2tBu
4-Br-Phenyl



314
2
CO2tBu
4-Br-Phenyl



315
3
CO2tBu
4-Br-Phenyl



316
1
CONHMe
4-Br-Phenyl



317
2
CONHMe
4-Br-Phenyl



318
3
CONHMe
4-Br-Phenyl



319
1
SO2Me
4-Br-Phenyl



320
2
SO2Me
4-Br-Phenyl



321
3
SO2Me
4-Br-Phenyl



322
1
SO2NH2
4-Br-Phenyl



323
2
SO2NH2
4-Br-Phenyl



324
3
SO2NH2
4-Br-Phenyl



325
1
H
3-CF3-Phenyl



326
2
H
3-CF3-Phenyl



327
3
H
3-CF3-Phenyl



328
1
Me
3-CF3-Phenyl



329
2
Me
3-CF3-Phenyl



330
3
Me
3-CF3-Phenyl



331
1
CH2Ph
3-CF3-Phenyl



332
2
CH2Ph
3-CF3-Phenyl



333
3
CH2Ph
3-CF3-Phenyl



334
1
COMe
3-CF3-Phenyl



335
2
COMe
3-CF3-Phenyl



336
3
COMe
3-CF3-Phenyl



337
1
CO2Me
3-CF3-Phenyl



338
2
CO2Me
3-CF3-Phenyl



339
3
CO2Me
3-CF3-Phenyl



340
1
CO2tBu
3-CF3-Phenyl



341
2
CO2tBu
3-CF3-Phenyl



342
3
CO2tBu
3-CF3-Phenyl



343
1
CONHMe
3-CF3-Phenyl



344
2
CONHMe
3-CF3-Phenyl



345
3
CONHMe
3-CF3-Phenyl



346
1
SO2Me
3-CF3-Phenyl



347
2
SO2Me
3-CF3-Phenyl



348
3
SO2Me
3-CF3-Phenyl



349
1
SO2NH2
3-CF3-Phenyl



350
2
SO2NH2
3-CF3-Phenyl



351
3
SO2NH2
3-CF3-Phenyl



352
1
H
2-iPr-Phenyl



353
2
H
2-iPr-Phenyl



354
3
H
2-iPr-Phenyl



355
1
Me
2-iPr-Phenyl



356
2
Me
2-iPr-Phenyl



357
3
Me
2-iPr-Phenyl



358
1
CH2Ph
2-iPr-Phenyl



359
2
CH2Ph
2-iPr-Phenyl



360
3
CH2Ph
2-iPr-Phenyl



361
1
COMe
2-iPr-Phenyl



362
2
COMe
2-iPr-Phenyl



363
3
COMe
2-iPr-Phenyl



364
1
CO2Me
2-iPr-Phenyl



365
2
CO2Me
2-iPr-Phenyl



366
3
CO2Me
2-iPr-Phenyl



367
1
CO2tBu
2-iPr-Phenyl



368
2
CO2tBu
2-iPr-Phenyl



369
3
CO2tBu
2-iPr-Phenyl



370
1
CONHMe
2-iPr-Phenyl



371
2
CONHMe
2-iPr-Phenyl



372
3
CONHMe
2-iPr-Phenyl



373
1
SO2Me
2-iPr-Phenyl



374
2
SO2Me
2-iPr-Phenyl



375
3
SO2Me
2-iPr-Phenyl



376
1
SO2NH2
2-iPr-Phenyl



377
2
SO2NH2
2-iPr-Phenyl



378
3
SO2NH2
2-iPr-Phenyl



379
1
H
4-iPr-Phenyl



380
2
H
4-iPr-Phenyl



381
3
H
4-iPr-Phenyl



382
1
Me
4-iPr-Phenyl



383
2
Me
4-iPr-Phenyl



384
3
Me
4-iPr-Phenyl



385
1
CH2Ph
4-iPr-Phenyl



386
2
CH2Ph
4-iPr-Phenyl



387
3
CH2Ph
4-iPr-Phenyl



388
1
COMe
4-iPr-Phenyl



389
2
COMe
4-iPr-Phenyl



390
3
COMe
4-iPr-Phenyl



391
1
CO2Me
4-iPr-Phenyl



392
2
CO2Me
4-iPr-Phenyl



393
3
CO2Me
4-iPr-Phenyl



394
1
CO2tBu
4-iPr-Phenyl



395
2
CO2tBu
4-iPr-Phenyl



396
3
CO2tBu
4-iPr-Phenyl



397
1
CONHMe
4-iPr-Phenyl



398
2
CONHMe
4-iPr-Phenyl



399
3
CONHMe
4-iPr-Phenyl



400
1
SO2Me
4-iPr-Phenyl



401
2
SO2Me
4-iPr-Phenyl



402
3
SO2Me
4-iPr-Phenyl



403
1
SO2NH2
4-iPr-Phenyl



404
2
SO2NH2
4-iPr-Phenyl



405
3
SO2NH2
4-iPr-Phenyl



406
1
H
3-NH2-Phenyl



407
2
H
3-NH2-Phenyl



408
3
H
3-NH2-Phenyl



409
1
Me
3-NH2-Phenyl



410
2
Me
3-NH2-Phenyl



411
3
Me
3-NH2-Phenyl



412
1
CH2Ph
3-NH2-Phenyl



413
2
CH2Ph
3-NH2-Phenyl



414
3
CH2Ph
3-NH2-Phenyl



415
1
COMe
3-NH2-Phenyl



416
2
COMe
3-NH2-Phenyl



417
3
COMe
3-NH2-Phenyl



418
1
CO2Me
3-NH2-Phenyl



419
2
CO2Me
3-NH2-Phenyl



420
3
CO2Me
3-NH2-Phenyl



421
1
CO2tBu
3-NH2-Phenyl



422
2
CO2tBu
3-NH2-Phenyl



423
3
CO2tBu
3-NH2-Phenyl



424
1
CONHMe
3-NH2-Phenyl



425
2
CONHMe
3-NH2-Phenyl



426
3
CONHMe
3-NH2-Phenyl



427
1
SO2Me
3-NH2-Phenyl



428
2
SO2Me
3-NH2-Phenyl



429
3
SO2Me
3-NH2-Phenyl



430
1
SO2NH2
3-NH2-Phenyl



431
2
SO2NH2
3-NH2-Phenyl



432
3
SO2NH2
3-NH2-Phenyl



433
1
H
2,4-di-Me-Phenyl



434
2
H
2,4-di-Me-Phenyl



435
3
H
2,4-di-Me-Phenyl



436
1
Me
2,4-di-Me-Phenyl



437
2
Me
2,4-di-Me-Phenyl



438
3
Me
2,4-di-Me-Phenyl



439
1
CH2Ph
2,4-di-Me-Phenyl



440
2
CH2Ph
2,4-di-Me-Phenyl



441
3
CH2Ph
2,4-di-Me-Phenyl



442
1
COMe
2,4-di-Me-Phenyl



443
2
COMe
2,4-di-Me-Phenyl



444
3
COMe
2,4-di-Me-Phenyl



445
1
CO2Me
2,4-di-Me-Phenyl



446
2
CO2Me
2,4-di-Me-Phenyl



447
3
CO2Me
2,4-di-Me-Phenyl



448
1
CO2tBu
2,4-di-Me-Phenyl



449
2
CO2tBu
2,4-di-Me-Phenyl



450
3
CO2tBu
2,4-di-Me-Phenyl



451
1
CONHMe
2,4-di-Me-Phenyl



452
2
CONHMe
2,4-di-Me-Phenyl



453
3
CONHMe
2,4-di-Me-Phenyl



454
1
SO2Me
2,4-di-Me-Phenyl



455
2
SO2Me
2,4-di-Me-Phenyl



456
3
SO2Me
2,4-di-Me-Phenyl



457
1
SO2NH2
2,4-di-Me-Phenyl



458
2
SO2NH2
2,4-di-Me-Phenyl



459
3
SO2NH2
2,4-di-Me-Phenyl



460
1
H
2,6-di-iPr-Phenyl



461
2
H
2,6-di-iPr-Phenyl



462
3
H
2,6-di-iPr-Phenyl



463
1
Me
2,6-di-iPr-Phenyl



464
2
Me
2,6-di-iPr-Phenyl



465
3
Me
2,6-di-iPr-Phenyl



466
1
CH2Ph
2,6-di-iPr-Phenyl



467
2
CH2Ph
2,6-di-iPr-Phenyl



468
3
CH2Ph
2,6-di-iPr-Phenyl



469
1
COMe
2,6-di-iPr-Phenyl



470
2
COMe
2,6-di-iPr-Phenyl



471
3
COMe
2,6-di-iPr-Phenyl



472
1
CO2Me
2,6-di-iPr-Phenyl



473
2
CO2Me
2,6-di-iPr-Phenyl



474
3
CO2Me
2,6-di-iPr-Phenyl



475
1
CO2tBu
2,6-di-iPr-Phenyl



476
2
CO2tBu
2,6-di-iPr-Phenyl



477
3
CO2tBu
2,6-di-iPr-Phenyl



478
1
CONHMe
2,6-di-iPr-Phenyl



479
2
CONHMe
2,6-di-iPr-Phenyl



480
3
CONHMe
2,6-di-iPr-Phenyl



481
1
SO2Me
2,6-di-iPr-Phenyl



482
2
SO2Me
2,6-di-iPr-Phenyl



483
3
SO2Me
2,6-di-iPr-Phenyl



484
1
SO2NH2
2,6-di-iPr-Phenyl



485
2
SO2NH2
2,6-di-iPr-Phenyl



486
3
SO2NH2
2,6-di-iPr-Phenyl



487
1
H
3-Ph-Phenyl



488
2
H
3-Ph-Phenyl



489
3
H
3-Ph-Phenyl



490
1
Me
3-Ph-Phenyl



491
2
Me
3-Ph-Phenyl



492
3
Me
3-Ph-Phenyl



493
1
CH2Ph
3-Ph-Phenyl



494
2
CH2Ph
3-Ph-Phenyl



495
3
CH2Ph
3-Ph-Phenyl



496
1
COMe
3-Ph-Phenyl



497
2
COMe
3-Ph-Phenyl



498
3
COMe
3-Ph-Phenyl



499
1
CO2Me
3-Ph-Phenyl



500
2
CO2Me
3-Ph-Phenyl



501
3
CO2Me
3-Ph-Phenyl



502
1
CO2tBu
3-Ph-Phenyl



503
2
CO2tBu
3-Ph-Phenyl



504
3
CO2tBu
3-Ph-Phenyl



505
1
CONHMe
3-Ph-Phenyl



506
2
CONHMe
3-Ph-Phenyl



507
3
CONHMe
3-Ph-Phenyl



508
1
SO2Me
3-Ph-Phenyl



509
2
SO2Me
3-Ph-Phenyl



510
3
SO2Me
3-Ph-Phenyl



511
1
SO2NH2
3-Ph-Phenyl



512
2
SO2NH2
3-Ph-Phenyl



513
3
SO2NH2
3-Ph-Phenyl



514
1
H
2-morpholino-phenyl



515
2
H
2-morpholino-phenyl



516
3
H
2-morpholino-phenyl



517
1
Me
2-morpholino-phenyl



518
2
Me
2-morpholino-phenyl



519
3
Me
2-morpholino-phenyl



520
1
CH2Ph
2-morpholino-phenyl



521
2
CH2Ph
2-morpholino-phenyl



522
3
CH2Ph
2-morpholino-phenyl



523
1
COMe
2-morpholino-phenyl



524
2
COMe
2-morpholino-phenyl



525
3
COMe
2-morpholino-phenyl



526
1
CO2Me
2-morpholino-phenyl



527
2
CO2Me
2-morpholino-phenyl



528
3
CO2Me
2-morpholino-phenyl



529
1
CO2tBu
2-morpholino-phenyl



530
2
CO2tBu
2-morpholino-phenyl



531
3
CO2tBu
2-morpholino-phenyl



532
1
CONHMe
2-morpholino-phenyl



533
2
CONHMe
2-morpholino-phenyl



534
3
CONHMe
2-morpholino-phenyl



535
1
SO2Me
2-morpholino-phenyl



536
2
SO2Me
2-morpholino-phenyl



537
3
SO2Me
2-morpholino-phenyl



538
1
SO2NH2
2-morpholino-phenyl



539
2
SO2NH2
2-morpholino-phenyl



540
3
SO2NH2
2-morpholino-phenyl



541
1
H
4-morpholino-phenyl



542
2
H
4-morpholino-phenyl



543
3
H
4-morpholino-phenyl



544
1
Me
4-morpholino-phenyl



545
2
Me
4-morpholino-phenyl



546
3
Me
4-morpholino-phenyl



547
1
CH2Ph
4-morpholino-phenyl



548
2
CH2Ph
4-morpholino-phenyl



549
3
CH2Ph
4-morpholino-phenyl



550
1
COMe
4-morpholino-phenyl



551
2
COMe
4-morpholino-phenyl



552
3
COMe
4-morpholino-phenyl



553
1
CO2Me
4-morpholino-phenyl



554
2
CO2Me
4-morpholino-phenyl



555
3
CO2Me
4-morpholino-phenyl



556
1
CO2tBu
4-morpholino-phenyl



557
2
CO2tBu
4-morpholino-phenyl



558
3
CO2tBu
4-morpholino-phenyl



559
1
CONHMe
4-morpholino-phenyl



560
2
CONHMe
4-morpholino-phenyl



561
3
CONHMe
4-morpholino-phenyl



562
1
SO2Me
4-morpholino-phenyl



563
2
SO2Me
4-morpholino-phenyl



564
3
SO2Me
4-morpholino-phenyl



565
1
SO2NH2
4-morpholino-phenyl



566
2
SO2NH2
4-morpholino-phenyl



567
3
SO2NH2
4-morpholino-phenyl



568
1
H
2-pyrimidinyl



569
2
H
2-pyrimidinyl



570
3
H
2-pyrimidinyl



571
1
Me
2-pyrimidinyl



572
2
Me
2-pyrimidinyl



573
3
Me
2-pyrimidinyl



574
1
CH2Ph
2-pyrimidinyl



575
2
CH2Ph
2-pyrimidinyl



576
3
CH2Ph
2-pyrimidinyl



577
1
COMe
2-pyrimidinyl



578
2
COMe
2-pyrimidinyl



579
3
COMe
2-pyrimidinyl



580
1
CO2Me
2-pyrimidinyl



581
2
CO2Me
2-pyrimidinyl



582
3
CO2Me
2-pyrimidinyl



583
1
CO2tBu
2-pyrimidinyl



584
2
CO2tBu
2-pyrimidinyl



585
3
CO2tBu
2-pyrimidinyl



586
1
CONHMe
2-pyrimidinyl



587
2
CONHMe
2-pyrimidinyl



588
3
CONHMe
2-pyrimidinyl



589
1
SO2Me
2-pyrimidinyl



590
2
SO2Me
2-pyrimidinyl



591
3
SO2Me
2-pyrimidinyl



592
1
SO2NH2
2-pyrimidinyl



593
2
SO2NH2
2-pyrimidinyl



594
3
SO2NH2
2-pyrimidinyl



595
1
H
2-methyl-1H-






benzo[d]imidazol-4-yl



596
2
H
2-methyl-1H-






benzo[d]imidazol-4-yl



597
3
H
2-methyl-1H-






benzo[d]imidazol-4-yl



598
1
Me
2-methyl-1H-






benzo[d]imidazol-4-yl



599
2
Me
2-methyl-1H-






benzo[d]imidazol-4-yl



600
3
Me
2-methyl-1H-






benzo[d]imidazol-4-yl



601
1
CH2Ph
2-methyl-1H-






benzo[d]imidazol-4-yl



602
2
CH2Ph
2-methyl-1H-






benzo[d]imidazol-4-yl



603
3
CH2Ph
2-methyl-1H-






benzo[d]imidazol-4-yl



604
1
COMe
2-methyl-1H-






benzo[d]imidazol-4-yl



605
2
COMe
2-methyl-1H-






benzo[d]imidazol-4-yl



606
3
COMe
2-methyl-1H-






benzo[d]imidazol-4-yl



607
1
CO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



608
2
CO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



609
3
CO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



610
1
CO2tBu
2-methyl-1H-






benzo[d]imidazol-4-yl



611
2
CO2tBu
2-methyl-1H-






benzo[d]imidazol-4-yl



612
3
CO2tBu
2-methyl-1H-






benzo[d]imidazol-4-yl



613
1
CONHMe
2-methyl-1H-






benzo[d]imidazol-4-yl



614
2
CONHMe
2-methyl-1H-






benzo[d]imidazol-4-yl



615
3
CONHMe
2-methyl-1H-






benzo[d]imidazol-4-yl



616
1
SO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



617
2
SO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



618
3
SO2Me
2-methyl-1H-






benzo[d]imidazol-4-yl



619
1
SO2NH2
2-methyl-1H-






benzo[d]imidazol-4-yl



620
2
SO2NH2
2-methyl-1H-






benzo[d]imidazol-4-yl



621
3
SO2NH2
2-methyl-1H-






benzo[d]imidazol-4-yl



622
1
H
4-OH-Phenyl



623
2
H
4-OH-Phenyl



624
3
H
4-OH-Phenyl



625
1
Me
4-OH-Phenyl



626
2
Me
4-OH-Phenyl



627
3
Me
4-OH-Phenyl



628
1
CH2Ph
4-OH-Phenyl



629
2
CH2Ph
4-OH-Phenyl



630
3
CH2Ph
4-OH-Phenyl



631
1
COMe
4-OH-Phenyl



632
2
COMe
4-OH-Phenyl



633
3
COMe
4-OH-Phenyl



634
1
CO2Me
4-OH-Phenyl



635
2
CO2Me
4-OH-Phenyl



636
3
CO2Me
4-OH-Phenyl



637
1
CO2tBu
4-OH-Phenyl



638
2
CO2tBu
4-OH-Phenyl



639
3
CO2tBu
4-OH-Phenyl



640
1
CONHMe
4-OH-Phenyl



641
2
CONHMe
4-OH-Phenyl



642
3
CONHMe
4-OH-Phenyl



643
1
SO2Me
4-OH-Phenyl



644
2
SO2Me
4-OH-Phenyl



645
3
SO2Me
4-OH-Phenyl



646
1
SO2NH2
4-OH-Phenyl



647
2
SO2NH2
4-OH-Phenyl



648
3
SO2NH2
4-OH-Phenyl



649
1
H
2-OH-Phenyl



650
2
H
2-OH-Phenyl



651
3
H
2-OH-Phenyl



652
1
Me
2-OH-Phenyl



653
2
Me
2-OH-Phenyl



654
3
Me
2-OH-Phenyl



655
1
CH2Ph
2-OH-Phenyl



656
2
CH2Ph
2-OH-Phenyl



657
3
CH2Ph
2-OH-Phenyl



658
1
COMe
2-OH-Phenyl



659
2
COMe
2-OH-Phenyl



660
3
COMe
2-OH-Phenyl



661
1
CO2Me
2-OH-Phenyl



662
2
CO2Me
2-OH-Phenyl



663
3
CO2Me
2-OH-Phenyl



664
1
CO2tBu
2-OH-Phenyl



665
2
CO2tBu
2-OH-Phenyl



666
3
CO2tBu
2-OH-Phenyl



667
1
CONHMe
2-OH-Phenyl



668
2
CONHMe
2-OH-Phenyl



669
3
CONHMe
2-OH-Phenyl



670
1
SO2Me
2-OH-Phenyl



671
2
SO2Me
2-OH-Phenyl



672
3
SO2Me
2-OH-Phenyl



673
1
SO2NH2
2-OH-Phenyl



674
2
SO2NH2
2-OH-Phenyl



675
3
SO2NH2
2-OH-Phenyl



676
1
H
4-OMe-Phenyl



677
2
H
4-OMe-Phenyl



678
3
H
4-OMe-Phenyl



679
1
Me
4-OMe-Phenyl



680
2
Me
4-OMe-Phenyl



681
3
Me
4-OMe-Phenyl



682
1
CH2Ph
4-OMe-Phenyl



683
2
CH2Ph
4-OMe-Phenyl



684
3
CH2Ph
4-OMe-Phenyl



685
1
COMe
4-OMe-Phenyl



686
2
COMe
4-OMe-Phenyl



687
3
COMe
4-OMe-Phenyl



688
1
CO2Me
4-OMe-Phenyl



689
2
CO2Me
4-OMe-Phenyl



690
3
CO2Me
4-OMe-Phenyl



691
1
CO2tBu
4-OMe-Phenyl



692
2
CO2tBu
4-OMe-Phenyl



693
3
CO2tBu
4-OMe-Phenyl



694
1
CONHMe
4-OMe-Phenyl



695
2
CONHMe
4-OMe-Phenyl



696
3
CONHMe
4-OMe-Phenyl



697
1
SO2Me
4-OMe-Phenyl



698
2
SO2Me
4-OMe-Phenyl



699
3
SO2Me
4-OMe-Phenyl



700
1
SO2NH2
4-OMe-Phenyl



701
2
SO2NH2
4-OMe-Phenyl



702
3
SO2NH2
4-OMe-Phenyl



703
1
H
2-OMe-Phenyl



704
2
H
2-OMe-Phenyl



705
3
H
2-OMe-Phenyl



706
1
Me
2-OMe-Phenyl



707
2
Me
2-OMe-Phenyl



708
3
Me
2-OMe-Phenyl



709
1
CH2Ph
2-OMe-Phenyl



710
2
CH2Ph
2-OMe-Phenyl



711
3
CH2Ph
2-OMe-Phenyl



712
1
COMe
2-OMe-Phenyl



713
2
COMe
2-OMe-Phenyl



714
3
COMe
2-OMe-Phenyl



715
1
CO2Me
2-OMe-Phenyl



716
2
CO2Me
2-OMe-Phenyl



717
3
CO2Me
2-OMe-Phenyl



718
1
CO2tBu
2-OMe-Phenyl



719
2
CO2tBu
2-OMe-Phenyl



720
3
CO2tBu
2-OMe-Phenyl



721
1
CONHMe
2-OMe-Phenyl



722
2
CONHMe
2-OMe-Phenyl



723
3
CONHMe
2-OMe-Phenyl



724
1
SO2Me
2-OMe-Phenyl



725
2
SO2Me
2-OMe-Phenyl



726
3
SO2Me
2-OMe-Phenyl



727
1
SO2NH2
2-OMe-Phenyl



728
2
SO2NH2
2-OMe-Phenyl



729
3
SO2NH2
2-OMe-Phenyl



730
1
H
3-CN-Phenyl



731
2
H
3-CN-Phenyl



732
3
H
3-CN-Phenyl



733
1
Me
3-CN-Phenyl



734
2
Me
3-CN-Phenyl



735
3
Me
3-CN-Phenyl



736
1
CH2Ph
3-CN-Phenyl



737
2
CH2Ph
3-CN-Phenyl



738
3
CH2Ph
3-CN-Phenyl



739
1
COMe
3-CN-Phenyl



740
2
COMe
3-CN-Phenyl



741
3
COMe
3-CN-Phenyl



742
1
CO2Me
3-CN-Phenyl



743
2
CO2Me
3-CN-Phenyl



744
3
CO2Me
3-CN-Phenyl



745
1
CO2tBu
3-CN-Phenyl



746
2
CO2tBu
3-CN-Phenyl



747
3
CO2tBu
3-CN-Phenyl



748
1
CONHMe
3-CN-Phenyl



749
2
CONHMe
3-CN-Phenyl



750
3
CONHMe
3-CN-Phenyl



751
1
SO2Me
3-CN-Phenyl



752
2
SO2Me
3-CN-Phenyl



753
3
SO2Me
3-CN-Phenyl



754
1
SO2NH2
3-CN-Phenyl



755
2
SO2NH2
3-CN-Phenyl



756
3
SO2NH2
3-CN-Phenyl



757
1
H
2-Me-Phenyl



758
2
H
2-Me-Phenyl



759
3
H
2-Me-Phenyl



760
1
Me
2-Me-Phenyl



761
2
Me
2-Me-Phenyl



762
3
Me
2-Me-Phenyl



763
1
CH2Ph
2-Me-Phenyl



764
2
CH2Ph
2-Me-Phenyl



765
3
CH2Ph
2-Me-Phenyl



766
1
COMe
2-Me-Phenyl



767
2
COMe
2-Me-Phenyl



768
3
COMe
2-Me-Phenyl



769
1
CO2Me
2-Me-Phenyl



770
2
CO2Me
2-Me-Phenyl



771
3
CO2Me
2-Me-Phenyl



772
1
CO2tBu
2-Me-Phenyl



773
2
CO2tBu
2-Me-Phenyl



774
3
CO2tBu
2-Me-Phenyl



775
1
CONHMe
2-Me-Phenyl



776
2
CONHMe
2-Me-Phenyl



777
3
CONHMe
2-Me-Phenyl



778
1
SO2Me
2-Me-Phenyl



779
2
SO2Me
2-Me-Phenyl



780
3
SO2Me
2-Me-Phenyl



781
1
SO2NH2
2-Me-Phenyl



782
2
SO2NH2
2-Me-Phenyl



783
3
SO2NH2
2-Me-Phenyl



784
1
H
4-Me-Phenyl



785
2
H
4-Me-Phenyl



786
3
H
4-Me-Phenyl



787
1
Me
4-Me-Phenyl



788
2
Me
4-Me-Phenyl



789
3
Me
4-Me-Phenyl



790
1
CH2Ph
4-Me-Phenyl



791
2
CH2Ph
4-Me-Phenyl



792
3
CH2Ph
4-Me-Phenyl



793
1
COMe
4-Me-Phenyl



794
2
COMe
4-Me-Phenyl



795
3
COMe
4-Me-Phenyl



796
1
CO2Me
4-Me-Phenyl



797
2
CO2Me
4-Me-Phenyl



798
3
CO2Me
4-Me-Phenyl



799
1
CO2tBu
4-Me-Phenyl



800
2
CO2tBu
4-Me-Phenyl



801
3
CO2tBu
4-Me-Phenyl



802
1
CONHMe
4-Me-Phenyl



803
2
CONHMe
4-Me-Phenyl



804
3
CONHMe
4-Me-Phenyl



805
1
SO2Me
4-Me-Phenyl



806
2
SO2Me
4-Me-Phenyl



807
3
SO2Me
4-Me-Phenyl



808
1
SO2NH2
4-Me-Phenyl



809
2
SO2NH2
4-Me-Phenyl



810
3
SO2NH2
4-Me-Phenyl



811
1
H
3-F-Phenyl



812
2
H
3-F-Phenyl



813
3
H
3-F-Phenyl



814
1
Me
3-F-Phenyl



815
2
Me
3-F-Phenyl



816
3
Me
3-F-Phenyl



817
1
CH2Ph
3-F-Phenyl



818
2
CH2Ph
3-F-Phenyl



819
3
CH2Ph
3-F-Phenyl



820
1
COMe
3-F-Phenyl



821
2
COMe
3-F-Phenyl



822
3
COMe
3-F-Phenyl



823
1
CO2Me
3-F-Phenyl



824
2
CO2Me
3-F-Phenyl



825
3
CO2Me
3-F-Phenyl



826
1
CO2tBu
3-F-Phenyl



827
2
CO2tBu
3-F-Phenyl



828
3
CO2tBu
3-F-Phenyl



829
1
CONHMe
3-F-Phenyl



830
2
CONHMe
3-F-Phenyl



831
3
CONHMe
3-F-Phenyl



832
1
SO2Me
3-F-Phenyl



833
2
SO2Me
3-F-Phenyl



834
3
SO2Me
3-F-Phenyl



835
1
SO2NH2
3-F-Phenyl



836
2
SO2NH2
3-F-Phenyl



837
3
SO2NH2
3-F-Phenyl



838
1
H
2-Cl-Phenyl



839
2
H
2-Cl-Phenyl



840
3
H
2-Cl-Phenyl



841
1
Me
2-Cl-Phenyl



842
2
Me
2-Cl-Phenyl



843
3
Me
2-Cl-Phenyl



844
1
CH2Ph
2-Cl-Phenyl



845
2
CH2Ph
2-Cl-Phenyl



846
3
CH2Ph
2-Cl-Phenyl



847
1
COMe
2-Cl-Phenyl



848
2
COMe
2-Cl-Phenyl



849
3
COMe
2-Cl-Phenyl



850
1
CO2Me
2-Cl-Phenyl



851
2
CO2Me
2-Cl-Phenyl



852
3
CO2Me
2-Cl-Phenyl



853
1
CO2tBu
2-Cl-Phenyl



854
2
CO2tBu
2-Cl-Phenyl



855
3
CO2tBu
2-Cl-Phenyl



856
1
CONHMe
2-Cl-Phenyl



857
2
CONHMe
2-Cl-Phenyl



858
3
CONHMe
2-Cl-Phenyl



859
1
SO2Me
2-Cl-Phenyl



860
2
SO2Me
2-Cl-Phenyl



861
3
SO2Me
2-Cl-Phenyl



862
1
SO2NH2
2-Cl-Phenyl



863
2
SO2NH2
2-Cl-Phenyl



864
3
SO2NH2
2-Cl-Phenyl



865
1
H
4-Cl-Phenyl



866
2
H
4-Cl-Phenyl



867
3
H
4-Cl-Phenyl



868
1
Me
4-Cl-Phenyl



869
2
Me
4-Cl-Phenyl



870
3
Me
4-Cl-Phenyl



871
1
CH2Ph
4-Cl-Phenyl



872
2
CH2Ph
4-Cl-Phenyl



873
3
CH2Ph
4-Cl-Phenyl



874
1
COMe
4-Cl-Phenyl



875
2
COMe
4-Cl-Phenyl



876
3
COMe
4-Cl-Phenyl



877
1
CO2Me
4-Cl-Phenyl



878
2
CO2Me
4-Cl-Phenyl



879
3
CO2Me
4-Cl-Phenyl



880
1
CO2tBu
4-Cl-Phenyl



881
2
CO2tBu
4-Cl-Phenyl



882
3
CO2tBu
4-Cl-Phenyl



883
1
CONHMe
4-Cl-Phenyl



884
2
CONHMe
4-Cl-Phenyl



885
3
CONHMe
4-Cl-Phenyl



886
1
SO2Me
4-Cl-Phenyl



887
2
SO2Me
4-Cl-Phenyl



888
3
SO2Me
4-Cl-Phenyl



889
1
SO2NH2
4-Cl-Phenyl



890
2
SO2NH2
4-Cl-Phenyl



891
3
SO2NH2
4-Cl-Phenyl



892
1
H
3-Br-Phenyl



893
2
H
3-Br-Phenyl



894
3
H
3-Br-Phenyl



895
1
Me
3-Br-Phenyl



896
2
Me
3-Br-Phenyl



897
3
Me
3-Br-Phenyl



898
1
CH2Ph
3-Br-Phenyl



899
2
CH2Ph
3-Br-Phenyl



900
3
CH2Ph
3-Br-Phenyl



901
1
COMe
3-Br-Phenyl



902
2
COMe
3-Br-Phenyl



903
3
COMe
3-Br-Phenyl



904
1
CO2Me
3-Br-Phenyl



905
2
CO2Me
3-Br-Phenyl



906
3
CO2Me
3-Br-Phenyl



907
1
CO2tBu
3-Br-Phenyl



908
2
CO2tBu
3-Br-Phenyl



909
3
CO2tBu
3-Br-Phenyl



910
1
CONHMe
3-Br-Phenyl



911
2
CONHMe
3-Br-Phenyl



912
3
CONHMe
3-Br-Phenyl



913
1
SO2Me
3-Br-Phenyl



914
2
SO2Me
3-Br-Phenyl



915
3
SO2Me
3-Br-Phenyl



916
1
SO2NH2
3-Br-Phenyl



917
2
SO2NH2
3-Br-Phenyl



918
3
SO2NH2
3-Br-Phenyl



919
1
H
2-CF3-Phenyl



920
2
H
2-CF3-Phenyl



921
3
H
2-CF3-Phenyl



922
1
Me
2-CF3-Phenyl



923
2
Me
2-CF3-Phenyl



924
3
Me
2-CF3-Phenyl



925
1
CH2Ph
2-CF3-Phenyl



926
2
CH2Ph
2-CF3-Phenyl



927
3
CH2Ph
2-CF3-Phenyl



928
1
COMe
2-CF3-Phenyl



929
2
COMe
2-CF3-Phenyl



930
3
COMe
2-CF3-Phenyl



931
1
CO2Me
2-CF3-Phenyl



932
2
CO2Me
2-CF3-Phenyl



933
3
CO2Me
2-CF3-Phenyl



934
1
CO2tBu
2-CF3-Phenyl



935
2
CO2tBu
2-CF3-Phenyl



936
3
CO2tBu
2-CF3-Phenyl



937
1
CONHMe
2-CF3-Phenyl



938
2
CONHMe
2-CF3-Phenyl



939
3
CONHMe
2-CF3-Phenyl



940
1
SO2Me
2-CF3-Phenyl



941
2
SO2Me
2-CF3-Phenyl



942
3
SO2Me
2-CF3-Phenyl



943
1
SO2NH2
2-CF3-Phenyl



944
2
SO2NH2
2-CF3-Phenyl



945
3
SO2NH2
2-CF3-Phenyl



946
1
H
4-CF3-Phenyl



947
2
H
4-CF3-Phenyl



948
3
H
4-CF3-Phenyl



949
1
Me
4-CF3-Phenyl



950
2
Me
4-CF3-Phenyl



951
3
Me
4-CF3-Phenyl



952
1
CH2Ph
4-CF3-Phenyl



953
2
CH2Ph
4-CF3-Phenyl



954
3
CH2Ph
4-CF3-Phenyl



955
1
COMe
4-CF3-Phenyl



956
2
COMe
4-CF3-Phenyl



957
3
COMe
4-CF3-Phenyl



958
1
CO2Me
4-CF3-Phenyl



959
2
CO2Me
4-CF3-Phenyl



960
3
CO2Me
4-CF3-Phenyl



961
1
CO2tBu
4-CF3-Phenyl



962
2
CO2tBu
4-CF3-Phenyl



963
3
CO2tBu
4-CF3-Phenyl



964
1
CONHMe
4-CF3-Phenyl



965
2
CONHMe
4-CF3-Phenyl



966
3
CONHMe
4-CF3-Phenyl



967
1
SO2Me
4-CF3-Phenyl



968
2
SO2Me
4-CF3-Phenyl



969
3
SO2Me
4-CF3-Phenyl



970
1
SO2NH2
4-CF3-Phenyl



971
2
SO2NH2
4-CF3-Phenyl



972
3
SO2NH2
4-CF3-Phenyl



973
1
H
3-iPr-Phenyl



974
2
H
3-iPr-Phenyl



975
3
H
3-iPr-Phenyl



976
1
Me
3-iPr-Phenyl



977
2
Me
3-iPr-Phenyl



978
3
Me
3-iPr-Phenyl



979
1
CH2Ph
3-iPr-Phenyl



980
2
CH2Ph
3-iPr-Phenyl



981
3
CH2Ph
3-iPr-Phenyl



982
1
COMe
3-iPr-Phenyl



983
2
COMe
3-iPr-Phenyl



984
3
COMe
3-iPr-Phenyl



985
1
CO2Me
3-iPr-Phenyl



986
2
CO2Me
3-iPr-Phenyl



987
3
CO2Me
3-iPr-Phenyl



988
1
CO2tBu
3-iPr-Phenyl



989
2
CO2tBu
3-iPr-Phenyl



990
3
CO2tBu
3-iPr-Phenyl



991
1
CONHMe
3-iPr-Phenyl



992
2
CONHMe
3-iPr-Phenyl



993
3
CONHMe
3-iPr-Phenyl



994
1
SO2Me
3-iPr-Phenyl



995
2
SO2Me
3-iPr-Phenyl



996
3
SO2Me
3-iPr-Phenyl



997
1
SO2NH2
3-iPr-Phenyl



998
2
SO2NH2
3-iPr-Phenyl



999
3
SO2NH2
3-iPr-Phenyl



1000
1
H
4-NH2-Phenyl



1001
2
H
4-NH2-Phenyl



1002
3
H
4-NH2-Phenyl



1003
1
Me
4-NH2-Phenyl



1004
2
Me
4-NH2-Phenyl



1005
3
Me
4-NH2-Phenyl



1006
1
CH2Ph
4-NH2-Phenyl



1007
2
CH2Ph
4-NH2-Phenyl



1008
3
CH2Ph
4-NH2-Phenyl



1009
1
COMe
4-NH2-Phenyl



1010
2
COMe
4-NH2-Phenyl



1011
3
COMe
4-NH2-Phenyl



1012
1
CO2Me
4-NH2-Phenyl



1013
2
CO2Me
4-NH2-Phenyl



1014
3
CO2Me
4-NH2-Phenyl



1015
1
CO2tBu
4-NH2-Phenyl



1016
2
CO2tBu
4-NH2-Phenyl



1017
3
CO2tBu
4-NH2-Phenyl



1018
1
CONHMe
4-NH2-Phenyl



1019
2
CONHMe
4-NH2-Phenyl



1020
3
CONHMe
4-NH2-Phenyl



1021
1
SO2Me
4-NH2-Phenyl



1022
2
SO2Me
4-NH2-Phenyl



1023
3
SO2Me
4-NH2-Phenyl



1024
1
SO2NH2
4-NH2-Phenyl



1025
2
SO2NH2
4-NH2-Phenyl



1026
3
SO2NH2
4-NH2-Phenyl



1027
1
H
2-NH2-Phenyl



1028
2
H
2-NH2-Phenyl



1029
3
H
2-NH2-Phenyl



1030
1
Me
2-NH2-Phenyl



1031
2
Me
2-NH2-Phenyl



1032
3
Me
2-NH2-Phenyl



1033
1
CH2Ph
2-NH2-Phenyl



1034
2
CH2Ph
2-NH2-Phenyl



1035
3
CH2Ph
2-NH2-Phenyl



1036
1
COMe
2-NH2-Phenyl



1037
2
COMe
2-NH2-Phenyl



1038
3
COMe
2-NH2-Phenyl



1039
1
CO2Me
2-NH2-Phenyl



1040
2
CO2Me
2-NH2-Phenyl



1041
3
CO2Me
2-NH2-Phenyl



1042
1
CO2tBu
2-NH2-Phenyl



1043
2
CO2tBu
2-NH2-Phenyl



1044
3
CO2tBu
2-NH2-Phenyl



1045
1
CONHMe
2-NH2-Phenyl



1046
2
CONHMe
2-NH2-Phenyl



1047
3
CONHMe
2-NH2-Phenyl



1048
1
SO2Me
2-NH2-Phenyl



1049
2
SO2Me
2-NH2-Phenyl



1050
3
SO2Me
2-NH2-Phenyl



1051
1
SO2NH2
2-NH2-Phenyl



1052
2
SO2NH2
2-NH2-Phenyl



1053
3
SO2NH2
2-NH2-Phenyl



1054
1
H
2,6-di-Me-Phenyl



1055
2
H
2,6-di-Me-Phenyl



1056
3
H
2,6-di-Me-Phenyl



1057
1
Me
2,6-di-Me-Phenyl



1058
2
Me
2,6-di-Me-Phenyl



1059
3
Me
2,6-di-Me-Phenyl



1060
1
CH2Ph
2,6-di-Me-Phenyl



1061
2
CH2Ph
2,6-di-Me-Phenyl



1062
3
CH2Ph
2,6-di-Me-Phenyl



1063
1
COMe
2,6-di-Me-Phenyl



1064
2
COMe
2,6-di-Me-Phenyl



1065
3
COMe
2,6-di-Me-Phenyl



1066
1
CO2Me
2,6-di-Me-Phenyl



1067
2
CO2Me
2,6-di-Me-Phenyl



1068
3
CO2Me
2,6-di-Me-Phenyl



1069
1
CO2tBu
2,6-di-Me-Phenyl



1070
2
CO2tBu
2,6-di-Me-Phenyl



1071
3
CO2tBu
2,6-di-Me-Phenyl



1072
1
CONHMe
2,6-di-Me-Phenyl



1073
2
CONHMe
2,6-di-Me-Phenyl



1074
3
CONHMe
2,6-di-Me-Phenyl



1075
1
SO2Me
2,6-di-Me-Phenyl



1076
2
SO2Me
2,6-di-Me-Phenyl



1077
3
SO2Me
2,6-di-Me-Phenyl



1078
1
SO2NH2
2,6-di-Me-Phenyl



1079
2
SO2NH2
2,6-di-Me-Phenyl



1080
3
SO2NH2
2,6-di-Me-Phenyl



1081
1
H
2-Ph-Phenyl



1082
2
H
2-Ph-Phenyl



1083
3
H
2-Ph-Phenyl



1084
1
Me
2-Ph-Phenyl



1085
2
Me
2-Ph-Phenyl



1086
3
Me
2-Ph-Phenyl



1087
1
CH2Ph
2-Ph-Phenyl



1088
2
CH2Ph
2-Ph-Phenyl



1089
3
CH2Ph
2-Ph-Phenyl



1090
1
COMe
2-Ph-Phenyl



1091
2
COMe
2-Ph-Phenyl



1092
3
COMe
2-Ph-Phenyl



1093
1
CO2Me
2-Ph-Phenyl



1094
2
CO2Me
2-Ph-Phenyl



1095
3
CO2Me
2-Ph-Phenyl



1096
1
CO2tBu
2-Ph-Phenyl



1097
2
CO2tBu
2-Ph-Phenyl



1098
3
CO2tBu
2-Ph-Phenyl



1099
1
CONHMe
2-Ph-Phenyl



1100
2
CONHMe
2-Ph-Phenyl



1101
3
CONHMe
2-Ph-Phenyl



1102
1
SO2Me
2-Ph-Phenyl



1103
2
SO2Me
2-Ph-Phenyl



1104
3
SO2Me
2-Ph-Phenyl



1105
1
SO2NH2
2-Ph-Phenyl



1106
2
SO2NH2
2-Ph-Phenyl



1107
3
SO2NH2
2-Ph-Phenyl



1108
1
H
4-Ph-Phenyl



1109
2
H
4-Ph-Phenyl



1110
3
H
4-Ph-Phenyl



1111
1
Me
4-Ph-Phenyl



1112
2
Me
4-Ph-Phenyl



1113
3
Me
4-Ph-Phenyl



1114
1
CH2Ph
4-Ph-Phenyl



1115
2
CH2Ph
4-Ph-Phenyl



1116
3
CH2Ph
4-Ph-Phenyl



1117
1
COMe
4-Ph-Phenyl



1118
2
COMe
4-Ph-Phenyl



1119
3
COMe
4-Ph-Phenyl



1120
1
CO2Me
4-Ph-Phenyl



1121
2
CO2Me
4-Ph-Phenyl



1122
3
CO2Me
4-Ph-Phenyl



1123
1
CO2tBu
4-Ph-Phenyl



1124
2
CO2tBu
4-Ph-Phenyl



1125
3
CO2tBu
4-Ph-Phenyl



1126
1
CONHMe
4-Ph-Phenyl



1127
2
CONHMe
4-Ph-Phenyl



1128
3
CONHMe
4-Ph-Phenyl



1129
1
SO2Me
4-Ph-Phenyl



1130
2
SO2Me
4-Ph-Phenyl



1131
3
SO2Me
4-Ph-Phenyl



1132
1
SO2NH2
4-Ph-Phenyl



1133
2
SO2NH2
4-Ph-Phenyl



1134
3
SO2NH2
4-Ph-Phenyl



1135
1
H
3-morpholino-phenyl



1136
2
H
3-morpholino-phenyl



1137
3
H
3-morpholino-phenyl



1138
1
Me
3-morpholino-phenyl



1139
2
Me
3-morpholino-phenyl



1140
3
Me
3-morpholino-phenyl



1141
1
CH2Ph
3-morpholino-phenyl



1142
2
CH2Ph
3-morpholino-phenyl



1143
3
CH2Ph
3-morpholino-phenyl



1144
1
COMe
3-morpholino-phenyl



1145
2
COMe
3-morpholino-phenyl



1146
3
COMe
3-morpholino-phenyl



1147
1
CO2Me
3-morpholino-phenyl



1148
2
CO2Me
3-morpholino-phenyl



1149
3
CO2Me
3-morpholino-phenyl



1150
1
CO2tBu
3-morpholino-phenyl



1151
2
CO2tBu
3-morpholino-phenyl



1152
3
CO2tBu
3-morpholino-phenyl



1153
1
CONHMe
3-morpholino-phenyl



1154
2
CONHMe
3-morpholino-phenyl



1155
3
CONHMe
3-morpholino-phenyl



1156
1
SO2Me
3-morpholino-phenyl



1157
2
SO2Me
3-morpholino-phenyl



1158
3
SO2Me
3-morpholino-phenyl



1159
1
SO2NH2
3-morpholino-phenyl



1160
2
SO2NH2
3-morpholino-phenyl



1161
3
SO2NH2
3-morpholino-phenyl



1162
1
H
2-pyrazinyl



1163
2
H
2-pyrazinyl



1164
3
H
2-pyrazinyl



1165
1
Me
2-pyrazinyl



1166
2
Me
2-pyrazinyl



1167
3
Me
2-pyrazinyl



1168
1
CH2Ph
2-pyrazinyl



1169
2
CH2Ph
2-pyrazinyl



1170
3
CH2Ph
2-pyrazinyl



1171
1
COMe
2-pyrazinyl



1172
2
COMe
2-pyrazinyl



1173
3
COMe
2-pyrazinyl



1174
1
CO2Me
2-pyrazinyl



1175
2
CO2Me
2-pyrazinyl



1176
3
CO2Me
2-pyrazinyl



1177
1
CO2tBu
2-pyrazinyl



1178
2
CO2tBu
2-pyrazinyl



1179
3
CO2tBu
2-pyrazinyl



1180
1
CONHMe
2-pyrazinyl



1181
2
CONHMe
2-pyrazinyl



1182
3
CONHMe
2-pyrazinyl



1183
1
SO2Me
2-pyrazinyl



1184
2
SO2Me
2-pyrazinyl



1185
3
SO2Me
2-pyrazinyl



1186
1
SO2NH2
2-pyrazinyl



1187
2
SO2NH2
2-pyrazinyl



1188
3
SO2NH2
2-pyrazinyl



1189
1
H
5-indolyl



1190
2
H
5-indolyl



1191
3
H
5-indolyl



1192
1
Me
5-indolyl



1193
2
Me
5-indolyl



1194
3
Me
5-indolyl



1195
1
CH2Ph
5-indolyl



1196
2
CH2Ph
5-indolyl



1197
3
CH2Ph
5-indolyl



1198
1
COMe
5-indolyl



1199
2
COMe
5-indolyl



1200
3
COMe
5-indolyl



1201
1
CO2Me
5-indolyl



1202
2
CO2Me
5-indolyl



1203
3
CO2Me
5-indolyl



1204
1
CO2tBu
5-indolyl



1205
2
CO2tBu
5-indolyl



1206
3
CO2tBu
5-indolyl



1207
1
CONHMe
5-indolyl



1208
2
CONHMe
5-indolyl



1209
3
CONHMe
5-indolyl



1210
1
SO2Me
5-indolyl



1211
2
SO2Me
5-indolyl



1212
3
SO2Me
5-indolyl



1213
1
SO2NH2
5-indolyl



1214
2
SO2NH2
5-indolyl



1215
3
SO2NH2
5-indolyl



1216
1
H
1H-benzo[d]imidazol-






4-yl



1217
2
H
1H-benzo[d]imidazol-






4-yl



1218
3
H
1H-benzo[d]imidazol-






4-yl



1219
1
Me
1H-benzo[d]imidazol-






4-yl



1220
2
Me
1H-benzo[d]imidazol-






4-yl



1221
3
Me
1H-benzo[d]imidazol-






4-yl



1222
1
CH2Ph
1H-benzo[d]imidazol-






4-yl



1223
2
CH2Ph
1H-benzo[d]imidazol-






4-yl



1224
3
CH2Ph
1H-benzo[d]imidazol-






4-yl



1225
1
COMe
1H-benzo[d]imidazol-






4-yl



1226
2
COMe
1H-benzo[d]imidazol-






4-yl



1227
3
COMe
1H-benzo[d]imidazol-






4-yl



1228
1
CO2Me
1H-benzo[d]imidazol-






4-yl



1229
2
CO2Me
1H-benzo[d]imidazol-






4-yl



1230
3
CO2Me
1H-benzo[d]imidazol-






4-yl



1231
1
CO2tBu
1H-benzo[d]imidazol-






4-yl



1232
2
CO2tBu
1H-benzo[d]imidazol-






4-yl



1233
3
CO2tBu
1H-benzo[d]imidazol-






4-yl



1234
1
CONHMe
1H-benzo[d]imidazol-






4-yl



1235
2
CONHMe
1H-benzo[d]imidazol-






4-yl



1236
3
CONHMe
1H-benzo[d]imidazol-






4-yl



1237
1
SO2Me
1H-benzo[d]imidazol-






4-yl



1238
2
SO2Me
1H-benzo[d]imidazol-






4-yl



1239
3
SO2Me
1H-benzo[d]imidazol-






4-yl



1240
1
SO2NH2
1H-benzo[d]imidazol-






4-yl



1241
2
SO2NH2
1H-benzo[d]imidazol-






4-yl



1242
3
SO2NH2
1H-benzo[d]imidazol-






4-yl










Exemplary embodiments include compounds having the formula (XIX)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 3.

















TABLE 3







Entry
n
R
R1a
R1b
R1c
R1d
























1
1
H
H
H
H
H



2
2
H
H
H
H
H



3
3
H
H
H
H
H



4
1
Me
H
H
H
H



5
2
Me
H
H
H
H



6
3
Me
H
H
H
H



7
1
CH2Ph
H
H
H
H



8
2
CH2Ph
H
H
H
H



9
3
CH2Ph
H
H
H
H



10
1
COMe
H
H
H
H



11
2
COMe
H
H
H
H



12
3
COMe
H
H
H
H



13
1
CO2Me
H
H
H
H



14
2
CO2Me
H
H
H
H



15
3
CO2Me
H
H
H
H



16
1
CO2tBu
H
H
H
H



17
2
CO2tBu
H
H
H
H



18
3
CO2tBu
H
H
H
H



19
1
CONHMe
H
H
H
H



20
2
CONHMe
H
H
H
H



21
3
CONHMe
H
H
H
H



22
1
SO2Me
H
H
H
H



23
2
SO2Me
H
H
H
H



24
3
SO2Me
H
H
H
H



25
1
SO2NH2
H
H
H
H



26
2
SO2NH2
H
H
H
H



27
3
SO2NH2
H
H
H
H



28
1
H
H
H
OH
H



29
2
H
H
H
OH
H



30
3
H
H
H
OH
H



31
1
Me
H
H
OH
H



32
2
Me
H
H
OH
H



33
3
Me
H
H
OH
H



34
1
CH2Ph
H
H
OH
H



35
2
CH2Ph
H
H
OH
H



36
3
CH2Ph
H
H
OH
H



37
1
COMe
H
H
OH
H



38
2
COMe
H
H
OH
H



39
3
COMe
H
H
OH
H



40
1
CO2Me
H
H
OH
H



41
2
CO2Me
H
H
OH
H



42
3
CO2Me
H
H
OH
H



43
1
CO2tBu
H
H
OH
H



44
2
CO2tBu
H
H
OH
H



45
3
CO2tBu
H
H
OH
H



46
1
CONHMe
H
H
OH
H



47
2
CONHMe
H
H
OH
H



48
3
CONHMe
H
H
OH
H



49
1
SO2Me
H
H
OH
H



50
2
SO2Me
H
H
OH
H



51
3
SO2Me
H
H
OH
H



52
1
SO2NH2
H
H
OH
H



53
2
SO2NH2
H
H
OH
H



54
3
SO2NH2
H
H
OH
H



55
1
H
H
H
OMe
H



56
2
H
H
H
OMe
H



57
3
H
H
H
OMe
H



58
1
Me
H
H
OMe
H



59
2
Me
H
H
OMe
H



60
3
Me
H
H
OMe
H



61
1
CH2Ph
H
H
OMe
H



62
2
CH2Ph
H
H
OMe
H



63
3
CH2Ph
H
H
OMe
H



64
1
COMe
H
H
OMe
H



65
2
COMe
H
H
OMe
H



66
3
COMe
H
H
OMe
H



67
1
CO2Me
H
H
OMe
H



68
2
CO2Me
H
H
OMe
H



69
3
CO2Me
H
H
OMe
H



70
1
CO2tBu
H
H
OMe
H



71
2
CO2tBu
H
H
OMe
H



72
3
CO2tBu
H
H
OMe
H



73
1
CONHMe
H
H
OMe
H



74
2
CONHMe
H
H
OMe
H



75
3
CONHMe
H
H
OMe
H



76
1
SO2Me
H
H
OMe
H



77
2
SO2Me
H
H
OMe
H



78
3
SO2Me
H
H
OMe
H



79
1
SO2NH2
H
H
OMe
H



80
2
SO2NH2
H
H
OMe
H



81
3
SO2NH2
H
H
OMe
H



82
1
H
H
H
Me
H



83
2
H
H
H
Me
H



84
3
H
H
H
Me
H



85
1
Me
H
H
Me
H



86
2
Me
H
H
Me
H



87
3
Me
H
H
Me
H



88
1
CH2Ph
H
H
Me
H



89
2
CH2Ph
H
H
Me
H



90
3
CH2Ph
H
H
Me
H



91
1
COMe
H
H
Me
H



92
2
COMe
H
H
Me
H



93
3
COMe
H
H
Me
H



94
1
CO2Me
H
H
Me
H



95
2
CO2Me
H
H
Me
H



96
3
CO2Me
H
H
Me
H



97
1
CO2tBu
H
H
Me
H



98
2
CO2tBu
H
H
Me
H



99
3
CO2tBu
H
H
Me
H



100
1
CONHMe
H
H
Me
H



101
2
CONHMe
H
H
Me
H



102
3
CONHMe
H
H
Me
H



103
1
SO2Me
H
H
Me
H



104
2
SO2Me
H
H
Me
H



105
3
SO2Me
H
H
Me
H



106
1
SO2NH2
H
H
Me
H



107
2
SO2NH2
H
H
Me
H



108
3
SO2NH2
H
H
Me
H



109
1
H
H
H
CF3
H



110
2
H
H
H
CF3
H



111
3
H
H
H
CF3
H



112
1
Me
H
H
CF3
H



113
2
Me
H
H
CF3
H



114
3
Me
H
H
CF3
H



115
1
CH2Ph
H
H
CF3
H



116
2
CH2Ph
H
H
CF3
H



117
3
CH2Ph
H
H
CF3
H



118
1
COMe
H
H
CF3
H



119
2
COMe
H
H
CF3
H



120
3
COMe
H
H
CF3
H



121
1
CO2Me
H
H
CF3
H



122
2
CO2Me
H
H
CF3
H



123
3
CO2Me
H
H
CF3
H



124
1
CO2tBu
H
H
CF3
H



125
2
CO2tBu
H
H
CF3
H



126
3
CO2tBu
H
H
CF3
H



127
1
CONHMe
H
H
CF3
H



128
2
CONHMe
H
H
CF3
H



129
3
CONHMe
H
H
CF3
H



130
1
SO2Me
H
H
CF3
H



131
2
SO2Me
H
H
CF3
H



132
3
SO2Me
H
H
CF3
H



133
1
SO2NH2
H
H
CF3
H



134
2
SO2NH2
H
H
CF3
H



135
3
SO2NH2
H
H
CF3
H



136
1
H
H
H
F
H



137
2
H
H
H
F
H



138
3
H
H
H
F
H



139
1
Me
H
H
F
H



140
2
Me
H
H
F
H



141
3
Me
H
H
F
H



142
1
CH2Ph
H
H
F
H



143
2
CH2Ph
H
H
F
H



144
3
CH2Ph
H
H
F
H



145
1
COMe
H
H
F
H



146
2
COMe
H
H
F
H



147
3
COMe
H
H
F
H



148
1
CO2Me
H
H
F
H



149
2
CO2Me
H
H
F
H



150
3
CO2Me
H
H
F
H



151
1
CO2tBu
H
H
F
H



152
2
CO2tBu
H
H
F
H



153
3
CO2tBu
H
H
F
H



154
1
CONHMe
H
H
F
H



155
2
CONHMe
H
H
F
H



156
3
CONHMe
H
H
F
H



157
1
SO2Me
H
H
F
H



158
2
SO2Me
H
H
F
H



159
3
SO2Me
H
H
F
H



160
1
SO2NH2
H
H
F
H



161
2
SO2NH2
H
H
F
H



162
3
SO2NH2
H
H
F
H



163
1
H
H
H
Cl
H



164
2
H
H
H
Cl
H



165
3
H
H
H
Cl
H



166
1
Me
H
H
Cl
H



167
2
Me
H
H
Cl
H



168
3
Me
H
H
Cl
H



169
1
CH2Ph
H
H
Cl
H



170
2
CH2Ph
H
H
Cl
H



171
3
CH2Ph
H
H
Cl
H



172
1
COMe
H
H
Cl
H



173
2
COMe
H
H
Cl
H



174
3
COMe
H
H
Cl
H



175
1
CO2Me
H
H
Cl
H



176
2
CO2Me
H
H
Cl
H



177
3
CO2Me
H
H
Cl
H



178
1
CO2tBu
H
H
Cl
H



179
2
CO2tBu
H
H
Cl
H



180
3
CO2tBu
H
H
Cl
H



181
1
CONHMe
H
H
Cl
H



182
2
CONHMe
H
H
Cl
H



183
3
CONHMe
H
H
Cl
H



184
1
SO2Me
H
H
Cl
H



185
2
SO2Me
H
H
Cl
H



186
3
SO2Me
H
H
Cl
H



187
1
SO2NH2
H
H
Cl
H



188
2
SO2NH2
H
H
Cl
H



189
3
SO2NH2
H
H
Cl
H



190
1
H
H
H
CN
H



191
2
H
H
H
CN
H



192
3
H
H
H
CN
H



193
1
Me
H
H
CN
H



194
2
Me
H
H
CN
H



195
3
Me
H
H
CN
H



196
1
CH2Ph
H
H
CN
H



197
2
CH2Ph
H
H
CN
H



198
3
CH2Ph
H
H
CN
H



199
1
COMe
H
H
CN
H



200
2
COMe
H
H
CN
H



201
3
COMe
H
H
CN
H



202
1
CO2Me
H
H
CN
H



203
2
CO2Me
H
H
CN
H



204
3
CO2Me
H
H
CN
H



205
1
CO2tBu
H
H
CN
H



206
2
CO2tBu
H
H
CN
H



207
3
CO2tBu
H
H
CN
H



208
1
CONHMe
H
H
CN
H



209
2
CONHMe
H
H
CN
H



210
3
CONHMe
H
H
CN
H



211
1
SO2Me
H
H
CN
H



212
2
SO2Me
H
H
CN
H



213
3
SO2Me
H
H
CN
H



214
1
SO2NH2
H
H
CN
H



215
2
SO2NH2
H
H
CN
H



216
3
SO2NH2
H
H
CN
H



217
1
H
H
OH
H
H



218
2
H
H
OH
H
H



219
3
H
H
OH
H
H



220
1
Me
H
OH
H
H



221
2
Me
H
OH
H
H



222
3
Me
H
OH
H
H



223
1
CH2Ph
H
OH
H
H



224
2
CH2Ph
H
OH
H
H



225
3
CH2Ph
H
OH
H
H



226
1
COMe
H
OH
H
H



227
2
COMe
H
OH
H
H



228
3
COMe
H
OH
H
H



229
1
CO2Me
H
OH
H
H



230
2
CO2Me
H
OH
H
H



231
3
CO2Me
H
OH
H
H



232
1
CO2tBu
H
OH
H
H



233
2
CO2tBu
H
OH
H
H



234
3
CO2tBu
H
OH
H
H



235
1
CONHMe
H
OH
H
H



236
2
CONHMe
H
OH
H
H



237
3
CONHMe
H
OH
H
H



238
1
SO2Me
H
OH
H
H



239
2
SO2Me
H
OH
H
H



240
3
SO2Me
H
OH
H
H



241
1
SO2NH2
H
OH
H
H



242
2
SO2NH2
H
OH
H
H



243
3
SO2NH2
H
OH
H
H



244
1
H
H
OMe
H
H



245
2
H
H
OMe
H
H



246
3
H
H
OMe
H
H



247
1
Me
H
OMe
H
H



248
2
Me
H
OMe
H
H



249
3
Me
H
OMe
H
H



250
1
CH2Ph
H
OMe
H
H



251
2
CH2Ph
H
OMe
H
H



252
3
CH2Ph
H
OMe
H
H



253
1
COMe
H
OMe
H
H



254
2
COMe
H
OMe
H
H



255
3
COMe
H
OMe
H
H



256
1
CO2Me
H
OMe
H
H



257
2
CO2Me
H
OMe
H
H



258
3
CO2Me
H
OMe
H
H



259
1
CO2tBu
H
OMe
H
H



260
2
CO2tBu
H
OMe
H
H



261
3
CO2tBu
H
OMe
H
H



262
1
CONHMe
H
OMe
H
H



263
2
CONHMe
H
OMe
H
H



264
3
CONHMe
H
OMe
H
H



265
1
SO2Me
H
OMe
H
H



266
2
SO2Me
H
OMe
H
H



267
3
SO2Me
H
OMe
H
H



268
1
SO2NH2
H
OMe
H
H



269
2
SO2NH2
H
OMe
H
H



270
3
SO2NH2
H
OMe
H
H



271
1
H
H
Me
H
H



272
2
H
H
Me
H
H



273
3
H
H
Me
H
H



274
1
Me
H
Me
H
H



275
2
Me
H
Me
H
H



276
3
Me
H
Me
H
H



277
1
CH2Ph
H
Me
H
H



278
2
CH2Ph
H
Me
H
H



279
3
CH2Ph
H
Me
H
H



280
1
COMe
H
Me
H
H



281
2
COMe
H
Me
H
H



282
3
COMe
H
Me
H
H



283
1
CO2Me
H
Me
H
H



284
2
CO2Me
H
Me
H
H



285
3
CO2Me
H
Me
H
H



286
1
CO2tBu
H
Me
H
H



287
2
CO2tBu
H
Me
H
H



288
3
CO2tBu
H
Me
H
H



289
1
CONHMe
H
Me
H
H



290
2
CONHMe
H
Me
H
H



291
3
CONHMe
H
Me
H
H



292
1
SO2Me
H
Me
H
H



293
2
SO2Me
H
Me
H
H



294
3
SO2Me
H
Me
H
H



295
1
SO2NH2
H
Me
H
H



296
2
SO2NH2
H
Me
H
H



297
3
SO2NH2
H
Me
H
H



298
1
H
H
CF3
H
H



299
2
H
H
CF3
H
H



300
3
H
H
CF3
H
H



301
1
Me
H
CF3
H
H



302
2
Me
H
CF3
H
H



303
3
Me
H
CF3
H
H



304
1
CH2Ph
H
CF3
H
H



305
2
CH2Ph
H
CF3
H
H



306
3
CH2Ph
H
CF3
H
H



307
1
COMe
H
CF3
H
H



308
2
COMe
H
CF3
H
H



309
3
COMe
H
CF3
H
H



310
1
CO2Me
H
CF3
H
H



311
2
CO2Me
H
CF3
H
H



312
3
CO2Me
H
CF3
H
H



313
1
CO2tBu
H
CF3
H
H



314
2
CO2tBu
H
CF3
H
H



315
3
CO2tBu
H
CF3
H
H



316
1
CONHMe
H
CF3
H
H



317
2
CONHMe
H
CF3
H
H



318
3
CONHMe
H
CF3
H
H



319
1
SO2Me
H
CF3
H
H



320
2
SO2Me
H
CF3
H
H



321
3
SO2Me
H
CF3
H
H



322
1
SO2NH2
H
CF3
H
H



323
2
SO2NH2
H
CF3
H
H



324
3
SO2NH2
H
CF3
H
H



325
1
H
H
F
H
H



326
2
H
H
F
H
H



327
3
H
H
F
H
H



328
1
Me
H
F
H
H



329
2
Me
H
F
H
H



330
3
Me
H
F
H
H



331
1
CH2Ph
H
F
H
H



332
2
CH2Ph
H
F
H
H



333
3
CH2Ph
H
F
H
H



334
1
COMe
H
F
H
H



335
2
COMe
H
F
H
H



336
3
COMe
H
F
H
H



337
1
CO2Me
H
F
H
H



338
2
CO2Me
H
F
H
H



339
3
CO2Me
H
F
H
H



340
1
CO2tBu
H
F
H
H



341
2
CO2tBu
H
F
H
H



342
3
CO2tBu
H
F
H
H



343
1
CONHMe
H
F
H
H



344
2
CONHMe
H
F
H
H



345
3
CONHMe
H
F
H
H



346
1
SO2Me
H
F
H
H



347
2
SO2Me
H
F
H
H



348
3
SO2Me
H
F
H
H



349
1
SO2NH2
H
F
H
H



350
2
SO2NH2
H
F
H
H



351
3
SO2NH2
H
F
H
H



352
1
H
H
Cl
H
H



353
2
H
H
Cl
H
H



354
3
H
H
Cl
H
H



355
1
Me
H
Cl
H
H



356
2
Me
H
Cl
H
H



357
3
Me
H
Cl
H
H



358
1
CH2Ph
H
Cl
H
H



359
2
CH2Ph
H
Cl
H
H



360
3
CH2Ph
H
Cl
H
H



361
1
COMe
H
Cl
H
H



362
2
COMe
H
Cl
H
H



363
3
COMe
H
Cl
H
H



364
1
CO2Me
H
Cl
H
H



365
2
CO2Me
H
Cl
H
H



366
3
CO2Me
H
Cl
H
H



367
1
CO2tBu
H
Cl
H
H



368
2
CO2tBu
H
Cl
H
H



369
3
CO2tBu
H
Cl
H
H



370
1
CONHMe
H
Cl
H
H



371
2
CONHMe
H
Cl
H
H



372
3
CONHMe
H
Cl
H
H



373
1
SO2Me
H
Cl
H
H



374
2
SO2Me
H
Cl
H
H



375
3
SO2Me
H
Cl
H
H



376
1
SO2NH2
H
Cl
H
H



377
2
SO2NH2
H
Cl
H
H



378
3
SO2NH2
H
Cl
H
H



379
1
H
H
CN
H
H



380
2
H
H
CN
H
H



381
3
H
H
CN
H
H



382
1
Me
H
CN
H
H



383
2
Me
H
CN
H
H



384
3
Me
H
CN
H
H



385
1
CH2Ph
H
CN
H
H



386
2
CH2Ph
H
CN
H
H



387
3
CH2Ph
H
CN
H
H



388
1
COMe
H
CN
H
H



389
2
COMe
H
CN
H
H



390
3
COMe
H
CN
H
H



391
1
CO2Me
H
CN
H
H



392
2
CO2Me
H
CN
H
H



393
3
CO2Me
H
CN
H
H



394
1
CO2tBu
H
CN
H
H



395
2
CO2tBu
H
CN
H
H



396
3
CO2tBu
H
CN
H
H



397
1
CONHMe
H
CN
H
H



398
2
CONHMe
H
CN
H
H



399
3
CONHMe
H
CN
H
H



400
1
SO2Me
H
CN
H
H



401
2
SO2Me
H
CN
H
H



402
3
SO2Me
H
CN
H
H



403
1
SO2NH2
H
CN
H
H



404
2
SO2NH2
H
CN
H
H



405
3
SO2NH2
H
CN
H
H










Exemplary embodiments include compounds having the formula (XX)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 4.

















TABLE 4







Entry
n
R
R1a
R1b
R1c
R1d
























1
1
H
H
H
H
H



2
2
H
H
H
H
H



3
3
H
H
H
H
H



4
1
Me
H
H
H
H



5
2
Me
H
H
H
H



6
3
Me
H
H
H
H



7
1
CH2Ph
H
H
H
H



8
2
CH2Ph
H
H
H
H



9
3
CH2Ph
H
H
H
H



10
1
COMe
H
H
H
H



11
2
COMe
H
H
H
H



12
3
COMe
H
H
H
H



13
1
CO2Me
H
H
H
H



14
2
CO2Me
H
H
H
H



15
3
CO2Me
H
H
H
H



16
1
CO2tBu
H
H
H
H



17
2
CO2tBu
H
H
H
H



18
3
CO2tBu
H
H
H
H



19
1
CONHMe
H
H
H
H



20
2
CONHMe
H
H
H
H



21
3
CONHMe
H
H
H
H



22
1
SO2Me
H
H
H
H



23
2
SO2Me
H
H
H
H



24
3
SO2Me
H
H
H
H



25
1
SO2NH2
H
H
H
H



26
2
SO2NH2
H
H
H
H



27
3
SO2NH2
H
H
H
H



28
1
H
H
H
OH
H



29
2
H
H
H
OH
H



30
3
H
H
H
OH
H



31
1
Me
H
H
OH
H



32
2
Me
H
H
OH
H



33
3
Me
H
H
OH
H



34
1
CH2Ph
H
H
OH
H



35
2
CH2Ph
H
H
OH
H



36
3
CH2Ph
H
H
OH
H



37
1
COMe
H
H
OH
H



38
2
COMe
H
H
OH
H



39
3
COMe
H
H
OH
H



40
1
CO2Me
H
H
OH
H



41
2
CO2Me
H
H
OH
H



42
3
CO2Me
H
H
OH
H



43
1
CO2tBu
H
H
OH
H



44
2
CO2tBu
H
H
OH
H



45
3
CO2tBu
H
H
OH
H



46
1
CONHMe
H
H
OH
H



47
2
CONHMe
H
H
OH
H



48
3
CONHMe
H
H
OH
H



49
1
SO2Me
H
H
OH
H



50
2
SO2Me
H
H
OH
H



51
3
SO2Me
H
H
OH
H



52
1
SO2NH2
H
H
OH
H



53
2
SO2NH2
H
H
OH
H



54
3
SO2NH2
H
H
OH
H



55
1
H
H
H
OMe
H



56
2
H
H
H
OMe
H



57
3
H
H
H
OMe
H



58
1
Me
H
H
OMe
H



59
2
Me
H
H
OMe
H



60
3
Me
H
H
OMe
H



61
1
CH2Ph
H
H
OMe
H



62
2
CH2Ph
H
H
OMe
H



63
3
CH2Ph
H
H
OMe
H



64
1
COMe
H
H
OMe
H



65
2
COMe
H
H
OMe
H



66
3
COMe
H
H
OMe
H



67
1
CO2Me
H
H
OMe
H



68
2
CO2Me
H
H
OMe
H



69
3
CO2Me
H
H
OMe
H



70
1
CO2tBu
H
H
OMe
H



71
2
CO2tBu
H
H
OMe
H



72
3
CO2tBu
H
H
OMe
H



73
1
CONHMe
H
H
OMe
H



74
2
CONHMe
H
H
OMe
H



75
3
CONHMe
H
H
OMe
H



76
1
SO2Me
H
H
OMe
H



77
2
SO2Me
H
H
OMe
H



78
3
SO2Me
H
H
OMe
H



79
1
SO2NH2
H
H
OMe
H



80
2
SO2NH2
H
H
OMe
H



81
3
SO2NH2
H
H
OMe
H



82
1
H
H
H
Me
H



83
2
H
H
H
Me
H



84
3
H
H
H
Me
H



85
1
Me
H
H
Me
H



86
2
Me
H
H
Me
H



87
3
Me
H
H
Me
H



88
1
CH2Ph
H
H
Me
H



89
2
CH2Ph
H
H
Me
H



90
3
CH2Ph
H
H
Me
H



91
1
COMe
H
H
Me
H



92
2
COMe
H
H
Me
H



93
3
COMe
H
H
Me
H



94
1
CO2Me
H
H
Me
H



95
2
CO2Me
H
H
Me
H



96
3
CO2Me
H
H
Me
H



97
1
CO2tBu
H
H
Me
H



98
2
CO2tBu
H
H
Me
H



99
3
CO2tBu
H
H
Me
H



100
1
CONHMe
H
H
Me
H



101
2
CONHMe
H
H
Me
H



102
3
CONHMe
H
H
Me
H



103
1
SO2Me
H
H
Me
H



104
2
SO2Me
H
H
Me
H



105
3
SO2Me
H
H
Me
H



106
1
SO2NH2
H
H
Me
H



107
2
SO2NH2
H
H
Me
H



108
3
SO2NH2
H
H
Me
H



109
1
H
H
H
CF3
H



110
2
H
H
H
CF3
H



111
3
H
H
H
CF3
H



112
1
Me
H
H
CF3
H



113
2
Me
H
H
CF3
H



114
3
Me
H
H
CF3
H



115
1
CH2Ph
H
H
CF3
H



116
2
CH2Ph
H
H
CF3
H



117
3
CH2Ph
H
H
CF3
H



118
1
COMe
H
H
CF3
H



119
2
COMe
H
H
CF3
H



120
3
COMe
H
H
CF3
H



121
1
CO2Me
H
H
CF3
H



122
2
CO2Me
H
H
CF3
H



123
3
CO2Me
H
H
CF3
H



124
1
CO2tBu
H
H
CF3
H



125
2
CO2tBu
H
H
CF3
H



126
3
CO2tBu
H
H
CF3
H



127
1
CONHMe
H
H
CF3
H



128
2
CONHMe
H
H
CF3
H



129
3
CONHMe
H
H
CF3
H



130
1
SO2Me
H
H
CF3
H



131
2
SO2Me
H
H
CF3
H



132
3
SO2Me
H
H
CF3
H



133
1
SO2NH2
H
H
CF3
H



134
2
SO2NH2
H
H
CF3
H



135
3
SO2NH2
H
H
CF3
H



136
1
H
H
H
F
H



137
2
H
H
H
F
H



138
3
H
H
H
F
H



139
1
Me
H
H
F
H



140
2
Me
H
H
F
H



141
3
Me
H
H
F
H



142
1
CH2Ph
H
H
F
H



143
2
CH2Ph
H
H
F
H



144
3
CH2Ph
H
H
F
H



145
1
COMe
H
H
F
H



146
2
COMe
H
H
F
H



147
3
COMe
H
H
F
H



148
1
CO2Me
H
H
F
H



149
2
CO2Me
H
H
F
H



150
3
CO2Me
H
H
F
H



151
1
CO2tBu
H
H
F
H



152
2
CO2tBu
H
H
F
H



153
3
CO2tBu
H
H
F
H



154
1
CONHMe
H
H
F
H



155
2
CONHMe
H
H
F
H



156
3
CONHMe
H
H
F
H



157
1
SO2Me
H
H
F
H



158
2
SO2Me
H
H
F
H



159
3
SO2Me
H
H
F
H



160
1
SO2NH2
H
H
F
H



161
2
SO2NH2
H
H
F
H



162
3
SO2NH2
H
H
F
H



163
1
H
H
H
Cl
H



164
2
H
H
H
Cl
H



165
3
H
H
H
Cl
H



166
1
Me
H
H
Cl
H



167
2
Me
H
H
Cl
H



168
3
Me
H
H
Cl
H



169
1
CH2Ph
H
H
Cl
H



170
2
CH2Ph
H
H
Cl
H



171
3
CH2Ph
H
H
Cl
H



172
1
COMe
H
H
Cl
H



173
2
COMe
H
H
Cl
H



174
3
COMe
H
H
Cl
H



175
1
CO2Me
H
H
Cl
H



176
2
CO2Me
H
H
Cl
H



177
3
CO2Me
H
H
Cl
H



178
1
CO2tBu
H
H
Cl
H



179
2
CO2tBu
H
H
Cl
H



180
3
CO2tBu
H
H
Cl
H



181
1
CONHMe
H
H
Cl
H



182
2
CONHMe
H
H
Cl
H



183
3
CONHMe
H
H
Cl
H



184
1
SO2Me
H
H
Cl
H



185
2
SO2Me
H
H
Cl
H



186
3
SO2Me
H
H
Cl
H



187
1
SO2NH2
H
H
Cl
H



188
2
SO2NH2
H
H
Cl
H



189
3
SO2NH2
H
H
Cl
H



190
1
H
H
H
CN
H



191
2
H
H
H
CN
H



192
3
H
H
H
CN
H



193
1
Me
H
H
CN
H



194
2
Me
H
H
CN
H



195
3
Me
H
H
CN
H



196
1
CH2Ph
H
H
CN
H



197
2
CH2Ph
H
H
CN
H



198
3
CH2Ph
H
H
CN
H



199
1
COMe
H
H
CN
H



200
2
COMe
H
H
CN
H



201
3
COMe
H
H
CN
H



202
1
CO2Me
H
H
CN
H



203
2
CO2Me
H
H
CN
H



204
3
CO2Me
H
H
CN
H



205
1
CO2tBu
H
H
CN
H



206
2
CO2tBu
H
H
CN
H



207
3
CO2tBu
H
H
CN
H



208
1
CONHMe
H
H
CN
H



209
2
CONHMe
H
H
CN
H



210
3
CONHMe
H
H
CN
H



211
1
SO2Me
H
H
CN
H



212
2
SO2Me
H
H
CN
H



213
3
SO2Me
H
H
CN
H



214
1
SO2NH2
H
H
CN
H



215
2
SO2NH2
H
H
CN
H



216
3
SO2NH2
H
H
CN
H



217
1
H
H
OH
H
H



218
2
H
H
OH
H
H



219
3
H
H
OH
H
H



220
1
Me
H
OH
H
H



221
2
Me
H
OH
H
H



222
3
Me
H
OH
H
H



223
1
CH2Ph
H
OH
H
H



224
2
CH2Ph
H
OH
H
H



225
3
CH2Ph
H
OH
H
H



226
1
COMe
H
OH
H
H



227
2
COMe
H
OH
H
H



228
3
COMe
H
OH
H
H



229
1
CO2Me
H
OH
H
H



230
2
CO2Me
H
OH
H
H



231
3
CO2Me
H
OH
H
H



232
1
CO2tBu
H
OH
H
H



233
2
CO2tBu
H
OH
H
H



234
3
CO2tBu
H
OH
H
H



235
1
CONHMe
H
OH
H
H



236
2
CONHMe
H
OH
H
H



237
3
CONHMe
H
OH
H
H



238
1
SO2Me
H
OH
H
H



239
2
SO2Me
H
OH
H
H



240
3
SO2Me
H
OH
H
H



241
1
SO2NH2
H
OH
H
H



242
2
SO2NH2
H
OH
H
H



243
3
SO2NH2
H
OH
H
H



244
1
H
H
OMe
H
H



245
2
H
H
OMe
H
H



246
3
H
H
OMe
H
H



247
1
Me
H
OMe
H
H



248
2
Me
H
OMe
H
H



249
3
Me
H
OMe
H
H



250
1
CH2Ph
H
OMe
H
H



251
2
CH2Ph
H
OMe
H
H



252
3
CH2Ph
H
OMe
H
H



253
1
COMe
H
OMe
H
H



254
2
COMe
H
OMe
H
H



255
3
COMe
H
OMe
H
H



256
1
CO2Me
H
OMe
H
H



257
2
CO2Me
H
OMe
H
H



258
3
CO2Me
H
OMe
H
H



259
1
CO2tBu
H
OMe
H
H



260
2
CO2tBu
H
OMe
H
H



261
3
CO2tBu
H
OMe
H
H



262
1
CONHMe
H
OMe
H
H



263
2
CONHMe
H
OMe
H
H



264
3
CONHMe
H
OMe
H
H



265
1
SO2Me
H
OMe
H
H



266
2
SO2Me
H
OMe
H
H



267
3
SO2Me
H
OMe
H
H



268
1
SO2NH2
H
OMe
H
H



269
2
SO2NH2
H
OMe
H
H



270
3
SO2NH2
H
OMe
H
H



271
1
H
H
Me
H
H



272
2
H
H
Me
H
H



273
3
H
H
Me
H
H



274
1
Me
H
Me
H
H



275
2
Me
H
Me
H
H



276
3
Me
H
Me
H
H



277
1
CH2Ph
H
Me
H
H



278
2
CH2Ph
H
Me
H
H



279
3
CH2Ph
H
Me
H
H



280
1
COMe
H
Me
H
H



281
2
COMe
H
Me
H
H



282
3
COMe
H
Me
H
H



283
1
CO2Me
H
Me
H
H



284
2
CO2Me
H
Me
H
H



285
3
CO2Me
H
Me
H
H



286
1
CO2tBu
H
Me
H
H



287
2
CO2tBu
H
Me
H
H



288
3
CO2tBu
H
Me
H
H



289
1
CONHMe
H
Me
H
H



290
2
CONHMe
H
Me
H
H



291
3
CONHMe
H
Me
H
H



292
1
SO2Me
H
Me
H
H



293
2
SO2Me
H
Me
H
H



294
3
SO2Me
H
Me
H
H



295
1
SO2NH2
H
Me
H
H



296
2
SO2NH2
H
Me
H
H



297
3
SO2NH2
H
Me
H
H



298
1
H
H
CF3
H
H



299
2
H
H
CF3
H
H



300
3
H
H
CF3
H
H



301
1
Me
H
CF3
H
H



302
2
Me
H
CF3
H
H



303
3
Me
H
CF3
H
H



304
1
CH2Ph
H
CF3
H
H



305
2
CH2Ph
H
CF3
H
H



306
3
CH2Ph
H
CF3
H
H



307
1
COMe
H
CF3
H
H



308
2
COMe
H
CF3
H
H



309
3
COMe
H
CF3
H
H



310
1
CO2Me
H
CF3
H
H



311
2
CO2Me
H
CF3
H
H



312
3
CO2Me
H
CF3
H
H



313
1
CO2tBu
H
CF3
H
H



314
2
CO2tBu
H
CF3
H
H



315
3
CO2tBu
H
CF3
H
H



316
1
CONHMe
H
CF3
H
H



317
2
CONHMe
H
CF3
H
H



318
3
CONHMe
H
CF3
H
H



319
1
SO2Me
H
CF3
H
H



320
2
SO2Me
H
CF3
H
H



321
3
SO2Me
H
CF3
H
H



322
1
SO2NH2
H
CF3
H
H



323
2
SO2NH2
H
CF3
H
H



324
3
SO2NH2
H
CF3
H
H



325
1
H
H
F
H
H



326
2
H
H
F
H
H



327
3
H
H
F
H
H



328
1
Me
H
F
H
H



329
2
Me
H
F
H
H



330
3
Me
H
F
H
H



331
1
CH2Ph
H
F
H
H



332
2
CH2Ph
H
F
H
H



333
3
CH2Ph
H
F
H
H



334
1
COMe
H
F
H
H



335
2
COMe
H
F
H
H



336
3
COMe
H
F
H
H



337
1
CO2Me
H
F
H
H



338
2
CO2Me
H
F
H
H



339
3
CO2Me
H
F
H
H



340
1
CO2tBu
H
F
H
H



341
2
CO2tBu
H
F
H
H



342
3
CO2tBu
H
F
H
H



343
1
CONHMe
H
F
H
H



344
2
CONHMe
H
F
H
H



345
3
CONHMe
H
F
H
H



346
1
SO2Me
H
F
H
H



347
2
SO2Me
H
F
H
H



348
3
SO2Me
H
F
H
H



349
1
SO2NH2
H
F
H
H



350
2
SO2NH2
H
F
H
H



351
3
SO2NH2
H
F
H
H



352
1
H
H
Cl
H
H



353
2
H
H
Cl
H
H



354
3
H
H
Cl
H
H



355
1
Me
H
Cl
H
H



356
2
Me
H
Cl
H
H



357
3
Me
H
Cl
H
H



358
1
CH2Ph
H
Cl
H
H



359
2
CH2Ph
H
Cl
H
H



360
3
CH2Ph
H
Cl
H
H



361
1
COMe
H
Cl
H
H



362
2
COMe
H
Cl
H
H



363
3
COMe
H
Cl
H
H



364
1
CO2Me
H
Cl
H
H



365
2
CO2Me
H
Cl
H
H



366
3
CO2Me
H
Cl
H
H



367
1
CO2tBu
H
Cl
H
H



368
2
CO2tBu
H
Cl
H
H



369
3
CO2tBu
H
Cl
H
H



370
1
CONHMe
H
Cl
H
H



371
2
CONHMe
H
Cl
H
H



372
3
CONHMe
H
Cl
H
H



373
1
SO2Me
H
Cl
H
H



374
2
SO2Me
H
Cl
H
H



375
3
SO2Me
H
Cl
H
H



376
1
SO2NH2
H
Cl
H
H



377
2
SO2NH2
H
Cl
H
H



378
3
SO2NH2
H
Cl
H
H



379
1
H
H
CN
H
H



380
2
H
H
CN
H
H



381
3
H
H
CN
H
H



382
1
Me
H
CN
H
H



383
2
Me
H
CN
H
H



384
3
Me
H
CN
H
H



385
1
CH2Ph
H
CN
H
H



386
2
CH2Ph
H
CN
H
H



387
3
CH2Ph
H
CN
H
H



388
1
COMe
H
CN
H
H



389
2
COMe
H
CN
H
H



390
3
COMe
H
CN
H
H



391
1
CO2Me
H
CN
H
H



392
2
CO2Me
H
CN
H
H



393
3
CO2Me
H
CN
H
H



394
1
CO2tBu
H
CN
H
H



395
2
CO2tBu
H
CN
H
H



396
3
CO2tBu
H
CN
H
H



397
1
CONHMe
H
CN
H
H



398
2
CONHMe
H
CN
H
H



399
3
CONHMe
H
CN
H
H



400
1
SO2Me
H
CN
H
H



401
2
SO2Me
H
CN
H
H



402
3
SO2Me
H
CN
H
H



403
1
SO2NH2
H
CN
H
H



404
2
SO2NH2
H
CN
H
H



405
3
SO2NH2
H
CN
H
H










Exemplary embodiments include compounds having the formula (XXI)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 5.

















TABLE 5







Entry
n
R
R1a
R1b
R1c
R1d
























1
1
H
H
H
H
H



2
2
H
H
H
H
H



3
3
H
H
H
H
H



4
1
Me
H
H
H
H



5
2
Me
H
H
H
H



6
3
Me
H
H
H
H



7
1
CH2Ph
H
H
H
H



8
2
CH2Ph
H
H
H
H



9
3
CH2Ph
H
H
H
H



10
1
COMe
H
H
H
H



11
2
COMe
H
H
H
H



12
3
COMe
H
H
H
H



13
1
CO2Me
H
H
H
H



14
2
CO2Me
H
H
H
H



15
3
CO2Me
H
H
H
H



16
1
CO2tBu
H
H
H
H



17
2
CO2tBu
H
H
H
H



18
3
CO2tBu
H
H
H
H



19
1
CONHMe
H
H
H
H



20
2
CONHMe
H
H
H
H



21
3
CONHMe
H
H
H
H



22
1
SO2Me
H
H
H
H



23
2
SO2Me
H
H
H
H



24
3
SO2Me
H
H
H
H



25
1
SO2NH2
H
H
H
H



26
2
SO2NH2
H
H
H
H



27
3
SO2NH2
H
H
H
H










Exemplary embodiments include compounds having the formula (XXII)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 6.

















TABLE 6







Entry
n
R
R1a
R1b
R1c
R1d
























1
1
H
H
H
H
H



2
2
H
H
H
H
H



3
3
H
H
H
H
H



4
1
Me
H
H
H
H



5
2
Me
H
H
H
H



6
3
Me
H
H
H
H



7
1
CH2Ph
H
H
H
H



8
2
CH2Ph
H
H
H
H



9
3
CH2Ph
H
H
H
H



10
1
COMe
H
H
H
H



11
2
COMe
H
H
H
H



12
3
COMe
H
H
H
H



13
1
CO2Me
H
H
H
H



14
2
CO2Me
H
H
H
H



15
3
CO2Me
H
H
H
H



16
1
CO2tBu
H
H
H
H



17
2
CO2tBu
H
H
H
H



18
3
CO2tBu
H
H
H
H



19
1
CONHMe
H
H
H
H



20
2
CONHMe
H
H
H
H



21
3
CONHMe
H
H
H
H



22
1
SO2Me
H
H
H
H



23
2
SO2Me
H
H
H
H



24
3
SO2Me
H
H
H
H



25
1
SO2NH2
H
H
H
H



26
2
SO2NH2
H
H
H
H



27
3
SO2NH2
H
H
H
H










Exemplary embodiments include compounds having the formula (XXIII)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 7.
















TABLE 7





Entry
n
X
R3
Entry
n
R
R3






















1
1
O
Phenyl
277
1
O
4-OH-Phenyl


2
2
O
Phenyl
278
2
O
4-OH-Phenyl


3
3
O
Phenyl
279
3
O
4-OH-Phenyl


4
1
S
Phenyl
280
1
S
4-OH-Phenyl


5
2
S
Phenyl
281
2
S
4-OH-Phenyl


6
3
S
Phenyl
282
3
S
4-OH-Phenyl


7
1
SO
Phenyl
283
1
SO
4-OH-Phenyl


8
2
SO
Phenyl
284
2
SO
4-OH-Phenyl


9
3
SO
Phenyl
285
3
SO
4-OH-Phenyl


10
1
SO2
Phenyl
286
1
SO2
4-OH-Phenyl


11
2
SO2
Phenyl
287
2
SO2
4-OH-Phenyl


12
3
SO2
Phenyl
288
3
SO2
4-OH-Phenyl


13
1
O
3-OH-Phenyl
289
1
O
2-OH-Phenyl


14
2
O
3-OH-Phenyl
290
2
O
2-OH-Phenyl


15
3
O
3-OH-Phenyl
291
3
O
2-OH-Phenyl


16
1
S
3-OH-Phenyl
292
1
S
2-OH-Phenyl


17
2
S
3-OH-Phenyl
293
2
S
2-OH-Phenyl


18
3
S
3-OH-Phenyl
294
3
S
2-OH-Phenyl


19
1
SO
3-OH-Phenyl
295
1
SO
2-OH-Phenyl


20
2
SO
3-OH-Phenyl
296
2
SO
2-OH-Phenyl


21
3
SO
3-OH-Phenyl
297
3
SO
2-OH-Phenyl


22
1
SO2
3-OH-Phenyl
298
1
SO2
2-OH-Phenyl


23
2
SO2
3-OH-Phenyl
299
2
SO2
2-OH-Phenyl


24
3
SO2
3-OH-Phenyl
300
3
SO2
2-OH-Phenyl


25
1
O
4-NO2-Phenyl
301
1
O
4-OMe-Phenyl


26
2
O
4-NO2-Phenyl
302
2
O
4-OMe-Phenyl


27
3
O
4-NO2-Phenyl
303
3
O
4-OMe-Phenyl


28
1
S
4-NO2-Phenyl
304
1
S
4-OMe-Phenyl


29
2
S
4-NO2-Phenyl
305
2
S
4-OMe-Phenyl


30
3
S
4-NO2-Phenyl
306
3
S
4-OMe-Phenyl


31
1
SO
4-NO2-Phenyl
307
1
SO
4-OMe-Phenyl


32
2
SO
4-NO2-Phenyl
308
2
SO
4-OMe-Phenyl


33
3
SO
4-NO2-Phenyl
309
3
SO
4-OMe-Phenyl


34
1
SO2
4-NO2-Phenyl
310
1
SO2
4-OMe-Phenyl


35
2
SO2
4-NO2-Phenyl
311
2
SO2
4-OMe-Phenyl


36
3
SO2
4-NO2-Phenyl
312
3
SO2
4-OMe-Phenyl


37
1
O
3-OMe-Phenyl
313
1
O
2-OMe-Phenyl


38
2
O
3-OMe-Phenyl
314
2
O
2-OMe-Phenyl


39
3
O
3-OMe-Phenyl
315
3
O
2-OMe-Phenyl


40
1
S
3-OMe-Phenyl
316
1
S
2-OMe-Phenyl


41
2
S
3-OMe-Phenyl
317
2
S
2-OMe-Phenyl


42
3
S
3-OMe-Phenyl
318
3
S
2-OMe-Phenyl


43
1
SO
3-OMe-Phenyl
319
1
SO
2-OMe-Phenyl


44
2
SO
3-OMe-Phenyl
320
2
SO
2-OMe-Phenyl


45
3
SO
3-OMe-Phenyl
321
3
SO
2-OMe-Phenyl


46
1
SO2
3-OMe-Phenyl
322
1
SO2
2-OMe-Phenyl


47
2
SO2
3-OMe-Phenyl
323
2
SO2
2-OMe-Phenyl


48
3
SO2
3-OMe-Phenyl
324
3
SO2
2-OMe-Phenyl


49
1
O
4-CN-Phenyl
325
1
O
3-CN-Phenyl


50
2
O
4-CN-Phenyl
326
2
O
3-CN-Phenyl


51
3
O
4-CN-Phenyl
327
3
O
3-CN-Phenyl


52
1
S
4-CN-Phenyl
328
1
S
3-CN-Phenyl


53
2
S
4-CN-Phenyl
329
2
S
3-CN-Phenyl


54
3
S
4-CN-Phenyl
330
3
S
3-CN-Phenyl


55
1
SO
4-CN-Phenyl
331
1
SO
3-CN-Phenyl


56
2
SO
4-CN-Phenyl
332
2
SO
3-CN-Phenyl


57
3
SO
4-CN-Phenyl
333
3
SO
3-CN-Phenyl


58
1
SO2
4-CN-Phenyl
334
1
SO2
3-CN-Phenyl


59
2
SO2
4-CN-Phenyl
335
2
SO2
3-CN-Phenyl


60
3
SO2
4-CN-Phenyl
336
3
SO2
3-CN-Phenyl


61
1
O
2-CN-Phenyl
337
1
O
2-Me-Phenyl


62
2
O
2-CN-Phenyl
338
2
O
2-Me-Phenyl


63
3
O
2-CN-Phenyl
339
3
O
2-Me-Phenyl


64
1
S
2-CN-Phenyl
340
1
S
2-Me-Phenyl


65
2
S
2-CN-Phenyl
341
2
S
2-Me-Phenyl


66
3
S
2-CN-Phenyl
342
3
S
2-Me-Phenyl


67
1
SO
2-CN-Phenyl
343
1
SO
2-Me-Phenyl


68
2
SO
2-CN-Phenyl
344
2
SO
2-Me-Phenyl


69
3
SO
2-CN-Phenyl
345
3
SO
2-Me-Phenyl


70
1
SO2
2-CN-Phenyl
346
1
SO2
2-Me-Phenyl


71
2
SO2
2-CN-Phenyl
347
2
SO2
2-Me-Phenyl


72
3
SO2
2-CN-Phenyl
348
3
SO2
2-Me-Phenyl


73
1
O
3-Me-Phenyl
349
1
O
4-Me-Phenyl


74
2
O
3-Me-Phenyl
350
2
O
4-Me-Phenyl


75
3
O
3-Me-Phenyl
351
3
O
4-Me-Phenyl


76
1
S
3-Me-Phenyl
352
1
S
4-Me-Phenyl


77
2
S
3-Me-Phenyl
353
2
S
4-Me-Phenyl


78
3
S
3-Me-Phenyl
354
3
S
4-Me-Phenyl


79
1
SO
3-Me-Phenyl
355
1
SO
4-Me-Phenyl


80
2
SO
3-Me-Phenyl
356
2
SO
4-Me-Phenyl


81
3
SO
3-Me-Phenyl
357
3
SO
4-Me-Phenyl


82
1
SO2
3-Me-Phenyl
358
1
SO2
4-Me-Phenyl


83
2
SO2
3-Me-Phenyl
359
2
SO2
4-Me-Phenyl


84
3
SO2
3-Me-Phenyl
360
3
SO2
4-Me-Phenyl


85
1
O
2-F-Phenyl
361
1
O
3-F-Phenyl


86
2
O
2-F-Phenyl
362
2
O
3-F-Phenyl


87
3
O
2-F-Phenyl
363
3
O
3-F-Phenyl


88
1
S
2-F-Phenyl
364
1
S
3-F-Phenyl


89
2
S
2-F-Phenyl
365
2
S
3-F-Phenyl


90
3
S
2-F-Phenyl
366
3
S
3-F-Phenyl


91
1
SO
2-F-Phenyl
367
1
SO
3-F-Phenyl


92
2
SO
2-F-Phenyl
368
2
SO
3-F-Phenyl


93
3
SO
2-F-Phenyl
369
3
SO
3-F-Phenyl


94
1
SO2
2-F-Phenyl
370
1
SO2
3-F-Phenyl


95
2
SO2
2-F-Phenyl
371
2
SO2
3-F-Phenyl


96
3
SO2
2-F-Phenyl
372
3
SO2
3-F-Phenyl


97
1
O
4-F-Phenyl
373
1
O
2-Cl-Phenyl


98
2
O
4-F-Phenyl
374
2
O
2-Cl-Phenyl


99
3
O
4-F-Phenyl
375
3
O
2-Cl-Phenyl


100
1
S
4-F-Phenyl
376
1
S
2-Cl-Phenyl


101
2
S
4-F-Phenyl
377
2
S
2-Cl-Phenyl


102
3
S
4-F-Phenyl
378
3
S
2-Cl-Phenyl


103
1
SO
4-F-Phenyl
379
1
SO
2-Cl-Phenyl


104
2
SO
4-F-Phenyl
380
2
SO
2-Cl-Phenyl


105
3
SO
4-F-Phenyl
381
3
SO
2-Cl-Phenyl


106
1
SO2
4-F-Phenyl
382
1
SO2
2-Cl-Phenyl


107
2
SO2
4-F-Phenyl
383
2
SO2
2-Cl-Phenyl


108
3
SO2
4-F-Phenyl
384
3
SO2
2-Cl-Phenyl


109
1
O
3-Cl-Phenyl
385
1
O
4-Cl-Phenyl


110
2
O
3-Cl-Phenyl
386
2
O
4-Cl-Phenyl


111
3
O
3-Cl-Phenyl
387
3
O
4-Cl-Phenyl


112
1
S
3-Cl-Phenyl
388
1
S
4-Cl-Phenyl


113
2
S
3-Cl-Phenyl
389
2
S
4-Cl-Phenyl


114
3
S
3-Cl-Phenyl
390
3
S
4-Cl-Phenyl


115
1
SO
3-Cl-Phenyl
391
1
SO
4-Cl-Phenyl


116
2
SO
3-Cl-Phenyl
392
2
SO
4-Cl-Phenyl


117
3
SO
3-Cl-Phenyl
393
3
SO
4-Cl-Phenyl


118
1
SO2
3-Cl-Phenyl
394
1
SO2
4-Cl-Phenyl


119
2
SO2
3-Cl-Phenyl
395
2
SO2
4-Cl-Phenyl


120
3
SO2
3-Cl-Phenyl
396
3
SO2
4-Cl-Phenyl


121
1
O
2-Br-Phenyl
397
1
O
3-Br-Phenyl


122
2
O
2-Br-Phenyl
398
2
O
3-Br-Phenyl


123
3
O
2-Br-Phenyl
399
3
O
3-Br-Phenyl


124
1
S
2-Br-Phenyl
400
1
S
3-Br-Phenyl


125
2
S
2-Br-Phenyl
401
2
S
3-Br-Phenyl


126
3
S
2-Br-Phenyl
402
3
S
3-Br-Phenyl


127
1
SO
2-Br-Phenyl
403
1
SO
3-Br-Phenyl


128
2
SO
2-Br-Phenyl
404
2
SO
3-Br-Phenyl


129
3
SO
2-Br-Phenyl
405
3
SO
3-Br-Phenyl


130
1
SO2
2-Br-Phenyl
406
1
SO2
3-Br-Phenyl


131
2
SO2
2-Br-Phenyl
407
2
SO2
3-Br-Phenyl


132
3
SO2
2-Br-Phenyl
408
3
SO2
3-Br-Phenyl


133
1
O
4-Br-Phenyl
409
1
O
2-CF3-Phenyl


134
2
O
4-Br-Phenyl
410
2
O
2-CF3-Phenyl


135
3
O
4-Br-Phenyl
411
3
O
2-CF3-Phenyl


136
1
S
4-Br-Phenyl
412
1
S
2-CF3-Phenyl


137
2
S
4-Br-Phenyl
413
2
S
2-CF3-Phenyl


138
3
S
4-Br-Phenyl
414
3
S
2-CF3-Phenyl


139
1
SO
4-Br-Phenyl
415
1
SO
2-CF3-Phenyl


140
2
SO
4-Br-Phenyl
416
2
SO
2-CF3-Phenyl


141
3
SO
4-Br-Phenyl
417
3
SO
2-CF3-Phenyl


142
1
SO2
4-Br-Phenyl
418
1
SO2
2-CF3-Phenyl


143
2
SO2
4-Br-Phenyl
419
2
SO2
2-CF3-Phenyl


144
3
SO2
4-Br-Phenyl
420
3
SO2
2-CF3-Phenyl


145
1
O
3-CF3-Phenyl
421
1
O
4-CF3-Phenyl


146
2
O
3-CF3-Phenyl
422
2
O
4-CF3-Phenyl


147
3
O
3-CF3-Phenyl
423
3
O
4-CF3-Phenyl


148
1
S
3-CF3-Phenyl
424
1
S
4-CF3-Phenyl


149
2
S
3-CF3-Phenyl
425
2
S
4-CF3-Phenyl


150
3
S
3-CF3-Phenyl
426
3
S
4-CF3-Phenyl


151
1
SO
3-CF3-Phenyl
427
1
SO
4-CF3-Phenyl


152
2
SO
3-CF3-Phenyl
428
2
SO
4-CF3-Phenyl


153
3
SO
3-CF3-Phenyl
429
3
SO
4-CF3-Phenyl


154
1
SO2
3-CF3-Phenyl
430
1
SO2
4-CF3-Phenyl


155
2
SO2
3-CF3-Phenyl
431
2
SO2
4-CF3-Phenyl


156
3
SO2
3-CF3-Phenyl
432
3
SO2
4-CF3-Phenyl


157
1
O
2-iPr-Phenyl
433
1
O
3-iPr-Phenyl


158
2
O
2-iPr-Phenyl
434
2
O
3-iPr-Phenyl


159
3
O
2-iPr-Phenyl
435
3
O
3-iPr-Phenyl


160
1
S
2-iPr-Phenyl
436
1
S
3-iPr-Phenyl


161
2
S
2-iPr-Phenyl
437
2
S
3-iPr-Phenyl


162
3
S
2-iPr-Phenyl
438
3
S
3-iPr-Phenyl


163
1
SO
2-iPr-Phenyl
439
1
SO
3-iPr-Phenyl


164
2
SO
2-iPr-Phenyl
440
2
SO
3-iPr-Phenyl


165
3
SO
2-iPr-Phenyl
441
3
SO
3-iPr-Phenyl


166
1
SO2
2-iPr-Phenyl
442
1
SO2
3-iPr-Phenyl


167
2
SO2
2-iPr-Phenyl
443
2
SO2
3-iPr-Phenyl


168
3
SO2
2-iPr-Phenyl
444
3
SO2
3-iPr-Phenyl


169
1
O
4-iPr-Phenyl
445
1
O
4-NH2-Phenyl


170
2
O
4-iPr-Phenyl
446
2
O
4-NH2-Phenyl


171
3
O
4-iPr-Phenyl
447
3
O
4-NH2-Phenyl


172
1
S
4-iPr-Phenyl
448
1
S
4-NH2-Phenyl


173
2
S
4-iPr-Phenyl
449
2
S
4-NH2-Phenyl


174
3
S
4-iPr-Phenyl
450
3
S
4-NH2-Phenyl


175
1
SO
4-iPr-Phenyl
451
1
SO
4-NH2-Phenyl


176
2
SO
4-iPr-Phenyl
452
2
SO
4-NH2-Phenyl


177
3
SO
4-iPr-Phenyl
453
3
SO
4-NH2-Phenyl


178
1
SO2
4-iPr-Phenyl
454
1
SO2
4-NH2-Phenyl


179
2
SO2
4-iPr-Phenyl
455
2
SO2
4-NH2-Phenyl


180
3
SO2
4-iPr-Phenyl
456
3
SO2
4-NH2-Phenyl


181
1
O
3-NH2-Phenyl
457
1
O
2-NH2-Phenyl


182
2
O
3-NH2-Phenyl
458
2
O
2-NH2-Phenyl


183
3
O
3-NH2-Phenyl
459
3
O
2-NH2-Phenyl


184
1
S
3-NH2-Phenyl
460
1
S
2-NH2-Phenyl


185
2
S
3-NH2-Phenyl
461
2
S
2-NH2-Phenyl


186
3
S
3-NH2-Phenyl
462
3
S
2-NH2-Phenyl


187
1
SO
3-NH2-Phenyl
463
1
SO
2-NH2-Phenyl


188
2
SO
3-NH2-Phenyl
464
2
SO
2-NH2-Phenyl


189
3
SO
3-NH2-Phenyl
465
3
SO
2-NH2-Phenyl


190
1
SO2
3-NH2-Phenyl
466
1
SO2
2-NH2-Phenyl


191
2
SO2
3-NH2-Phenyl
467
2
SO2
2-NH2-Phenyl


192
3
SO2
3-NH2-Phenyl
468
3
SO2
2-NH2-Phenyl


193
1
O
2,4-di-Me-Phenyl
469
1
O
2,6-di-Me-Phenyl


194
2
O
2,4-di-Me-Phenyl
470
2
O
2,6-di-Me-Phenyl


195
3
O
2,4-di-Me-Phenyl
471
3
O
2,6-di-Me-Phenyl


196
1
S
2,4-di-Me-Phenyl
472
1
S
2,6-di-Me-Phenyl


197
2
S
2,4-di-Me-Phenyl
473
2
S
2,6-di-Me-Phenyl


198
3
S
2,4-di-Me-Phenyl
474
3
S
2,6-di-Me-Phenyl


199
1
SO
2,4-di-Me-Phenyl
475
1
SO
2,6-di-Me-Phenyl


200
2
SO
2,4-di-Me-Phenyl
476
2
SO
2,6-di-Me-Phenyl


201
3
SO
2,4-di-Me-Phenyl
477
3
SO
2,6-di-Me-Phenyl


202
1
SO2
2,4-di-Me-Phenyl
478
1
SO2
2,6-di-Me-Phenyl


203
2
SO2
2,4-di-Me-Phenyl
479
2
SO2
2,6-di-Me-Phenyl


204
3
SO2
2,4-di-Me-Phenyl
480
3
SO2
2,6-di-Me-Phenyl


205
1
O
2,6-di-iPr-Phenyl
481
1
O
2-Ph-Phenyl


206
2
O
2,6-di-iPr-Phenyl
482
2
O
2-Ph-Phenyl


207
3
O
2,6-di-iPr-Phenyl
483
3
O
2-Ph-Phenyl


208
1
S
2,6-di-iPr-Phenyl
484
1
S
2-Ph-Phenyl


209
2
S
2,6-di-iPr-Phenyl
485
2
S
2-Ph-Phenyl


210
3
S
2,6-di-iPr-Phenyl
486
3
S
2-Ph-Phenyl


211
1
SO
2,6-di-iPr-Phenyl
487
1
SO
2-Ph-Phenyl


212
2
SO
2,6-di-iPr-Phenyl
488
2
SO
2-Ph-Phenyl


213
3
SO
2,6-di-iPr-Phenyl
489
3
SO
2-Ph-Phenyl


214
1
SO2
2,6-di-iPr-Phenyl
490
1
SO2
2-Ph-Phenyl


215
2
SO2
2,6-di-iPr-Phenyl
491
2
SO2
2-Ph-Phenyl


216
3
SO2
2,6-di-iPr-Phenyl
492
3
SO2
2-Ph-Phenyl


217
1
O
3-Ph-Phenyl
493
1
O
4-Ph-Phenyl


218
2
O
3-Ph-Phenyl
494
2
O
4-Ph-Phenyl


219
3
O
3-Ph-Phenyl
495
3
O
4-Ph-Phenyl


220
1
S
3-Ph-Phenyl
496
1
S
4-Ph-Phenyl


221
2
S
3-Ph-Phenyl
497
2
S
4-Ph-Phenyl


222
3
S
3-Ph-Phenyl
498
3
S
4-Ph-Phenyl


223
1
SO
3-Ph-Phenyl
499
1
SO
4-Ph-Phenyl


224
2
SO
3-Ph-Phenyl
500
2
SO
4-Ph-Phenyl


225
3
SO
3-Ph-Phenyl
501
3
SO
4-Ph-Phenyl


226
1
SO2
3-Ph-Phenyl
502
1
SO2
4-Ph-Phenyl


227
2
SO2
3-Ph-Phenyl
503
2
SO2
4-Ph-Phenyl


228
3
SO2
3-Ph-Phenyl
504
3
SO2
4-Ph-Phenyl


229
1
O
2-morpholino-phenyl
505
1
O
3-morpholino-phenyl


230
2
O
2-morpholino-phenyl
506
2
O
3-morpholino-phenyl


231
3
O
2-morpholino-phenyl
507
3
O
3-morpholino-phenyl


232
1
S
2-morpholino-phenyl
508
1
S
3-morpholino-phenyl


233
2
S
2-morpholino-phenyl
509
2
S
3-morpholino-phenyl


234
3
S
2-morpholino-phenyl
510
3
S
3-morpholino-phenyl


235
1
SO
2-morpholino-phenyl
511
1
SO
3-morpholino-phenyl


236
2
SO
2-morpholino-phenyl
512
2
SO
3-morpholino-phenyl


237
3
SO
2-morpholino-phenyl
513
3
SO
3-morpholino-phenyl


238
1
SO2
2-morpholino-phenyl
514
1
SO2
3-morpholino-phenyl


239
2
SO2
2-morpholino-phenyl
515
2
SO2
3-morpholino-phenyl


240
3
SO2
2-morpholino-phenyl
516
3
SO2
3-morpholino-phenyl


241
1
O
4-morpholino-phenyl
517
1
O
2-pyrazinyl


242
2
O
4-morpholino-phenyl
518
2
O
2-pyrazinyl


243
3
O
4-morpholino-phenyl
519
3
O
2-pyrazinyl


244
1
S
4-morpholino-phenyl
520
1
S
2-pyrazinyl


245
2
S
4-morpholino-phenyl
521
2
S
2-pyrazinyl


246
3
S
4-morpholino-phenyl
522
3
S
2-pyrazinyl


247
1
SO
4-morpholino-phenyl
523
1
SO
2-pyrazinyl


248
2
SO
4-morpholino-phenyl
524
2
SO
2-pyrazinyl


249
3
SO
4-morpholino-phenyl
525
3
SO
2-pyrazinyl


250
1
SO2
4-morpholino-phenyl
526
1
SO2
2-pyrazinyl


251
2
SO2
4-morpholino-phenyl
527
2
SO2
2-pyrazinyl


252
3
SO2
4-morpholino-phenyl
528
3
SO2
2-pyrazinyl


253
1
O
2-pyrimidinyl
529
1
O
5-indolyl


254
2
O
2-pyrimidinyl
530
2
O
5-indolyl


255
3
O
2-pyrimidinyl
531
3
O
5-indolyl


256
1
S
2-pyrimidinyl
532
1
S
5-indolyl


257
2
S
2-pyrimidinyl
533
2
S
5-indolyl


258
3
S
2-pyrimidinyl
534
3
S
5-indolyl


259
1
SO
2-pyrimidinyl
535
1
SO
5-indolyl


260
2
SO
2-pyrimidinyl
536
2
SO
5-indolyl


261
3
SO
2-pyrimidinyl
537
3
SO
5-indolyl


262
1
SO2
2-pyrimidinyl
538
1
SO2
5-indolyl


263
2
SO2
2-pyrimidinyl
539
2
SO2
5-indolyl


264
3
SO2
2-pyrimidinyl
540
3
SO2
5-indolyl


265
1
O
2-methyl-1H-
541
1
O
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


266
2
O
2-methyl-1H-
542
2
O
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


267
3
O
2-methyl-1H-
543
3
O
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


268
1
S
2-methyl-1H-
544
1
S
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


269
2
S
2-methyl-1H-
545
2
S
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


270
3
S
2-methyl-1H-
546
3
S
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


271
1
SO
2-methyl-1H-
547
1
SO
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


272
2
SO
2-methyl-1H-
548
2
SO
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


273
3
SO
2-methyl-1H-
549
3
SO
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


274
1
SO2
2-methyl-1H-
550
1
SO2
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


275
2
SO2
2-methyl-1H-
551
2
SO2
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


276
3
SO2
2-methyl-1H-
552
3
SO2
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl









Exemplary embodiments include compounds having the formula (XXIV)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 8.
















TABLE 8





Entry
n
X
R3
Entry
n
R
R3






















1
1
O
Phenyl
277
1
O
4-OH-Phenyl


2
2
O
Phenyl
278
2
O
4-OH-Phenyl


3
3
O
Phenyl
279
3
O
4-OH-Phenyl


4
1
S
Phenyl
280
1
S
4-OH-Phenyl


5
2
S
Phenyl
281
2
S
4-OH-Phenyl


6
3
S
Phenyl
282
3
S
4-OH-Phenyl


7
1
SO
Phenyl
283
1
SO
4-OH-Phenyl


8
2
SO
Phenyl
284
2
SO
4-OH-Phenyl


9
3
SO
Phenyl
285
3
SO
4-OH-Phenyl


10
1
SO2
Phenyl
286
1
SO2
4-OH-Phenyl


11
2
SO2
Phenyl
287
2
SO2
4-OH-Phenyl


12
3
SO2
Phenyl
288
3
SO2
4-OH-Phenyl


13
1
O
3-OH-Phenyl
289
1
O
2-OH-Phenyl


14
2
O
3-OH-Phenyl
290
2
O
2-OH-Phenyl


15
3
O
3-OH-Phenyl
291
3
O
2-OH-Phenyl


16
1
S
3-OH-Phenyl
292
1
S
2-OH-Phenyl


17
2
S
3-OH-Phenyl
293
2
S
2-OH-Phenyl


18
3
S
3-OH-Phenyl
294
3
S
2-OH-Phenyl


19
1
SO
3-OH-Phenyl
295
1
SO
2-OH-Phenyl


20
2
SO
3-OH-Phenyl
296
2
SO
2-OH-Phenyl


21
3
SO
3-OH-Phenyl
297
3
SO
2-OH-Phenyl


22
1
SO2
3-OH-Phenyl
298
1
SO2
2-OH-Phenyl


23
2
SO2
3-OH-Phenyl
299
2
SO2
2-OH-Phenyl


24
3
SO2
3-OH-Phenyl
300
3
SO2
2-OH-Phenyl


25
1
O
4-NO2-Phenyl
301
1
O
4-OMe-Phenyl


26
2
O
4-NO2-Phenyl
302
2
O
4-OMe-Phenyl


27
3
O
4-NO2-Phenyl
303
3
O
4-OMe-Phenyl


28
1
S
4-NO2-Phenyl
304
1
S
4-OMe-Phenyl


29
2
S
4-NO2-Phenyl
305
2
S
4-OMe-Phenyl


30
3
S
4-NO2-Phenyl
306
3
S
4-OMe-Phenyl


31
1
SO
4-NO2-Phenyl
307
1
SO
4-OMe-Phenyl


32
2
SO
4-NO2-Phenyl
308
2
SO
4-OMe-Phenyl


33
3
SO
4-NO2-Phenyl
309
3
SO
4-OMe-Phenyl


34
1
SO2
4-NO2-Phenyl
310
1
SO2
4-OMe-Phenyl


35
2
SO2
4-NO2-Phenyl
311
2
SO2
4-OMe-Phenyl


36
3
SO2
4-NO2-Phenyl
312
3
SO2
4-OMe-Phenyl


37
1
O
3-OMe-Phenyl
313
1
O
2-OMe-Phenyl


38
2
O
3-OMe-Phenyl
314
2
O
2-OMe-Phenyl


39
3
O
3-OMe-Phenyl
315
3
O
2-OMe-Phenyl


40
1
S
3-OMe-Phenyl
316
1
S
2-OMe-Phenyl


41
2
S
3-OMe-Phenyl
317
2
S
2-OMe-Phenyl


42
3
S
3-OMe-Phenyl
318
3
S
2-OMe-Phenyl


43
1
SO
3-OMe-Phenyl
319
1
SO
2-OMe-Phenyl


44
2
SO
3-OMe-Phenyl
320
2
SO
2-OMe-Phenyl


45
3
SO
3-OMe-Phenyl
321
3
SO
2-OMe-Phenyl


46
1
SO2
3-OMe-Phenyl
322
1
SO2
2-OMe-Phenyl


47
2
SO2
3-OMe-Phenyl
323
2
SO2
2-OMe-Phenyl


48
3
SO2
3-OMe-Phenyl
324
3
SO2
2-OMe-Phenyl


49
1
O
4-CN-Phenyl
325
1
O
3-CN-Phenyl


50
2
O
4-CN-Phenyl
326
2
O
3-CN-Phenyl


51
3
O
4-CN-Phenyl
327
3
O
3-CN-Phenyl


52
1
S
4-CN-Phenyl
328
1
S
3-CN-Phenyl


53
2
S
4-CN-Phenyl
329
2
S
3-CN-Phenyl


54
3
S
4-CN-Phenyl
330
3
S
3-CN-Phenyl


55
1
SO
4-CN-Phenyl
331
1
SO
3-CN-Phenyl


56
2
SO
4-CN-Phenyl
332
2
SO
3-CN-Phenyl


57
3
SO
4-CN-Phenyl
333
3
SO
3-CN-Phenyl


58
1
SO2
4-CN-Phenyl
334
1
SO2
3-CN-Phenyl


59
2
SO2
4-CN-Phenyl
335
2
SO2
3-CN-Phenyl


60
3
SO2
4-CN-Phenyl
336
3
SO2
3-CN-Phenyl


61
1
O
2-CN-Phenyl
337
1
O
2-Me-Phenyl


62
2
O
2-CN-Phenyl
338
2
O
2-Me-Phenyl


63
3
O
2-CN-Phenyl
339
3
O
2-Me-Phenyl


64
1
S
2-CN-Phenyl
340
1
S
2-Me-Phenyl


65
2
S
2-CN-Phenyl
341
2
S
2-Me-Phenyl


66
3
S
2-CN-Phenyl
342
3
S
2-Me-Phenyl


67
1
SO
2-CN-Phenyl
343
1
SO
2-Me-Phenyl


68
2
SO
2-CN-Phenyl
344
2
SO
2-Me-Phenyl


69
3
SO
2-CN-Phenyl
345
3
SO
2-Me-Phenyl


70
1
SO2
2-CN-Phenyl
346
1
SO2
2-Me-Phenyl


71
2
SO2
2-CN-Phenyl
347
2
SO2
2-Me-Phenyl


72
3
SO2
2-CN-Phenyl
348
3
SO2
2-Me-Phenyl


73
1
O
3-Me-Phenyl
349
1
O
4-Me-Phenyl


74
2
O
3-Me-Phenyl
350
2
O
4-Me-Phenyl


75
3
O
3-Me-Phenyl
351
3
O
4-Me-Phenyl


76
1
S
3-Me-Phenyl
352
1
S
4-Me-Phenyl


77
2
S
3-Me-Phenyl
353
2
S
4-Me-Phenyl


78
3
S
3-Me-Phenyl
354
3
S
4-Me-Phenyl


79
1
SO
3-Me-Phenyl
355
1
SO
4-Me-Phenyl


80
2
SO
3-Me-Phenyl
356
2
SO
4-Me-Phenyl


81
3
SO
3-Me-Phenyl
357
3
SO
4-Me-Phenyl


82
1
SO2
3-Me-Phenyl
358
1
SO2
4-Me-Phenyl


83
2
SO2
3-Me-Phenyl
359
2
SO2
4-Me-Phenyl


84
3
SO2
3-Me-Phenyl
360
3
SO2
4-Me-Phenyl


85
1
O
2-F-Phenyl
361
1
O
3-F-Phenyl


86
2
O
2-F-Phenyl
362
2
O
3-F-Phenyl


87
3
O
2-F-Phenyl
363
3
O
3-F-Phenyl


88
1
S
2-F-Phenyl
364
1
S
3-F-Phenyl


89
2
S
2-F-Phenyl
365
2
S
3-F-Phenyl


90
3
S
2-F-Phenyl
366
3
S
3-F-Phenyl


91
1
SO
2-F-Phenyl
367
1
SO
3-F-Phenyl


92
2
SO
2-F-Phenyl
368
2
SO
3-F-Phenyl


93
3
SO
2-F-Phenyl
369
3
SO
3-F-Phenyl


94
1
SO2
2-F-Phenyl
370
1
SO2
3-F-Phenyl


95
2
SO2
2-F-Phenyl
371
2
SO2
3-F-Phenyl


96
3
SO2
2-F-Phenyl
372
3
SO2
3-F-Phenyl


97
1
O
4-F-Phenyl
373
1
O
2-Cl-Phenyl


98
2
O
4-F-Phenyl
374
2
O
2-Cl-Phenyl


99
3
O
4-F-Phenyl
375
3
O
2-Cl-Phenyl


100
1
S
4-F-Phenyl
376
1
S
2-Cl-Phenyl


101
2
S
4-F-Phenyl
377
2
S
2-Cl-Phenyl


102
3
S
4-F-Phenyl
378
3
S
2-Cl-Phenyl


103
1
SO
4-F-Phenyl
379
1
SO
2-Cl-Phenyl


104
2
SO
4-F-Phenyl
380
2
SO
2-Cl-Phenyl


105
3
SO
4-F-Phenyl
381
3
SO
2-Cl-Phenyl


106
1
SO2
4-F-Phenyl
382
1
SO2
2-Cl-Phenyl


107
2
SO2
4-F-Phenyl
383
2
SO2
2-Cl-Phenyl


108
3
SO2
4-F-Phenyl
384
3
SO2
2-Cl-Phenyl


109
1
O
3-Cl-Phenyl
385
1
O
4-Cl-Phenyl


110
2
O
3-Cl-Phenyl
386
2
O
4-Cl-Phenyl


111
3
O
3-Cl-Phenyl
387
3
O
4-Cl-Phenyl


112
1
S
3-Cl-Phenyl
388
1
S
4-Cl-Phenyl


113
2
S
3-Cl-Phenyl
389
2
S
4-Cl-Phenyl


114
3
S
3-Cl-Phenyl
390
3
S
4-Cl-Phenyl


115
1
SO
3-Cl-Phenyl
391
1
SO
4-Cl-Phenyl


116
2
SO
3-Cl-Phenyl
392
2
SO
4-Cl-Phenyl


117
3
SO
3-Cl-Phenyl
393
3
SO
4-Cl-Phenyl


118
1
SO2
3-Cl-Phenyl
394
1
SO2
4-Cl-Phenyl


119
2
SO2
3-Cl-Phenyl
395
2
SO2
4-Cl-Phenyl


120
3
SO2
3-Cl-Phenyl
396
3
SO2
4-Cl-Phenyl


121
1
O
2-Br-Phenyl
397
1
O
3-Br-Phenyl


122
2
O
2-Br-Phenyl
398
2
O
3-Br-Phenyl


123
3
O
2-Br-Phenyl
399
3
O
3-Br-Phenyl


124
1
S
2-Br-Phenyl
400
1
S
3-Br-Phenyl


125
2
S
2-Br-Phenyl
401
2
S
3-Br-Phenyl


126
3
S
2-Br-Phenyl
402
3
S
3-Br-Phenyl


127
1
SO
2-Br-Phenyl
403
1
SO
3-Br-Phenyl


128
2
SO
2-Br-Phenyl
404
2
SO
3-Br-Phenyl


129
3
SO
2-Br-Phenyl
405
3
SO
3-Br-Phenyl


130
1
SO2
2-Br-Phenyl
406
1
SO2
3-Br-Phenyl


131
2
SO2
2-Br-Phenyl
407
2
SO2
3-Br-Phenyl


132
3
SO2
2-Br-Phenyl
408
3
SO2
3-Br-Phenyl


133
1
O
4-Br-Phenyl
409
1
O
2-CF3-Phenyl


134
2
O
4-Br-Phenyl
410
2
O
2-CF3-Phenyl


135
3
O
4-Br-Phenyl
411
3
O
2-CF3-Phenyl


136
1
S
4-Br-Phenyl
412
1
S
2-CF3-Phenyl


137
2
S
4-Br-Phenyl
413
2
S
2-CF3-Phenyl


138
3
S
4-Br-Phenyl
414
3
S
2-CF3-Phenyl


139
1
SO
4-Br-Phenyl
415
1
SO
2-CF3-Phenyl


140
2
SO
4-Br-Phenyl
416
2
SO
2-CF3-Phenyl


141
3
SO
4-Br-Phenyl
417
3
SO
2-CF3-Phenyl


142
1
SO2
4-Br-Phenyl
418
1
SO2
2-CF3-Phenyl


143
2
SO2
4-Br-Phenyl
419
2
SO2
2-CF3-Phenyl


144
3
SO2
4-Br-Phenyl
420
3
SO2
2-CF3-Phenyl


145
1
O
3-CF3-Phenyl
421
1
O
4-CF3-Phenyl


146
2
O
3-CF3-Phenyl
422
2
O
4-CF3-Phenyl


147
3
O
3-CF3-Phenyl
423
3
O
4-CF3-Phenyl


148
1
S
3-CF3-Phenyl
424
1
S
4-CF3-Phenyl


149
2
S
3-CF3-Phenyl
425
2
S
4-CF3-Phenyl


150
3
S
3-CF3-Phenyl
426
3
S
4-CF3-Phenyl


151
1
SO
3-CF3-Phenyl
427
1
SO
4-CF3-Phenyl


152
2
SO
3-CF3-Phenyl
428
2
SO
4-CF3-Phenyl


153
3
SO
3-CF3-Phenyl
429
3
SO
4-CF3-Phenyl


154
1
SO2
3-CF3-Phenyl
430
1
SO2
4-CF3-Phenyl


155
2
SO2
3-CF3-Phenyl
431
2
SO2
4-CF3-Phenyl


156
3
SO2
3-CF3-Phenyl
432
3
SO2
4-CF3-Phenyl


157
1
O
2-iPr-Phenyl
433
1
O
3-iPr-Phenyl


158
2
O
2-iPr-Phenyl
434
2
O
3-iPr-Phenyl


159
3
O
2-iPr-Phenyl
435
3
O
3-iPr-Phenyl


160
1
S
2-iPr-Phenyl
436
1
S
3-iPr-Phenyl


161
2
S
2-iPr-Phenyl
437
2
S
3-iPr-Phenyl


162
3
S
2-iPr-Phenyl
438
3
S
3-iPr-Phenyl


163
1
SO
2-iPr-Phenyl
439
1
SO
3-iPr-Phenyl


164
2
SO
2-iPr-Phenyl
440
2
SO
3-iPr-Phenyl


165
3
SO
2-iPr-Phenyl
441
3
SO
3-iPr-Phenyl


166
1
SO2
2-iPr-Phenyl
442
1
SO2
3-iPr-Phenyl


167
2
SO2
2-iPr-Phenyl
443
2
SO2
3-iPr-Phenyl


168
3
SO2
2-iPr-Phenyl
444
3
SO2
3-iPr-Phenyl


169
1
O
4-iPr-Phenyl
445
1
O
4-NH2-Phenyl


170
2
O
4-iPr-Phenyl
446
2
O
4-NH2-Phenyl


171
3
O
4-iPr-Phenyl
447
3
O
4-NH2-Phenyl


172
1
S
4-iPr-Phenyl
448
1
S
4-NH2-Phenyl


173
2
S
4-iPr-Phenyl
449
2
S
4-NH2-Phenyl


174
3
S
4-iPr-Phenyl
450
3
S
4-NH2-Phenyl


175
1
SO
4-iPr-Phenyl
451
1
SO
4-NH2-Phenyl


176
2
SO
4-iPr-Phenyl
452
2
SO
4-NH2-Phenyl


177
3
SO
4-iPr-Phenyl
453
3
SO
4-NH2-Phenyl


178
1
SO2
4-iPr-Phenyl
454
1
SO2
4-NH2-Phenyl


179
2
SO2
4-iPr-Phenyl
455
2
SO2
4-NH2-Phenyl


180
3
SO2
4-iPr-Phenyl
456
3
SO2
4-NH2-Phenyl


181
1
O
3-NH2-Phenyl
457
1
O
2-NH2-Phenyl


182
2
O
3-NH2-Phenyl
458
2
O
2-NH2-Phenyl


183
3
O
3-NH2-Phenyl
459
3
O
2-NH2-Phenyl


184
1
S
3-NH2-Phenyl
460
1
S
2-NH2-Phenyl


185
2
S
3-NH2-Phenyl
461
2
S
2-NH2-Phenyl


186
3
S
3-NH2-Phenyl
462
3
S
2-NH2-Phenyl


187
1
SO
3-NH2-Phenyl
463
1
SO
2-NH2-Phenyl


188
2
SO
3-NH2-Phenyl
464
2
SO
2-NH2-Phenyl


189
3
SO
3-NH2-Phenyl
465
3
SO
2-NH2-Phenyl


190
1
SO2
3-NH2-Phenyl
466
1
SO2
2-NH2-Phenyl


191
2
SO2
3-NH2-Phenyl
467
2
SO2
2-NH2-Phenyl


192
3
SO2
3-NH2-Phenyl
468
3
SO2
2-NH2-Phenyl


193
1
O
2,4-di-Me-Phenyl
469
1
O
2,6-di-Me-Phenyl


194
2
O
2,4-di-Me-Phenyl
470
2
O
2,6-di-Me-Phenyl


195
3
O
2,4-di-Me-Phenyl
471
3
O
2,6-di-Me-Phenyl


196
1
S
2,4-di-Me-Phenyl
472
1
S
2,6-di-Me-Phenyl


197
2
S
2,4-di-Me-Phenyl
473
2
S
2,6-di-Me-Phenyl


198
3
S
2,4-di-Me-Phenyl
474
3
S
2,6-di-Me-Phenyl


199
1
SO
2,4-di-Me-Phenyl
475
1
SO
2,6-di-Me-Phenyl


200
2
SO
2,4-di-Me-Phenyl
476
2
SO
2,6-di-Me-Phenyl


201
3
SO
2,4-di-Me-Phenyl
477
3
SO
2,6-di-Me-Phenyl


202
1
SO2
2,4-di-Me-Phenyl
478
1
SO2
2,6-di-Me-Phenyl


203
2
SO2
2,4-di-Me-Phenyl
479
2
SO2
2,6-di-Me-Phenyl


204
3
SO2
2,4-di-Me-Phenyl
480
3
SO2
2,6-di-Me-Phenyl


205
1
O
2,6-di-iPr-Phenyl
481
1
O
2-Ph-Phenyl


206
2
O
2,6-di-iPr-Phenyl
482
2
O
2-Ph-Phenyl


207
3
O
2,6-di-iPr-Phenyl
483
3
O
2-Ph-Phenyl


208
1
S
2,6-di-iPr-Phenyl
484
1
S
2-Ph-Phenyl


209
2
S
2,6-di-iPr-Phenyl
485
2
S
2-Ph-Phenyl


210
3
S
2,6-di-iPr-Phenyl
486
3
S
2-Ph-Phenyl


211
1
SO
2,6-di-iPr-Phenyl
487
1
SO
2-Ph-Phenyl


212
2
SO
2,6-di-iPr-Phenyl
488
2
SO
2-Ph-Phenyl


213
3
SO
2,6-di-iPr-Phenyl
489
3
SO
2-Ph-Phenyl


214
1
SO2
2,6-di-iPr-Phenyl
490
1
SO2
2-Ph-Phenyl


215
2
SO2
2,6-di-iPr-Phenyl
491
2
SO2
2-Ph-Phenyl


216
3
SO2
2,6-di-iPr-Phenyl
492
3
SO2
2-Ph-Phenyl


217
1
O
3-Ph-Phenyl
493
1
O
4-Ph-Phenyl


218
2
O
3-Ph-Phenyl
494
2
O
4-Ph-Phenyl


219
3
O
3-Ph-Phenyl
495
3
O
4-Ph-Phenyl


220
1
S
3-Ph-Phenyl
496
1
S
4-Ph-Phenyl


221
2
S
3-Ph-Phenyl
497
2
S
4-Ph-Phenyl


222
3
S
3-Ph-Phenyl
498
3
S
4-Ph-Phenyl


223
1
SO
3-Ph-Phenyl
499
1
SO
4-Ph-Phenyl


224
2
SO
3-Ph-Phenyl
500
2
SO
4-Ph-Phenyl


225
3
SO
3-Ph-Phenyl
501
3
SO
4-Ph-Phenyl


226
1
SO2
3-Ph-Phenyl
502
1
SO2
4-Ph-Phenyl


227
2
SO2
3-Ph-Phenyl
503
2
SO2
4-Ph-Phenyl


228
3
SO2
3-Ph-Phenyl
504
3
SO2
4-Ph-Phenyl


229
1
O
2-morpholino-phenyl
505
1
O
3-morpholino-phenyl


230
2
O
2-morpholino-phenyl
506
2
O
3-morpholino-phenyl


231
3
O
2-morpholino-phenyl
507
3
O
3-morpholino-phenyl


232
1
S
2-morpholino-phenyl
508
1
S
3-morpholino-phenyl


233
2
S
2-morpholino-phenyl
509
2
S
3-morpholino-phenyl


234
3
S
2-morpholino-phenyl
510
3
S
3-morpholino-phenyl


235
1
SO
2-morpholino-phenyl
511
1
SO
3-morpholino-phenyl


236
2
SO
2-morpholino-phenyl
512
2
SO
3-morpholino-phenyl


237
3
SO
2-morpholino-phenyl
513
3
SO
3-morpholino-phenyl


238
1
SO2
2-morpholino-phenyl
514
1
SO2
3-morpholino-phenyl


239
2
SO2
2-morpholino-phenyl
515
2
SO2
3-morpholino-phenyl


240
3
SO2
2-morpholino-phenyl
516
3
SO2
3-morpholino-phenyl


241
1
O
4-morpholino-phenyl
517
1
O
2-pyrazinyl


242
2
O
4-morpholino-phenyl
518
2
O
2-pyrazinyl


243
3
O
4-morpholino-phenyl
519
3
O
2-pyrazinyl


244
1
S
4-morpholino-phenyl
520
1
S
2-pyrazinyl


245
2
S
4-morpholino-phenyl
521
2
S
2-pyrazinyl


246
3
S
4-morpholino-phenyl
522
3
S
2-pyrazinyl


247
1
SO
4-morpholino-phenyl
523
1
SO
2-pyrazinyl


248
2
SO
4-morpholino-phenyl
524
2
SO
2-pyrazinyl


249
3
SO
4-morpholino-phenyl
525
3
SO
2-pyrazinyl


250
1
SO2
4-morpholino-phenyl
526
1
SO2
2-pyrazinyl


251
2
SO2
4-morpholino-phenyl
527
2
SO2
2-pyrazinyl


252
3
SO2
4-morpholino-phenyl
528
3
SO2
2-pyrazinyl


253
1
O
2-pyrimidinyl
529
1
O
5-indolyl


254
2
O
2-pyrimidinyl
530
2
O
5-indolyl


255
3
O
2-pyrimidinyl
531
3
O
5-indolyl


256
1
S
2-pyrimidinyl
532
1
S
5-indolyl


257
2
S
2-pyrimidinyl
533
2
S
5-indolyl


258
3
S
2-pyrimidinyl
534
3
S
5-indolyl


259
1
SO
2-pyrimidinyl
535
1
SO
5-indolyl


260
2
SO
2-pyrimidinyl
536
2
SO
5-indolyl


261
3
SO
2-pyrimidinyl
537
3
SO
5-indolyl


262
1
SO2
2-pyrimidinyl
538
1
SO2
5-indolyl


263
2
SO2
2-pyrimidinyl
539
2
SO2
5-indolyl


264
3
SO2
2-pyrimidinyl
540
3
SO2
5-indolyl


265
1
O
2-methyl-1H-
541
1
O
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


266
2
O
2-methyl-1H-
542
2
O
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


267
3
O
2-methyl-1H-
543
3
O
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


268
1
S
2-methyl-1H-
544
1
S
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


269
2
S
2-methyl-1H-
545
2
S
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


270
3
S
2-methyl-1H-
546
3
S
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


271
1
SO
2-methyl-1H-
547
1
SO
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


272
2
SO
2-methyl-1H-
548
2
SO
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


273
3
SO
2-methyl-1H-
549
3
SO
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


274
1
SO2
2-methyl-1H-
550
1
SO2
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


275
2
SO2
2-methyl-1H-
551
2
SO2
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl


276
3
SO2
2-methyl-1H-
552
3
SO2
1H-benzo[d]imidazol-





benzo[d]imidazol-4-yl



4-yl









Exemplary embodiments include compounds having the formula (XXV)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 9











TABLE 9





Entry
R2d
R3

















1
ethyl
4-CH3-phenyl


2
n-propyl
4-CH3-phenyl


3
isopropyl
4-CH3-phenyl


4
—CH2CH(CH3)2
4-CH3-phenyl


5
CF3
4-CH3-phenyl


6
—CH2CF3
4-CH3-phenyl


7
—CH2CH2CF3
4-CH3-phenyl


8
cyclopropyl
4-CH3-phenyl


9
Cyclobutyl
4-CH3-phenyl


10
cyclopentyl
4-CH3-phenyl


11
cyclohexyl
4-CH3-phenyl


12
3-pyridyl
4-CH3-phenyl


13
1-methyl-1H-
4-CH3-phenyl



pyrazol-4-yl


14
1H-imidazol-4-yl
4-CH3-phenyl


15
2-furanyl
4-CH3-phenyl


16
ethyl
3-CH3-phenyl


17
n-propyl
3-CH3-phenyl


18
isopropyl
3-CH3-phenyl


19
—CH2CH(CH3)2
3-CH3-phenyl


20
—CF3
3-CH3-phenyl


21
—CH2CF3
3-CH3-phenyl


22
—CH2CH2CF3
3-CH3-phenyl


23
cyclopropyl
3-CH3-phenyl


24
Cyclobutyl
3-CH3-phenyl


25
cyclopentyl
3-CH3-phenyl


26
cyclohexyl
3-CH3-phenyl


27
3-pyridyl
3-CH3-phenyl


28
1-methyl-1H-
3-CH3-phenyl



pyrazol-4-yl


29
1H-imidazol-4-yl
3-CH3-phenyl


30
2-furanyl
3-CH3-phenyl


31
ethyl
3-OH-Phenyl


32
n-propyl
3-OH-Phenyl


33
isopropyl
3-OH-Phenyl


34
—CH2CH(CH3)2
3-OH-Phenyl


35
—CF3
3-OH-Phenyl


36
—CH2CF3
3-OH-Phenyl


37
—CH2CH2CF3
3-OH-Phenyl


38
cyclopropyl
3-OH-Phenyl


39
Cyclobutyl
3-OH-Phenyl


40
cyclopentyl
3-OH-Phenyl


41
cyclohexyl
3-OH-Phenyl


42
3-pyridyl
3-OH-Phenyl


43
1-methyl-1H-
3-OH-Phenyl



pyrazol-4-yl


44
1H-imidazol-4-yl
3-OH-Phenyl


45
2-furanyl
3-OH-Phenyl


46
ethyl
4-OMe-Phenyl


47
n-propyl
4-OMe-Phenyl


48
isopropyl
4-OMe-Phenyl


49
—CH2CH(CH3)2
4-OMe-Phenyl


50
—CF3
4-OMe-Phenyl


51
—CH2CF3
4-OMe-Phenyl


52
—CH2CH2CF3
4-OMe-Phenyl


53
cyclopropyl
4-OMe-Phenyl


54
Cyclobutyl
4-OMe-Phenyl


55
cyclopentyl
4-OMe-Phenyl


56
cyclohexyl
4-OMe-Phenyl


57
3-pyridyl
4-OMe-Phenyl


58
1-methyl-1H-
4-OMe-Phenyl



pyrazol-4-yl


59
1H-imidazol-4-yl
4-OMe-Phenyl


60
2-furanyl
4-OMe-Phenyl


61
ethyl
2-OMe-Phenyl


62
n-propyl
2-OMe-Phenyl


63
isopropyl
2-OMe-Phenyl


64
—CH2CH(CH3)2
2-OMe-Phenyl


65
—CF3
2-OMe-Phenyl


66
—CH2CF3
2-OMe-Phenyl


67
—CH2CH2CF3
2-OMe-Phenyl


68
cyclopropyl
2-OMe-Phenyl


69
Cyclobutyl
2-OMe-Phenyl


70
cyclopentyl
2-OMe-Phenyl


71
cyclohexyl
2-OMe-Phenyl


72
3-pyridyl
2-OMe-Phenyl


73
1-methyl-1H-
2-OMe-Phenyl



pyrazol-4-yl


74
1H-imidazol-4-yl
2-OMe-Phenyl


75
2-furanyl
2-OMe-Phenyl


76
ethyl
3-CN-Phenyl


77
n-propyl
3-CN-Phenyl


78
isopropyl
3-CN-Phenyl


79
—CH2CH(CH3)2
3-CN-Phenyl


80
—CF3
3-CN-Phenyl


81
—CH2CF3
3-CN-Phenyl


82
—CH2CH2CF3
3-CN-Phenyl


83
cyclopropyl
3-CN-Phenyl


84
Cyclobutyl
3-CN-Phenyl


85
cyclopentyl
3-CN-Phenyl


86
cyclohexyl
3-CN-Phenyl


87
3-pyridyl
3-CN-Phenyl


88
1-methyl-1H-
3-CN-Phenyl



pyrazol-4-yl


89
1H-imidazol-4-yl
3-CN-Phenyl


90
2-furanyl
3-CN-Phenyl


91
ethyl
2-F-Phenyl


92
n-propyl
2-F-Phenyl


93
isopropyl
2-F-Phenyl


94
—CH2CH(CH3)2
2-F-Phenyl


95
—CF3
2-F-Phenyl


96
—CH2CF3
2-F-Phenyl


97
—CH2CH2CF3
2-F-Phenyl


98
cyclopropyl
2-F-Phenyl


99
Cyclobutyl
2-F-Phenyl


100
cyclopentyl
2-F-Phenyl


101
cyclohexyl
2-F-Phenyl


102
3-pyridyl
2-F-Phenyl


103
1-methyl-1H-
2-F-Phenyl



pyrazol-4-yl


104
1H-imidazol-4-yl
2-F-Phenyl


105
2-furanyl
2-F-Phenyl


106
ethyl
4-F-Phenyl


107
n-propyl
4-F-Phenyl


108
isopropyl
4-F-Phenyl


109
—CH2CH(CH3)2
4-F-Phenyl


110
—CF3
4-F-Phenyl


111
—CH2CF3
4-F-Phenyl


112
—CH2CH2CF3
4-F-Phenyl


113
cyclopropyl
4-F-Phenyl


114
Cyclobutyl
4-F-Phenyl


115
cyclopentyl
4-F-Phenyl


116
cyclohexyl
4-F-Phenyl


117
3-pyridyl
4-F-Phenyl


118
1-methyl-1H-
4-F-Phenyl



pyrazol-4-yl


119
1H-imidazol-4-yl
4-F-Phenyl


120
2-furanyl
4-F-Phenyl


121
ethyl
3-Cl-Phenyl


122
n-propyl
3-Cl-Phenyl


123
isopropyl
3-Cl-Phenyl


124
—CH2CH(CH3)2
3-Cl-Phenyl


125
—CF3
3-Cl-Phenyl


126
—CH2CF3
3-Cl-Phenyl


127
—CH2CH2CF3
3-Cl-Phenyl


128
cyclopropyl
3-Cl-Phenyl


129
Cyclobutyl
3-Cl-Phenyl


130
cyclopentyl
3-Cl-Phenyl


131
cyclohexyl
3-Cl-Phenyl


132
3-pyridyl
3-Cl-Phenyl


133
1-methyl-1H-
3-Cl-Phenyl



pyrazol-4-yl


134
1H-imidazol-4-yl
3-Cl-Phenyl


135
2-furanyl
3-Cl-Phenyl


136
ethyl
2-Br-Phenyl


137
n-propyl
2-Br-Phenyl


138
isopropyl
2-Br-Phenyl


139
—CH2CH(CH3)2
2-Br-Phenyl


140
—CF3
2-Br-Phenyl


141
—CH2CF3
2-Br-Phenyl


142
—CH2CH2CF3
2-Br-Phenyl


143
cyclopropyl
2-Br-Phenyl


144
Cyclobutyl
2-Br-Phenyl


145
cyclopentyl
2-Br-Phenyl


146
cyclohexyl
2-Br-Phenyl


147
3-pyridyl
2-Br-Phenyl


148
1-methyl-1H-
2-Br-Phenyl



pyrazol-4-yl


149
1H-imidazol-4-yl
2-Br-Phenyl


150
2-furanyl
2-Br-Phenyl


151
ethyl
4-Br-Phenyl


152
n-propyl
4-Br-Phenyl


153
isopropyl
4-Br-Phenyl


154
—CH2CH(CH3)2
4-Br-Phenyl


155
—CF3
4-Br-Phenyl


156
—CH2CF3
4-Br-Phenyl


157
—CH2CH2CF3
4-Br-Phenyl


158
cyclopropyl
4-Br-Phenyl


159
Cyclobutyl
4-Br-Phenyl


160
cyclopentyl
4-Br-Phenyl


161
cyclohexyl
4-Br-Phenyl


162
3-pyridyl
4-Br-Phenyl


163
1-methyl-1H-
4-Br-Phenyl



pyrazol-4-yl


164
1H-imidazol-4-yl
4-Br-Phenyl


165
2-furanyl
4-Br-Phenyl


166
ethyl
3-CF3-Phenyl


167
n-propyl
3-CF3-Phenyl


168
isopropyl
3-CF3-Phenyl


169
—CH2CH(CH3)2
3-CF3-Phenyl


170
—CF3
3-CF3-Phenyl


171
—CH2CF3
3-CF3-Phenyl


172
—CH2CH2CF3
3-CF3-Phenyl


173
cyclopropyl
3-CF3-Phenyl


174
Cyclobutyl
3-CF3-Phenyl


175
cyclopentyl
3-CF3-Phenyl


176
cyclohexyl
3-CF3-Phenyl


177
3-pyridyl
3-CF3-Phenyl


178
1-methyl-1H-
3-CF3-Phenyl



pyrazol-4-yl


179
1H-imidazol-4-yl
3-CF3-Phenyl


180
2-furanyl
3-CF3-Phenyl


181
ethyl
2-iPr-Phenyl


182
n-propyl
2-iPr-Phenyl


183
isopropyl
2-iPr-Phenyl


184
—CH2CH(CH3)2
2-iPr-Phenyl


185
—CF3
2-iPr-Phenyl


186
—CH2CF3
2-iPr-Phenyl


187
—CH2CH2CF3
2-iPr-Phenyl


188
cyclopropyl
2-iPr-Phenyl


189
Cyclobutyl
2-iPr-Phenyl


190
cyclopentyl
2-iPr-Phenyl


191
cyclohexyl
2-iPr-Phenyl


192
3-pyridyl
2-iPr-Phenyl


193
1-methyl-1H-
2-iPr-Phenyl



pyrazol-4-yl


194
1H-imidazol-4-yl
2-iPr-Phenyl


195
2-furanyl
2-iPr-Phenyl


196
ethyl
4-iPr-Phenyl


197
n-propyl
4-iPr-Phenyl


198
isopropyl
4-iPr-Phenyl


199
—CH2CH(CH3)2
4-iPr-Phenyl


200
—CF3
4-iPr-Phenyl


201
—CH2CF3
4-iPr-Phenyl


202
—CH2CH2CF3
4-iPr-Phenyl


203
cyclopropyl
4-iPr-Phenyl


204
Cyclobutyl
4-iPr-Phenyl


205
cyclopentyl
4-iPr-Phenyl


206
cyclohexyl
4-iPr-Phenyl


207
3-pyridyl
4-iPr-Phenyl


208
1-methyl-1H-
4-iPr-Phenyl



pyrazol-4-yl


209
1H-imidazol-4-yl
4-iPr-Phenyl


210
2-furanyl
4-iPr-Phenyl


211
ethyl
3-morpholino-phenyl


212
n-propyl
3-morpholino-phenyl


213
isopropyl
3-morpholino-phenyl


214
—CH2CH(CH3)2
3-morpholino-phenyl


215
—CF3
3-morpholino-phenyl


216
—CH2CF3
3-morpholino-phenyl


217
—CH2CH2CF3
3-morpholino-phenyl


218
cyclopropyl
3-morpholino-phenyl


219
Cyclobutyl
3-morpholino-phenyl


220
cyclopentyl
3-morpholino-phenyl


221
cyclohexyl
3-morpholino-phenyl


222
3-pyridyl
3-morpholino-phenyl


223
1-methyl-1H-
3-morpholino-phenyl



pyrazol-4-yl


224
1H-imidazol-4-yl
3-morpholino-phenyl


225
2-furanyl
3-morpholino-phenyl


226
ethyl
4-cyano-2-morpholino-




phenyl


227
n-propyl
4-cyano-2-morpholino-




phenyl


228
isopropyl
4-cyano-2-morpholino-




phenyl


229
—CH2CH(CH3)2
4-cyano-2-morpholino-




phenyl


230
—CF3
4-cyano-2-morpholino-




phenyl


231
—CH2CF3
4-cyano-2-morpholino-




phenyl


232
—CH2CH2CF3
4-cyano-2-morpholino-




phenyl


233
cyclopropyl
4-cyano-2-morpholino-




phenyl


234
Cyclobutyl
4-cyano-2-morpholino-




phenyl


235
cyclopentyl
4-cyano-2-morpholino-




phenyl


236
cyclohexyl
4-cyano-2-morpholino-




phenyl


237
3-pyridyl
4-cyano-2-morpholino-




phenyl


238
1-methyl-1H-
4-cyano-2-morpholino-



pyrazol-4-yl
phenyl


239
1H-imidazol-4-yl
4-cyano-2-morpholino-




phenyl


240
2-furanyl
4-cyano-2-morpholino-




phenyl


241
ethyl
4-hydroxy-2-




morpholino-phenyl


242
n-propyl
4-hydroxy-2-




morpholino-phenyl


243
isopropyl
4-hydroxy-2-




morpholino-phenyl


244
—CH2CH(CH3)2
4-hydroxy-2-




morpholino-phenyl


245
—CF3
4-hydroxy-2-




morpholino-phenyl


246
—CH2CF3
4-hydroxy-2-




morpholino-phenyl


247
—CH2CH2CF3
4-hydroxy-2-




morpholino-phenyl


248
cyclopropyl
4-hydroxy-2-




morpholino-phenyl


249
Cyclobutyl
4-hydroxy-2-




morpholino-phenyl


250
cyclopentyl
4-hydroxy-2-




morpholino-phenyl


251
cyclohexyl
4-hydroxy-2-




morpholino-phenyl


252
3-pyridyl
4-hydroxy-2-




morpholino-phenyl


253
1-methyl-1H-
4-hydroxy-2-



pyrazol-4-yl
morpholino-phenyl


254
1H-imidazol-4-yl
4-hydroxy-2-




morpholino-phenyl


255
2-furanyl
4-hydroxy-2-




morpholino-phenyl


256
ethyl
2-CH3-phenyl


257
n-propyl
2-CH3-phenyl


258
isopropyl
2-CH3-phenyl


259
—CH2CH(CH3)2
2-CH3-phenyl


260
CF3
2-CH3-phenyl


261
—CH2CF3
2-CH3-phenyl


262
—CH2CH2CF3
2-CH3-phenyl


263
cyclopropyl
2-CH3-phenyl


264
Cyclobutyl
2-CH3-phenyl


265
cyclopentyl
2-CH3-phenyl


266
cyclohexyl
2-CH3-phenyl


267
3-pyridyl
2-CH3-phenyl


268
1-methyl-1H-
2-CH3-phenyl



pyrazol-4-yl


269
1H-imidazol-4-yl
2-CH3-phenyl


270
2-furanyl
2-CH3-phenyl


271
ethyl
4-OH-Phenyl


272
n-propyl
4-OH-Phenyl


273
isopropyl
4-OH-Phenyl


274
—CH2CH(CH3)2
4-OH-Phenyl


275
—CF3
4-OH-Phenyl


276
—CH2CF3
4-OH-Phenyl


277
—CH2CH2CF3
4-OH-Phenyl


278
cyclopropyl
4-OH-Phenyl


279
Cyclobutyl
4-OH-Phenyl


280
cyclopentyl
4-OH-Phenyl


281
cyclohexyl
4-OH-Phenyl


282
3-pyridyl
4-OH-Phenyl


283
1-methyl-1H-
4-OH-Phenyl



pyrazol-4-yl


284
1H-imidazol-4-yl
4-OH-Phenyl


285
2-furanyl
4-OH-Phenyl


286
ethyl
2-OH-Phenyl


287
n-propyl
2-OH-Phenyl


288
isopropyl
2-OH-Phenyl


289
—CH2CH(CH3)2
2-OH-Phenyl


290
—CF3
2-OH-Phenyl


291
—CH2CF3
2-OH-Phenyl


292
—CH2CH2CF3
2-OH-Phenyl


293
cyclopropyl
2-OH-Phenyl


294
Cyclobutyl
2-OH-Phenyl


295
cyclopentyl
2-OH-Phenyl


296
cyclohexyl
2-OH-Phenyl


297
3-pyridyl
2-OH-Phenyl


298
1-methyl-1H-
2-OH-Phenyl



pyrazol-4-yl


299
1H-imidazol-4-yl
2-OH-Phenyl


300
2-furanyl
2-OH-Phenyl


301
ethyl
3-OMe-Phenyl


302
n-propyl
3-OMe-Phenyl


303
isopropyl
3-OMe-Phenyl


304
—CH2CH(CH3)2
3-OMe-Phenyl


305
—CF3
3-OMe-Phenyl


306
—CH2CF3
3-OMe-Phenyl


307
—CH2CH2CF3
3-OMe-Phenyl


308
cyclopropyl
3-OMe-Phenyl


309
Cyclobutyl
3-OMe-Phenyl


310
cyclopentyl
3-OMe-Phenyl


311
cyclohexyl
3-OMe-Phenyl


312
3-pyridyl
3-OMe-Phenyl


313
1-methyl-1H-
3-OMe-Phenyl



pyrazol-4-yl


314
1H-imidazol-4-yl
3-OMe-Phenyl


315
2-furanyl
3-OMe-Phenyl


316
ethyl
4-CN-Phenyl


317
n-propyl
4-CN-Phenyl


318
isopropyl
4-CN-Phenyl


319
—CH2CH(CH3)2
4-CN-Phenyl


320
—CF3
4-CN-Phenyl


321
—CH2CF3
4-CN-Phenyl


322
—CH2CH2CF3
4-CN-Phenyl


323
cyclopropyl
4-CN-Phenyl


324
Cyclobutyl
4-CN-Phenyl


325
cyclopentyl
4-CN-Phenyl


326
cyclohexyl
4-CN-Phenyl


327
3-pyridyl
4-CN-Phenyl


328
1-methyl-1H-
4-CN-Phenyl



pyrazol-4-yl


329
1H-imidazol-4-yl
4-CN-Phenyl


330
2-furanyl
4-CN-Phenyl


331
ethyl
2-CN-Phenyl


332
n-propyl
2-CN-Phenyl


333
isopropyl
2-CN-Phenyl


334
—CH2CH(CH3)2
2-CN-Phenyl


335
—CF3
2-CN-Phenyl


336
—CH2CF3
2-CN-Phenyl


337
—CH2CH2CF3
2-CN-Phenyl


338
cyclopropyl
2-CN-Phenyl


339
Cyclobutyl
2-CN-Phenyl


340
cyclopentyl
2-CN-Phenyl


341
cyclohexyl
2-CN-Phenyl


342
3-pyridyl
2-CN-Phenyl


343
1-methyl-1H-
2-CN-Phenyl



pyrazol-4-yl


344
1H-imidazol-4-yl
2-CN-Phenyl


345
2-furanyl
2-CN-Phenyl


346
ethyl
3-F-Phenyl


347
n-propyl
3-F-Phenyl


348
isopropyl
3-F-Phenyl


349
—CH2CH(CH3)2
3-F-Phenyl


350
—CF3
3-F-Phenyl


351
—CH2CF3
3-F-Phenyl


352
—CH2CH2CF3
3-F-Phenyl


353
cyclopropyl
3-F-Phenyl


354
Cyclobutyl
3-F-Phenyl


355
cyclopentyl
3-F-Phenyl


356
cyclohexyl
3-F-Phenyl


357
3-pyridyl
3-F-Phenyl


358
1-methyl-1H-
3-F-Phenyl



pyrazol-4-yl


359
1H-imidazol-4-yl
3-F-Phenyl


360
2-furanyl
3-F-Phenyl


361
ethyl
2-Cl-Phenyl


362
n-propyl
2-Cl-Phenyl


363
isopropyl
2-Cl-Phenyl


364
—CH2CH(CH3)2
2-Cl-Phenyl


365
—CF3
2-Cl-Phenyl


366
—CH2CF3
2-Cl-Phenyl


367
—CH2CH2CF3
2-Cl-Phenyl


368
cyclopropyl
2-Cl-Phenyl


369
Cyclobutyl
2-Cl-Phenyl


370
cyclopentyl
2-Cl-Phenyl


371
cyclohexyl
2-Cl-Phenyl


372
3-pyridyl
2-Cl-Phenyl


373
1-methyl-1H-
2-Cl-Phenyl



pyrazol-4-yl


374
1H-imidazol-4-yl
2-Cl-Phenyl


375
2-furanyl
2-Cl-Phenyl


376
ethyl
4-Cl-Phenyl


377
n-propyl
4-Cl-Phenyl


378
isopropyl
4-Cl-Phenyl


379
—CH2CH(CH3)2
4-Cl-Phenyl


380
—CF3
4-Cl-Phenyl


381
—CH2CF3
4-Cl-Phenyl


382
—CH2CH2CF3
4-Cl-Phenyl


383
cyclopropyl
4-Cl-Phenyl


384
Cyclobutyl
4-Cl-Phenyl


385
cyclopentyl
4-Cl-Phenyl


386
cyclohexyl
4-Cl-Phenyl


387
3-pyridyl
4-Cl-Phenyl


388
1-methyl-1H-
4-Cl-Phenyl



pyrazol-4-yl


389
1H-imidazol-4-yl
4-Cl-Phenyl


390
2-furanyl
4-Cl-Phenyl


391
ethyl
3-Br-Phenyl


392
n-propyl
3-Br-Phenyl


393
isopropyl
3-Br-Phenyl


394
—CH2CH(CH3)2
3-Br-Phenyl


395
—CF3
3-Br-Phenyl


396
—CH2CF3
3-Br-Phenyl


397
—CH2CH2CF3
3-Br-Phenyl


398
cyclopropyl
3-Br-Phenyl


399
Cyclobutyl
3-Br-Phenyl


400
cyclopentyl
3-Br-Phenyl


401
cyclohexyl
3-Br-Phenyl


402
3-pyridyl
3-Br-Phenyl


403
1-methyl-1H-
3-Br-Phenyl



pyrazol-4-yl


404
1H-imidazol-4-yl
3-Br-Phenyl


405
2-furanyl
3-Br-Phenyl


406
ethyl
2-CF3-Phenyl


407
n-propyl
2-CF3-Phenyl


408
isopropyl
2-CF3-Phenyl


409
—CH2CH(CH3)2
2-CF3-Phenyl


410
—CF3
2-CF3-Phenyl


411
—CH2CF3
2-CF3-Phenyl


412
—CH2CH2CF3
2-CF3-Phenyl


413
cyclopropyl
2-CF3-Phenyl


414
Cyclobutyl
2-CF3-Phenyl


415
cyclopentyl
2-CF3-Phenyl


416
cyclohexyl
2-CF3-Phenyl


417
3-pyridyl
2-CF3-Phenyl


418
1-methyl-1H-
2-CF3-Phenyl



pyrazol-4-yl


419
1H-imidazol-4-yl
2-CF3-Phenyl


420
2-furanyl
2-CF3-Phenyl


421
ethyl
4-CF3-Phenyl


422
n-propyl
4-CF3-Phenyl


423
isopropyl
4-CF3-Phenyl


424
—CH2CH(CH3)2
4-CF3-Phenyl


425
—CF3
4-CF3-Phenyl


426
—CH2CF3
4-CF3-Phenyl


427
—CH2CH2CF3
4-CF3-Phenyl


428
cyclopropyl
4-CF3-Phenyl


429
Cyclobutyl
4-CF3-Phenyl


430
cyclopentyl
4-CF3-Phenyl


431
cyclohexyl
4-CF3-Phenyl


432
3-pyridyl
4-CF3-Phenyl


433
1-methyl-1H-
4-CF3-Phenyl



pyrazol-4-yl


434
1H-imidazol-4-yl
4-CF3-Phenyl


435
2-furanyl
4-CF3-Phenyl


436
ethyl
3-iPr-Phenyl


437
n-propyl
3-iPr-Phenyl


438
isopropyl
3-iPr-Phenyl


439
—CH2CH(CH3)2
3-iPr-Phenyl


440
—CF3
3-iPr-Phenyl


441
—CH2CF3
3-iPr-Phenyl


442
—CH2CH2CF3
3-iPr-Phenyl


443
cyclopropyl
3-iPr-Phenyl


444
Cyclobutyl
3-iPr-Phenyl


445
cyclopentyl
3-iPr-Phenyl


446
cyclohexyl
3-iPr-Phenyl


447
3-pyridyl
3-iPr-Phenyl


448
1-methyl-1H-
3-iPr-Phenyl



pyrazol-4-yl


449
1H-imidazol-4-yl
3-iPr-Phenyl


450
2-furanyl
3-iPr-Phenyl


451
ethyl
2-morpholino-




phenyl


452
n-propyl
2-morpholino-




phenyl


453
isopropyl
2-morpholino-




phenyl


454
—CH2CH(CH3)2
2-morpholino-




phenyl


455
—CF3
2-morpholino-




phenyl


456
—CH2CF3
2-morpholino-




phenyl


457
—CH2CH2CF3
2-morpholino-




phenyl


458
cyclopropyl
2-morpholino-




phenyl


459
Cyclobutyl
2-morpholino-




phenyl


460
cyclopentyl
2-morpholino-




phenyl


461
cyclohexyl
2-morpholino-




phenyl


462
3-pyridyl
2-morpholino-




phenyl


463
1-methyl-1H-
2-morpholino-



pyrazol-4-yl
phenyl


464
1H-imidazol-4-yl
2-morpholino-




phenyl


465
2-furanyl
2-morpholino-




phenyl


466
ethyl
4-morpholino-




phenyl


467
n-propyl
4-morpholino-




phenyl


468
isopropyl
4-morpholino-




phenyl


469
—CH2CH(CH3)2
4-morpholino-




phenyl


470
—CF3
4-morpholino-




phenyl


471
—CH2CF3
4-morpholino-




phenyl


472
—CH2CH2CF3
4-morpholino-




phenyl


473
cyclopropyl
4-morpholino-




phenyl


474
Cyclobutyl
4-morpholino-




phenyl


475
cyclopentyl
4-morpholino-




phenyl


476
cyclohexyl
4-morpholino-




phenyl


477
3-pyridyl
4-morpholino-




phenyl


478
1-methyl-1H-
4-morpholino-



pyrazol-4-yl
phenyl


479
1H-imidazol-4-yl
4-morpholino-




phenyl


480
2-furanyl
4-morpholino-




phenyl


481
ethyl
4-methyl-2-




morpholino-phenyl


482
n-propyl
4-methyl-2-




morpholino-phenyl


483
isopropyl
4-methyl-2-




morpholino-phenyl


484
—CH2CH(CH3)2
4-methyl-2-




morpholino-phenyl


485
—CF3
4-methyl-2-




morpholino-phenyl


486
—CH2CF3
4-methyl-2-




morpholino-phenyl


487
—CH2CH2CF3
4-methyl-2-




morpholino-phenyl


488
cyclopropyl
4-methyl-2-




morpholino-phenyl


489
Cyclobutyl
4-methyl-2-




morpholino-phenyl


490
cyclopentyl
4-methyl-2-




morpholino-phenyl


491
cyclohexyl
4-methyl-2-




morpholino-phenyl


492
3-pyridyl
4-methyl-2-




morpholino-phenyl


493
1-methyl-1H-
4-methyl-2-



pyrazol-4-yl
morpholino-phenyl


494
1H-imidazol-4-yl
4-methyl-2-




morpholino-phenyl


495
2-furanyl
4-methyl-2-




morpholino-phenyl









Exemplary embodiments include compounds having the formula (XXVI)




embedded image


or a pharmaceutically acceptable salt form thereof defined herein below in Table 10.











TABLE 10





Entry
R2d
R3

















1
ethyl
4-CH3-phenyl


2
n-propyl
4-CH3-phenyl


3
isopropyl
4-CH3-phenyl


4
—CH2CH(CH3)2
4-CH3-phenyl


5
CF3
4-CH3-phenyl


6
—CH2CF3
4-CH3-phenyl


7
—CH2CH2CF3
4-CH3-phenyl


8
cyclopropyl
4-CH3-phenyl


9
Cyclobutyl
4-CH3-phenyl


10
cyclopentyl
4-CH3-phenyl


11
cyclohexyl
4-CH3-phenyl


12
3-pyridyl
4-CH3-phenyl


13
1-methyl-1H-
4-CH3-phenyl



pyrazol-4-yl


14
1H-imidazol-4-yl
4-CH3-phenyl


15
2-furanyl
4-CH3-phenyl


16
ethyl
3-CH3-phenyl


17
n-propyl
3-CH3-phenyl


18
isopropyl
3-CH3-phenyl


19
—CH2CH(CH3)2
3-CH3-phenyl


20
—CF3
3-CH3-phenyl


21
—CH2CF3
3-CH3-phenyl


22
—CH2CH2CF3
3-CH3-phenyl


23
cyclopropyl
3-CH3-phenyl


24
Cyclobutyl
3-CH3-phenyl


25
cyclopentyl
3-CH3-phenyl


26
cyclohexyl
3-CH3-phenyl


27
3-pyridyl
3-CH3-phenyl


28
1-methyl-1H-
3-CH3-phenyl



pyrazol-4-yl


29
1H-imidazol-4-yl
3-CH3-phenyl


30
2-furanyl
3-CH3-phenyl


31
ethyl
3-OH-Phenyl


32
n-propyl
3-OH-Phenyl


33
isopropyl
3-OH-Phenyl


34
—CH2CH(CH3)2
3-OH-Phenyl


35
—CF3
3-OH-Phenyl


36
—CH2CF3
3-OH-Phenyl


37
—CH2CH2CF3
3-OH-Phenyl


38
cyclopropyl
3-OH-Phenyl


39
Cyclobutyl
3-OH-Phenyl


40
cyclopentyl
3-OH-Phenyl


41
cyclohexyl
3-OH-Phenyl


42
3-pyridyl
3-OH-Phenyl


43
1-methyl-1H-
3-OH-Phenyl



pyrazol-4-yl


44
1H-imidazol-4-yl
3-OH-Phenyl


45
2-furanyl
3-OH-Phenyl


46
ethyl
4-OMe-Phenyl


47
n-propyl
4-OMe-Phenyl


48
isopropyl
4-OMe-Phenyl


49
—CH2CH(CH3)2
4-OMe-Phenyl


50
—CF3
4-OMe-Phenyl


51
—CH2CF3
4-OMe-Phenyl


52
—CH2CH2CF3
4-OMe-Phenyl


53
cyclopropyl
4-OMe-Phenyl


54
Cyclobutyl
4-OMe-Phenyl


55
cyclopentyl
4-OMe-Phenyl


56
cyclohexyl
4-OMe-Phenyl


57
3-pyridyl
4-OMe-Phenyl


58
1-methyl-1H-
4-OMe-Phenyl



pyrazol-4-yl


59
1H-imidazol-4-yl
4-OMe-Phenyl


60
2-furanyl
4-OMe-Phenyl


61
ethyl
2-OMe-Phenyl


62
n-propyl
2-OMe-Phenyl


63
isopropyl
2-OMe-Phenyl


64
—CH2CH(CH3)2
2-OMe-Phenyl


65
—CF3
2-OMe-Phenyl


66
—CH2CF3
2-OMe-Phenyl


67
—CH2CH2CF3
2-OMe-Phenyl


68
cyclopropyl
2-OMe-Phenyl


69
Cyclobutyl
2-OMe-Phenyl


70
cyclopentyl
2-OMe-Phenyl


71
cyclohexyl
2-OMe-Phenyl


72
3-pyridyl
2-OMe-Phenyl


73
1-methyl-1H-
2-OMe-Phenyl



pyrazol-4-yl


74
1H-imidazol-4-yl
2-OMe-Phenyl


75
2-furanyl
2-OMe-Phenyl


76
ethyl
3-CN-Phenyl


77
n-propyl
3-CN-Phenyl


78
isopropyl
3-CN-Phenyl


79
—CH2CH(CH3)2
3-CN-Phenyl


80
—CF3
3-CN-Phenyl


81
—CH2CF3
3-CN-Phenyl


82
—CH2CH2CF3
3-CN-Phenyl


83
cyclopropyl
3-CN-Phenyl


84
Cyclobutyl
3-CN-Phenyl


85
cyclopentyl
3-CN-Phenyl


86
cyclohexyl
3-CN-Phenyl


87
3-pyridyl
3-CN-Phenyl


88
1-methyl-1H-
3-CN-Phenyl



pyrazol-4-yl


89
1H-imidazol-4-yl
3-CN-Phenyl


90
2-furanyl
3-CN-Phenyl


91
ethyl
2-F-Phenyl


92
n-propyl
2-F-Phenyl


93
isopropyl
2-F-Phenyl


94
—CH2CH(CH3)2
2-F-Phenyl


95
—CF3
2-F-Phenyl


96
—CH2CF3
2-F-Phenyl


97
—CH2CH2CF3
2-F-Phenyl


98
cyclopropyl
2-F-Phenyl


99
Cyclobutyl
2-F-Phenyl


100
cyclopentyl
2-F-Phenyl


101
cyclohexyl
2-F-Phenyl


102
3-pyridyl
2-F-Phenyl


103
1-methyl-1H-
2-F-Phenyl



pyrazol-4-yl


104
1H-imidazol-4-yl
2-F-Phenyl


105
2-furanyl
2-F-Phenyl


106
ethyl
4-F-Phenyl


107
n-propyl
4-F-Phenyl


108
isopropyl
4-F-Phenyl


109
—CH2CH(CH3)2
4-F-Phenyl


110
—CF3
4-F-Phenyl


111
—CH2CF3
4-F-Phenyl


112
—CH2CH2CF3
4-F-Phenyl


113
cyclopropyl
4-F-Phenyl


114
Cyclobutyl
4-F-Phenyl


115
cyclopentyl
4-F-Phenyl


116
cyclohexyl
4-F-Phenyl


117
3-pyridyl
4-F-Phenyl


118
1-methyl-1H-
4-F-Phenyl



pyrazol-4-yl


119
1H-imidazol-4-yl
4-F-Phenyl


120
2-furanyl
4-F-Phenyl


121
ethyl
3-Cl-Phenyl


122
n-propyl
3-Cl-Phenyl


123
isopropyl
3-Cl-Phenyl


124
—CH2CH(CH3)2
3-Cl-Phenyl


125
—CF3
3-Cl-Phenyl


126
—CH2CF3
3-Cl-Phenyl


127
—CH2CH2CF3
3-Cl-Phenyl


128
cyclopropyl
3-Cl-Phenyl


129
Cyclobutyl
3-Cl-Phenyl


130
cyclopentyl
3-Cl-Phenyl


131
cyclohexyl
3-Cl-Phenyl


132
3-pyridyl
3-Cl-Phenyl


133
1-methyl-1H-
3-Cl-Phenyl



pyrazol-4-yl


134
1H-imidazol-4-yl
3-Cl-Phenyl


135
2-furanyl
3-Cl-Phenyl


136
ethyl
2-Br-Phenyl


137
n-propyl
2-Br-Phenyl


138
isopropyl
2-Br-Phenyl


139
—CH2CH(CH3)2
2-Br-Phenyl


140
—CF3
2-Br-Phenyl


141
—CH2CF3
2-Br-Phenyl


142
—CH2CH2CF3
2-Br-Phenyl


143
cyclopropyl
2-Br-Phenyl


144
Cyclobutyl
2-Br-Phenyl


145
cyclopentyl
2-Br-Phenyl


146
cyclohexyl
2-Br-Phenyl


147
3-pyridyl
2-Br-Phenyl


148
1-methyl-1H-
2-Br-Phenyl



pyrazol-4-yl


149
1H-imidazol-4-yl
2-Br-Phenyl


150
2-furanyl
2-Br-Phenyl


151
ethyl
4-Br-Phenyl


152
n-propyl
4-Br-Phenyl


153
isopropyl
4-Br-Phenyl


154
—CH2CH(CH3)2
4-Br-Phenyl


155
—CF3
4-Br-Phenyl


156
—CH2CF3
4-Br-Phenyl


157
—CH2CH2CF3
4-Br-Phenyl


158
cyclopropyl
4-Br-Phenyl


159
Cyclobutyl
4-Br-Phenyl


160
cyclopentyl
4-Br-Phenyl


161
cyclohexyl
4-Br-Phenyl


162
3-pyridyl
4-Br-Phenyl


163
1-methyl-1H-
4-Br-Phenyl



pyrazol-4-yl


164
1H-imidazol-4-yl
4-Br-Phenyl


165
2-furanyl
4-Br-Phenyl


166
ethyl
3-CF3-Phenyl


167
n-propyl
3-CF3-Phenyl


168
isopropyl
3-CF3-Phenyl


169
—CH2CH(CH3)2
3-CF3-Phenyl


170
—CF3
3-CF3-Phenyl


171
—CH2CF3
3-CF3-Phenyl


172
—CH2CH2CF3
3-CF3-Phenyl


173
cyclopropyl
3-CF3-Phenyl


174
Cyclobutyl
3-CF3-Phenyl


175
cyclopentyl
3-CF3-Phenyl


176
cyclohexyl
3-CF3-Phenyl


177
3-pyridyl
3-CF3-Phenyl


178
1-methyl-1H-
3-CF3-Phenyl



pyrazol-4-yl


179
1H-imidazol-4-yl
3-CF3-Phenyl


180
2-furanyl
3-CF3-Phenyl


181
ethyl
2-iPr-Phenyl


182
n-propyl
2-iPr-Phenyl


183
isopropyl
2-iPr-Phenyl


184
—CH2CH(CH3)2
2-iPr-Phenyl


185
—CF3
2-iPr-Phenyl


186
—CH2CF3
2-iPr-Phenyl


187
—CH2CH2CF3
2-iPr-Phenyl


188
cyclopropyl
2-iPr-Phenyl


189
Cyclobutyl
2-iPr-Phenyl


190
cyclopentyl
2-iPr-Phenyl


191
cyclohexyl
2-iPr-Phenyl


192
3-pyridyl
2-iPr-Phenyl


193
1-methyl-1H-
2-iPr-Phenyl



pyrazol-4-yl


194
1H-imidazol-4-yl
2-iPr-Phenyl


195
2-furanyl
2-iPr-Phenyl


196
ethyl
4-iPr-Phenyl


197
n-propyl
4-iPr-Phenyl


198
isopropyl
4-iPr-Phenyl


199
—CH2CH(CH3)2
4-iPr-Phenyl


200
—CF3
4-iPr-Phenyl


201
—CH2CF3
4-iPr-Phenyl


202
—CH2CH2CF3
4-iPr-Phenyl


203
cyclopropyl
4-iPr-Phenyl


204
Cyclobutyl
4-iPr-Phenyl


205
cyclopentyl
4-iPr-Phenyl


206
cyclohexyl
4-iPr-Phenyl


207
3-pyridyl
4-iPr-Phenyl


208
1-methyl-1H-
4-iPr-Phenyl



pyrazol-4-yl


209
1H-imidazol-4-yl
4-iPr-Phenyl


210
2-furanyl
4-iPr-Phenyl


211
ethyl
3-morpholino-




phenyl


212
n-propyl
3-morpholino-




phenyl


213
isopropyl
3-morpholino-




phenyl


214
—CH2CH(CH3)2
3-morpholino-




phenyl


215
—CF3
3-morpholino-




phenyl


216
—CH2CF3
3-morpholino-




phenyl


217
—CH2CH2CF3
3-morpholino-




phenyl


218
cyclopropyl
3-morpholino-




phenyl


219
Cyclobutyl
3-morpholino-




phenyl


220
cyclopentyl
3-morpholino-




phenyl


221
cyclohexyl
3-morpholino-




phenyl


222
3-pyridyl
3-morpholino-




phenyl


223
1-methyl-1H-
3-morpholino-



pyrazol-4-yl
phenyl


224
1H-imidazol-4-yl
3-morpholino-




phenyl


225
2-furanyl
3-morpholino-




phenyl


226
ethyl
4-cyano-2-




morpholino-phenyl


227
n-propyl
4-cyano-2-




morpholino-phenyl


228
isopropyl
4-cyano-2-




morpholino-phenyl


229
—CH2CH(CH3)2
4-cyano-2-




morpholino-phenyl


230
—CF3
4-cyano-2-




morpholino-phenyl


231
—CH2CF3
4-cyano-2-




morpholino-phenyl


232
—CH2CH2CF3
4-cyano-2-




morpholino-phenyl


233
cyclopropyl
4-cyano-2-




morpholino-phenyl


234
Cyclobutyl
4-cyano-2-




morpholino-phenyl


235
cyclopentyl
4-cyano-2-




morpholino-phenyl


236
cyclohexyl
4-cyano-2-




morpholino-phenyl


237
3-pyridyl
4-cyano-2-




morpholino-phenyl


238
1-methyl-1H-
4-cyano-2-



pyrazol-4-yl
morpholino-phenyl


239
1H-imidazol-4-yl
4-cyano-2-




morpholino-phenyl


240
2-furanyl
4-cyano-2-




morpholino-phenyl


241
ethyl
4-hydroxy-2-




morpholino-phenyl


242
n-propyl
4-hydroxy-2-




morpholino-phenyl


243
isopropyl
4-hydroxy-2-




morpholino-phenyl


244
—CH2CH(CH3)2
4-hydroxy-2-




morpholino-phenyl


245
—CF3
4-hydroxy-2-




morpholino-phenyl


246
—CH2CF3
4-hydroxy-2-




morpholino-phenyl


247
—CH2CH2CF3
4-hydroxy-2-




morpholino-phenyl


248
cyclopropyl
4-hydroxy-2-




morpholino-phenyl


249
Cyclobutyl
4-hydroxy-2-




morpholino-phenyl


250
cyclopentyl
4-hydroxy-2-




morpholino-phenyl


251
cyclohexyl
4-hydroxy-2-




morpholino-phenyl


252
3-pyridyl
4-hydroxy-2-




morpholino-phenyl


253
1-methyl-1H-
4-hydroxy-2-



pyrazol-4-yl
morpholino-phenyl


254
1H-imidazol-4-yl
4-hydroxy-2-




morpholino-phenyl


255
2-furanyl
4-hydroxy-2-




morpholino-phenyl


256
ethyl
2-CH3-phenyl


257
n-propyl
2-CH3-phenyl


258
isopropyl
2-CH3-phenyl


259
—CH2CH(CH3)2
2-CH3-phenyl


260
CF3
2-CH3-phenyl


261
—CH2CF3
2-CH3-phenyl


262
—CH2CH2CF3
2-CH3-phenyl


263
cyclopropyl
2-CH3-phenyl


264
Cyclobutyl
2-CH3-phenyl


265
cyclopentyl
2-CH3-phenyl


266
cyclohexyl
2-CH3-phenyl


267
3-pyridyl
2-CH3-phenyl


268
1-methyl-1H-
2-CH3-phenyl



pyrazol-4-yl


269
1H-imidazol-4-yl
2-CH3-phenyl


270
2-furanyl
2-CH3-phenyl


271
ethyl
4-OH-Phenyl


272
n-propyl
4-OH-Phenyl


273
isopropyl
4-OH-Phenyl


274
—CH2CH(CH3)2
4-OH-Phenyl


275
—CF3
4-OH-Phenyl


276
—CH2CF3
4-OH-Phenyl


277
—CH2CH2CF3
4-OH-Phenyl


278
cyclopropyl
4-OH-Phenyl


279
Cyclobutyl
4-OH-Phenyl


280
cyclopentyl
4-OH-Phenyl


281
cyclohexyl
4-OH-Phenyl


282
3-pyridyl
4-OH-Phenyl


283
1-methyl-1H-
4-OH-Phenyl



pyrazol-4-yl


284
1H-imidazol-4-yl
4-OH-Phenyl


285
2-furanyl
4-OH-Phenyl


286
ethyl
2-OH-Phenyl


287
n-propyl
2-OH-Phenyl


288
isopropyl
2-OH-Phenyl


289
—CH2CH(CH3)2
2-OH-Phenyl


290
—CF3
2-OH-Phenyl


291
—CH2CF3
2-OH-Phenyl


292
—CH2CH2CF3
2-OH-Phenyl


293
cyclopropyl
2-OH-Phenyl


294
Cyclobutyl
2-OH-Phenyl


295
cyclopentyl
2-OH-Phenyl


296
cyclohexyl
2-OH-Phenyl


297
3-pyridyl
2-OH-Phenyl


298
1-methyl-1H-
2-OH-Phenyl



pyrazol-4-yl


299
1H-imidazol-4-yl
2-OH-Phenyl


300
2-furanyl
2-OH-Phenyl


301
ethyl
3-OMe-Phenyl


302
n-propyl
3-OMe-Phenyl


303
isopropyl
3-OMe-Phenyl


304
—CH2CH(CH3)2
3-OMe-Phenyl


305
—CF3
3-OMe-Phenyl


306
—CH2CF3
3-OMe-Phenyl


307
—CH2CH2CF3
3-OMe-Phenyl


308
cyclopropyl
3-OMe-Phenyl


309
Cyclobutyl
3-OMe-Phenyl


310
cyclopentyl
3-OMe-Phenyl


311
cyclohexyl
3-OMe-Phenyl


312
3-pyridyl
3-OMe-Phenyl


313
1-methyl-1H-
3-OMe-Phenyl



pyrazol-4-yl


314
1H-imidazol-4-yl
3-OMe-Phenyl


315
2-furanyl
3-OMe-Phenyl


316
ethyl
4-CN-Phenyl


317
n-propyl
4-CN-Phenyl


318
isopropyl
4-CN-Phenyl


319
—CH2CH(CH3)2
4-CN-Phenyl


320
—CF3
4-CN-Phenyl


321
—CH2CF3
4-CN-Phenyl


322
—CH2CH2CF3
4-CN-Phenyl


323
cyclopropyl
4-CN-Phenyl


324
Cyclobutyl
4-CN-Phenyl


325
cyclopentyl
4-CN-Phenyl


326
cyclohexyl
4-CN-Phenyl


327
3-pyridyl
4-CN-Phenyl


328
1-methyl-1H-
4-CN-Phenyl



pyrazol-4-yl


329
1H-imidazol-4-yl
4-CN-Phenyl


330
2-furanyl
4-CN-Phenyl


331
ethyl
2-CN-Phenyl


332
n-propyl
2-CN-Phenyl


333
isopropyl
2-CN-Phenyl


334
—CH2CH(CH3)2
2-CN-Phenyl


335
—CF3
2-CN-Phenyl


336
—CH2CF3
2-CN-Phenyl


337
—CH2CH2CF3
2-CN-Phenyl


338
cyclopropyl
2-CN-Phenyl


339
Cyclobutyl
2-CN-Phenyl


340
cyclopentyl
2-CN-Phenyl


341
cyclohexyl
2-CN-Phenyl


342
3-pyridyl
2-CN-Phenyl


343
1-methyl-1H-
2-CN-Phenyl



pyrazol-4-yl


344
1H-imidazol-4-yl
2-CN-Phenyl


345
2-furanyl
2-CN-Phenyl


346
ethyl
3-F-Phenyl


347
n-propyl
3-F-Phenyl


348
isopropyl
3-F-Phenyl


349
—CH2CH(CH3)2
3-F-Phenyl


350
—CF3
3-F-Phenyl


351
—CH2CF3
3-F-Phenyl


352
—CH2CH2CF3
3-F-Phenyl


353
cyclopropyl
3-F-Phenyl


354
Cyclobutyl
3-F-Phenyl


355
cyclopentyl
3-F-Phenyl


356
cyclohexyl
3-F-Phenyl


357
3-pyridyl
3-F-Phenyl


358
1-methyl-1H-
3-F-Phenyl



pyrazol-4-yl


359
1H-imidazol-4-yl
3-F-Phenyl


360
2-furanyl
3-F-Phenyl


361
ethyl
2-Cl-Phenyl


362
n-propyl
2-Cl-Phenyl


363
isopropyl
2-Cl-Phenyl


364
—CH2CH(CH3)2
2-Cl-Phenyl


365
—CF3
2-Cl-Phenyl


366
—CH2CF3
2-Cl-Phenyl


367
—CH2CH2CF3
2-Cl-Phenyl


368
cyclopropyl
2-Cl-Phenyl


369
Cyclobutyl
2-Cl-Phenyl


370
cyclopentyl
2-Cl-Phenyl


371
cyclohexyl
2-Cl-Phenyl


372
3-pyridyl
2-Cl-Phenyl


373
1-methyl-1H-
2-Cl-Phenyl



pyrazol-4-yl


374
1H-imidazol-4-yl
2-Cl-Phenyl


375
2-furanyl
2-Cl-Phenyl


376
ethyl
4-Cl-Phenyl


377
n-propyl
4-Cl-Phenyl


378
isopropyl
4-Cl-Phenyl


379
—CH2CH(CH3)2
4-Cl-Phenyl


380
—CF3
4-Cl-Phenyl


381
—CH2CF3
4-Cl-Phenyl


382
—CH2CH2CF3
4-Cl-Phenyl


383
cyclopropyl
4-Cl-Phenyl


384
Cyclobutyl
4-Cl-Phenyl


385
cyclopentyl
4-Cl-Phenyl


386
cyclohexyl
4-Cl-Phenyl


387
3-pyridyl
4-Cl-Phenyl


388
1-methyl-1H-
4-Cl-Phenyl



pyrazol-4-yl


389
1H-imidazol-4-yl
4-Cl-Phenyl


390
2-furanyl
4-Cl-Phenyl


391
ethyl
3-Br-Phenyl


392
n-propyl
3-Br-Phenyl


393
isopropyl
3-Br-Phenyl


394
—CH2CH(CH3)2
3-Br-Phenyl


395
—CF3
3-Br-Phenyl


396
—CH2CF3
3-Br-Phenyl


397
—CH2CH2CF3
3-Br-Phenyl


398
cyclopropyl
3-Br-Phenyl


399
Cyclobutyl
3-Br-Phenyl


400
cyclopentyl
3-Br-Phenyl


401
cyclohexyl
3-Br-Phenyl


402
3-pyridyl
3-Br-Phenyl


403
1-methyl-1H-
3-Br-Phenyl



pyrazol-4-yl


404
1H-imidazol-4-yl
3-Br-Phenyl


405
2-furanyl
3-Br-Phenyl


406
ethyl
2-CF3-Phenyl


407
n-propyl
2-CF3-Phenyl


408
isopropyl
2-CF3-Phenyl


409
—CH2CH(CH3)2
2-CF3-Phenyl


410
—CF3
2-CF3-Phenyl


411
—CH2CF3
2-CF3-Phenyl


412
—CH2CH2CF3
2-CF3-Phenyl


413
cyclopropyl
2-CF3-Phenyl


414
Cyclobutyl
2-CF3-Phenyl


415
cyclopentyl
2-CF3-Phenyl


416
cyclohexyl
2-CF3-Phenyl


417
3-pyridyl
2-CF3-Phenyl


418
1-methyl-1H-
2-CF3-Phenyl



pyrazol-4-yl


419
1H-imidazol-4-yl
2-CF3-Phenyl


420
2-furanyl
2-CF3-Phenyl


421
ethyl
4-CF3-Phenyl


422
n-propyl
4-CF3-Phenyl


423
isopropyl
4-CF3-Phenyl


424
—CH2CH(CH3)2
4-CF3-Phenyl


425
—CF3
4-CF3-Phenyl


426
—CH2CF3
4-CF3-Phenyl


427
—CH2CH2CF3
4-CF3-Phenyl


428
cyclopropyl
4-CF3-Phenyl


429
Cyclobutyl
4-CF3-Phenyl


430
cyclopentyl
4-CF3-Phenyl


431
cyclohexyl
4-CF3-Phenyl


432
3-pyridyl
4-CF3-Phenyl


433
1-methyl-1H-
4-CF3-Phenyl



pyrazol-4-yl


434
1H-imidazol-4-yl
4-CF3-Phenyl


435
2-furanyl
4-CF3-Phenyl


436
ethyl
3-iPr-Phenyl


437
n-propyl
3-iPr-Phenyl


438
isopropyl
3-iPr-Phenyl


439
—CH2CH(CH3)2
3-iPr-Phenyl


440
—CF3
3-iPr-Phenyl


441
—CH2CF3
3-iPr-Phenyl


442
—CH2CH2CF3
3-iPr-Phenyl


443
cyclopropyl
3-iPr-Phenyl


444
Cyclobutyl
3-iPr-Phenyl


445
cyclopentyl
3-iPr-Phenyl


446
cyclohexyl
3-iPr-Phenyl


447
3-pyridyl
3-iPr-Phenyl


448
1-methyl-1H-
3-iPr-Phenyl



pyrazol-4-yl


449
1H-imidazol-4-yl
3-iPr-Phenyl


450
2-furanyl
3-iPr-Phenyl


451
ethyl
2-morpholino-




phenyl


452
n-propyl
2-morpholino-




phenyl


453
isopropyl
2-morpholino-




phenyl


454
—CH2CH(CH3)2
2-morpholino-




phenyl


455
—CF3
2-morpholino-




phenyl


456
—CH2CF3
2-morpholino-




phenyl


457
—CH2CH2CF3
2-morpholino-




phenyl


458
cyclopropyl
2-morpholino-




phenyl


459
Cyclobutyl
2-morpholino-




phenyl


460
cyclopentyl
2-morpholino-




phenyl


461
cyclohexyl
2-morpholino-




phenyl


462
3-pyridyl
2-morpholino-




phenyl


463
1-methyl-1H-
2-morpholino-



pyrazol-4-yl
phenyl


464
1H-imidazol-4-yl
2-morpholino-




phenyl


465
2-furanyl
2-morpholino-




phenyl


466
ethyl
4-morpholino-




phenyl


467
n-propyl
4-morpholino-




phenyl


468
isopropyl
4-morpholino-




phenyl


469
—CH2CH(CH3)2
4-morpholino-




phenyl


470
—CF3
4-morpholino-




phenyl


471
—CH2CF3
4-morpholino-




phenyl


472
—CH2CH2CF3
4-morpholino-




phenyl


473
cyclopropyl
4-morpholino-




phenyl


474
Cyclobutyl
4-morpholino-




phenyl


475
cyclopentyl
4-morpholino-




phenyl


476
cyclohexyl
4-morpholino-




phenyl


477
3-pyridyl
4-morpholino-




phenyl


478
1-methyl-1H-
4-morpholino-



pyrazol-4-yl
phenyl


479
1H-imidazol-4-yl
4-morpholino-




phenyl


480
2-furanyl
4-morpholino-




phenyl


481
ethyl
4-methyl-2-




morpholino-phenyl


482
n-propyl
4-methyl-2-




morpholino-phenyl


483
isopropyl
4-methyl-2-




morpholino-phenyl


484
—CH2CH(CH3)2
4-methyl-2-




morpholino-phenyl


485
—CF3
4-methyl-2-




morpholino-phenyl


486
—CH2CF3
4-methyl-2-




morpholino-phenyl


487
—CH2CH2CF3
4-methyl-2-




morpholino-phenyl


488
cyclopropyl
4-methyl-2-




morpholino-phenyl


489
Cyclobutyl
4-methyl-2-




morpholino-phenyl


490
cyclopentyl
4-methyl-2-




morpholino-phenyl


491
cyclohexyl
4-methyl-2-




morpholino-phenyl


492
3-pyridyl
4-methyl-2-




morpholino-phenyl


493
1-methyl-1H-
4-methyl-2-



pyrazol-4-yl
morpholino-phenyl


494
1H-imidazol-4-yl
4-methyl-2-




morpholino-phenyl


495
2-furanyl
4-methyl-2-




morpholino-phenyl









For the purposes of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:




embedded image


has the chemical name 8-(methylsulfonyl)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one.


For the purposes of demonstrating the manner in which the compounds of the present invention are named and referred to herein, the compound having the formula:




embedded image


has the chemical name 8-(methylsulfonyl)-3-(2-(5-phenylhexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one.


For the purposes of the present invention, a compound depicted by the racemic formula, for example:




embedded image


will stand equally well for either of the two enantiomers having the formula:




embedded image


or the formula:




embedded image


or mixtures thereof, or in the case where a second chiral center is present, all diastereomers.


In all of the embodiments provided herein, examples of suitable optional substituents are not intended to limit the scope of the claimed invention. The compounds of the invention may contain any of the substituents, or combinations of substituents, provided herein.


Process for Preparing the 5-Hydroxytryptamine Receptor 7 Activity Modulators of the Invention


The present invention further relates to a process for preparing the 5-hydroxytryptamine receptor 7 activity modulators of the present invention.


Compounds of the present teachings can be prepared in accordance with the procedures outlined herein, from commercially available starting materials, compounds known in the literature, or readily prepared intermediates, by employing standard synthetic methods and procedures known to those skilled in the art. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be readily obtained from the relevant scientific literature or from standard textbooks in the field. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions can vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures. Those skilled in the art of organic synthesis will recognize that the nature and order of the synthetic steps presented can be varied for the purpose of optimizing the formation of the compounds described herein.


The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatography such as high pressure liquid chromatograpy (HPLC), gas chromatography (GC), gel-permeation chromatography (GPC), or thin layer chromatography (TLC).


Preparation of the compounds can involve protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene et al., Protective Groups in Organic Synthesis, 2d. Ed. (Wiley & Sons, 1991), the entire disclosure of which is incorporated by reference herein for all purposes.


The reactions or the processes described herein can be carried out in suitable solvents which can be readily selected by one skilled in the art of organic synthesis. Suitable solvents typically are substantially nonreactive with the reactants, intermediates, and/or products at the temperatures at which the reactions are carried out, i.e., temperatures that can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected.


The compounds of these teachings can be prepared by methods known in the art of organic chemistry. The reagents used in the preparation of the compounds of these teachings can be either commercially obtained or can be prepared by standard procedures described in the literature. For example, compounds of the present invention can be prepared according to the method illustrated in the General Synthetic Schemes:


General Synthetic Schemes for Preparation of Compounds


The reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. In accordance with this invention, compounds in the genus may be produced by one of the following reaction schemes.


Compounds of the disclosure may be prepared according to the process outlined in Scheme 1-x.




embedded image


A suitably substituted compound of formula (1), a known compound or compound prepared by known methods wherein X1 is an C1-6 alkyl, is reacted with benzyl bromide in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like in the presence of a solvent such as ethanol, methanol, isopropanol, tetrahydrofuran, 1,4-dioxane, methylene chloride, N,N-dimethyl formamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (2). A compound of the formula (2) is reacted with a compound of the formula (3), a known compound or a compound prepared by known methods in which LG is a leaving group such as chlorine, bromine, iodine, mesylate, tosylate, and the like, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, and the like in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, to provide a compound of the formula (4). A compound of the formula (4) is then treated with paraformaldehyde in the presence of an acid such as sulfuric acid, hydrochloric acid, and the like, in an the presence of acetic acid, and optionally in an organic solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (5). A compound of the formula (5) is then treated with a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in an solvent such as water, methanol, ethanol, isopropanol, and the like, optionally with heating, and then treated with an acid such as sulfuric acid, hydrochloric acid, and the like, in a solvent such as water, methanol, ethanol, isopropanol, and the like, to provide a compound of the formula (6). A compound of the formula (6) is reacted with tert-butyldimethylchlorosilane in the presence of imidazole, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (7). Alternatively, a compound of the formula (6) is reacted with tert-butyldimethylsilyl trifluoromethanesulfonate in the presence of a base such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (7).




embedded image


A compound of the formula (7) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula (8). A compound of the formula (8) is reacted with Di-tert-butyl dicarbonate in the presence of a base such as such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (9). A compound of the formula (9) is reacted with Tetra-n-butylammonium fluoride in the presence of solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (10).




embedded image


A compound of the formula (10) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (11). A compound of the formula (11) is reacted with a compound of the formula (12), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (13). A compound of the formula (13) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (14).




embedded image


A compound of the formula (14) is reacted with a compound of the formula (15), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (16).




embedded image


A compound of the formula (14) is reacted with a compound of the formula (17), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (18).




embedded image


A compound of the formula (14) is reacted with a compound of the formula (19), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (20).




embedded image


A compound of the formula (14) is reacted with a compound of the formula (21), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (22).




embedded image


A compound of the formula (14) is reacted with a compound of the formula (23), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (24).




embedded image


A compound of the formula (14) is reacted with a compound of the formula (25), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (26).




embedded image


A suitably substituted compound of formula (27), a known compound or compound prepared by known methods wherein X1 is an C1-6 alkyl, is reacted with a compound of the formula (28), a known compound or a compound prepared by known methods in which LG is a leaving group such as chlorine, bromine, iodine, mesylate, tosylate, and the like, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, and the like in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, to provide a compound of the formula (29). A compound of the formula (29) is then treated with paraformaldehyde in the presence of an acid such as sulfuric acid, hydrochloric acid, and the like, in an the presence of acetic acid, and optionally in an organic solvent such as methanol, ethanol, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (30). A compound of the formula (30) is then treated with a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in an solvent such as water, methanol, ethanol, isopropanol, and the like, optionally with heating, and then treated with an acid such as sulfuric acid, hydrochloric acid, and the like, in a solvent such as water, methanol, ethanol, isopropanol, and the like, to provide a compound of the formula (31). A compound of the formula (31) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (32). A compound of the formula (32) is reacted with a compound of the formula (33), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (34).




embedded image


A compound of the formula (29) is then reacted with iodine in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, and the like to provide a compound of the formula (35). A compound of the formula (35) is reacted with a compound of the formula (36), a known compound or compound prepared by known methods, in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6 lutidine, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (37).




embedded image


A compound of the formula (4) is then reacted with iodine in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, and the like to provide a compound of the formula (38). A compound of the formula (38) is reacted with a compound of the formula (39), a known compound or compound prepared by known methods, in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6 lutidine, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (40). A compound of the formula (40) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula (41).




embedded image


A compound of the formula (41) is reacted with a compound of the formula (42), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (43).




embedded image


A compound of the formula (41) is reacted with a compound of the formula (44), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (45).




embedded image


A compound of the formula (41) is reacted with a compound of the formula (46), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (47).




embedded image


A compound of the formula (41) is reacted with a compound of the formula (48), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (49).




embedded image


A compound of the formula (41) is reacted with a compound of the formula (50), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (51).




embedded image


A compound of the formula (41) is reacted with a compound of the formula (52), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (53).




embedded image


A compound of the formula (4) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (54). A compound of the formula (54) is reacted with a compound of the formula (55), a known compound or compound prepared by known methods, wherein X2 is a halogen, in the presence of a solvent such as ethyl ether, tetrahydrofuran, 1,4-dioxane and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (56). A compound of the formula (56) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (57). A compound of the formula (57) is reacted with a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride and the like, in a solvent such as methanol, ethanol, isopropanol, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (58). A compound of the formula (58) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (59). A compound of the formula (59) is reacted with a compound of the formula (60), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (61).




embedded image


A compound of the formula (62) is then converted to a compound of the formula (63), wherein LG is a mesylate, tosylate, nosylate, and the like, using methods that are known to one skilled in the art. Thus, a compound of the formula (62) is treated with a sulfonyl chloride such as methanesulfonyl chloride, toluenesulfonyl chloride p-nitrophenyl sulfonyl chloride, and the like, in the presence of a base such as triethylamine, diisopropyl amine, pyridine, 2,6-lutidine, and the like, in an organic solvent such as methylene chloride, dichloroethane, tetrahydrofuran, 1,4-dioxane, N, N-dimethylformamide, tetrahydrofuran, 1,4-dioxane and the like to provide a compound of the formula (63). A compound of the formula (63) is reacted with a compound of the formula (64), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (65).




embedded image


A compound of the formula (4) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (66). A compound of the formula (66) is reacted with a compound of the formula (67), a known compound or compound prepared by known methods, wherein X2 is a halogen, in the presence of a solvent such as ethyl ether, tetrahydrofuran, 1,4-dioxane and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (68). A compound of the formula (68) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (69). A compound of the formula (69) is reacted with a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride and the like, in a solvent such as methanol, ethanol, isopropanol, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (70). A compound of the formula (70) is reacted with tert-butyldimethylchlorosilane in the presence of imidazole, in the presence of a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (71). Alternatively, a compound of the formula (70) is reacted with tert-butyldimethylsilyl trifluoromethanesulfonate in the presence of a base such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (71).




embedded image


A compound of the formula (71) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula (72). A compound of the formula (72) is reacted with Di-tert-butyl dicarbonate in the presence of a base such as such as pyridine, 2,6-lutidine, triethylamine, diisopropylethylamine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (73). A compound of the formula (73) is reacted with Tetra-n-butylammonium fluoride in the presence of solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (74).




embedded image


A compound of the formula (74) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (75). A compound of the formula (75) is reacted with a compound of the formula (76), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (77). A compound of the formula (77) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (78).




embedded image


A compound of the formula (78) is reacted with a compound of the formula (79), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (80).




embedded image


A compound of the formula (78) is reacted with a compound of the formula (81), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (82).




embedded image


A compound of the formula (78) is reacted with a compound of the formula (83), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (84).




embedded image


A compound of the formula (78) is reacted with a compound of the formula (85), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (86).




embedded image


A compound of the formula (78) is reacted with a compound of the formula (87), a known compound or a compound prepared by known methods, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (88).




embedded image


A compound of the formula (78) is reacted with a compound of the formula (89), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (90).




embedded image


Diethanolamine (91) is reacted with 4-nitrobenzenesulfonyl chloride (NosCl) in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like in a solvent such as tetrahydrofuran, 1,4-dioxane, methylene chloride and the like to provide a compound of the formula (92). A compound of the formula (92) is then reacted with a compound of the formula (93), a known compound or one prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like, in a solvent such as acetonitrile, methanol, ethanol, dimethyl formamide, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (94). A compound of the formula (94) is reacted with a thiophenol in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, acetonitrile and the like, optionally in the presence of dimethylsulfoxide, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (95).




embedded image


A compound of the formula (96), a known compound or a compound prepared by known methods, is reacted with a compound of the formula (97), a known compound or a compound prepared by known methods in which X3 is selected from the group consisting of chlorine, bromine, iodine, and methanetrifluorosulfonate, in the presence of a base such as sodium tert-butoxide, lithium tert-butoxide, potassium tert-butoxide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethyl amine, pyridine, 2,6-lutidine, and the like, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), tris(dibenzylideneacetone)dipalladium(0), and the like, in the presence of a solvent such as toluene, benzene, methylene chloride, 1,2-dichloroethae, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (98). A compound of the formula (98) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (99).




embedded image


A compound of the formula (100), a known compound or a compound prepared by known methods, is reacted with a compound of the formula (101), a known compound or a compound prepared by known methods in which X3 is selected from the group consisting of chlorine, bromine, iodine, and methanetrifluorosulfonate, in the presence of a base such as sodium tert-butoxide, lithium tert-butoxide, potassium tert-butoxide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethyl amine, pyridine, 2,6-lutidine, and the like, in the presence of a palladium catalyst such as palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), tris(dibenzylideneacetone)dipalladium(0), and the like, in the presence of a solvent such as toluene, benzene, methylene chloride, 1,2-dichloroethae, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (102). A compound of the formula (102) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (103).




embedded image


A compound of the formula (104), a known compound or a compound prepared by known methods in which X4 is an C1-6 alkyl, is reacted with di-tert-butyl dicarbonate in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6-lutidine, and the like, in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, 1,4-dioxane, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (105). A compound of the formula (105) is reacted with a compound of the formula (106), a known compound or a compound prepared by known methods where in LG1 is a leaving group such as chlorine, bromine, iodine, mesylate, tosylate, and the like, in the presence of a base such as lithium diisopropylamide, sodium diisopropylamide, potassium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, sodium hydride, and the like in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, to provide a compound of the formula (107).




embedded image


A compound of the formula (107) is reacted with a base such as sodium hydroxide, lithium hydroxide, potassium hydroxide, sodium carbonate, lithium carbonate, potassium carbonate, and the like in a solvent such as methanol, ethanol, isopropanol, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, and the like, optionally in the presence of water, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (108). A compound of the formula (108) is then reacted with iodine in the presence of a base such as sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium carbonate, potassium carbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, and the like, in the presence of a solvent such as tetrahydrofuran, ethyl ether, 1,4-dioxane, and the like to provide a compound of the formula (109).




embedded image


A compound of the formula (109) is reacted with a compound of the formula (110), a known compound or compound prepared by known methods, in an organic solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dimethylformamide, dimethylacetamide, and the like, optionally in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, 2,6 lutidine, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (111). A compound of the formula (111) is reacted with an acid such as trifluoroacetic acid, formic acid, acetic acid, hydrochloric acid, sulfuric acid, and the like, optionally in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (112).




embedded image


A compound of the formula (113) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (114). A compound of the formula (114) is reacted with a compound of the formula (115), a known compound or compound prepared by known methods, wherein X5 is a halogen, in the presence of a solvent such as ethyl ether, tetrahydrofuran, 1,4-dioxane and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (116). A compound of the formula (116) is reacted with ruthenium chloride in the presence of sodium periodate in a solvent such as acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation, to provide a compound of the formula (117). A compound of the formula (117) is reacted with a reducing agent such as lithium borohydride, sodium borohydride, sodium cyanoborohydride and the like, in a solvent such as methanol, ethanol, isopropanol, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (118).




embedded image


A compound of the formula (7) is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium on carbon, palladium on barium sulfate, palladium (II) acetate, tetrakis(triphenylphosphine)palladium(0), dichlorobis (triphenylphosphine)palladium(II), palladium on carbon, bis(acetonitrile)dichloropalladium(II), and the like, in an organic solvent such as methanol, ethanol, ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N,N-dimethylformamide, and the like, to provide a compound of the formula (119). A compound of the formula (119) is reacted with a compound of the formula (15), a known compound or a compound prepared by known methods, in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (120). A compound of the formula (120) is reacted with tetra-n-butylammonium fluoride in the presence of solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (121). A compound of the formula (121) is treated with carbon tetrabromide in the presence of triphenylphosphine, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (122). A compound of the formula (122) is reacted with a compound of the formula (12), a known compound or a compound prepared by known methods, in the presence of a base such as sodium carbonate, potassium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, triethylamine, diisopropylethylamine, pyridine, and the like, in a solvent such as methylene chloride, 1,2-dichloroethane, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, methanol, ethanol, isopropanol, and the like, optionally with heating, optionally with microwave irradiation to provide a compound of the formula (123).


The Examples provided below provide representative methods for preparing exemplary compounds of the present invention. The skilled practitioner will know how to substitute the appropriate reagents, starting materials and purification methods known to those skilled in the art, in order to prepare the compounds of the present invention.


Examples

The practice of the invention is illustrated by the following non-limiting examples. The Examples provided below provide representative methods for preparing exemplary compounds of the present invention. The skilled practitioner will know how to substitute the appropriate reagents, starting materials and purification methods known to those skilled in the art, in order to prepare the compounds of the present invention.


In the examples that follow, 1H-NMR spectra were obtained on a Varian Mercury 300-MHz NMR. Purity (%) and mass spectral data were determined with a Waters Alliance 2695 HPLC/MS (Waters Symmetry C18, 4.6×75 mm, 3.5 μm) with a 2996 diode array detector from 210-400 nm.




embedded image


Example 1

Preparation of ethyl 1-benzylpiperidine-4-carboxylate: To a solution of ethyl piperidine-4-carboxylate (5.0 g, 31.8 mmol, 1.0 eq) and ethanol (15.0 mL), benzyl bromide (7.07 g, mmol, 1.3 eq) was added dropwise at 0° C. Following, triethylamine (1.06 g, 10.5 mmol, 1.5 eq) was added in one portion while at 0° C. The resulting mixture was allowed to warm to RT and stir overnight. The reaction was concentrated in vacuo to remove the presence of ethanol. The resulting residue was suspended in a mixture of ethyl acetate: D.I. water (20 mL:20 mL). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2×10 mL). The combined extract was dried over Na2SO4, then filtered through a plug of silica gel and washed with ethyl acetate. The filtrated was concentrated in vacuo to give product that was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.41-7.20 (m, 5H), 4.14 (q, J=7.2 Hz, 2H), 3.51 (s, 2H), 2.87 (dt, J=3.5, 11.8 Hz, 2H), 2.29 (m, 1H), 2.04 (td, J=2.5, 11.4 Hz, 2H), 1.95-1.85 (m, 2H), 1.85-1.70 (m, 2H), 1.26 (t, J=7.1 Hz, 3H).




embedded image


Example 2

Preparation of methyl 4-allyltetrahydro-2H-pyran-4-carboxylate: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a solution of lithium diisopropylamide (1M, 1.20 equiv) in dry tetrahydrofuran (4.16 mL), methyl tetrahydro-2H-pyran-4-carboxylate (0.5 g, 3.47 mmol, 1.0 equiv), in 5 mL dry THF, was added dropwise during 0.5 hours at −78° C. The mixture was allowed to stir at this temperature for 1 hr followed by the addition of allyl bromide (0.457 g, 3.78 mmol, 1.1 eq) dropwise. The reaction mixture was allowed to warm to RT over a 1 hr period. The reaction was quenched with 10% HCl (while cooling in ice bath) until acidic (pH=2). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3×10 mL). The extract was dried over Na2SO4 and then concentrated in vacuo to give product that was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 5.68-5.52 (m, 1H), 5.03-4.91 (m, 2H), 3.75 (dt, J=3.7, 11.8 Hz, 2H), 3.63 (s, 3H), 3.37 (td, J=2.1, 11.6 Hz, 2H), 2.21 (d, J=7.4 Hz, 2H), 2.03-1.95 (m, 2H), 1.53-1.40 (m, 2H).




embedded image


Example 3

Preparation of ethyl 4-allyl-1-benzylpiperidine-4-carboxylate: This reaction was performed in oven-dried glassware under a nitrogen atmosphere. To a solution of ethyl 1-benzylpiperidine-4-carboxylate (6.24 g, 26.7 mmol, 1.0 eq) and dry THF (50 mL), lithium diisopropylamide (1M, 1.10 equiv) in dry tetrahydrofuran (29.3 mL) was added dropwise during 0.5 hours at −78° C. The mixture was allowed to stir at this temperature for 1 hr followed by the addition of allyl iodine (6.73 g, 3.78 mmol, 1.5 eq) dropwise. The reaction mixture was allowed to warm to RT and stir for 2 hr. The reaction was quenched with sat. aq. NH4Cl until neutral pH (while cooling in ice bath). The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2×50 mL). The combined extract was dried over Na2SO4, then filtered through a plug of silica gel and washed with ethyl acetate. The filtrated was concentrated in vacuo to give product that was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.37-7.20 (m, 5H), 5.78-5.62 (m, 1H), 5.10-4.97 (m, 2H), 4.17 (q, J=7.1 Hz, 2H), 3.47 (s, 2H), 2.78-2.64 (m, 2H), 2.28 (d, J=7.4 Hz, 2H), 2.18-2.03 (m, 4H), 1.61-1.46 (m, 2H), 1.26 (t, J=7.1 Hz, 3H).




embedded image


Example 4

Preparation of 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-1-one: A mixture of glacial acetic acid (10.9 g, 180 mmol, 53.6 eq), paraformaldehyde (0.309 g, 10.3 mmol, 3.0 eq) and H2SO4 (0.191 g, 1.95 mmol, 0.57 eq) was stirred for 30 min at 70° C. before methyl 4-allyltetrahydro-2H-pyran-4-carboxylate (0.632 g, 3.43 mmol, 1.0 equiv) was added dropwise during 10 min. The reaction mixture was then maintained at 70-80° C. and allowed to stir overnight. Acetic acid was removed under reduced pressure and the reaction was quenched with 10% NaHCO3 solution. The mixture was then extracted with ethyl acetate (3×10 mL) and the combined organic phase was concentrated in vacuo to give a crude oil. The crude oil was used for next step without further purification.


A mixture of the crude oil (715 mg) and 30% NaOH (2.86 g NaOH, 4× crude oil) aqueous solution was refluxed for 2 hours. The mixture was cooled in an ice bath and excess 30% H2SO4 was added until acidic (pH<2). The resulting mixture was extracted with ethyl acetate (3×25 mL), the combined organic phase was washed with 10% NaHCO3, (50 mL), brine (50 mL), dried over Na2SO4 and concentrated in vacuo to give a crude product which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 4.57 (m, 1H), 3.91 (dt, J=4.5, 11.8 Hz, 1H), 3.79 (dt, J=4.5, 12.0 Hz, 1H), 3.66 (t, J=6.0 Hz, 2H), 3.54-3.44 (m, 1H), 3.43-3.34 (m, 1H), 3.13 (b, 1H), 2.41 (dd, J=6.1, 13.2 Hz, 1H), 2.01-1.91 (m, 1H), 1.89-1.64 (m, 4H), 1.54-1.44 (m, 1H), 1.42-1.33 (m, 1H).




embedded image


Example 5

Preparation of 8-benzyl-3-(2-hydroxyethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A mixture of glacial acetic acid (78.1 g, 1.3 mol, 53.6 eq), paraformaldehyde (2.21 g, 73.5 mmol, 3.0 eq) and H2SO4 (3.63 g, 37 mmol, 1.5 eq) was stirred for 30 min at 70° C. before ethyl 4-allyl-1-benzylpiperidine-4-carboxylate (7.03 g, 24.5 mmol, 1.0 equiv) was added dropwise during 10 min. The reaction mixture was then maintained at 70-80° C. and allowed to stir overnight. Acetic acid was removed under reduced pressure and the reaction was quenched with 10% NaHCO3 solution. The mixture was then extracted with ethyl acetate (3×40 mL) and the combined organic phase was concentrated in vacuo to give a crude oil. The crude oil was used for next step without further purification.


A mixture of the crude oil (7.07 mg) and 30% NaOH (28 g NaOH, 4× crude oil) aqueous solution was refluxed for 2 hours. The mixture was cooled in an ice bath and excess 30% H2SO4 was added until acidic (pH<2). The resulting mixture was the neutralized (pH=8-9) with sat. aq. NaHCO3 solution and then extracted with ethyl acetate (3×100 mL), the combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude product which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.39-7.22 (m, 5H), 4.65 (m, 1H), 3.83 (t, J=5.6 Hz, 2H), 3.54 (s, 2H), 2.95-2.84 (m, 1H), 2.83-2.73 (m, 1H), 2.42 (dd, J=6.1, 13.0 Hz, 1H), 2.30-2.07 (m, 4H), 2.00-1.84 (m, 3H), 1.75-1.59 (m, 2H), 1.58-1.48 (m, 1H).




embedded image


Example 6

Preparation of 8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: To a solution of 8-benzyl-3-(2-hydroxyethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (10.0 g, 34.6 mmol, 1.0 eq.), imidazole (2.47 g, 36.3 mmol, 1.05 eq.) and dichloromethane (70 mL), was added a solution of tert-Butyldimethylsilyl chloride (1M, 5.47 g, 36.3 mmol, 1.05 eq.) in dichloromethane (36.3 mL). The reaction was allowed to stir at RT for 2 hr, before being quenched with D.I. water (50 mL). The organic layer was separated and the aqueous layer was extracted with dichloromethane (2×50 mL). The combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude product which was further purified by column chromatography (Ethyl acetate/Hexanes, 0%˜20%). 1H NMR (400 MHz, CDCl3) δ 7.32-7.11 (m, 5H), 4.52 (m, 1H), 3.73-3.65 (m, 2H), 3.46 (s, 2H), 2.87-2.76 (m, 1H), 2.72 (dt, J=4.5, 11.8 Hz, 1H), 2.31 (dd, J=6.2, 12.9 Hz, 1H), 2.22-2.08 (m, 1H), 2.08-1.97 (m, 2H), 1.91-1.70 (m, 3H), 1.62 (dd, J=9.8, 12.8 Hz, 1H), 1.59-1.50 (m, 1H), 1.49-1.38 (m, 1H), 0.83 (s, 9H), 0.00 (s, 6H).




embedded image


Example 7

Preparation of tert-butyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A mixture of 8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (4.77 g, 11.8 mmol, 1 eq.), Pd/C (954 mg, 20% wt) and MeOH (79 mL) was stirred at RT under 1 atm of H2 (filled balloon) overnight. The mixture was filtered through a plug of Celite, washed with MeOH (50 mL) and concentrated in vacuo to give a crude oil. The crude oil (3.78 g) was dissolved in dichloromethane (79 mL) and cooled to 0° C. before the addition of Di-tert-butyl dicarbonate (2.83 g, 13.0 mmol, 1.1 eq.) and trimethylamine (1.8 g, 17.7 mmol, 1.5 eq.). The reaction was allowed to warm to RT and stir for 45 min. At this point the reaction was diluted with sat. aq. NaHCO3 solution and then extracted with ethyl acetate (3×50 mL), the combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude product which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 4.57 (m, 1H), 3.91 (b, 1H), 3.77 (b, 1H), 3.73-3.66 (m, 2H), 3.17-3.05 (m, 1H), 3.04-2.93 (m, 1H), 2.31 (dd, J=6.2, 13.0 Hz, 1H), 1.96-1.81 (m, 2H), 1.81-1.64 (m, 3H), 1.59-1.48 (m, 1H), 1.48-1.32 (m, 10H), 0.83 (s, 9H), 0.00 (s, 6H).




embedded image


Example 8

Preparation of tert-butyl 3-(2-hydroxyethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: To a solution of tert-butyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (4.88 g, 11.8 mmol, 1 eq.) and THF (70 mL) was added tetra-n-butylammonium fluoride (3.24 g, 12.4 mmol, 1.05 eq.); using THF (10 mL) to complete transfer. The resulting solution was allowed to stir at RT for 30 min before being concentrated in vacuo to give a crude product which was further purified by column chromatography (MeOH/DCM, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 4.67 (m, 1H), 3.95 (dt, J=5.0, 13.6 Hz, 1H), 3.87-3.73 (m, 3H), 3.23-3.10 (m, 1H), 3.09-2.98 (m, 1H), 2.39 (dd, J=6.0, 13.0 Hz, 1H), 1.99-1.84 (m, 4H), 1.83-1.68 (m, 2H), 1.63-1.53 (m, 1H), 1.53-1.36 (m, 10H).




embedded image


Example 9

Preparation of 3-(2-bromoethyl)-2,8-dioxaspiro[4.5]decan-1-one: A solution of 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-1-one (0.320 g, 1.60 mmol, 1 eq.) and THF (15 mL) was cooled to 0° C. before triphenylphosphine (0.630 g, 2.4 mmol, 1.5 eq.) and carbon tetrabromide (0.795 g, 2.4 mmol, 1.5 eq.) were sequentially added to the solution. The reaction solution was allowed to warm to RT and stir overnight. The resulting mixture was then filtered and concentrated in vacuo to give a crude mixture. This mixture was suspended in diethyl ether (50 mL) and filtered 2× using diethyl ether to wash the filter cakes. The final filtrate was loaded onto Celite in vacuo and further purified by column chromatography (ethyl acetate/hexanes, 0%˜40%). 1H NMR (400 MHz, CDCl3) δ 4.67 (m, 1H), 4.04 (dt, J=4.6, 11.8 Hz, 1H), 3.91 (dt, J=4.6, 12.1 Hz, 1H), 3.60 (m, 1H), 3.56-3.45 (m, 3H), 2.50 (dd, J=6.1, 12.9 Hz, 1H), 2.30-2.02 (m, 3H), 1.91 (m, 1H), 1.76 (dd, J=9.8, 13.0 Hz, 1H), 1.64-1.55 (m, 1H), 1.52-1.44 (m, 1H).




embedded image


Example 10

Preparation of tert-butyl 3-(2-bromoethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for 3-(2-bromoethyl)-2,8-dioxaspiro[4.5]decan-1-one, except tert-butyl 3-(2-hydroxyethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was substituted for 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-1-one: 1H NMR (400 MHz, CDCl3) δ 4.68 (m, 1H), 3.97 (dt, J=5.0, 13.5 Hz, 1H), 3.83 (dt, J=5.0, 13.7 Hz, 1H), 3.54 (dd, J=5.3, 7.5 Hz, 2H), 3.27-3.14 (m, 1H), 3.13-3.01 (m, 1H), 2.42 (dd, J=6.0, 13.0 Hz, 1H), 2.31-2.20 (m, 1H), 2.20-2.09 (m, 1H), 2.01-1.90 (m, 1H), 1.89-1.78 (m, 1H), 1.74 (dd, J=9.8, 12.8 Hz, 1H), 1.66-1.56 (m, 1H), 1.54-1.36 (m, 10H).




embedded image


Example 11

Preparation of 8-benzyl-3-(2-bromoethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: A solution of 3-(2-hydroxyethyl)-2,8-dioxaspiro[4.5]decan-1-one (2.07 g, 7.16 mmol, 1 eq.) and THF (70 mL) was cooled to 0° C. before triphenylphosphine (2.83 g. 10.8 mmol, 1.5 eq.) and carbon tetrabromide (3.58 g, 10.8 mmol, 1.5 eq.) were sequentially added to the solution. The reaction solution was allowed to warm to RT and stir overnight. The resulting mixture was then filtered and concentrated in vacuo to give a crude mixture. This mixture was suspended in diethyl ether (50 mL) and filtered 2× using diethyl ether to wash the filter cakes. The final filtrate was loaded onto Celite in vacuo and further purified by column chromatography on a C18 column. (ACN/H2O, 0%˜100%, w/0.1% formic acid). 1H NMR (400 MHz, MeOD) δ 7.53 (b, 2H), 7.47 (b, 3H), 4.75 (m, 1H), 4.27 (s, 2H), 3.64-3.47 (m, 3H), 3.34 (m, 1H), 3.19 (b, 1H), 3.08 (b, 1H), 2.52 (m, 1H), 2.35-2.15 (m, 3H), 2.15-1.97 (m, 2H), 1.96-1.81 (m, 2H).




embedded image


Example 12

Preparation of 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one: A solution of 3-(2-bromoethyl)-2,8-dioxaspiro[4.5]decan-1-one (0.050 g, 0.190 mmol, 1 eq.), THF (4 mL) and 1-phenylpiperazine (0.065 g, 0.399 mmol, 2.1 eq.) was heated and stirred at 60° C. for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (methanol/dichloromethane, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 7.27 (m, 2H), 6.93 (d, J=8.3 Hz, 2H), 6.86 (t, J=7.3 Hz, 1H), 4.58 (m, 1H), 4.06 (dt, J=4.6, 11.9 Hz, 1H), 3.93 (dt, J=4.6, 12.0 Hz, 1H), 3.61 (m, 1H), 3.51 (m, 1H), 3.21 (t, J=5.0 Hz, 4H), 2.70-2.52 (m, 6H), 2.47 (dd, J=6.0, 12.8 Hz, 1H), 2.11 (m, 1H), 2.01-1.83 (m, 3H), 1.79 (dd, J=9.7, 13.1 Hz, 1H), 1.65-1.54 (m, 1H), 1.54-1.45 (m, 1H); MS (LC/MS, M+H+): 344.8.




embedded image


Example 13

Preparation of 3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one, except 4-(piperazin-1-yl)phenol was substituted for 1-phenylpiperazine: 1H NMR (400 MHz, CDCl3) δ 6.74 (d, J=8.9 Hz, 2H), 6.63 (d, J=8.9 Hz, 2H), 4.45 (m, 1H), 3.97 (dt, J=4.6, 11.8 Hz, 1H), 3.83 (dt, J=4.5, 12.3 Hz, 1H), 3.51 (m, 1H), 3.42 (m, 1H), 3.00 (t, J=4.7 Hz, 4H), 2.67-2.42 (m, 6H), 2.35 (dd, J=6.1, 12.1 Hz, 1H), 2.00 (m, 1H), 1.92-1.74 (m, 3H), 1.67 (dd, J=9.6, 12.9 Hz, 1H), 1.52-1.43 (m, 1H), 1.43-1.34 (m, 1H); MS (LC/MS, M+H+): 360.8.




embedded image


Example 14

Preparation of 8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A solution of 8-benzyl-3-(2-bromoethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate (0.545 g, 1.37 mmol, 1 eq.), THF (13.7 mL), 1-(p-tolyl)piperazine (0.507 g, 2.88 mmol, 2.1 eq.) and triethylamine (0.107 g, 1.5 mmol, 1.1 eq.) was heated and stirred at 60° C. for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (methanol/dichloromethane, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 7.39-7.23 (m, 5H), 7.10 (d, J=8.3 Hz, 2H), 6.87 (d, J=8.6 Hz, 2H), 4.53 (m, 1H), 3.54 (s, 2H), 3.17 (t, J=5.0 Hz, 4H), 2.95-2.85 (m, 1H), 2.84-2.75 (m, 1H), 2.70-2.49 (m, 6H), 2.40 (dd, J=6.2, 12.8 Hz, 1H), 2.30 (s, 3H), 2.27-2.05 (m, 3H), 2.01-1.79 (m, 3H), 1.76-1.58 (m, 2H), 1.58-1.46 (m, 1H); MS (LC/MS, M+H+): 447.8.




embedded image


Example 15

Preparation of 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A mixture of 8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (445 mg, 0.993 mmol, 1 eq.), Pd/C (90 mg, 20% wt) and EtOH (6.6 mL) was stirred at RT under 1 atm of H2 (filled balloon) for 48 hrs. The mixture was filtered through a plug of Celite, washed with MeOH (50 mL) and concentrated in vacuo to give a crude oil. 1H NMR (400 MHz, MeOD) δ 6.95 (d, J=8.2 Hz, 2H), 6.77 (d, J=8.5 Hz, 2H), 4.56 (m, 1H), 3.47 (m, 1H), 3.28-3.18 (m, 1H), 3.17-3.09 (m, 1H), 3.08-2.96 (m, 5H), 2.66-2.46 (m, 6H), 2.42 (dd, J=6.0, 13.0 Hz, 1H), 2.14 (s, 3H), 2.10-2.00 (m, 1H), 2.00-1.91 (m, 1H), 1.91-1.80 (m, 4H), 1.80-1.70 (m, 1H); MS (LC/MS, M+H+): 357.8.




embedded image


Example 16

Preparation of methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (0.05 g, 0.14 mmol, 1 eq.), dichloromethane (2 mL) and triethylamine (0.44 g, 0.41 mmol, 3 eq.) was cooled to 0° C. before methyl chloroformate (0.027 g. 0.28 mmol, 2 eq.) was added to the solution. The reaction solution was allowed to warm to RT and stir for 3 hours. The reaction was diluted with dichloromethane and loaded onto Celite in vacuo and further purified by column chromatography on a C18 column. (ACN/H2O, 0%˜100%, w/0.1% formic acid). The resulting formate acid salt was dissolved in MeOH (2 mL) and Amberlite IRA-400(OH) resin was added. This mixture was allowed to stir at RT for 30 min and then filtered and concentrated in vacuo to afford pure free based product. 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J=8.4 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 4.59 (m, 1H), 4.02 (b, 1H), 3.85 (b, 1H), 3.72 (s, 3H), 3.35-3.24 (m, 1H), 3.23-3.10 (m, 5H), 2.71-2.50 (m, 6H), 2.38 (dd, J=6.0, 12.8 Hz, 1H), 2.28 (s, 3H), 2.07-1.72 (m, 5H), 1.69-1.47 (m, 2H); MS (LC/MS, M+H+): 415.8.




embedded image


Example 17

Preparation of 8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except acetic anhydride was substituted for methyl chloroformate: 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J=8.3 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 4.60 (m, 1H), 4.19 (m, 0.5H), 4.04-3.84 (m, 1H), 3.72 (m, 0.5H), 3.45-3.22 (m, 2H), 3.15 (t, J=4.8 Hz, 4H), 2.70-2.49 (m, 6H), 2.43-2.32 (m, 1H), 2.27 (s, 3H), 2.10 (s, 3H), 2.05-1.72 (m, 5H), 1.69-1.49 (m, 2H); MS (LC/MS, M+H+): 399.8.




embedded image


Example 18

Preparation of N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide: The title compound was prepared according to the procedure for methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except N-methyl-1H-imidazole-1-carboxamide was substituted for methyl chloroformate: 1H NMR (400 MHz, MeOD) δ 6.96 (d, J=8.3 Hz, 2H), 6.78 (d, J=8.2 Hz, 2H), 4.52 (m, 1H), 3.79 (dt, J=4.7, 13.8 Hz, 1H), 3.68 (dt, J=4.5, 13.8 Hz, 1H), 3.22 (m, 1H), 3.16-2.86 (m, 6H), 2.63 (s, 3H), 2.59-2.36 (m, 7H), 2.15 (s, 3H), 1.91-1.67 (m, 3H), 1.66-1.50 (m, 2H), 1.50-1.38 (m, 1H); MS (LC/MS, M+H+): 414.8.




embedded image


Example 20

Preparation of tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A mixture of tert-butyl 3-(2-bromoethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.500 g, 1.38 mmol, 1 eq.), ACN (7 mL), 1-(2-isopropylphenyl)piperazine (0.337 g, 1.65 mmol, 1.2 eq.) and K2CO3 (0.954 g, 6.9 mmol, 5 eq.) was heated and stirred at 80° C. for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (methanol/dichloromethane, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 7.16 (dd, J=1.6, 7.4 Hz, 1H), 7.09-6.94 (m, 3H), 4.49 (m, 1H), 3.89 (b, 1H), 3.75 (b, 1H), 3.40 (sep, J=6.9 Hz, 1H), 3.09 (m, 1H), 2.98 (m, 1H), 2.81 (t, J=4.6 Hz, 4H), 2.65-2.39 (m, 5H), 2.30 (dd, J=6.1, 12.8 Hz, 1H), 1.99-1.60 (m, 5H), 1.51 (m, 1H), 1.46-1.29 (m, 11H), 1.12 (s, 3H), 1.10 (s, 6H); MS (LC/MS, M+H+): 485.8




embedded image


Example 21

Preparation of tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 1,2,3,4-tetrahydroisoquinoline hydrochloride was substituted for 1-(2-isopropylphenyl)piperazine: 1H NMR (400 MHz, CDCl3) δ 7.07-6.96 (m, 3H), 6.95-6.87 (m, 1H), 4.53 (m, 1H), 3.87 (b, 1H), 3.72 (b, 1H), 3.60-3.46 (m, 2H), 3.06 (m, 1H), 2.95 (m, 1H), 2.80 (t, J=5.8 Hz, 2H), 2.64 (t, J=6.0 Hz, 2H), 2.58 (t, J=7.3 Hz, 2H), 2.28 (dd, J=6.1, 12.9 Hz, 1H), 1.97-1.75 (m, 3H), 1.74-1.58 (m, 2H), 1.54-1.26 (m, 11H); MS (LC/MS, M+H+): 414.8




embedded image


Example 22

Preparation of tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of tert-butyl 3-(2-bromoethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (1.5 g, 4.11 mmol, 1.1 eq.), THF (36 mL), 1-(p-tolyl)piperazine (0.660 g, 3.74 mmol, 1 eq.) and triethylamine (0.416 g, 4.11 mmol, 1.1 eq.) was heated and stirred at 70° C. for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was further purified by column chromatography (methanol/dichloromethane, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 7.05 (d, J=8.3 Hz, 2H), 6.82 (d, J=8.5 Hz, 2H), 4.55 (m, 1H), 3.96 (m, 1H), 3.81 (m, 1H), 3.22-2.98 (m, 6H), 2.67-2.45 (m, 6H), 2.36 (dd, J=6.2, 12.9 Hz, 1H), 2.25 (s, 3H), 2.00-1.66 (m, 5H), 1.57 (m, 1H), 1.53-1.34 (m, 10H); MS (LC/MS, M+H+): 457.8




embedded image


Example 23

Preparation of tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of tert-butyl 3-(2-bromoethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.5 g, 1.38 mmol, 1. eq.), THF (12 mL), 2-methyl-7-(piperazin-1-yl)-1H-benzo[d]imidazole (0.549 g, 1.65 mmol, 1.2 eq.) and triethylamine (0.500 g, 4.95 mmol, 3.5 eq.) was heated and stirred at 70° C. for 3 days. The resulting mixture was then filtered and concentrated in vacuo to give a crude residue that was first purified by column chromatography (methanol/dichloromethane, 0%˜10%). The resulting fractions were further purified by column chromatography on a C18 column. (ACN/H2O, 0%˜100%, w/0.1% NH4OH)1H NMR (400 MHz, CDCl3) δ 7.16-6.97 (m, 2H), 6.65 (m, 1H), 4.54 (m, 1H), 3.98 (m, 1H), 3.83 (m, 1H), 3.40 (b, 4H), 3.17 (t, J=11.1 Hz, 1H), 3.06 (t, J=11.5 Hz, 1H), 2.68-2.42 (m, 9H), 2.36 (dd, J=6.2, 13.0 Hz, 1H), 1.99-1.66 (m, 5H), 1.58 (m, 1H), 1.54-1.33 (m, 10H); MS (LC/MS, M+H+): 497.8




embedded image


Example 24

Preparation of tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 4-(2-(piperazin-1-yl)phenyl)morpholine was substituted for 2-methyl-7-(piperazin-1-yl)-1H-benzo[d]imidazole: 1H NMR (400 MHz, CDCl3) δ 6.94-6.87 (m, 2H), 6.87-6.78 (m, 2H), 4.51 (m, 1H), 3.90 (m, 1H), 3.81-3.66 (m, 5H), 3.34-2.84 (m, 10H), 2.67-2.37 (m, 6H), 2.31 (dd, J=6.2, 12.9 Hz, 1H), 1.93-1.59 (m, 5H), 1.52 (m, 1H), 1.47-1.30 (m, 10H); MS (LC/MS, M+H+): 528.8




embedded image


Example 25

Preparation of 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: To a solution of tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.450 g, 0.930 mmol, 1 eq.) in dichloromethane (3 mL) at 0° C. was added trifluoroacetic acid (3 mL). The reaction was allowed to stir at RT for 30 min before being diluted with MeOH and concentrated in vacuo to afford the product as a TFA salt. The resulting TFA salt was dissolved in MeOH (2 mL) and Amberlite IRA-400(OH) resin was added. This mixture was allowed to stir at RT for 30 min and then filtered and concentrated in vacuo to afford pure free based product. 1H NMR (400 MHz, MeOD) δ 7.16 (d, J=7.5 Hz, 1H), 7.07-6.93 (m, 3H), 4.50 (m, 1H), 3.44 (sep, J=6.9 Hz, 1H), 2.99 (dt, J=4.3, 12.6 Hz, 1H), 2.89 (dt, J=4.3, 13.2 Hz, 1H), 2.82 (t, J=4.7 Hz, 4H), 2.74-2.37 (m, 9H), 1.91-1.78 (m, 3H), 1.77-1.50 (m, 3H), 1.42 (m, 1H), 1.12 (s, 3H), 1.10 (s, 3H); MS (LC/MS, M+H+): 385.8




embedded image


Example 26

Preparation of 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, except tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was substituted for tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: 1H NMR (400 MHz, MeOD) δ 7.18-7.09 (m, 3H), 7.09-7.03 (m, 1H), 4.64 (m, 1H), 3.68 (s, 2H), 3.25 (dt, J=5.0, 13.1 Hz, 1H), 3.10 (dt, J=5.0, 13.4 Hz, 1H), 2.99-2.88 (m, 3H), 2.85-2.61 (m, 5H), 2.55 (dd, J=6.1, 12.9 Hz, 1H), 2.09-1.95 (m, 3H), 1.90-1.70 (m, 3H), 1.63 (m, 1H); MS (LC/MS, M+H+): 314.8




embedded image


Example 27

Preparation of 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: A solution of 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (0.05 g, 0.14 mmol, 1 eq.), dichloromethane (2 mL) and triethylamine (0.44 g, 0.41 mmol, 3 eq.) was cooled to 0° C. before methanesulfonyl chloride (0.032 g. 0.28 mmol, 2 eq.) was added to the solution. The reaction solution was allowed to warm to RT and stir for 3 hours. The reaction was diluted with dichloromethane and loaded onto Celite in vacuo and further purified by column chromatography on a C18 column. (ACN/H2O, 0%˜100%, w/0.1% formic acid). 1H NMR (400 MHz, DMSO) δ 7.01 (d, J=8.5 Hz, 2H), 6.82 (d, J=8.5 Hz, 2H), 4.59 (m, 1H), 3.58-3.45 (m, 1H), 3.44-3.33 (m, 1H), 3.13-2.95 (m, 5H), 2.88 (s, 3H), 2.86-2.78 (m, 1H), 2.62-2.31 (m, 7H), 2.19 (s, 3H), 1.97-1.57 (m, 7H); MS (LC/MS, M+H+): 435.8




embedded image


Example 28

Preparation of 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was substituted for 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: 1H NMR (400 MHz, MeOD) δ 7.34-7.27 (m, 1H), 7.23-7.08 (m, 3H), 4.67 (m, 1H), 3.70 (dt, J=4.8, 12.3 Hz, 1H), 3.61-3.47 (m, 2H), 3.40-3.09 (m, 11H), 3.04 (m, 1H), 2.88 (s, 3H), 2.56 (dd, J=6.4, 12.8 Hz, 1H), 2.29-2.10 (m, 2H), 2.05 (m, 1H), 1.96-1.80 (m, 3H), 1.75 (m, 1H), 1.24 (s, 3H), 1.22 (s, 3H); MS (LC/MS, M+H+): 463.7




embedded image


Example 29

Preparation of 8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was substituted for 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: 1H NMR (400 MHz, MeOD) δ 7.13-6.90 (m, 4H), 4.67 (m, 1H), 3.86 (t, J=4.6 Hz, 4H), 3.70 (dt, J=4.7, 12.3 Hz, 1H), 3.61-3.08 (m, 16H), 3.04 (m, 1H), 2.88 (s, 3H), 2.56 (dd, J=5.9, 13.0 Hz, 1H), 2.29-2.11 (m, 2H), 2.05 (m, 1H), 1.97-1.81 (m, 3H), 1.75 (m, 1H); MS (LC/MS, M+H+): 507.2




embedded image


Example 30

Preparation of 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was substituted for 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: 1H NMR (400 MHz, MeOD) δ 7.47-7.26 (m, 2H), 7.04 (d, J=6.7 Hz, 1H), 4.69 (m, 1H), 3.79-3.28 (m, 12H), 3.14 (m, 1H), 3.01 (m, 1H), 2.87 (s, 3H), 2.79 (s, 3H), 2.58 (dd, J=5.9, 12.9 Hz, 1H), 2.38-2.14 (m, 2H), 2.12-1.98 (m, 1H), 1.96-1.80 (m, 3H), 1.75 (m, 1H); MS (LC/MS, M+H+): 476.2




embedded image


Example 31

Preparation of 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one was substituted for 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: 1H NMR (400 MHz, MeOD) δ 7.31-7.21 (m, 3H), 7.20-7.15 (m, 1H), 4.67 (m, 1H), 4.26 (s, 2H), 3.70 (dt, J=4.9, 12.3 Hz, 1H), 3.53 (dt, J=5.2, 12.5 Hz, 1H), 3.39 (t, J=6.2 Hz, 2H), 3.31-3.10 (m, 5H), 3.03 (m, 1H), 2.88 (s, 3H), 2.56 (dd, J=6.0, 12.9 Hz, 1H), 2.30-2.12 (m, 2H), 2.05 (m, 1H), 1.97-1.80 (m, 3H), 1.75 (m, 1H); MS (LC/MS, M+H+): 392.7.




embedded image


Example 32

Preparation of 8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except benzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.69 (m, 2H), 7.53 (m, 1H), 7.46 (m, 2H), 7.00 (d, J=8.3 Hz, 2H), 6.75 (d, J=8.5 Hz, 2H), 4.44 (m, 1H), 3.46 (m, 1H), 3.22 (m, 1H), 3.10 (t, J=4.7 Hz, 4H), 2.97 (m, 1H), 2.87 (m, 1H), 2.75-2.44 (m, 6H), 2.19 (s, 3H), 2.12 (dd, J=6.1, 13.0 Hz, 1H), 2.02-1.77 (m, 4H), 1.72-1.53 (m, 3H); MS (LC/MS, M+H+): 498.2.




embedded image


Example 33

Preparation of 8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 4-methoxybenzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J=9.0 Hz, 2H), 6.99 (d, J=8.3 Hz, 2H), 6.91 (d, J=8.9 Hz, 2H), 6.75 (d, J=8.6 Hz, 2H), 4.45 (m, 1H), 3.80 (s, 3H), 3.42 (m, 1H), 3.18 (m, 1H), 3.04 (t, J=4.9 Hz, 4H), 2.95 (m, 1H), 2.86 (m, 1H), 2.57-2.39 (m, 6H), 2.19 (s, 3H), 2.11 (dd, J=6.1, 12.9 Hz, 1H), 2.01-1.86 (m, 2H), 1.86-1.50 (m, 5H); MS (LC/MS, M+H+): 528.2.




embedded image


Example 34

Preparation of 8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 4-chlorobenzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J=8.6 Hz, 2H), 7.37 (d, J=8.5 Hz, 2H), 6.93 (d, J=8.4 Hz, 2H), 6.69 (d, J=8.6 Hz, 2H), 4.40 (m, 1H), 3.37 (m, 1H), 3.10 (m, 1H), 3.02 (t, J=4.7 Hz, 4H), 2.96 (m, 1H), 2.87 (m, 1H), 2.59-2.34 (m, 6H), 2.13 (s, 3H), 2.06 (dd, J=5.9, 12.9 Hz, 1H), 1.95-1.81 (m, 2H), 1.81-1.67 (m, 2H), 1.66-1.49 (m, 3H); MS (LC/MS, M+H+): 532.2.




embedded image


Example 35

Preparation of 8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except tetrahydro-2H-pyran-4-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J=8.3 Hz, 2H), 6.84 (d, J=8.5 Hz, 2H), 4.60 (m, 1H), 4.08 (dd, J=3.6, 11.5 Hz, 2H), 3.80 (m, 1H), 3.57-3.42 (m, 4H), 3.41-3.30 (m, 3H), 3.22-3.06 (m, 5H), 2.69-2.47 (m, 6H), 2.30 (dd, J=6.1, 12.9 Hz, 1H), 2.27 (s, 3H), 2.03-1.65 (m, 9H); MS (LC/MS, M+H+): 506.2.




embedded image


Example 36

Preparation of 8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except thiophene-2-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.53 (dd, J=1.2, 5.0 Hz, 1H), 7.46 (dd, 1.3, 3.8 Hz, 1H), 7.06 (dd, J=3.8, 5.0 Hz, 1H), 6.99 (d, J=8.4 Hz, 2H), 6.75 (d, J=8.5 Hz, 2H), 4.46 (m, 1H), 3.49 (m, 1H), 3.24 (m, 1H), 3.12-2.97 (m, 5H), 2.92 (m, 1H), 2.61-2.41 (m, 6H), 2.19 (s, 3H), 2.14 (dd, J=6.0, 13.0 Hz, 1H), 2.04-1.88 (m, 2H), 1.88-1.73 (m, 2H), 1.73-1.57 (m, 3H); MS (LC/MS, M+H+): 504.1.




embedded image


Example 37

Preparation of 4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 4-cyanobenzenesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J=8.1 Hz, 2H), 7.85 (d, 7.8 Hz, 2H), 7.08 (d, J=8.2 Hz, 2H), 6.84 (d, J=8.5 Hz, 2H), 4.57 (m, 1H), 3.53 (m, 1H), 3.24 (m, 2H), 3.20-3.07 (m, 5H), 2.68-2.48 (m, 6H), 2.28 (s, 3H), 2.21 (dd, J=6.0, 13.0 Hz, 1H), 2.08-1.97 (m, 2H), 1.97-1.65 (m, 5H); MS (LC/MS, M+H+): 523.2.




embedded image


Example 38

Preparation of 8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 6-chloroimidazo[2,1-b]thiazole-5-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J=4.5 Hz, 1H), 7.11-7.02 (m, 3H), 6.84 (d, J=8.6 Hz, 2H), 4.57 (m, 1H), 3.74 (m, 1H), 3.52 (m, 1H), 3.26 (m, 1H), 3.20-3.06 (m, 5H), 2.67-2.47 (m, 6H), 2.32-2.21 (m, 4H), 2.13-1.97 (m, 2H), 1.97-1.82 (m, 2H), 1.82-1.65 (m, 3H); MS (LC/MS, M+H+): 578.1.




embedded image


Example 39

Preparation of 8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except (methylsulfonyl)methanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J=8.3 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 4.61 (m, 1H), 4.45 (s, 2H), 3.89 (m, 1H), 3.66 (m, 1H), 3.45 (m, 1H), 3.34 (m, 1H), 3.23 (s, 3H), 3.17 (t, J=4.9 Hz, 4H), 2.73-2.52 (m, 6H), 2.37 (dd, J=6.1, 12.9 Hz, 1H), 2.28 (s, 3H), 2.15-1.85 (m, 4H), 1.85-1.65 (m, 3H); MS (LC/MS, M+H+): 514.2.




embedded image


Example 40

Preparation of 2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except cyanomethanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J=8.3 Hz, 2H), 6.86 (d, J=8.5 Hz, 2H), 4.64 (m, 1H), 4.02-3.91 (m, 3H), 3.69 (m, 1H), 3.58 (m, 1H), 3.48 (m, 1H), 3.18 (t, J=4.9 Hz, 4H), 2.73-2.54 (m, 6H), 2.34 (dd, J=6.1, 13.0 Hz, 1H), 2.29 (s, 3H), 2.13-2.02 (m, 2H), 2.02-1.89 (m, 2H), 1.89-1.71 (m, 3H); MS (LC/MS, M+H+): 461.2.




embedded image


Example 41

Preparation of 8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 1-propanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J=8.3 Hz, 2H), 6.85 (d, J=8.4 Hz, 2H), 4.61 (m, 1H), 3.73 (m, 1H), 3.48-3.35 (m, 2H), 3.34-3.25 (m, 1H), 3.16 (t, J=4.8 Hz, 4H), 2.92 (m, 2H), 2.69-2.50 (m, 6H), 2.30 (dd, J=6.0, 12.9 Hz, 1H), 2.28 (s, 3H), 2.07-1.65 (m, 9H), 1.07 (t, J=7.4 Hz, 3H); MS (LC/MS, M+H+): 464




embedded image


Example 42

Preparation of 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except trifluoromethanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 6.96 (d, J=8.3 Hz, 2H), 6.72 (d, J=8.5 Hz, 2H), 4.50 (m, 1H), 3.87 (m, 1H), 3.70-3.23 (b, 3H), 3.03 (t, J=4.9 Hz, 4H), 2.56-2.38 (m, 6H), 2.19 (dd, J=6.2, 12.9 Hz, 1H), 2.15 (s, 3H), 1.98-1.86 (m, 2H), 1.86-1.52 (m, 5H); MS (LC/MS, M+H+): 490




embedded image


Example 43

Preparation of 8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 2-propanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J=8.2 Hz, 2H), 6.72 (d, J=8.6 Hz, 2H), 4.47 (m, 1H), 3.67 (m, 1H), 3.44 (m, 1H), 3.35 (m, 1H), 3.25 (m, 1H), 3.12-2.94 (m, 5H), 2.58-2.36 (m, 6H), 2.18 (dd, J=6.0, 12.9 Hz, 1H), 2.14 (s, 3H), 1.92-1.71 (m, 4H), 1.71-1.45 (m, 3H); MS (LC/MS, M+H+):




embedded image


Example 44

Preparation of 8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except cyclopropanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J=8.3 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 4.61 (m, 1H), 3.78 (m, 1H), 3.50 (m, 1H), 3.37 (m, 1H), 3.28 (m, 1H), 3.16 (t, J=4.9 Hz, 4H), 2.70-2.50 (m, 6H), 2.36-2.25 (m, 5H), 2.10-1.98 (m, 2H), 1.98-1.65 (m, 5H), 1.23-1.11 (m, 2H), 1.07-0.95 (m, 2H); MS (LC/MS, M+H+): 462




embedded image


Example 45

Preparation of 3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 3,3,3-trifluoropropane-1-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J=8.3 Hz, 2H), 6.72 (d, J=8.5 Hz, 2H), 4.49 (m, 1H), 3.64 (m, 1H), 3.38-3.27 (m, 2H), 3.23 (m, 1H), 3.09-2.93 (m, 6H), 2.59-2.36 (m, 8H), 2.17 (dd, J=5.9, 13.0 Hz, 1H), 2.15 (s, 3H), 1.96-1.85 (m, 2H), 1.85-1.56 (m, 5H); MS (LC/MS, M+H+): 518




embedded image


Example 46

Preparation of 8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except isobutanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0% 10%): 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J=8.3 Hz, 2H), 6.85 (d, J=8.5 Hz, 2H), 4.61 (m, 1H), 3.70 (m, 1H), 3.45-3.33 (m, 2H), 3.29 (m, 1H) 3.16 (t, J=4.8 Hz, 4H), 2.79 (dd, J=2.2, 6.6 Hz, 2H), 2.70-2.49 (m, 6H), 2.37-2.20 (m, 5H), 2.07-1.97 (m, 2H), 1.97-1.67 (m, 5H), 1.12 (d, J=6.7 Hz, 6H); MS (LC/MS, M+H+): 478




embedded image


Example 47

Preparation of 8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except cyclopentanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J=8.3 Hz, 2H), 6.72 (d, J=8.6 Hz, 2H), 4.47 (m, 1H), 3.64 (m, 1H), 3.42-3.22 (m, 3H), 3.18 (m, 1H) 3.03 (t, J=4.9 Hz, 4H), 2.57-2.37 (m, 6H), 2.18 (dd, J=6.1, 12.9 Hz, 1H), 2.15 (s, 3H), 1.95-1.42 (m, 15H); MS (LC/MS, M+H+): 490




embedded image


Example 48

Preparation of 8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except cyclohexanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 6.95 (d, J=8.3 Hz, 2H), 6.72 (d, J=8.4 Hz, 2H), 4.47 (m, 1H), 3.66 (m, 1H), 3.38 (m, 1H), 3.27 (m, 1H), 3.18 (m, 1H), 3.03 (t, J=4.9 Hz, 4H), 2.77 (tt, J=3.4, 12.0 Hz, 1H), 2.59-2.36 (m, 6H), 2.19 (dd, J=6.0, 12.9 Hz, 1H), 2.15 (s, 3H), 2.06-1.94 (b, 2H), 1.91-1.72 (m, 6H), 1.72-1.49 (m, 4H), 1.37 (qd, J=3.3, 12.3 Hz, 2H), 1.23-0.99 (m, 3H); MS (LC/MS, M+H+): 504




embedded image


Example 49

Preparation of 8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except ethanesulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J=8.2 Hz, 2H), 6.85 (d, J=8.6 Hz, 2H), 4.61 (m, 1H), 3.75 (m, 1H), 3.51-3.35 (m, 2H), 3.30 (m, 1H), 3.15 (t, J=4.9 Hz, 4H), 2.98 (q, J=7.4 Hz, 2H), 2.70-2.48 (m, 6H), 2.31 (dd, J=6.2, 13.0 Hz, 1H), 2.28 (s, 3H), 2.07-1.96 (m, 2H), 1.96-1.66 (m, 5), 1.38 (t, J=7.4 Hz, 3H); MS (LC/MS, M+H+): 450




embedded image


Example 50

Preparation of 8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except pyridine-3-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 9.00 (d, J=2.3 Hz, 1H), 8.84 (dd, J=1.5, 4.8 Hz, 1H), 8.06 (dt, J=1.9, 8.0 Hz, 1H), 7.5 (dd, J=4.9, 7.9 Hz, 1H), 7.08 (d, J=8.3 Hz, 2H), 6.84 (d, J=8.5 Hz, 2H), 4.55 (m, 1H), 3.56 (m, 1H), 3.29 (m, 1H), 3.24-3.05 (m, 6H), 2.66-2.47 (m, 6H), 2.27 (s, 3H) 2.09 (dd, J=6.0, 13.0 Hz, 1H), 2.09-1.96 (m, 2H), 1.96-1.64 (m, 5H); MS (LC/MS, M+H+): 499




embedded image


Example 51

Preparation of 8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 1-methyl-1H-pyrazole-4-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 7.71 (s, 1H), 7.07 (d, J=8.4 Hz, 2H), 6.84 (d, J=8.6 Hz, 2H), 4.55 (m, 1H), 3.95 (s, 3H), 3.48 (m, 1H), 3.23 (m, 1H), 3.13 (t, J=4.9 Hz, 4H), 3.02 (m, 1H), 2.93 (m, 1H), 2.67-2.48 (m, 6H), 2.27 (s, 3H), 2.22 (dd, J=6.1, 12.9 Hz, 1H), 2.11-1.96 (m, 2H), 1.96-1.64 (m, 5H); MS (LC/MS, M+H+): 502




embedded image


Example 52

Preparation of 8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except 1H-imidazole-4-sulfonyl chloride was substituted for methanesulfonyl chloride: 1H NMR (400 MHz, MeOD) δ 7.88 (s, 1H), 7.74 (s, 1H), 7.09 (d, J=8.4 Hz, 2H), 6.90 (d, J=8.4 Hz, 2H), 4.58 (b, 1H), 3.67 (m, 1H), 3.53 (m, 1H), 3.40-3.05 (m, 10H), 2.99 (m, 1H), 2.85 (m, 1H), 2.38 (dd, J=5.7, 12.9 Hz, 1H), 2.26 (s, 3H), 2.19-1.91 (m, 3H), 1.90-1.72 (m, 3H), 1.72-1.58 (m, 1H); MS (LC/MS, M+H+): 488




embedded image


Example 53

Preparation of 8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for 8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one formate, except furan-2-sulfonyl chloride was substituted for methanesulfonyl chloride and the title compound was purified by column chromatography on a silica gel column. (MeOH/DCM, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 7.07 (d, J=8.4 Hz, 2H), 7.02 (d, J=3.4 Hz, 1H), 6.84 (d, J=8.4 Hz, 2H), 6.52 (dd, J=1.7, 3.3 Hz, 1H), 4.56 (m, 1H), 3.70 (m, 1H), 3.47 (m, 1H), 3.24 (m, 1H), 3.19-3.07 (m, 5H), 2.68-2.46 (m, 6H), 2.33-2.18 (m, 4H), 2.07-1.79 (m, 4H), 1.79-1.60 (m, 3H); MS (LC/MS, M+H+): 488




embedded image


Example 54

Preparation of 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A mixture of 8-benzyl-3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (3.25 g, 8.04 mmol, 1 eq.), Pd/C (0.65 g, 20% wt) and MeOH (54 mL) was stirred at RT under 1 atm of H2 (filled balloon) overnight. The mixture was filtered through a plug of Celite, washed with MeOH (50 mL) and concentrated in vacuo to give a crude oil. The crude oil (2.43 g) was dissolved in dichloromethane (50 mL), followed by addition of triethylamine (5.55 mL, 38.8 mmol, 5 eq.). Cooled to 0° C. before the addition of methanesulfonyl chloride (2.83 g, 13.0 mmol, 1.1 eq.). The reaction was allowed to warm to RT and stir for 30 min. At this point the reaction was diluted with D.I. water and then extracted with dichloromethane (3×50 mL), the combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude product which was further purified by column chromatography (EtOAc/DCM, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 4.61 (m, 1H), 3.75-3.65 (m, 2H), 3.60 (m, 1H), 3.37-3.18 (m, 3H), 2.75 (s, 3H), 2.21 (dd, J=6.0, 13.0 Hz, 1H), 2.02-1.91 (m, 2H), 1.91-1.62 (m, 5H), 0.83 (s, 9H), 0.00 (s, 6H).




embedded image


Example 55

Preparation of 3-(2-hydroxyethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for tert-butyl 3-(2-hydroxyethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one was substituted for tert-butyl 3-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate and the product was initially purified by column chromatography on a C18 column. (ACN/H2O, 0%˜100%, w/0.1% formic acid), followed by purification on a silica gel column (MeOH/DCM, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 4.73 (m, 1H), 3.84 (t, J=5.5 Hz, 2H), 3.68 (m, 1H), 3.41-3.32 (m, 2H), 3.29 (m, 1H), 2.83 (s, 3H), 2.33 (dd, J=6.0, 13.0 Hz, 1H), 2.10-2.00 (m, 2H), 2.10-1.71 (m, 6H).




embedded image


Example 56

Preparation of 3-(2-bromoethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A solution of 3-(2-hydroxyethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one (0.890 g, 3.21 mmol, 1 eq.) and dichloromethane (12 mL) was cooled to 0° C. before triphenylphosphine (1.26 g. 4.81 mmol, 1.5 eq.) and carbon tetrabromide (1.6 g, 4.81 mmol, 1.5 eq.) were sequentially added to the solution. The reaction solution was allowed to warm to RT and for 4 hrs. The resulting mixture was then filtered and concentrated in vacuo to give a crude mixture. This mixture was suspended in diethyl ether (50 mL) and filtered 2× using diethyl ether to wash the filter cakes. The final filtrate was loaded onto Celite in vacuo and further purified by column chromatography (EtOAc/DCM, 0%˜40%). 1H NMR (400 MHz, MeOD) δ 4.72 (m, 1H), 3.67 (m, 1H), 3.54 (dd, J=5.3, 7.6 Hz, 2H), 3.44-3.25 (m, 3H), 2.82 (s, 3H), 2.34 (dd, J=6.0, 12.9 Hz, 1H), 2.31-2.21 (m, 1H), 2.21-2.10 (m, 1H), 2.10-1.98 (m, 2H), 1.88-1.71 (m, 3H).




embedded image


Example 57

Preparation of 3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A solution of 3-(2-bromoethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one (50 mg, 0.147 mmol, 1 eq.), 1-(4-methoxyphenyl)-piperazine (59.33 mg, 0.308 mmol, 2.1 eq.) and Acetonitrile (2 mL) was microwaved for 1 hour at 120° C. The solvent was then evaporated in vacuo and the product was suspended in 15 mL of saturated NaHCO3 and extracted in dichloromethane (3×15 mL). The combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude mixture that was then dissolved in dichloromethane and purified by column chromatography (methanol/dichloromethane, 0%˜10%). 1H NMR (400 MHz, CDCl3) δ 7.4 (d, J=9.2 Hz, 2H), 6.5 (d, J=9.2 Hz, 2H), 4.61 (m, 1H), 3.77 (s, 3H), 3.67 (m, 1H), 3.36 (m, 2H), 3.29 (m, 1H), 3.1 (t, J=7.1 Hz, 4H), 2.8 (s, 3H), 2.62 (m, 4H), 2.56 (t, J=7.1 Hz, 2H), 2.29 (dd, J=7.2, 6 Hz, 1H), 2.05 (m, 2H), 1.99-1.71 (m, 6H); MS (LC/MS, M+H+): 452.




embedded image


Example 58

Preparation of 3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that 1-(4-trifluoromethylphenyl)-piprazine was substituted for 1-(4-methoxyphenyl)-piprazine. 1H NMR (400 MHz, CDCl3) δ 7.5 (d, J=8.76 Hz, 2H), 6.94 (d, J=8.7 Hz, 2H), 4.64 (m, 1H), 3.68 (m, 1H), 3.46-3.28 (m, 7H), 2.83 (s, 3H), 2.67-2.55 (m, 6H), 2.3 (dd, J=7.1, 6.1 Hz, 1H), 2.11-2.01 (m, 2H), 2.0-1.74 (m, 5H); MS (LC/MS, M+H+): 490




embedded image


Example 59

Preparation of 4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that triethylamine (0.06 mL, 0.44 mmol, 3 eq.) was added in the microwave mixture and 1-(4-cyanophenyl)-piprazine was substituted for 1-(4-methoxyphenyl)-piprazine: 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J=8.4 Hz, 2H), 6.85 (d, J=8.4 Hz, 2H), 4.61 (m, 1H), 3.65 (m, 1H), 3.43-3.26 (m, 7H), 2.81 (s, 3H), 2.64-2.52 (m, 6H), 2.28 (dd, J=6.8, 5.9 Hz, 1H), 2.02 (m, 2H), 1.96-1.74 (m, 5H); MS (LC/MS, M+H+): 447




embedded image


Example 60

Preparation of 8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that it was microwaved for 1.5 hours at 120° C. and 1-(4-nitrophenyl)-piprazine was substituted for 1-(4-methoxyphenyl)-piprazine. 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J=9.3 Hz, 2H), 6.82 (d, J=9.3 Hz, 2H), 4.62 (m, 1H), 3.66 (m, 1H), 3.46-3.36 (m, 4H), 3.36-3.28 (m, 3H), 2.8 (s, 3H), 2.67-2.5 (b, 6H), 2.28 (dd, J=6.8, 5.9 Hz, 1H), 2.08-1.98 (m, 2H), 1.95-1.72 (m, 5H); MS (LC/MS, M+H+): 467




embedded image


Example 61

Preparation of 3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that it was microwaved for 2 hours at 120° C. and 1-(4-chlorophenyl)-piprazine was substituted for 1-(4-methoxyphenyl)-piprazine. 1H NMR (400 MHz, CDCl3) δ 7.19 (d, J=8.9 Hz, 2H), 6.82 (d, J=8.9 Hz, 2H), 4.6 (m, 1H), 3.65 (m, 1H), 3.42-3.26 (m, 3H), 3.15 (t, J=4.9 Hz, 4H), 2.8 (s, 3H), 2.66-2.52 (m, 6H), 2.27 (dd, J=6.8, 5.9 Hz, 1H), 2.07-1.98 (m, 2H), 1.97-1.7 (m, 5H); MS (LC/MS, M+H+): 456




embedded image


Example 62

Preparation of 3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that and 1-(4-iodophenyl)-piprazine was substituted for 1-(4-methoxyphenyl)-piprazine. 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J=8.8 Hz, 2H), 6.65 (d, J=8.8 Hz, 2H), 4.58 (m, 1H), 3.64 (m, 1H), 3.4-3.24 (m, 3H), 3.15 (t, J=4.8 Hz, 4H), 2.79 (s, 3H), 2.62-2.5 (m, 6H), 2.26 (dd, J=6.8, 6 Hz, 1H), 2.0-1.96 (m, 2H), 1.95-1.69 (m, 5H); MS (LC/MS, M+H+): 548




embedded image


Example 63

Preparation of 3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The tittle compound was prepared and purified according to the procedure for 3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one except that and 1-(4-fluorophenyl)-piprazine was substituted for 1-(4-methoxyphenyl)-piprazine. 1H NMR (400 MHz, CDCl3) δ 6.94 (m, 2H), 6.85 (m, 2H), 4.59 (m, 1H), 3.65 (m, 1H), 3.4-3.24 (m, 3H), 3.1 (t, J=4.8 Hz, 4H), 2.8 (s, 3H), 2.65-2.5 (m, 6H), 2.27 (dd, J=6.7, 5.9 Hz, 1H), 2.0 (m, 2H), 1.97-1.69 (m, 5H); MS (LC/MS, M+H+): 440.




embedded image


Preparation of 3-morpholino-4-nitrobenzonitrile: A solution of 3-fluoro-4-nitrobenzonitrile (0.6 g, 3.61 mmol, 1 eq.) and morpholine (0.629 g, 7.22 mmol, 2 eq.) in dimethyl sulfoxide (6.57 mL) was heated at 60° C. for 4 hours. The reaction solution was diluted with water 20 mL and extracted with ethyl acetate (3×20 mL). The combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude product which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J=8.3 Hz, 1H), 7.40 (d, J=1.5 Hz, 1H), 7.33 (dd, J=1.6, 8.3 Hz, 1H), 3.86 (m, 4H), 3.11 (m, 4H); MS (LC/MS, M+H+): 234




embedded image


Preparation of 4-(5-methyl-2-nitrophenyl)morpholine: The title compound was prepared according to the procedure for 3-morpholino-4-nitrobenzonitrile, except 2-fluoro-4-methyl-1-nitrobenzene was substituted for 3-fluoro-4-nitrobenzonitrile. 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J=8.2 Hz, 1H), 6.93 (b, 1H), 6.88 (d, J=8.3 Hz, 1H), 3.86 (m, 4H), 3.06 (m, 4H), 2.40 (s, 3H); MS (LC/MS, M+H+): 223




embedded image


Preparation of 3-morpholino-4-nitrophenol: The title compound was prepared according to the procedure for 3-morpholino-4-nitrobenzonitrile, except 3-fluoro-4-nitrophenol was substituted for 3-fluoro-4-nitrobenzonitrile. 1H NMR (400 MHz, MeOD) δ 7.90 (d, J=9.0 Hz, 1H), 6.56 (d, J=2.4 Hz, 1H), 6.49 (dd, J=2.5, 9.0 Hz, 1H), 3.83 (m, 4H), 3.02 (m, 4H); MS (LC/MS, M+H+): 225




embedded image


Preparation of 4-(2-nitro-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine: A solution of 3-morpholino-4-nitrophenol (1.34 g, 5.98 mmol, 1 eq.), 2-(trimethylsilyl)ethoxymethyl chloride (1.05 g, 6.28 mmol, 1.05 eq.) and N,N-diisopropylethylamine (2.31 g, 17.9 mmol, 3 eq.) in dichloromethane (30.0 mL) was stirred at 25° C. for 16 hours. The reaction solution was diluted with 40 mL of water and extracted with dichloromethane (3×40 mL). The combined organic phase was dried over Na2SO4 and concentrated in vacuo to give a crude product which was used in the next step without further purification. 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J=9.7 Hz, 1H), 6.68 (m, 2H), 5.24 (s, 2H), 3.85 (m, 4H), 3.74 (m, 2H), 3.04 (m, 4H), 0.94 (m, 2H), 0.00 (s, 9H); MS (LC/MS, M+H+): 355




embedded image


Preparation of 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)phenyl)morpholine: A mixture of 4-(5-methyl-2-nitrophenyl)morpholine (1.58 g, 7.11 mmol, 1 eq.), Pd on carbon (316 mg, 20% wt) and methanol (72 mL) was stirred at 25° C. under 1 atm of H2 (filled balloon) for 48 hours. The mixture was filtered through a plug of Celite, washed with methanol (50 mL) and concentrated in vacuo to give the crude intermediate, 4-methyl-2-morpholinoaniline.


(((4-nitrophenyl)sulfonyl)azanediyl)bis(ethane-2,1-diyl)bis(4-nitrobenzenesulfonate) (1.0 g, 1.5 mmol, 1 eq.), 4-methyl-2-morpholinoaniline (0.346 g, 1.8 mmol, 1.2 eq.), N,N-diisopropylethylamine (1.55 g, 12.0 mmol, 4 eq.) and acetonitrile (4.7 mL) were mixed in a microwave reaction vial (10 mL) fitted with a no-invasive vial cap. The reaction vials containing the mixture were reacted in the microwave for 1 h at 175° C. After 1 h, the solvent was removed under reduced pressure. The residue was dissolved in dichloromethane and washed with HCl (10%, 3×30 mL) and saturated NaHCO3 (40 mL). The organic phase was dried over Na2SO4 and concentrated in vacuo to afford the crude product. The title compound was purified by column chromatography on a silica gel column. (ethyl acetate/dichlorormethane, 0%˜10%): 1H NMR (400 MHz, CDCl3) δ 8.44 (d, J=8.9 Hz, 2H), 8.02 (d, J=9.0 Hz, 2H), 6.82 (m, 2H), 6.74 (b, 1H), 3.71 (t, J=4.2 Hz, 4H), 3.24 (b, 8H), 3.05 (m, 4H), 2.29 (s, 3H); MS (LC/MS, M+H+): 447




embedded image


Preparation of 3-morpholino-4-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)benzonitrile: The title compound was prepared according to the procedure for 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)phenyl)morpholine, except 3-morpholino-4-nitrobenzonitrile was substituted for 4-(5-methyl-2-nitrophenyl)morpholine and 4-amino-3-morpholinobenzonitrile for 4-methyl-2-morpholinoaniline. 1H NMR (400 MHz, CDCl3) δ 8.43 (d, J=8.8 Hz, 2H), 8.01 (d, J=8.8 Hz, 2H), 7.30 (dd, J=1.8, 8.2 Hz, 1H), 7.14 (d, J=1.8 Hz, 1H), 6.90 (d, J=8.3 Hz, 1H), 3.73 (t, J=4.5 Hz, 4H), 3.36 (m, 4H), 3.26 (m, 4H), 3.02 (t, J=4.3 Hz, 4H); MS (LC/MS, M+H+): 458




embedded image


Preparation of 4-(2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine: The title compound was prepared according to the procedure for 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)phenyl)morpholine, except 4-(2-nitro-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine was substituted for 4-(5-methyl-2-nitrophenyl)morpholine and 2-morpholino-4-((2-(trimethylsilyl)ethoxy)methoxy)aniline for 4-methyl-2-morpholinoaniline. 1H NMR (400 MHz, CDCl3) δ 8.41 (d, J=8.8 Hz, 2H), 8.01 (d, J=8.7 Hz, 2H), 6.80 (d, J=8.7 Hz, 1H), 6.67 (dd, J=2.7, 8.7 Hz, 1H), 6.60 (d, J=2.6 Hz, 1H), 5.14 (s, 2H), 3.74 (m, 2H). 3.68 (t, J=4.4 Hz, 4H), 3.23 (b, 4H), 3.16 (b, 4H), 3.03 (b, 4H), 0.95 (m, 2H), 0.00 (s, 9H); MS (LC/MS, M+H+): 579




embedded image


Preparation of 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine: Potassium carbonate (1.5 g, 10.8 mmol 12 eq.) was added to a mixture of acetonitrile and dimethylsulfoxide (CH3CN/DMSO 49:1, 2.4 mL) and heated to 50° C. Thiophenol (0.988 g, 8.96 mmol, 10 eq.) was added dropwise via syringe to the mixture with stirring. After 30 minutes a solution of 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)phenyl)morpholine (0.410 g, 0.896 mmol, 1 eq.) in acetonitrile and dimethyl sulfoxide (acetonitrile/dimethyl sulfoxide 49:1, 4.5 mL) was added dropwise. The reaction mixture was stirred for 3 hours, quenched with excess NaOH solution (40%) and concentrated under reduced pressure. The residue was extracted with dichloromethane (5×30 mL) and the organic phase was dried over MgSO4, and concentrated in vacuo to give a crude oil. The oil was purified by reverse phase chromatography (acetonitrile in H2O, gradient from 1%˜100% with 0.1% formic acid) to afford the formic acid salt of the desired piperazine. The salt was dissolved in dichloromethane, washed with saturated NaHCO3 solution, and the organic phase concentrated in vacuo to provide the product. 1H NMR (400 MHz, CDCl3) δ 6.87-6.76 (m, 2H), 6.71 (s, 1H), 3.84 (t, J=4.5 Hz, 4H), 3.18 (b, 4H), 3.07 (b, 4H), 2.98 (b, 4H), 2.29 (s, 3H); MS (LC/MS, M+H+): 262




embedded image


Preparation of 3-morpholino-4-(piperazin-1-yl)benzonitrile: The title compound was prepared according to the procedure for 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine, except 3-morpholino-4-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)benzonitrile was substituted for 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)phenyl)morpholine. 1H NMR (400 MHz, CDCl3) δ 7.24 (dd, J=1.8, 8.2 Hz, 1H), 7.08 (d, J=1.8 Hz, 1H), 6.88 (d, J=8.4 Hz, 1H), 3.81 (t, J=4.6 Hz, 4H), 3.21 (b, 4H), 3.11 (b, 4H), 3.00 (b, 4H); MS (LC/MS, M+H+): 273




embedded image


Preparation of 4-(2-(piperazin-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine: The title compound was prepared according to the procedure for 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine, except 4-(2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine was substituted for 4-(5-methyl-2-(4-((4-nitrophenyl)sulfonyl)piperazin-1-yl)phenyl)morpholine. 1H NMR (400 MHz, CDCl3) δ 6.83 (d, J=8.6 Hz, 1H), 6.67 (dd, J=2.7, 8.5 Hz, 1H), 6.59 (d, J=2.8 Hz, 1H), 3.82 (t, J=4.7 Hz, 4H), 3.74 (m, 2H), 3.18 (b, 4H), 3.10-2.92 (b, 8H), 0.95 (m, 2H), 0.00 (s, 9H); MS (LC/MS, M+H+): 394




embedded image


Preparation of tert-butyl 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: A solution of tert-butyl 3-(2-bromoethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.05 g, 0.138 mmol, 1 eq.), 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine (0.044 g, 0.166 mmol, 1.2 eq.), and triethylamine (0.070 g, 0.69 mmol, 5 eq.) in acetonitrile (2 mL) was microwaved at 120° C. for 1 hour. The reaction mixture was filtered and the filtrate was concentrated in vacuo to give a crude product. The title compound was purified by column chromatography on a silica gel column. (methanol/dichloromethane, 0%˜10%)1H NMR (400 MHz, CDCl3) δ 6.87-6.76 (m, 2H), 6.71 (s, 1H), 4.59 (m, 1H), 3.98 (m, 1H), 3.90-3.73 (m, 5H), 3.31-2.94 (m, 10H), 2.70-2.47 (m, 6H), 2.39 (dd, J=6.2, 12.8 Hz, 1H), 2.28 (s, 3H), 2.03-1.70 (m, 5H), 1.60 (m, 1H), 1.55-1.38 (m, 10H); MS (LC/MS, M+H+): 543




embedded image


Preparation of tert-butyl 3-(2-(4-(4-cyano-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 3-morpholino-4-(piperazin-1-yl)benzonitrile was substituted for 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine. 1H NMR (400 MHz, CDCl3) δ 7.26 (dd, J=1.8, 8.3 Hz, 1H), 7.09 (d, J=1.6 Hz, 1H), 6.89 (d, J=8.3 Hz, 1H), 4.57 (m, 1H), 3.96 (m, 1H), 3.89-3.73 (m, 5H), 3.40-2.98 (m, 10H), 2.72-2.45 (m, 6H), 2.37 (dd, J=6.1, 12.8 Hz, 1H), 2.03-1.67 (m, 5H), 1.58 (m, 1H), 1.54-1.38 (m, 10H); MS (LC/MS, M+H+): 554




embedded image


Preparation of 8-(methylsulfonyl)-3-(2-(4-(2-morpholino-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one: The title compound was prepared according to the procedure for tert-butyl 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate, except 4-(2-(piperazin-1-yl)-5-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)morpholine was substituted for 4-(5-methyl-2-(piperazin-1-yl)phenyl)morpholine and 3-(2-bromoethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one for tert-butyl 3-(2-bromoethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate. 1H NMR (400 MHz, CDCl3) δ 6.83 (d, J=8.6 Hz, 1H), 6.66 (dd, J=2.7, 8.6 Hz, 1H), 6.59 (d, J=2.7 Hz, 1H), 5.14 (s, 2H), 4.61 (m, 1H), 3.81 (t, J=4.4 Hz, 4H), 3.74 (m, 2H), 3.66 (m, 1H), 3.35 (m, 2H), 3.26 (m, 1H), 3.21-2.94 (b, 8H), 2.80 (s, 3H), 2.70-2.41 (m, 6H), 2.30 (dd, J=5.6, 12.9 Hz, 1H), 2.08-1.67 (m, 7H), 0.95 (m, 2H), 0.00 (s, 9H); MS (LC/MS, M+H+): 653




embedded image


Preparation of 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: A solution of tert-butyl 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate (0.077 g, 0.142 mmol, 1 eq.) in trifluoroacetic acid:dichlroromethane (1:3, 2 mL) was allowed to stir at 25° C. for 30 minutes. The reaction solution was diluted with methanol (2 mL) and concentrated in vacuo to give a crude intermediate as a trifluoroacetic acid salt. The resulting material was dissolved in dicloromethane (10 mL) and washed with sat. NaHCO3 (aq.) solution (10 mL). The aqueous layer was backwashed with dicloromethane (2×10 mL) and the combined organic layers were dried over Na2SO4 and concentrated in vacuo to give a crude intermediate as a free base.


The resulting free base (0.052 g, 0.114 mmol, 1 eq.) was dissolved in dicloromethane (2 mL) and cooled to 0° C., and trimethylamine (0.058 g, 0.57 mmol, 5 eq.) and methanesulfonyl chloride (0.026, 0.228 mmol, 2 eq.) were added. The reaction solution was allowed to stir at 25° C. for 30 minutes and then concentrated in vacuo to give a crude solid. The title compound was purified by column chromatography on a silica gel column. (methanol/dichloromethane, 0%˜10%)1H NMR (400 MHz, CDCl3) δ 6.79-6.68 (m, 2H), 6.64 (s, 1H), 4.54 (m, 1H), 3.75 (t, J=4.4 Hz, 4H), 3.59 (m, 1H), 3.37-2.88 (b, 11H), 2.74 (s, 3H), 2.69-2.33 (b, 6H), 2.27-2.16 (m, 4H), 2.02-1.92 (m, 2H), 1.92-1.62 (m, 5H); MS (LC/MS, M+H+): 521




embedded image


Preparation of 4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)-3-morpholinobenzonitrile: The title compound was prepared according to the procedure for 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one, except tert-butyl 3-(2-(4-(4-cyano-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate was substituted for 3-(2-(4-(4-methyl-2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate. 1H NMR (400 MHz, CDCl3) δ 7.29 (dd, J=1.8, 8.3 Hz, 1H), 7.12 (d, J=1.7 Hz, 1H), 6.91 (d, J=8.3 Hz, 1H), 4.63 (m, 1H), 3.85 (t, J=4.3 Hz, 4H), 3.67 (m, 1H), 3.55-2.96 (b, 11H), 2.83 (s, 3H), 2.75-2.40 (b, 6H), 2.30 (dd, J=6.0, 12.9 Hz, 1H), 2.12-1.99 (m, 2H), 1.99-1.71 (m, 5H); MS (LC/MS, M+H+): 532




embedded image


Preparation of 3-(2-(4-(4-hydroxy-2-morpholinophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one: To a small vial, 8-(methylsulfonyl)-3-(2-(4-(2-morpholino-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one (0.190 g, 0.291 mmol, 1 eq.) was added and dissolved in hexamethylphosphoramide (1.5 mL). Tetra-n-butylanmoniumn fluoride trihydrate (0.230 g, 0.873 mmol, 3 eq.) was added, followed by 300 mg of 4 Å molecular sieves. The reaction mixture was stirred at 60° C. for 48 hours before being filtered and concentrated in vacuo to give a crude oil. The title compound was purified by column chromatography on a silica gel column. (methanol/dichloromethane, 0%˜10%) 1H NMR (400 MHz, CDCl3) δ 6.70 (d, J=9.2 Hz, 1H), 6.40-6.32 (m, 2H), 4.53 (m, 1H), 3.75 (t, J=4.3 Hz, 4H), 3.58 (m, 1H), 3.38-2.84 (b, 11H), 2.74 (s, 3H), 2.70-2.33 (b, 6H), 2.21 (dd, J=5.9, 12.8 Hz, 1H), 2.01-1.80 (m, 4H), 1.79-1.60 (m, 3H); MS (LC/MS, M+H+): 523.


Formulations


The present invention also relates to compositions or formulations which comprise the 5-hydroxytryptamine receptor 7 activity modulators according to the present invention. In general, the compositions of the present invention comprise an effective amount of one or more compounds of the disclosure and salts thereof according to the present invention which are effective for providing modulation of 5-hydroxytryptamine receptor 7 activity; and one or more excipients.


For the purposes of the present invention the term “excipient” and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”


The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability.


The present teachings also provide pharmaceutical compositions that include at least one compound described herein and one or more pharmaceutically acceptable carriers, excipients, or diluents. Examples of such carriers are well known to those skilled in the art and can be prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, Pa. (1985), the entire disclosure of which is incorporated by reference herein for all purposes. As used herein, “pharmaceutically acceptable” refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient. Accordingly, pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and are biologically acceptable. Supplementary active ingredients can also be incorporated into the pharmaceutical compositions.


Compounds of the present teachings can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents, or encapsulating materials. The compounds can be formulated in conventional manner, for example, in a manner similar to that used for known 5-hydroxytryptamine receptor 7 activity modulators. Oral formulations containing a compound disclosed herein can comprise any conventionally used oral form, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. In powders, the carrier can be a finely divided solid, which is an admixture with a finely divided compound. In tablets, a compound disclosed herein can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets can contain up to 99% of the compound.


Capsules can contain mixtures of one or more compound(s) disclosed herein with inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.


Useful tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidine, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, and ion exchange resins. Surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations herein can utilize standard delay or time-release formulations to alter the absorption of the compound(s). The oral formulation can also consist of administering a compound disclosed herein in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed.


Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups, elixirs, and for inhaled delivery. A compound of the present teachings can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a mixture of both, or a pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators. Examples of liquid carriers for oral and parenteral administration include, but are not limited to, water (particularly containing additives as described herein, e.g., cellulose derivatives such as a sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration, the carrier can be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants.


Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration can be in either liquid or solid form.


Preferably the pharmaceutical composition is in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the pharmaceutical composition can be sub-divided in unit dose(s) containing appropriate quantities of the compound. The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. Alternatively, the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. Such unit dosage form can contain from about 1 mg/kg of compound to about 500 mg/kg of compound, and can be given in a single dose or in two or more doses. Such doses can be administered in any manner useful in directing the compound(s) to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.


When administered for the treatment or inhibition of a particular disease state or disorder, it is understood that an effective dosage can vary depending upon the particular compound utilized, the mode of administration, and severity of the condition being treated, as well as the various physical factors related to the individual being treated. In therapeutic applications, a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications. The dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician. The variables involved include the specific condition and its state as well as the size, age and response pattern of the patient.


In some cases it may be desirable to administer a compound directly to the airways of the patient, using devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multidose dry-powder inhalers, pumps, squeeze-actuated nebulized spray dispensers, aerosol dispensers, and aerosol nebulizers. For administration by intranasal or intrabronchial inhalation, the compounds of the present teachings can be formulated into a liquid composition, a solid composition, or an aerosol composition. The liquid composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser. The solvents can be, for example, isotonic saline or bacteriostatic water. The solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation. The aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device. The propellants can be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other propellants that are physiologically and environmentally acceptable.]


Compounds described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or a pharmaceutically acceptable salts, hydrates, or esters thereof can be prepared in water suitably mixed with a surfactant such as hydroxyl-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms.


The pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form can sterile and its viscosity permits it to flow through a syringe. The form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.


Compounds described herein can be administered transdermally, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administration can be carried out using the compounds of the present teachings including pharmaceutically acceptable salts, hydrates, or esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).


Transdermal administration can be accomplished through the use of a transdermal patch containing a compound, such as a compound disclosed herein, and a carrier that can be inert to the compound, can be non-toxic to the skin, and can allow delivery of the compound for systemic absorption into the blood stream via the skin. The carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the compound can also be suitable. A variety of occlusive devices can be used to release the compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound. Other occlusive devices are known in the literature.


Compounds described herein can be administered rectally or vaginally in the form of a conventional suppository. Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water-soluble suppository bases, such as polyethylene glycols of various molecular weights, can also be used.


Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells either in vitro or in vivo. Lipid formulations and nanocapsules can be prepared by methods known in the art.


To increase the effectiveness of compounds of the present teachings, it can be desirable to combine a compound with other agents effective in the treatment of the target disease. For example, other active compounds (i.e., other active ingredients or agents) effective in treating the target disease can be administered with compounds of the present teachings. The other agents can be administered at the same time or at different times than the compounds disclosed herein.


Compounds of the present teachings can be useful for the treatment or inhibition of a pathological condition or disorder in a mammal, for example, a human subject. The present teachings accordingly provide methods of treating or inhibiting a pathological condition or disorder by providing to a mammal a compound of the present teachings including its pharmaceutically acceptable salt) or a pharmaceutical composition that includes one or more compounds of the present teachings in combination or association with pharmaceutically acceptable carriers. Compounds of the present teachings can be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment or inhibition of the pathological condition or disorder.


Non-limiting examples of compositions according to the present invention include from about 0.001 mg to about 1000 mg of one or more compounds of the disclosure according to the present invention and one or more excipients; from about 0.01 mg to about 100 mg of one or more compounds of the disclosure according to the present invention and one or more excipients; and from about 0.1 mg to about 10 mg of one or more compounds of the disclosure according to the present invention; and one or more excipients.


Procedures


The following procedures can be utilized in evaluating and selecting compounds as 5-hydroxytryptamine receptor 7 activity modulators.


Radiolabel Binding Studies for Serotonin 5HT7 Receptors, Method 1:


A solution of the compound of the disclosure to be tested is prepared as a 1-mg/ml stock in Assay Buffer or DMSO according to its solubility. A similar stock of the reference compound chlorpromazine is also prepared as a positive control. Eleven dilutions (5× assay concentration) of the compound of the disclosure and chlorpromazine are prepared in the Assay Buffer by serial dilution to yield final corresponding assay concentrations ranging from 10 pM to 10 μM.


A stock concentration of 5 nM [3H]LSD (lysergic acid diethyl amide) is prepared in 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, pH 7.4 (Assay Buffer). Aliquots (50 μl) of radioligand are dispensed into the wells of a 96-well plate containing 100 μl of Assay Buffer. Duplicate 50-μl aliquots of the compound of the disclosure test and chlorpromazine positive control reference compound serial dilutions are added.


Membrane fractions of cells expressing recombinant 5HT7 receptors (50 μL) are dispensed into each well. The membranes are prepared from stably transfected cell lines expressing 5HT7 receptors cultured on 10-cm plates by harvesting PBS-rinsed monolayers, resuspending and lysing in chilled, hypotonic 50 mM Tris-HCl, pH 7.4, centrifuging at 20,000×g, decanting the supernatant and storing at −80° C.; the membrane preparations are resuspended in 3 ml of chilled Assay Buffer and homogenized by several passages through a 26 gauge needle before using in the assay.


The 250-μl reactions are incubated at room temperature for 1.5 hours, then harvested by rapid filtration onto 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester. Four rapid 500-μl washes are performed with chilled Assay Buffer to reduce non-specific binding. The filter mats are dried, then scintillant is added to the filters and the radioactivity retained on the filters is counted in a Microbeta scintillation counter.


Raw data (dpm) representing total radioligand binding (i.e., specific+non-specific binding) are plotted as a function of the logarithm of the molar concentration of the competitor (i.e., test or reference compound). Non-linear regression of the normalized (i.e., percent radioligand binding compared to that observed in the absence of test or reference compound) raw data is performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model describing ligand competition binding to radioligand-labeled sites:






y=bottom+[(top−bottom)/(1+10×−log IC50)]


where bottom equals the residual radioligand binding measured in the presence of 10 μM reference compound (i.e., non-specific binding) and top equals the total radioligand binding observed in the absence of competitor. The log IC50 (i.e., the log of the ligand concentration that reduces radioligand binding by 50%) is thus estimated from the data and used to obtain the Ki by applying the Cheng-Prusoff approximation:






Ki=IC
50/(1+[ligand]/KD)


where [ligand] equals the assay radioligand concentration and KD equals the affinity constant of the radioligand for the target receptor.


Compounds of the disclosure are also screened at a single concentration of 10 μM using the same method described for the Radiolabel Binding Studies for Serotonin 5HT7 receptors to determine the percent inhibition of [3H]LSD binding.


Radiolabel Binding Studies for Serotonin 5-HT7 Receptors, Method 2:


A solution of the compound of the disclosure to be tested is prepared as a 1-mg/ml stock in Assay Buffer or DMSO according to its solubility. A similar stock of the reference compound chlorpromazine is also prepared as a positive control. Eleven dilutions (5× assay concentration) of the compound of the disclosure and chlorpromazine are prepared in the Assay Buffer by serial dilution to yield final corresponding assay concentrations ranging from 10 pM to 10 μM.


A stock concentration of 5 nM [3H]-5-Hydroxytryptamine ([3H]-5HT) is prepared in 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EDTA, pH 7.4 (Assay Buffer). Aliquots (50 μl) of radioligand are dispensed into the wells of a 96-well plate containing 100 al of Assay Buffer. Duplicate 50-μl aliquots of the compound of the disclosure test and chlorpromazine positive control reference compound serial dilutions are added.


Membrane fractions of cells expressing recombinant 5HT7 receptors (50 μL) are dispensed into each well. The membranes are prepared from stably transfected cell lines expressing 5HT7 receptors cultured on 10-cm plates by harvesting PBS-rinsed monolayers, resuspending and lysing in chilled, hypotonic 50 mM Tris-HCl, pH 7.4, centrifuging at 20,000×g, decanting the supernatant and storing at −80° C.; the membrane preparations are resuspended in 3 ml of chilled Assay Buffer and homogenized by several passages through a 26 gauge needle before using in the assay.


The 250-μl reactions are incubated at room temperature for 1.5 hours, then harvested by rapid filtration onto 0.3% polyethyleneimine-treated, 96-well filter mats using a 96-well Filtermate harvester. Four rapid 500-μl washes are performed with chilled Assay Buffer to reduce non-specific binding. The filter mats are dried, then scintillant is added to the filters and the radioactivity retained on the filters is counted in a Microbeta scintillation counter.


Raw data (dpm) representing total radioligand binding (i.e., specific+non-specific binding) are plotted as a function of the logarithm of the molar concentration of the competitor (i.e., test or reference compound). Non-linear regression of the normalized (i.e., percent radioligand binding compared to that observed in the absence of test or reference compound) raw data is performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model describing ligand competition binding to radioligand-labeled sites:






y=bottom+[(top−bottom)/(1+10×−log IC50)]


where bottom equals the residual radioligand binding measured in the presence of 10 μM reference compound (i.e., non-specific binding) and top equals the total radioligand binding observed in the absence of competitor. The log IC50 (i.e., the log of the ligand concentration that reduces radioligand binding by 50%) is thus estimated from the data and used to obtain the Ki by applying the Cheng-Prusoff approximation:






Ki=IC
50/(1+[ligand]/KD)


where [ligand] equals the assay radioligand concentration and KD equals the affinity constant of the radioligand for the target receptor.


Compounds of the disclosure are also screened at a single concentration of 10 μM using the same method described for the Radiolabel Binding Studies for Serotonin 5HT7 receptors to determine the percent inhibition of [3H]-5HT binding.


Results for representative compounds according to the present invention are listed in Table 11.









TABLE 11







Radiolabel Binding Studies for Serotonin 5HT7 receptors results for exemplary compounds


of the disclosure












5-HT7%
5-HT7




inhib @
IC50


Entry
Structure
10 uM
(nm)













1


embedded image


96.5
18





2


embedded image


88.8
149





3


embedded image


90
81





4


embedded image


88.5
122





5


embedded image


91.6
102





6


embedded image


90.5
93





7


embedded image


N.D.
34





8


embedded image


100
46





9


embedded image


N.D.
303





10


embedded image


N.D.
64





11


embedded image


N.D.
77





12


embedded image


N.D.
108





13


embedded image


N.D.
96





14


embedded image


N.D.
47





15


embedded image


N.D.
131





16


embedded image


N.D.
56





17


embedded image


N.D.
116





18


embedded image


N.D.
86





19


embedded image


N.D.
461





20


embedded image


N.D.
67





21


embedded image


N.D.
75





22


embedded image


N.D.
202





N.D. = not determined






Functional Serotonin 5HT7 Assay, Method 1:


Cell lines stably expressing human 5HT7 receptors are seeded in 96-well, poly-L-lysine-coated plates 48 hours prior to the assay (40,000 cells per well) in Dulbecco's Modified Eagle Medium (DMEM) containing 5% dialyzed serum. Twenty hours prior to the assay, the medium is changed to serum-free DMEM. On the day of the assay, the DMEM is washed and replaced with 30 μl of assay buffer (1× Krebs-Ringer bicarbonate glucose buffer, 0.75 mM IBMX, pH 7.4). A 10-min pre-incubation is performed in a 37-degree centigrade, humidified incubator. Then, the cells are stimulated by addition of 30 μl of 2× dilutions of compounds of the disclosure or chlorpromazine (final concentrations ranging from 0.1 nM to 10 μM, each concentration assayed in triplicate). A positive control (100 μM forskolin) is also included. Accumulation of cAMP is allowed to continue for 15 min, after which the buffer is removed and the cells are lysed with Cell Lysis Buffer (CatchPoint cAMP Assay Kit, Molecular Devices). Next, the lysates are transferred to 96-well, glass-bottom plates coated with goat anti-rabbit IgG and adsorbed with rabbit anti-cAMP (Molecular Devices). Following a 5 minute incubation, horseradish peroxidase-cAMP conjugate is added (Molecular Devices) and a 2-hour incubation is performed at room temperature. Then, after three washes with Wash Buffer (Molecular Devices), Stoplight Red substrate (Molecular Devices), reconstituted in Substrate Buffer (Molecular Devices) containing freshly-added 1 mM H2O2, is added and, after a 15-min incubation at room temperature, fluorescence is measured (excitation 510-545 nm, emission 565-625 nm). For each assay, a cAMP calibration curve is generated and controls without lysate and without antibody are included.


For agonist tests, raw data (maximum fluorescence, fluorescence units) for each concentration of the compounds of the disclosure or chlorpromazine are normalized to the basal (vehicle-stimulated) fluorescence (reported as fold increase over basal) and plotted as a function of the logarithm of the molar concentration of the drug (i.e., test or reference compound). Non-linear regression of the normalized data is performed in Prism 4.0 (GraphPad Software) using the built-in three parameter logistic model (i.e., sigmoidal concentration-response) describing agonist-stimulated activation of one receptor population:






y=bottom+[(top−bottom)/(1+10×−log EC50)]


where bottom equals the best-fit basal fluorescence and top equals the best-fit maximal fluorescence stimulated by the compound of the disclosure or chlorpromazine. The log EC50 (i.e., the log of the drug concentration that increases fluorescence by 50% of the maximum fluorescence observed for the compound of the disclosure or chlorpromazine is thus estimated from the data, and the EC50 (agonist potency) is obtained. To obtain an estimate of the relative efficacy of the test compound (Rel. Emax), its best-fit top is compared to and expressed as a ratio of that for the chlorpromazine (Rel. Emax of the reference agonist is 1.00).


To ascertain whether compounds of the disclosure are antagonists, a double-addition paradigm is employed. First, 30 μl of a compound of the disclosure (20 μM) is added (10 μM final concentration) and a 15 minute incubation is performed. Then, 30 μl of chlorpromazine (3×; EC90) is added (final concentration of agonist is EC30) and cAMP accumulation is allowed to proceed for 15 minutes. The samples are then processed for cAMP measurements as detailed above. Measurements of chlorpromazine-induced cAMP accumulation are compared to the signals elicited by the chlorpromazine following addition of vehicle instead of test compound and expressed as a ratio. ‘Hits’ (compounds that antagonize chlorpromazine-stimulated increases in baseline-normalized fluorescence by at least 50%) are then characterized by a modified Schild analysis.


For modified Schild analysis, a family of chlorpromazine concentration-response isotherms is generated in the absence and presence of graded concentrations of test compound (added 15 min prior to reference agonist). Theoretically, compounds that are competitive antagonists cause a dextral shift of agonist concentration-response isotherms without reducing the maximum response to agonist (i.e., surmountable antagonism). However, on occasion, factors such as non-competitive antagonism, hemiequilibria, and/or receptor reserve cause apparent insurmountable antagonism. To account for such deviations, we apply the modified Lew-Angus method to ascertain antagonist potency (Christopoulos et al., 1999). Briefly, equieffective concentrations of agonist (concentrations of agonist that elicit a response equal to the EC25% of the agonist control curve) are plotted as a function of the compound of the disclosure concentration present in the wells in which they were measured. Non-linear regression of the baseline-normalized data is performed in Prism 4.0 using the following equation:






pEC25%=−log([B]+10−pK)−log c


where EC25% equals the concentration of agonist that elicits a response equal to 25% of the maximum agonist control curve response and [B] equals the antagonist concentration; K, c, and s are fit parameters. The parameter s is equal to the Schild slope factor. If s is not significantly different from unity, pK equals pKB; otherwise, pA2 is calculated (pA2=pK/s). The parameter c equals the ratio EC25%[B].


Functional Efficacy Assay for 5-HT7 Receptors Method 2:


Functional efficacy of the compounds of the disclosure on 5-HT7 serotonin receptors were measured in a cell based cAMP enzyme fragment complementation assay using the HitHunter cAMP assay (DiscoveRx). Cells stably expressing human 5HT7 receptors were plated in 96-well plates at 4000 cells/well, 16-20 hours prior to assay in growth media (Ultraculture medium, 2 mM GlutaMax and G418 1 mg/mL. Serial dilutions of the agonist, 5-Carboxamidotryptamine (5-CT), were prepared in a final concentration range of 10 μM to 10 nM. Compounds of the disclosure were prepared in 3-fold serial dilutions to obtain a final concentration range of 10 μM to 0.1 nM. Compounds of the disclosure are tested for agonist activity in the absence of 5-CT and antagonist activity in the presence of 5-CT. For the cAMP assay, the protocol was followed according to the instructions provided by the supplier. Briefly, cells were incubated with a compound of the disclosure for 30 minutes at 37° C. prior to addition of EC70 concentration of 5-CT. After an additional 30 minutes, cAMP antibody/cell lysis solution was added (20 μL/well) and incubated for 60 minutes at room temperature. cAMP XS+EA reagent is added (20 μL/well) and incubated for 2 hours at room temperature. Luminescence was read on the Envision Multilabel plate reader.


The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety.


While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Claims
  • 1. A compound having formula (I):
  • 2. The compound of claim 1, having the formula (II):
  • 3. The compound of claim 1, having the formula (III):
  • 4. The compound of claim 1, having the formula (IV):
  • 5. The compound of claim 1, having the formula (V):
  • 6. The compound of claim 1, having the formula (VI):
  • 7. The compound of claim 1, having the formula (VII):
  • 8. The compound of claim 1, having the formula (VIII):
  • 9. The compound of claim 1, having the formula (IX):
  • 10. The compound of claim 1, having the formula (X):
  • 11. The compound of claim 1, having the formula (XI):
  • 12. The compound of claim 1, having the formula (XII):
  • 13. The compound of claim 1, having the formula (XIII):
  • 14. The compound of claim 1, having the formula (XIV):
  • 15. The compound of claim 1, having the formula (XV):
  • 16. The compound of claim 1, having the formula (XVI):
  • 17. A compound of claim 1, wherein the compound is selected from the group consisting of:
  • 18. (R)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one, (R)-3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(R)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)—N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide,(R)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile,(R)-8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, and(R)-2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile,(R)-8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile,(R)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(S)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)—N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide,(S)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl) sulfonyl)benzonitrile,(S)-8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, and(S)-2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile,(S)-8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile,(S)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,or a pharmaceutically acceptable form thereof.
  • 19. A composition comprising an effective amount of at least one compound according to claim 1.
  • 20. A composition according to claim 19, further comprising at least one excipient.
  • 21. A composition according to claim 20, wherein the at least one compound is at least one member comprising: (R)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(R)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)—N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide,(R)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile,(R)-8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, and(R)-2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile,(R)-8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile,(R)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(S)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)—N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide,(S)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile,(S)-8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, and(S)-2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile,(S)-8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile,(S)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,or a pharmaceutically acceptable form thereof.
  • 22. A method of treating a disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity, said method comprising administering to a subject an effective amount of at least one compound according to the claim 1 to treat the disease.
  • 23. The method of claim 22, wherein the at least one compound is administered in a composition further comprising at least one excipient.
  • 24. The method of claim 22, wherein the at least one compound is at least one member comprising: (R)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(R)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)—N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide,(R)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile,(R)-8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, and(R)-2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile,(R)-8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile,(R)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(R)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-phenylpiperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-hydroxyphenyl)piperazin-1-yl)ethyl)-2,8-dioxaspiro[4.5]decan-1-one,(S)-8-benzyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-methyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-8-acetyl-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)—N-methyl-1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxamide,(S)-tert-butyl 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-tert-butyl 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-1-oxo-2-oxa-8-azaspiro[4.5]decane-8-carboxylate,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(methylsulfonyl)-3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(2-methyl-1H-benzo[d]imidazol-7-yl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(phenylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-methoxyphenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((4-chlorophenyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((tetrahydro-2H-pyran-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(thiophen-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-4-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)benzonitrile,(S)-8-((6-chloroimidazo[2,1-b]thiazol-5-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(((methylsulfonyl)methyl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one, and(S)-2-((1-oxo-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-8-yl)sulfonyl)acetonitrile,(S)-8-(propylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((trifluoromethyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(isopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclopropylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-8-((3,3,3-trifluoropropyl)sulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(isobutylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclopentylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(cyclohexylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(ethylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(pyridin-3-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-((1H-imidazol-4-yl)sulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-8-(furan-2-ylsulfonyl)-3-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-methoxyphenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-4-(4-(2-(8-(methylsulfonyl)-1-oxo-2-oxa-8-azaspiro[4.5]decan-3-yl)ethyl)piperazin-1-yl)benzonitrile,(S)-8-(methylsulfonyl)-3-(2-(4-(4-nitrophenyl)piperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-iodophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,(S)-3-(2-(4-(4-fluorophenyl)piperazin-1-yl)ethyl)-8-(methylsulfonyl)-2-oxa-8-azaspiro[4.5]decan-1-one,or a pharmaceutically acceptable form thereof.
  • 25. The method of claim 22, wherein the disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity comprises: inflammatory bowel disease, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder.
  • 26. The method of claim 23, wherein the disease associated with dysregulation of 5-hydroxytryptamine receptor 7 activity comprises: inflammatory bowel disease, circadian rhythm disorder, depression, schizophrenia, neurogenic inflammation, hypertension, peripheral, vascular diseases, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, hippocampal signaling disorder, sleep disorder, attention deficit/hyperactivity disorder, anxiety, avoidant personality disorder, premature ejaculation, eating disorder, premenstrual syndrome, premenstrual dysphonic disorder, seasonal affective disorder, or bipolar disorder.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application No. 62/422,344, filed Nov. 15, 2016, which is herein incorporated by reference in its entirety.

STATEMENT OF FEDERALLY FUNDED RESEARCH

The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grant number HHSN-271-2008-00025-C awarded by the National Institute of Mental Health.

PCT Information
Filing Document Filing Date Country Kind
PCT/US17/61677 11/15/2017 WO 00
Provisional Applications (1)
Number Date Country
62422344 Nov 2016 US